An investigation into factors which have an impact on access to and utilisation of the genetic and endoscopic surveillance clinic offered to high-risk members of known Lynch families by Bruwer, Zandré
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 
























AN INVESTIGATION INTO FACTORS WHICH HAVE AN 
IMPACT ON ACCESS TO AND UTILISATION OF THE 
GENETIC AND ENDOSCOPIC SURVEILLANCE CLINIC 










Thesis presented for the degree of 
 
DOCTOR OF PHILOSOPHY  
 
In the Division of Human Genetics 
 
UNIVERSITY OF CAPE TOWN 
 








Supervisor: Professor Rajkumar Ramesar 
Co-supervisors: Dr Merle Futter 




Division of Human Genetics 
Department of Clinical Laboratory Medicine 















I, Zandré Bruwer, hereby declare that the work on which this dissertation is 
based is my original work (except where acknowledgements indicate 
otherwise) and that neither the whole work nor any part of it has been, is 






















The Genetic and Endoscopic Surveillance Clinic has been in operation for 
more than a decade and provides predictive testing and life-saving colorectal 
cancer screening services to individuals with Lynch syndrome, in the 
Western and Northern Cape provinces of South Africa. The risk of colorectal 
cancer is reduced by 50% and mortality is decreased by 65% with regular 
colonoscopic screening; however, the attendance rate at the clinic has been 
declining over several years. Obvious concerns exist for those individuals 
undergoing screening at levels below the desired recomme dations in light of 
the recognised preventative benefits of frequent surveillance. It was thus 
opportune for a formal evaluation of both the surveillance and predictive 
testing programmes to be conducted to determine factors affecting the 
access, utilisation and satisfaction with the service, from the perspective of 
the service users.  
 
AIMS 
The aims of this study were: 
 To appraise the clinic from the users’ perspective using face-to-face 
interviews to ascertain their experiences and level of satisfaction with 
the surveillance and predictive testing aspects of the clinic;  
 To measure the level of the adherence to recommended surveillance 
screening guidelines; 
 To determine the impact of socio-economic status, education, physical 
barriers and psychosocial factors on adherence to the recommended 
surveillance programme;  
 To determine the uptake of predictive testing among participants and 
their family members; 
 To identify and explore the referral pathways and communication 














The research used a phenomenological design with a ‘multi-method’ 
approach of both qualitative and quantitative methods. A semi-structured 
interview schedule, consisting of both open- and closed-ended questions, 
was developed and two cohorts were interviewed to evaluate the surveillance 
and the predictive testing programme offered through the Genetic and 
Endoscopic Surveillance Clinic. 
 
The two groups comprised: 
 Group A. A cross-sectional design was utilised to gather information 
from participants already involved in the screening programme for 
longer than one year (n=83).  
 Group B. A longitudinal approach, consisting of three interviews, was 
used to collect data from individuals requesting predictive testing 
(n=33). 
 
Audio-recordings were conducted for each interview, and the data was 
transcribed and captured on Excel spreadsheets. The quantitative data was 
analysed by Categorical Principle Component Analysis and qualitative data 
by means of a thematic analysis approach. 
 
FINDINGS 
The majority of participants within Group A were satisfied with the services 
offered by the clinic (90.2%). Although their average level of knowledge of 
Lynch syndrome was relatively poor, a higher knowledge score appeared to 
relate to a longer period within the programme. Participants who missed most 
of their colonoscopic appointments were generally female, over the age of 50 
years, and needed to travel for longer than one hour on the free ambulance 
transportation service to get to the surveillance clinic. Rates of compliance to 
recommended colonoscopies differed when comparing figures obtained from 
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participants were adherent with all their recommended screening 
appointments. The barriers to screening pertained mostly to colon 
preparation and transport concerns. Additional factors affecting compliance 
and unique to the clinic, were identified. Although participants disclosed their 
genetic test result to their immediate family members on the same day that 
they received the information, the implications and option of predictive testing 
were not always relayed immediately. The calculated uptake rate of 
predictive testing among siblings and eligible children was 97% and 73.6%, 
respectively. Under-exposure rather than over-exposure to the familial cancer 
was found to be an important predictor of psychological distress in individuals 
with Lynch syndrome. 
 
The vast majority of participants in Group B judged the predictive testing 
programme as ‘highly satisfactory’ (80.3%) and had been referred to the 
clinic by a family member, usually a parent with Lynch syndrome. Regret of 
having undergone predictive testing for the familial susceptibility was not 
expressed and all participants stated that they would recommend testing to 
their family members. Of concern were the 39.4% of participants who could 
not explain the purpose of predictive testing following their pre-test 
counselling session. These individuals were mostly from a lower socio-
economic and education background and of Mixed Ancestry. The uptake rate 
of predictive testing, however, remained high with a 100% of participants 
accepting testing and 70% presenting within a year of learning about the 
availability of a genetic test. The psychological impact of predictive testing, 
on anxiety and depression, was congruent with reported findings in the 
literature. However, cancer worry scores were unexpectedly higher among 
mutation-negative individuals when compared to the mutation-positive cohort. 
 
CONCLUSION 
Recommendations for improvements in both the surveillance and predictive 
testing services offered through the Genetic and Endoscopic Surveillance 
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researcher. The majority of these changes have been implemented, 
however, they will also require further evaluation after the improved services 
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Adenoma: A benign tumour that develops from epithelial tissue. 
Adenocarcinoma: A malignant tumour that develops from epithelial cells, originating in glandular 
tissue. 
Autosomal dominant inheritance: The expression of a gene in the heterozygous state, located on an 
autosome.  
Colonoscopy: A medical procedure which permits the visual examination of the entire colon, using an 
illuminated flexible endoscope. 
Colectomy: Surgical removal of part of or the entire colon. 
DNA: The genetic material of a cell which allows for the transmission of genetic information from one 
generation to the next. 
Extracolonic: Developing outside of the colon. 
Founder effect: Loss of genetic variation as a result of a new population being established by a few
members from the larger population – a type of genetic drift.
Gene: A sequence of DNA that codes for a particular protein.
Germline mutation: A heritable mutation in the lineage of germ cells. These mutations are transmitted
to offspring.
HNPCC/Lynch syndrome: An autosomal dominant cancer syndrome characterised by early-onset
colorectal cancer with an absence or limited number of colonic polyps, usually occurring in the proximal
colon. There is also a predisposition to other extracolonic cancers.
Huntington Disease: An autosomal dominant neurodegenerative disorder involving chorea, cognitive
decline and dementia.
Ileorectal anastomosis: Surgery involving the removal of the colon, which leaves the rectum intact by
attaching the ileum to the rectum. 
Metachronous: Tumours occurring more than six months after surgical resection for colorectal cancer. 
Mutation: An alteration in the DNA sequence or chromosome structure, damaging the function of a 
gene and may be disease-causing. 
Mutation-negative: An individual who does not have a gene mutation. If an individual is mutation-
negative for a specific genetic disorder, they are not at-risk of developing the disorder. 
Mutation-positive: An individual who does have a gene mutation. If an individual is mutation-positive 
for a specific genetic disorder, they are at-risk of developing the disorder. 
Polyp: A mucousal protuberance into the lumen of the colon. 
Predictive testing: A form of genetic testing which is capable of identifying the presence of a mutation 
in a gene prior to the individual developing any symptoms of the disease. The detection of the genetic 










                                                                                                                                                GLOSSARY 
xx 
 
Predisposition: Having a greater than average risk of developing a disease as a result of an inherited 
gene mutation. 
Prophylactic surgery: Surgery performed before a particular phenotype manifests itself in the 
individual. 
Proximal: Ascending and transverse colon. 
Rectum: The last 10-12 centimetres of the digestive tract before the anus. 
Rural: an area consisting of a commercial farm, small settlement or rural village beyond an urban area. 
Sigmoid colon: The area of the colon that comes after the descending colon and before the rectum. 
Sigmoidoscopy: A medical procedure involving the examination of the rectum and the lower portion of 
the colon (sigmoid colon) through an illuminated sigmoidoscope. 
Synchronous: Multiple tumours seen at or within six months of surgical resection for colorectal 
cancer. 
Tumour: An abnormal mass of tissue resulting from excessive cell division. This may be benign (non-
cancerous) or malignant (cancerous). 
Urban: An area that includes a town, city or metropolitan area. 















This work will refer to the following terms when describing the study 
participants and the population of South Africa. 
 
Mixed Ancestry/Coloured Population: Refers to a heterogeneous group of 
persons from a mixed racial ancestry. While the label ‘Coloured’ is a 
contentious term, it is still used to describe the mixed race population, 
descended from slaves brought in from East and Central Africa, the 
indigenous Khoisan, indigenous Africans and the White European settlers. A 
marked regional concentration of Coloured people exists within the Western 
Cape and Johannesburg. 
 
The majority of individuals within the Coloured group speak Afrikaans (a 
language similar to Dutch). 
 
Black African population: In accordance with accepted terminology, this 
group of individuals are referred to as the ‘Black population’ of South Africa. 
The Black population is neither culturally nor linguistically homogenous, with 
nine of the countries official 11 languages being African. The group includes 
the Nguni, South-Tswana, Tsonga and the Venda. 
 
Caucasian/White population: The white population descends largely from 
the colonial immigrants of the late 17th to 19th century and includes settlers 
from Netherlands, Germany, France and England. Linguistically, they are 
divided into Afrikaans- and English-speaking groups. 
 
Certain terms have been used interchangeably in this work, and include: 
‘adherence’ and ‘compliance’. These terms both describe a patient’s 
fulfilment of the healthcare professional’s recommendation, which in this work 
pertains to the regular attendance of colonoscopic screening. ‘Non-














The terms ‘mutation-positive’ and ‘carrier’ are both used to describe an 
individual with an inherited predisposition to Lynch syndrome, and ‘mutation-
negative’ and ‘non-carrier’ an individual without the predisposition. 
Furthermore, ‘findings’ and ‘results’ are used interchangeably within 
Chapter Four (analysis, findings/results and discussion) and refers to both 
the qualitative and quantitative data. 
 
‘Client’ and ‘counselee’ are also used interchangeably and these terms are 
used to describe the individuals attending for genetic counselling.  
 
Photos have been included in the results and discussion section to illustrate 
the living conditions, where a written report would not have sufficed. The 
















Figure A. Map of Southern Africa. The outreach Genetic and Endoscopic Surveillance Clinic 
runs annually from Cape Town (in the Western Cape) along the western coast to the alluvial 
diamond mining village of Kleinsee. The route is closely interlinked to the location of known 
Lynch syndrome families residing in the Western and Northern Cape provinces. The red 























CHAPTER ONE: INTRODUCTION 





1.1  INTRODUCTION 
Lynch syndrome (LS) is an inherited predisposition to early-onset colorectal 
and endometrial cancer, caused by mutations in DNA mismatch repair genes 
(Lynch et al 1998). It is the most common form of hereditary colorectal cancer 
(CRC) and has a worldwide prevalence of 1 in 3 000 persons (Young 2001). 
 
The first clinical description of LS in South Africa (SA) was in 1985 (Goldblatt 
et al 1990). The diagnosis was based on an affected 30 year old man who 
had a cancer of his colon resected at the age of 19 years, and a detailed 
family pedigree showing autosomal dominant inheritance over three 
generations (Ramesar et al 2000). The identification of LS in this family 
occurred prior to molecular genetic testing being available in SA. All blood 
relatives of the proband were therefore at an empirical risk of developing LS, 
as identified through their lineage (Anderson et al 2007; Goldblatt et al 1990). 
 
Surveillance guidelines for LS differ from those recommendations for 
population based colon cancer risk, in general. A full colonoscopy is 
recommended at a young age because of a higher risk for right-sided tumours 
in LS compared to the involvement of the rectum and sigmoid colon, more 
commonly seen in sporadic cancer (Vasen et al 1999). The younger age of 
onset warrants earlier screening, and the higher incidence of a secondary 
metachronous or synchronous malignancy, a shorter interval time between 
colonoscopies. Current guidelines propose that the surveillance of the colon, 
in at-risk individuals, be initiated at the age of 20-25 years and be repeated 
every one to three years (Vasen et al 1991; Vasen et al 1999). In SA, 
colonoscopic screening for LS is recommended biannually until 30 years of 
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Because of an established founder effect, it is now recognised that many 
individuals at a high risk of developing LS are clustered in specific areas in 
the Western Cape (WC) and Northern Cape (NC) Province of SA (Goldberg 
et al 1998). Access to surveillance services and the provision of ongoing 
management at the afore-mentioned intervals create major logistical 
difficulties, as most of those at risk are located in remote areas of these 
provinces (Anderson et al 2007). In an attempt to facilitate access, an 
outreach endoscopic programme was initiated and runs in conjunction with 
the colonoscopic services offered in the established endoscopic unit at 
Groote Schuur Hospital (GSH) in Cape Town in the WC Province (Goldblatt 
et al 1990). This outreach service is intended to provide an annual mobile 
service in small district hospitals and clinics. All of the surveillance equipment 
is transported, and trained staff travel from Cape Town, along the western 
coast of SA to the Namibian border, to conduct such a surveillance clinic 
(Figure A). In addition to the surveillance service, the mobile unit created a 
platform to recruit family members, based on empirical risk, into research 
programmes. This research led to the discovery of the causative mutation in 
1996 by the University of Cape Town (UCT) Human Genetics group and to 
the establishment of a predictive testing (PT) and counselling programme 
which was integrated into the mobile endoscopic unit‘s service in 1996/1997 
(Figure 1) (Goldberg et al 1998; Ramesar et al 2000).  
 
 
Figure 1: Timeline of the key events leading to the establishment of the outreach (mobile) 
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Genetic testing is capable of optimally utilising limited surveillance expertise 
and equipment in LS families, and can greatly reduce the demand of 
colonoscopic procedures at hospitals and the efforts of the yearly outreach 
endoscopic mobile clinic (Goldberg et al 1998). Mutation-positive individuals 
(at a high risk of developing CRC) should receive regular endoscopic 
surveillance and mutation-negative individuals, should undergo screening 
according to general population guidelines (Lynch et al 1998). Essentially, 
regular endoscopic surveillance in individuals at risk of developing LS can 
prevent CRC by removing the precancerous lesion or enabling the treatment 
of cancer at an early stage (Järvinen et al 2000). The importance of access to 
a surveillance service is thus crucial for at-risk individuals and has been 
fundamental in the establishment and maintenance of a mobile genetic and 
endoscopic surveillance service.  
 
Unfortunately, attendance at this outreach service has been declining. In 
2008, approximately half the patients scheduled to attend on a single 
outreach visit, did not attend. This declining pattern is depicted in Figure 2 
which illustrates the attendance rate (total number of expected visits 
compared to the total number seen) over the five-year period prior to the 









Figure 2: A five-year overview (2004-2008) of the attendance at the Genetic and 
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1.2  SIGNIFICANCE OF THE STUDY 
Intervention strategies, dedicated to improving health and preventing cancer, 
are only as effective as the number of patients they serve. Clearly, offering 
regular colonoscopic screening to individuals at risk for LS, at the outreach 
clinic, is not sufficient to prevent or treat cancer. In 2008, 46% of the known 
at-risk population did not attend their appointments (Figure 2). There is thus 
an obvious need to evaluate factors affecting the access, utilisation and 
satisfaction with this service, from the perspective of the service users. 
 
The evaluation of genetic counselling services, in general, is not a unique 
aspect in the literature and the most common criteria assessed include: 
knowledge, risk comprehension or recall, psychological distress, patient 
satisfaction and reproductive decision-making (Bernhardt et al 2000; Bjorvatn 
et al 2007; Collins et al 2000; Kessler 1989; Michie et al 1997; Pilnick and 
Dingwall 2001). These measures have been used to assess the services in 
order to improve the process of genetic counselling and care provided to 
individuals concerned about a genetic risk.  
 
The Genetic and Endoscopic Surveillance Clinic (GESC) has been in 
operation for more than a decade, however, few changes have been 
implemented during this time and no formal evaluation has previously been 
undertaken. The value of conducting an investigation into the effectiveness of 
the current service, the ability to meet the patients‘ needs and the potential to 
identify areas amenable to improvement is obvious when considering the 
declining attendance (Figure 2). In order to conduct this investigation, a broad 
social profile of the individuals attending for surveillance (after receiving a 
mutation-positive test result) and of those entering into the PT programme is 
needed to appraise the GESC. Furthermore, comparison between the service 
offered in an established centre and the outreach clinic should be made to 
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Extensive research has also been conducted on LS. The avenues that have
been investigated and for which a great deal of information is available
include: the molecular cause, clinical features, lifetime cancer-related risks 
and the management and surveillance options and benefits. Since the
identification of the molecular cause of the disease, genetic testing, PT 
programmes, genetic counselling and the psychosocial impact of the
condition on the individual as well as the family, have been assessed
comprehensively in western developed countries. However, data pertaining to
LS within a developing country and especially focused on individuals from a
low socio-economic background are sparse. Therefore, this research project
intended to evaluate the service experienced by individuals involved in the PT 
programme as well as the satisfaction with the surveillance service offered to
patients with LS, within this specific context. By providing further details of the
individuals‘ socio-economic environment, greater insight into the impact of 
these factors on their clinical, social and psychological aspects, can be
gained.
This study aimed to identify and provide further insight into patients‘ needs
and their experience of the healthcare service offered. By gaining an
understanding of the facilitators and barriers to attendance, it was hoped to
increase the level of patient satisfaction as well as the uptake of genetic
testing and compliance with screening regimens. Furthermore, knowledge
derived from the investigation can be extrapolated to developing policy 
guidelines for the establishment of similar services in the other provinces of 
SA (currently the outreach service is only offered in the Western and Northern 
Cape Province).
1.3  AIMS OF THE STUDY 
The aims of this study were: 
 To appraise the GESC from the users‘ perspective using face-to-face
interviews to ascertain their experiences and level of satisfaction with
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 To measure the level of the adherence to recommended surveillance 
screening guidelines; 
 To determine the impact of socio-economic status, education, physical 
barriers and psychosocial factors on adherence to the recommended 
surveillance programme;  
 To determine the uptake of PT among participants and their family 
members; 
 To identify and explore the referral pathways and communication 
networks, leading to attendance at the GESC. 
 
1.4  OBJECTIVES OF THE STUDY 
The objectives of the study were divided into four categories: 
 
1.4.1. BACKGROUND INFORMATION 
 To compile a profile of the participants attending the GESC;  
 To measure the extent of adherence to the recommended screening 
guidelines; 
 To identify facilitators and barriers affecting the level of adherence to 
the recommended surveillance programme; 
 To compare uptake rates of PT among family of the participants (first-
degree relatives); 
 To explore the reasons for the uptake of genetic testing among PT 
participants; 
 To explore the reasons for non-uptake of genetic testing among PT 
participants. 
 
1.4.2. UNDERSTANDING, EXPERIENCE, AND SATISFACTION WITH THE 
SERVICE DELIVERED 
 To identify the sources of information relating to the participant‘s 
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 To explore the level of genetic knowledge of LS amongst high-risk 
individuals attending the service; 
 To measure the level of satisfaction with the endoscopic surveillance 
service; 
 To measure the level of satisfaction with genetic counselling and the 
PT programme; 
 To describe the psychological impact of participating in the endoscopic 
surveillance and the PT programme. 
 
1.4.3. REFERRAL PATHWAYS AND COMMUNICATION NETWORKS 
LEADING TO ATTENDANCE AT THE SERVICE 
 To identify and investigate the referral pathways to the service; 
 To determine the accessibility of the service; 
 To determine to who the participant discloses his or her genetic test 
result and the reasons for the choice of the specific person(s); 
 To investigate the transmission of information about genetic risk within 
the immediate family; 
 To explore the participants‘ experience of informing family members 
about the genetic risk; 
 To determine the role of the healthcare providers in: (1) maintaining 
confidentiality with the individual‘s genetic test results and (2) the 
healthcare provider‘s responsibility to inform family members of their 
at-risk status.  
 
1.4.4. IMPROVE SERVICE OFFERED TO PARTICIPANTS AND THEIR 
FAMILIES 
 To explore the participants‘ experience of their involvement in previous 
research and attitude to involvement in future research programmes; 
 To determine the recommendations the users make to improve the 
service; 
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 To determine the general health of the participant to facilitate 
appropriate referral if bowel-related concerns are identified. 
 
1.5  OUTLINE OF RESEARCH DESIGN AND METHODOLOGY 
The study used a combination of qualitative and quantitative methods within a 
phenomenological research design. Two groups of participants were 
interviewed utilising a semi-structured interview schedule. The first group 
included individuals who had received a mutation-positive test result and were 
recommended to adhere to regular colonoscopic screening. The second 
group involved interviews with individuals entering the PT programme.  
 
A cross-sectional approach was used to facilitate the gathering of information 
from participants required to attend for regular screening, while a longitudinal 
approach, consisting of three interviews (prior to PT, post PT and one month 
after PT result was received) was used for those individuals embarking on the 
PT process. Interviews were conducted within the participant‘s homes, a 
private room at the clinic or a private venue of the participant‘s choice.  
 
1.6  ORGANISATION OF THE STUDY 
Chapter Two: an overview of the current literature on LS, placing it in the 
context of developments in science, medicine, psychology and genetic 
counselling is provided. It explores all the published literature relating to the 
genetic and surveillance services for LS as well as describing the 
development of a mobile GESC in the Western and Northern Cape. The end 
of the chapter presents further information on the historical and current socio-
economic background of individuals affected by and at-risk of developing LS 
in SA. 
 
Chapter Three: the methodology design and outline of the research process 
is discussed. The steps involved in selecting participants are described and 
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discussed. A description of the data collection and analysis is provided while 
addressing ethical principles. 
 
Chapter Four: the results of the research study are presented and 
discussed. Analysis and discussion are included in the same chapter to 
prevent unnecessary repetition of information and to aid the clarity and 
understanding of the results of the study. This form of co-presenting results 
and the discussion is in line with recommendations for qualitative research 
(McMillan and Schumacher 2001). 
 
Chapter Five: the main findings as summarised in the conclusion of the study 
are described. 
 























‟I inherited two things from my grandmother: a delicate Royal albert tea service, and 
a genetic condition called HNPCC. I would have preferred to have just the fine china, 
really. My grandmother’s gene gives me an 80% chance of getting colorectal cancer, 
40% chance of getting womb cancer, and slightly lower odds on a veritable 
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2.1  INTRODUCTION 
The literature review presents an extensive overview of CRC, with specific 
reference to LS, including information on the natural history, epidemiology, 
clinical features, clinical and molecular diagnosis, management and 
surveillance recommendations. The psychosocial impact of the disease, 
predictive testing, genetic counselling, family communication and satisfaction 
with genetic services are also addressed. 
 
As it is essential to understand the context from which the study cohort 
originated and within which the research was conducted a brief introduction of 
the history of SA is provided. The effect the ‗apartheid‘ political system had on 
different population groups of the nation, through its discriminatory legislature, 
is also briefly described. The ensuing impact that this has had on the health 
care system is discussed to ensure that the reader is familiar with the medical 
background and social environment of the families in the study. 
 
Literature searches were conducted using the following terms: ‗Lynch 
syndrome‘, ‗HNPCC‘, ‗hereditary colorectal cancer‘, ‗genetic testing‘, 
‗predictive testing‘, ‗genetic susceptibility testing‘, ‗testing for cancer 
susceptibility‘, ‗uptake‘, ‗genetic counselling‘, ‗psychological impact‘, 
‗psychosocial impact‘, ‗adverse outcomes‘, ‗distress‘, ‗Lynch syndrome/ 
HNPCC management‘, ‗surveillance‘, ‗screening‘, ‗risk‘, ‗at-risk‘, ‗disclosure‘, 
‗communication‘, ‗patient satisfaction‘, ‗assessment‘ and ‗population statistics‘ 
on Pubmed, ScienceDirect, Ebscohost, CancerLit, Ovid, wwwstatssa.gov.za, 
CINHL, Google Scholar, African studies library and UCT (medical and main) 
libraries. The literature review mainly refers to studies conducted in the United 
Kingdom (UK), Europe, United States of America (USA), Canada and 
Australia as a result of the paucity of published information available from 
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2.2  COLORECTAL CANCER (CRC) 
CRC is the most common visceral cancer in developed countries and the 
second most-frequent malignancy to affect both men and women in western 
civilisations. The estimated annual worldwide incidence of CRC is escalating 
and has recently reached a figure of 1, 023 152, with approximately half a 
million deaths attributed to this disease each year (Parkin et al 2005). 
 
CRC is typically associated with a westernised diet and sedentary lifestyle, 
thus developed countries and affluent societies, particularly, North America 
and Western Europe illustrate higher incidence rates than those in Asia and 
Africa. While Africa is classified as a developing country, SA is more reflective 
of a western society, reporting among the highest cancer rates of the 
continent. The South African Cancer Registry for 1998-1999 indicates that the 
age-standardised incidence rate for CRC is 9.74 per 100 000 inhabitants for 
males and 6.61 for females. The lifetime risk of developing bowel cancer, in 
SA, is 1 in 91 for men and 1 in 134 for women (National Cancer Registry 
1999). The epidemiology of CRC among White SA‘s, specifically, appears to 
follow the classic western trend (Cronje et al 2009). In contrast the risk of 
CRC is reported to be lowest among Black men and women compared to the 
other population groups (Mqoqi et al 2004; Walker and Segal 2002). 
 
Of great concern is that the overall incidence of CRC in SA has increased 
dramatically over the last decade. In 1989, CRC featured as the tenth most 
common cancer to affect both genders. The latest statistics (National Cancer 
Registry 1999) reflect a sharp increase in this cancer, now ranked as the fifth 
most common cancer in males and third most common in females (Mqoqi et 
al 2004).  
 
2.2.1 ETIOLOGY OF COLORECTAL CANCER  
Cancer develops as a result of mutations accumulating over time, in genes 
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(Vogelstein and Kinzler 1993). In 80% of individuals, CRC results as a 
sporadic disease with no evidence of an inherited predisposition whereby 
environmental and dietary factors play a key role (Lalloo et al 2005; 
Schulmann et al 2002). Several prospective studies have linked a typical 
westernised diet associated with an increased consumption of red meat and 
saturated fat, alcohol and cigarette smoking to a greater risk of developing 
colorectal malignancies (Giovannucci et al 1992; Willett et al 1990). 
Conversely, low consumption of red meat, dietary fat and a high consumption 
of folate, vegetables and fibre suggest a protective effect. Recent data from 
observational studies and negative results from randomised trials, however, 
contradict the association between fibre and CRC risk (Campos et al 2005; 
Michels et al 2005; Tsubono et al 2005).  
 
Migrant studies provide further evidence of the role of environmental and 
dietary influences in the development of CRC. These studies have reported 
an increase in incidence of CRC when immigration occurs from a low-risk to a 
high-risk country (Kolonel et al 1980; McMichael et al 1980). This 
phenomenon is also illustrated in individuals relocating from high- to low-risk 
areas (McMichael et al 1980). Interestingly, the study found that amongst 
these immigrants the incidence of CRC was shown to decrease to those of 
the host country within only one generation. Walker and Segal (2002) 
propose similar trends in the Black SA population, where a rising occurrence 
of CRC has been reported specifically in the urban population as compared to 
their rural counterparts. In the Utah population (USA), CRC risk was also 
significantly different when Mormons were compared to non-Mormons. The 
Mormons generally have strong proscriptions against the use of certain 
dietary components (meat, sugar, cheese, alcohol and tobacco), some of 
which have an association with cancer risk (Jorde 2001; National Research 
Council 1982).  
 
The risk of developing CRC increases with the number of affected relatives 
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of patients who do not fall within the sporadic CRC group, familial CRC is 
apparent and the underlying predisposition, attributed to an inherited 
susceptibility to disease. LS, the most common of the inherited CRC‘s, 
accounts conservatively, for approximately 20-35% of such cancers (Figure 3) 
(Lynch and Krush 1971; Warthin 1913). 
 
 
Figure 3: Contribution of Lynch syndrome to the colorectal cancer burden (Lynch and 
de la Chapelle 2003; Lynch and Lynch 2000; Lynch and Krush 1971). 
 
2.3  OVERVIEW OF LYNCH SYNDROME (LS) 
Historically, the first report of LS was described by Aldred Warthin in 1985. 
The pathologist‘s observation of an hereditary nature of cancer was initiated 
by his seamstress‘s anxiety concerning her family history of malignancy and 
her fears of mortality in light of the proclivity towards cancers in her family 
(Warthin et al 1913). The pedigree of this family, now known as Family G, 
was published by Warthin in 1913 and similar families presenting with an 
analogous constellation of cancers were subsequently described under the 
appellation of ‗Cancer Family Syndrome‘ (CFS) (Lynch et al 1966; Lynch and 
Krush 1971).  
 
Following the recognition of an autosomal dominant mode of inheritance of 
CRC, CFS became better known as LS (Douglas et al 2005; Lynch and 
Smyrk 1996; Vasen and Morreau 2002). To differentiate families where 
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extracolonic cancers were additionally apparent, LS Ι and LS II were
delineated (Mecklin et al 1986; Vasen et al 1989). Families with early onset
CRC were grouped into the first category, while those cases with a litany of 
integral cancers in addition to CRC became known as LS II (Lynch and Lynch
2000). A series of international publications documented the existence of 
families with LS in Europe (Itoh et al 1990; Mecklin et al 1986; Ponz de Leon
et al 1989; Vasen et al 1989), New Zealand (Jass et al 1992) and Israel 
(Abusamra et al 1987). Following this global recognition the more descriptive
acronym, Hereditary Nonpolyposis Colorectal Cancer (HNPCC), came into
use. The term was chosen to place emphasis on the hereditary nature of the
condition and to differentiate it from the polyposis syndromes. Presently, a 
new definition favours the use of LS for genetically proven cases of the
condition (with molecular evidence of a mismatch repair defect) (Boland 2005; 
Lindor et al 2006; Lynch et al 2009; Vasen et al 2007).
To prevent any confusion in this research project, the condition will hereforth
be referred to as LS. However, should LS only be suspected on a clinical
basis, without proof of a genetic confirmation, it will clearly be indicated in the
review.
2.4 MOLECULAR BASIS OF LYNCH SYNDROME
LS is an autosomal dominant condition caused by mutations in DNA 
mismatch repair (MMR) genes causing multiple generations within the family
to be affected with CRC (Lynch and de la Chapelle 2003). The discovery of 
the genetic basis for LS began with Peltomäki et al (1993) linking the cancer-
susceptibility locus to chromosome 2p. A second predisposing locus, on
chromosome 3p, was described by Lindblom et al (1993) shortly afterwards.
Currently four genes have been implicated in the MMR pathway and are
known to be associated with LS. These include MLH1, MSH2, MSH6 and
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MMR genes function to maintain the fidelity of the DNA by repairing errors of 
DNA replication created by misincorporations or slippage of the DNA-
polymerase (Annie Yu et al 2003). MMR mutations associated with LS are 
described and maintained by the International Collaborative Group on 
Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC) (INSIGHT 2008). 
 
The proportion of LS families due to mutations within each gene remains to 
be elucidated. Data thus far has suggested that MLH1 and MSH2 account for 
the majority of cases (90%) followed by MSH6 (7-10%), with PMS2 fewer 
than 5% (Berends et al 2002; Miyaki et al 1997; Peltomäki et al 2003). 
 
2.5  CLINICAL FEATURES OF LYNCH SYNDROME 
Individuals with a predisposing mutation have an approximate 70-80% lifetime 
risk of developing CRC at an early age (mean of approximately 45 years) with 
a predilection to right-sided tumours (Mecklin 1987; Rodriquez-Bigas et al 
1997; Lynch et al 1993b). This is in contrast to sporadic CRC which occurs 
later in life, at approximately 65 years, and usually shows predominance for 
the left colon (Annie Yu et al 2003; Lynch et al 1998; Vasen et al 1999; 
Watson et al 1998). Typical colonic features of LS include the excess of 
synchronous (multiple tumours seen at or within six months of surgical 
resection for CRC) and metachronous (tumours occurring more than six 
months after surgery) tumours (Lynch and de la Chapelle 1999). Additionally, 
LS patients present with a paucity of adenomatous colonic polyps, whereby 
the precursor lesions are often more villous, with areas of high-grade 
dysplasia, than those from the general population with sporadic CRC. 
Consequently a more rapid adenoma to carcinoma progression occurs during 
malignant transformation in LS (Annie Yu et al 2003; Jass and Stewart 1992; 
Lynch and Lynch 2000). Greater detail, with respect to the clinical features of 
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Table 1: The characteristics which typify Lynch syndrome.  
 Autosomal dominant inheritance pattern present in the family pedigree 
 Earlier average age of onset as compared to the general population 
o 45 years in LS versus 69 years in the general population (Vasen et al 1999) 
 Predilection for proximal (right-sided) CRC 
o Approximately 70% of cases develop proximal to the splenic flexure (Annie 
Yu et al 2003) 
 Accelerated carcinogenesis 
o Carcinomas develop within 2-3 years in LS versus 8-10 years in the general 
population (Jass and Stewart 1992; Lynch and de la Chapelle 2003) 
 Increased risk for secondary CRCs 
o 25-30% of patients develop a second CRC within 10 years of surgical 
resection (if surgery does not include a subtotal colectomy) (Barrow et al 
2009; Watson et al 2008) 
 Increased malignancy risk for extracolonic tumours 
 Endometrium, ovary, stomach, small bowel, hepatobiliary tract, pancreas, 
ureter and renal pelvis, brain (Turcot syndrome variant of LS), skin including 
sebaceous adenomas, carcinomas and keratoacanthomas (Muir-Torre 
syndrome variant of LS) 
 Typical pathology: poorly differentiated carcinomas with an excess of mucoid 
and signet-cell features, Crohn’s-like reaction and tumour infiltrating 
lymphocytes within the tumour 
 Increased survival as compared to sporadic CRC 
o A relative survival rate of 65% in LS patients compared to 44% in sporadic 
CRC cases (Sankila et al 1996) 
 The diagnosis of a germline mutation within MLH1, MSH2, MSH6 or PMS2 
 
Malignancy associated with LS is not only limited to the colon. Individuals are 
at risk of a variety of other extracolonic cancers, namely, endometrial cancer 
in females (Watson et al 1994). The trait is additionally associated with an 
increased lifetime risk of gastric cancer (particularly in Asian countries such 
as Japan and Korea), urinary and biliary tract adenocarcinomas (Aarnio et al 
1995; Aarnio et al 1999; Barrow et al 2009; Park et al 2000). An excess of 
pancreas, larynx, brain and hematopoietic cancers has also been described 










                                                                                                                                                                  CHAPTER TWO: LITERATURE REVIEW                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
20 
 
controversial and the debate, in this regard, is ongoing. Vasen et al (2001a) 
did not show breast cancer to be part of the spectrum; however Barrow et al 
(2009), Blokhuis et al (2008) and Scott et al (2001) did prove the incidence to 
be higher than the population risk.  
 
2.5.1. GENDER DIFFERENCES  
Gender has been suggested to modify tumour expression in LS. In a Scottish 
study involving 67 patients who harboured mutations in MMR genes, the risk 
of developing CRC to age 70 was significantly higher for males as compared 
to females (p=0.006). CRC manifested in 74% of males compared to only 
30% of females. Interestingly, the risk for uterine ca cer considerably 
exceeded the lifetime risk for CRC in females from this cohort (42% versus 
30%) (Dunlop et al 1997). The latest literature suggests similar gender 
differences with respect to the expression of the LS phenotype in females 
(Aarnio et al 1999; Hampel et al 2005b). 
 
2.5.2 GENOTYPE-PHENOTYPE  
The existence of genotype-phenotype correlations are gaining clarity. In a 
recent study, an American group determined the prevalence of cancer in 
1914 unrelated probands with an identified germline mutation. The results 
described a marked discrepancy between cancer prevalence when different 
gene mutations were considered. While the endometrial cancer risk was 
similar between MLH1 and MSH2 mutation carriers, MLH1 carriers had a ten 
percent higher risk for CRC than individuals with an MSH2 mutation. 
Additionally, the mean age of CRC was younger for MLH1 mutation carriers 
(42.2 versus 44.8 years) (Kastrinos et al 2008).  
 
2.5.3 HISTOPATHOLOGY 
No robust biomarkers exist for LS. The pathological features of CRC are often 
distinguishable, but not entirely predictive of all cases of inherited CRC. The 
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extracellular mucin and illustrate a lymphoid (Crohn‘s-like pattern or 
peritumoural lymphocytes) host response to the tumour (Smyrk et al 1990) or 
signet cell pathology (Jass et al 2007). The most useful biomarker has been 
microsatellite instability (MSI), which is further described under Section 2.6.3. 
 
2.6  DIAGNOSTIC CRITERIA 
The recognition of LS is not straightforward and diagnostic criteria continue to 
evolve as the understanding and characterisation of the disorder improves. 
Currently, the diagnosis of LS is made on the basis of clinical Amsterdam 
criteria or molecular diagnosis by testing for germline mutations in one of the 
MMR genes.  
 
2.6.1 AMSTERDAM CRITERIA 
The Amsterdam criteria were established to define LS on the basis of a 
clinical history (Table 2A).  
 
Table 2A: Amsterdam criteria I.  
AMSTERDAM CRITERIA I (Vasen et al 1991) 
At least three relatives affected with histologically verified CRC: 
 One of the affected should be a first-degree relative of the other two affected 
individuals; 
 At least one of the CRC cases should be identified before the age of 50 years; 
 FAP should be excluded;  
 Tumours should be verified by pathology a. 
aAll the preceding criteria need to be present. CRC-Colorectal cancer. 
 
These criteria, created in 1990 by the ICG-HNPCC, were developed for the 
purpose of standardising diagnostic criteria in the recruitment of suspected 
cases of LS patients for collaborative studies (Vasen et al 1991). Essentially 
the guidelines stipulate that the family history must represent one or more 
CRC‘s diagnosed before 50 years of age and at least three relatives with 
CRC in two generations, where one must be a first-degree relative of the 
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Amsterdam criteria do not account for patients from small families or with 
other LS-related cancers. In response to this criticism, the Amsterdam II 
criteria were developed in 1999 to be more inclusive of extracolonic cancers 
and the Modified Amsterdam criteria was developed for assessing smaller 
families (Bellacosa et al 1996; Vasen et al 1999) (Table 2B). 
Table 2B: Amsterdam criteria II. 
AMSERDAM CRITERIA II (Vasen et al 1999) 
At least three affected relatives should be affected with LS-related cancer, including 
CRC, cancer of the endometrium, stomach, small bowel, ovary, ureter (renal pelvis), 
brain, hepatobiliary tract and skin (sebaceous tumours): 
 One of the affected individuals should be a first-degree relative of the other two 
affected individuals;
 At least two successive generations should include affected family members;
 At least one of the syndrome associated cancers should be diagnosed before the
age of 50 yearsa;
 FAP should be excluded;
 Tumours should be verified by pathologyb.
aThe syndrome associated tumour spectrum includes: CRC, endometrial, stomach, small bowel, ovarian, pancreas,
ureter (renal pelvis), biliary tract, brain (Turcot syndrome), sebaceous gland adenomas and keratoacanthomas (Muir-
Torre syndrome).
bAll the preceding criteria need to be present.
CRC-Colorectal cancer.
The accuracy of the clinical criteria (Amsterdam I and II and modified
Amsterdam) strongly depends on the accuracy of the reported family history 
and Katballe et al (2001) suggested that this could be further enhanced by
verifying diagnoses with pathology reports. When considering the original 
Amsterdam criteria, the sensitivity and specificity for identifying a mutation in 
MLH1 and MSH2 has been documented at 61% and 67% respectively. This 
can be increased to 72% and 78% when the modified and Amsterdam II
criteria are used (Syngal et al 2000). Importantly, when Syngal et al (2000)
classified the accuracy of existing clinical criteria, they found that up to 39% of
families with a germline MMR mutation did not meet the Amsterdam criteria
and concluded that the Amsterdam guidelines should not be the sole criterion
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2.6.2 BETHESDA GUIDELINES 
The Bethesda criteria were drafted to guide decisions for determining which 
tumours should undergo genetic testing (Table 2C). These guidelines 
included Amsterdam criteria as well as further pathological evaluation, 
allowing for a less stringent assessment. Original guidelines were proposed in 
1996 and subsequently revised in 2002 following further developments in the 
field (Umar et al 2004).  
 
Table 2C: Revised Bethesda Guidelines for testing of colorectal tumours for microsatellite 
instability. 
BETHESDA GUIDELINES (Laghi et al 2004) 
Tumours from any of the following should be tested for microsatellite instability and 
then proceed to molecular analysis if positive: 
 
 CRC diagnosed in a patient under the age of 50 years; 
 Presence of synchronous or metachronous CRC or any other syndrome related 
tumours regardless of age; 
 CRC with microsatellite instability-highb histologyc in a patient who is less than 60 
years of age;  
 CRC or a syndrome-related tumour diagnosed under the age of 50 years in at least 
one first-degree relative; 
 CRC or a syndrome-related tumour diagnosed at any age but present in two first or 
second degree-relatives. 
aThe syndrome associated tumour spectrum includes: CRC, endometrial, stomach, small bowel, ovarian, pancreas, 
ureter (renal pelvis), biliary tract, brain (Turcot syndrome), sebaceous gland adenomas and keratoacanthomas (Muir-
Torre syndrome). 
bMSI-H tumours are associated with changes in two or more of the five microsatellite markers. 
cPresence of tumour infiltrating lymphocytes, Crohn disease-like lymphocytic reaction, mucinous or signet-ring 
differentiation, or medullary growth pattern. 
CRC-Colorectal cancer. 
 
The revised Bethesda criteria, recommend MSI and or immunohistochemistry 
(IHC) prior to starting with mutation analysis. The fulfilment of only one 
guideline is sufficient for MSI and or IHC testing to be performed and acts as 
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2.6.3 MICROSATELLITE INSTABILITY (MSI) 
Microsatellites are length variations of short repetitive DNA sequences which 
are particularly susceptible to acquiring somatic mutations when the MMR 
gene function is impaired (Vasen and Morreau 2002). Cancer arising in a cell 
with a flawed MMR system will exhibit an inconsistent number of 
microsatelillite repeats when compared to normal tissue, thereby manifesting 
microsatellite instability (MSI). Testing for MSI identifies tumour 
characteristics predictive of underlying MMR mutations.  
 
The National Cancer Institute workshop on LS proposed that a panel of five 
markers be incorporated to assess MSI. These markers are microsatellites 
present in regions of the genome that are irrelevant to malignant 
transformation (Resnick et al 2009). Classification occurs according to three 
categories: MSI-high, defined as two or more markers showing instability; 
MSI-low, if one marker reflects instability; and MSI-stable where no markers 
show instability. The occurrence of MSI is higher in tumours of patients who 
are clinically diagnosed with LS (Aaltonen et al 1998; Boland et al 1998; 
Cunningham et al 2001), occurring in 85-92% of colorectal carcinomas and in 
at least 75% of endometrial carcinomas associated with LS (Aaltonen et al 
1994). Significantly lower estimates occur in sporadic colorectal (10-15%) and 
endometrial (17%) carcinomas (de Leeu et al 2000; Thibodeau et al 1993). 
The general recommendation is to use MSI as a pre-screening tool, to 
determine which families are likely to benefit from mutation analysis as the 
process is labour intensive, expensive and time-consuming. Testing for the 
presence of promotor hypermethylation and/or a somatic mutation (V600E) in 
the BRAF gene is a strong indicator of a sporadic CRC, and combining these 
strategies can reduce costs associated with mutational analysis (Domingo et 
al 2004). 
 
In addition to MSI‘s screening use, the test is also important as MSI-H 
tumours are associated with a better clinical prognosis, stage for stage and 
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response to adjuvant chemotherapy for stage I and II tumours (Ribic et al 
2003).  
 
As stated earlier, MSI is sensitive, but not specific to LS as a germline 
mutation will only be identified in 20-25% of all MSI-H tumours. For this 
reason, IHC is of a complementary value.  
 
2.6.4 IMMUNOHISTOCHEMISTRY (IHC)  
IHC is used to determine if there is expression of the MMR gene protein 
product. IHC can be used in combination with MSI to fast-track the 
identification of the specific MMR gene underlying the germline mutation. IHC 
for MLH1, MSH2, MSH6 and PMS2 is commercially available and is 
approximately 95% sensitive in the identification of MMR protein deficiency. 
As a result of MMR interactions, ambiguous staining can take place and 
experience on the part of the pathologist interpreting the slides is a requisite 
(Lynch et al 2009). In a large study involving 818 unselected CRC cases, 
Lindor et al (2002) concluded that IHC was 100% specific and 92.3% 
sensitive. Vasen and Boland (2005) suggested that the selection of IHC 
versus MSI should be based on the probability of identifying a genetic 
mutation. IHC might be the more feasible first step in families meeting the 
Amsterdam criteria where a higher possibility of finding a MMR gene mutation 
exists. If normal IHC results are found, supplementary MSI may be 
conducted. The reversal might be considered in patients meeting Bethesda 
criteria but who fail to be included in the Amsterdam criteria. These findings 
were in contrast to Hampel et al (2005a) who argued that a combination of 
MSI and IHC detected all mutations (23/23), while genotyping with IHC alone 
(2/23 cases were missed) or MSI alone (similarly 2/23 missed) failed to 
identify two probands. In a more recent publication by the same author, IHC is 
regarded as an almost equally sensitive screening tool to MSI and the group 
motivate for IHC due to its ability to direct genetic testing to a specific gene 
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2.6.5 RISK ASSESSMENT MODELS 
Barnetson et al (2006) suggest that pre-screening still misses an appreciable 
amount of mutations in MMR genes and proposed a new two-step approach 
developed from a population-based study of unselected patients under the 
age of 55 years with CRC. From their study the authors were able to identify 
the most pertinent clinical features suggestive of an underlying MMR 
mutation. Their computer-based algorithm incorporates a scoring system 
based on clinical features, providing a quantitative prediction of the likelihood 
of finding a MMR mutation. A threshold can be selected when using the 
equation, thereby taking into account the preferences and resources of the 
centre conducting the testing. While the benefits of the resource are evident 
and superior to that of the Amsterdam and Bethesda criteria (at a 0.5% 
likelihood), the model has only been assessed on 73 patients with proven 
mutations and a replication set of 155 subjects. The replication set was 
recruited retrospectively and showed a much younger age of onset of CRC, 
compared to that of the patients on which the model was developed. A variety 
of other models exist (Leiden Model, MMRPro, PREMM Model), each with 
their own benefits and limitations. 
 
2.6.6 MOLECULAR TESTING 
Clinical genetic testing is available beyond the SA border for MLH1, MSH2 
and MSH6 for approximately R8 000 to R22 000 (USA$ 1000-3000). The 
preferred laboratory techniques used to detect mutations predisposing to LS 
include mutation screening (detection rate of 60-69% in MLH1, 50-69% in 
MSH2) and sequence analysis (detection rate of 90-95% in MLH1, 50-80% in 
MSH2). Large deletions and rearrangements may be missed by these 
methods and a further 5-10% in MLH1 and 17-50% in MSH2 can be gained 
with the use of supplementary procedures such as Multiplex Ligation-
Dependent Probe Amplification and Southern-blotting (Genereviews 2006). 
Screening of MSH6 rarely yields mutations as a minority of LS families are 
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Testing in SA is currently offered free-of-charge on a research basis in one 
laboratory in the Western Cape. Denaturing high–performance liquid 
chromatography analysis is used to screen for DNA variations in MLH1, 
MSH2 and MSH6, with subsequent direct-cycle sequencing performed to 
characterise detected variations. The 12 existing mutations (seven in MLH1 
and five in MSH2) identified in the SA cohort through this research, are used 
to screen referrals of cases with suspected LS. At present, two private SA 
laboratories are in the process of setting up clinical genetic testing for LS.  
2.7  EPIDEMIOLOGY OF LYNCH SYNDROME 
The frequency of LS has been estimated to contribute to as much as 13% of 
the total CRC burden (Lynch and de la Chapelle 1999; Lynch and Smyrk
1996), however, most appraisals predict significantly lower frequencies of
approximately one to six percent (Lynch and de la Chapelle 2003; Mecklin
1987; Mecklin and Ponz de Leon 1994). The disparity is largely due to the
difficulty in diagnosing LS as a result of the variety of clinical phenotypes
associated with the syndrome in different centres or countries (Bellacosa et al
1996; Rodriguez-Bigas et al 1997). 
Initially the ICG-HNPCC defined clinical diagnostic criteria (Amsterdam
criteria) for LS to promote uniformity in collaborative studies (Vasen et al
1991). Several study groups have estimated Amsterdam-defined LS. Mecklin
et al (1995) estimated the proportion of clinically suspected cases of LS in
406 CRC cases to be 0.7% in a prospective multicentre study from ten
hospitals in Finland. Evans et al (1997) reported a frequency of 0.3% in their
analysis of 1137 English registry patients, while the Danish group found three
cases out of 1328 (0.3%) fulfilled the Amsterdam criteria (Katballe et al 2002). 
Not only does the estimated frequency of LS fluctuate according to different 
countries, geographic variations in the frequency of LS also exist. Modica et 
al (1995) and Ponz de Leon et al (1999), for example, showed that incidence 
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Ponz de Leon et al (1993) reported that Amsterdam-defined cases of LS 
occurred in 3.4% of CRC cases in Northern Italy as opposed to a prevalence 
of 0.45% in Southern Italy. The population studied by Cornaggia et al (2000), 
who drew on information from the Lombardy Cancer Registry, demonstrated 
a much lower frequency in their study (0.5%) compared to other areas in Italy.  
 
The disparities among population groups may reflect actual population 
differences. However, it has been suggested that variations may be further 
compounded by differences in the ability to verify diagnoses among family 
members and the level of proof required by each study to verify the diagnosis, 
as pertains to the Amsterdam criteria (Katballe et al 2002; Wang et al 2007). 
Another approach to diagnosing LS has focused on screening for germline 
mutations in MMR genes predisposing to LS, primarily MLH1 and MSH2. A 
Finnish group estimated the frequency of LS, based on 535 consecutive CRC 
patients tested for MLH1 and MSH2 germline mutations, to be 3.4% 
(Salovaara et al 2000). The current trend in similar studies conducted in 
China (Wang et al 2007), the Baltic States (Irmejs et al 2007) and USA 
(Samowitz et al 2001) is to use less strict criteria when selecting patients for 
molecular analysis, as mutations have been found in cases of suspected LS 
where the proband did not meet the Amsterdam criteria (Aaltonen et al 1998; 
Ravnik-Glavik et al 2000; Tanyi 2009). 
 
Thus discordant results are not only likely to reflect population differences, but 
additionally the varied methodologies used to extrapolate the frequency of LS 
among CRC cases (Irmejs et al 2007; Samowitz et al 2001). While studies 
are currently indicating lower incidences of LS than previously thought, it 
remains clear that the Amsterdam criteria are stringent and the rigid 
application thereof, as it is used to define suspected cases of LS, may lead to 
many missed classifications of CRC as LS-related. A similar proclamation can 
be made for figures derived from studies utilising screening analysis to 
diagnose LS, as only two of the known five causative genes predisposing to 
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Taking this into consideration, it is possible that future research studies may 
point to LS contributing to a greater proportion of all CRC malignancies.  
 
Table 3 lists all the published incidence figures for LS. The incidence 
percentage is given in accordance with the methodology used, either defined 
by an entry under ‗Amsterdam criteria or mutational analysis‘, or two entries if 
both methods were used to ascertain the reported frequency of LS. The 
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  ASIA    
China 1988 5.7% 1.3% 
Prospective; consecutive patients from a single institution; four year 
recruitment 
Wang et al 2007 
  EUROPE    
Denmark 1200 1.5% 1.7% 
Prospective; multicentre study on consecutive CRC patients; four year 
recruitment 
Katballe et al 2002 
England 1137 0.3%  
Retrospective and prospective; review of all CRC cases from one 
institution; recruited over 14 years 
Evans et al 1997 
Finland 509  2% Prospective; consecutive patients from nine hospitals; two year study Aaltonen et al 1998 
Finland 535  3.4% 
Retrospective and prospective multicentre of all recruited CRC patients; 
collection phase of two years 
Salovaara et al 
2000 
Finland 406 0.7%  
Prospective; multicentre study of CRC patients; one year recruitment 
phase 
Mecklin et al 1995 
Hungary 809 6% 1.7% 
Retrospective and prospective; single institution recruitment of patients; 
collection phase spanning nine years 
Tanyi 2009 
Ireland 1241 1-2.6%  Retrospective; review of CRC cases over three year study period 
Kee and Collins 
1991 
Italy 485 1%  
Prospective; multicentre study on consecutive CRC patients (collection 
period not indicated) 
Riegler et al 1999 
Italy 817 3.4%  Retrospective;  review of cancer registry over six year period 
Ponz de Leon et al 
1993 
Italy 197 0.5%  Retrospective; review of cancer registry (collection period not indicated) 
Cornaggia et al 
2000 
Italy 1721 2.6%  Retrospective; review of cancer registry over 12 years 
Ponz de Leon et al 
1999 
Italy 389 4.3%  Retrospective; review of two cancer  registries over three years Modica et al 1995 
Italy 213 0.46%  Retrospective; review of two cancer  registries over three years Modica et al 1995 
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  Europe    
Latvia 702 0.14% 1% 
Prospective; multicentre study on consecutive patients; recruitment 
over four years 
Irmejs et al 2007 
Poland 170 2.4%  
Prospective; CRC surgical patients seen in a single centre; recruited 
over three years 
Jawien and 
Banaszkiewicz 1998 
Slovenia 300  1% Prospective; multicentre study conducted over a two year period 
Ravnik-Glavac et al 
2000 
  Australia    
Australia/ 
North America 8369 9.5%  Prospective; CRC Registry of six centres over 10 year period 
Newcomb et al 2007 
Australia 786  0.8% 
Prospective; CRC patients from one institution (collection period not 
indicated) 
Ward et al 2005 
  North America    
Israel/New York 686  0.69% 
Retrospective; multicentre collaborative study of Ashkenazi Jews 
(screening for a common founder mutation only in MSH2- collection 
period not indicated) 
Foulkes et al 2002 
USA 1134 0.9%  Prospective; Multicentre study over three year period Peel et al 2000 
USA 257  1.9% 
Prospective; Unselected patients referred for CRC resection over one 
and a half year period 
Cunningham et al 
2001 
USA 1066  0.86% Retrospective; multicentre study over three year period Samowitz et al 2001 
USA 1066  2.2% Retrospective; CRC patients recruited over 15 years Hampel et al 2005a 
USA 1566  2.8% 
Prospective; CRC patients from six institutions seen over a five year 
period 
Hampel et al 2008 
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2.7.1 FOUNDER MUTATIONS  
Mutations that occur at high frequencies within a specific population group 
may be de nova or ancestral (founder effect) in nature. The two can be 
relatively easily distinguished from one another through haplotype analysis. 
Founder mutations occur on the same haplotype while recurrent de nova 
mutations do not. A founder mutation results in an unusually high frequency 
of a particular allele or haplotype in a population, implying that all the 
individuals with the sequence descended from the same ancestors 
(Turnpenny et al 2005). Typically, founder effects occur following rapidly 
growing populations from a small number of founders, with or without the 
influence of influx of people from different origins (Lynch and de la Chapelle 
1999). Another mechanism for this effect is through the expansion of 
populations following a bottleneck (reducing the population to a smaller 
number), whereby the mutation becomes more prevalent in a larger 
proportion of the population, namely, through gene enrichment (Read and 
Donnai 2009).  
 
Founder mutations have generated considerable interest in molecular genetic 
studies as screening in a population known to have a founder mutation, can 
facilitate targeted testing to the mutation, allowing for a more rapid and less 
expensive test (Lynch et al 2009; Neuhausen 2000; Zeegers et al 2004). 
Reports on founder mutations predisposing to cancer have only recently 
emerged. The best-known recurrent mutation predisposing to LS is the A to T 
transversion in intron 5 of MSH2. The mutation accounts for up to 10% of all 
cases of LS and has been reported worldwide (Desai et al 2000; Froggat et al 
1999; Hampel 2005a; Liu et al 1994). 
 
Moisio et al (1996) identified the ‗Finland 1‘ mutation which involves a deletion 
of exon 16 on MLH1. The mutation was identified in 40 unrelated families in 
Sweden and Finland. Genealogical evidence has shown that the majority of 
affected individuals with the mutation were descendants of a common founder 
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thousand years (Moisio et al 1996; Nyström-Lahti et al 1994). Interestingly, 
the founder mutation was identified in over two thirds of LS diagnoses in a 
Finnish study determining incidence among 509 consecutive CRC patients 
(Aaltonen et al 1998; Mecklin et al 1995; Nyström-Lahti et al 1994). 
In a more recent study, Foulkes et al (2002) reported on a founder mutation in 
MSH2 to be highly enriched in their study of 15 families of Ashkenazi Jewish 
descent. The genetic change, a substitution of proline for alanine, accounts 
for approximately 20% of LS cases among the diaspora of Ashkenazi Jews 
from Europe. The estimated age of the mutation is in the range of 200-500 
years.  
In SA, a common, A to T transversion in exon 13 of MLH1, has been
described (Ramesar et al 2000). The mutation has only been observed in 
families of Mixed Ancestry in SA and has not been reported in any other
populations as verified by the human genome mutation database (HGMD
2008). Research, involving haplotype analysis, has confirmed that this
mutation spread along the west coast of SA as a result of a founder effect
(Savanhu et al 2005). Founder mutations have additionally been described for
the Northern American (Wagner et al 2003), Italian (Caluseriu et al 2004;
Lastella et al 2011; Stella et al 2007; Thiffault et al 2004) and Chinese
populations (Chan et al 2004). 
2.8  CANCER SPECTRUM AND SURVEILLANCE 
Surveillance in LS is largely influenced by the efficacy of a particular 
prevention strategy and the estimates of cancer risk associated with LS. As 
recommendations are principally based on studies that are retrospective in 
nature, considerable weighting to such recommendations has been 
recommended by panels of experts (Vasen et al 2007). For screening to be 
routinely offered and recommended, the following should be taken into 
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be treatable if detected early; (3) the outcome should be serious if the tumour 
is advanced, while being treatable if detected early; (4) accurate detection 
methods for pre-malignant tumours should exist (Lambert 1983). 
 
2.8.1 COLORECTAL CANCER 
CRC is the most common tumour type occurring in individuals with mutations 
in MMR genes, accounting for between 53-94% and 63-96% lifetime CRC risk 
with MLH1 and MSH2 mutations respectively (Aarnio et al 1999; Barrow et al 
2008; Lin et al 1998; Stupart et al 2009a; Voskuil et al 1997). MSH6 mutation 
carriers present with a lower incidence of CRC and a later age of onset 
(Plaschke et al 2004). Several studies have suggested higher CRC risk in 
males as compared to females (Dunlop et al 1997; Hendriks et al 2004). For 
both genders, CRC risk is much higher than the risk in the general population 
and warrants the same intensive screening in females as in males (Watson 
and Lynch 2001).  
 
Full colonoscopy is mandatory in MMR gene mutation carriers as tumour 
distribution is predominantly right-sided (Järvinen et al 2000; Stupart et al 
2009a). Regular surveillance is recommended as the adenoma-carcinoma 
sequence is accelerated in individuals with LS (Natarajan et al 2010; 
Stormorken et al 2007; de Jong et al 2004). The precursor lesion, adenoma, 
may develop i to a carcinoma within two to three years as opposed to eight to 
ten years in sporadic CRC (Jass and Stewart 1992; Lynch and de la Chapelle 
1999). Current guidelines propose surveillance of the colon to be initiated at 
the age of 20-25 years, or ten years prior to the onset in the youngest 
affected family member, and should be repeated every one to three years 
(Vasen et al 1991; Vasen et al 1999).The longer interval (two yearly) during 
the first decade of screening relates to the low risk of CRC before the age of 
30 years (Barrow et al 2009; Hampel et al 2005a; Hendriks et al 2004; 
Plashchke et al 2004; Quehenberger et al 2005). Guidelines relating to the 
upper age limit of screening are scarce within the literature. De Jong et al 
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cohort of mutation carriers, was low relative to their life expectancy. In SA, 
screening is recommended every two years until 30 years of age and 
annually thereafter (Goldberg et al 1998). Currently, international studies are 
following this trend and advocating more intensive surveillance (Engel et al 
2010; Vasen et al 2010).  
 
A clinical trial extending over 15 years evaluated the efficacy of regular 
colonoscopic surveillance in families with LS (Järvinen et al 1995). The study 
established that screening for CRC, on a three yearly basis, halved the risk of 
CRC and decreased mortality by 65% in such families. In a later study by the 
same Finnish group, surveillance outcomes of 56 families were assessed.  
Twenty-one cancers were identified following a ‗clean colonoscopy‘, with half 
of the cancers presenting within the three year interval period (Järvinen et al 
2000). Optimal screening currently lies between one and two years and is 
largely dependant on the centre offering surveillance.  
 
The risk of a second colonic tumour has been reported to be as high as 16% 
in an individual with LS (de Vos tot Nederveen Cappel et al 2002). Preferred 
treatment is thus to offer a subtotal colectomy with ilieorectal anastomosis as 
the primary surgical intervention and not segmental resection (Natarajan et al 
2010; Stupart et al 2010; Vasen et al 2007; Vasen and de Vos tot Nederveen 
Cappel 2011). Unfortunately, due to the small risk of a rectal carcinoma, 
lifelong endoscopic surveillance of the rectum is still recommended following 
surgical removal of the large bowel (Nataranjan et al 2010; Stupart et al 
2010). The debate of whether or not prophylactic subtotal colectomy should 
routinely be considered is ongoing. Surprisingly, a Finnish study evaluating 
surveillance outcome among 242 mutation-positive individuals identified that 
only 1.2% of their participants, had opted for prophylactic colectomy over the 
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2.8.2 ENDOMETRIAL CANCER  
The cumulative lifetime risk for women with LS ranges from 19-71% as 
opposed to 3% in the general population (Aarnio et al 1995; Dunlop et al 
1997; Hendriks et al 2004; Lin et al 1998, Vasen et al 2007). Interestingly, the 
lifetime risk of endometrial cancer often exceeds the CRC risk for women 
predisposed to LS (Hampel et al 2005b). Risks conferred by MLH1 and MSH2 
are lower than MSH6 mutation carriers. In a recent study by Barrow and co-
workers (2009), 121 LS families were assessed for the cumulative lifetime risk 
of endometrial cancer. Their study demonstrated a significant risk for all three 
gene mutations, specifically MSH6 which predisposed to a 48.8% lifetime risk 
at age 70 years. Hendriks et al (2004) also found that women with an MSH6 
mutation have a more than two-fold greater risk of endometrial cancer when 
compared to their MLH1 and MSH2 counterparts. In an earlier study by 
Goodfellow et al (2003) the prevalence of MSH6 mutations in an unselected 
endometrial cancer cohort, showed that seven of 441 endometrial cancers 
were as a result of an MSH6 mutation. They suggested that mutations in 
MSH6 were relatively common in endometrial cancer patients. 
 
The average age of onset of an endometrial cancer in LS is approximately 50 
years, ten years earlier than that of a sporadic endometrial cancer (Aarnio et 
al 1999; Dunlop et al 1997). Regular surveillance of the endometrium is not 
currently performed in the general population due to the low prevalence of the 
disease. As a result information on the sensitivity and specificity of this 
screening is limited.  
 
Screening modalities that have been suggested for women with LS include 
transvaginal ultrasound (TVU) and intrauterine biopsies of the endometrium. 
A collaborative study involving British and Dutch investigators evaluated the 
outcome of transvaginal surveillance in 269 women from suspected LS 
families. Ultrasound was performed on a one- to two-yearly basis. No 
premalignant lesions or endometrial cancers were detected. Unfortunately, 










                                                                                                                                                                  CHAPTER TWO: LITERATURE REVIEW                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
37 
 
suggesting this method may not effectively detect early endometrial 
carcinoma (Dove-Edwin et al 2002). Renkonen-Sinisalo et al (2007) assessed 
gynaecological surveillance consisting of TVU and intrauterine biopsies of the 
endometrium in 175 women with LS. Remarkably, of the 14 endometrial 
cancers that were diagnosed, 11 were detected as a result of surveillance. 
Furthermore, if aspiration biopsy had not been introduced in addition to TVU, 
six of the 11 identified cancers would have escaped detection. Although 
evidence relating to the effectiveness of endometrial surveillance is limited, 
TVU and endometrial sampling is recommended from the age of 30-35 years.  
 
As a result of the high risk of endometrial cancers, specifically in MSH6 
mutation carriers, hysterectomy may be suggested as a prophylactic option 
following menopause. It has also been considered as an option for carriers of 
MLH1 and MSH2 mutations requiring surgery for CRC (Vasen et al 2007).  
 
2.8.3 OVARIAN CANCER 
Data on ovarian surveillance is meagre as most research studies have 
focused on the endometrial component when determining gynaecological 
surveillance. However, screening has not been effective in Hereditary Breast 
and Ovarian Cancer (HBOC) families, which confer high risks for inherited 
ovarian cancer (Van der Velde 2009). Screening for ovarian cancer in LS is, 
therefore, not a recommended guideline. Furthermore in the study by 
Renkonen-Sinisalo et al (2007), four ovarian cancers were undetected by 
TVU.  
 
It has been suggested that women requiring CRC surgery should be given the 
option of a prophylactic hysterectomy. However, bilateral salpingo-
oophorectomy could also be considered to eliminate the ovarian cancer risk. 
Two studies have confirmed the efficacy of prophylactic surgery. Schmeler et 
al (2006) assessed the outcome of 315 women with LS over a ten-year 
period. Individuals were grouped into two categories, control group (patients 
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(hysterectomy and bilateral salpingo-oophorectomy). Endometrial cancer was 
identified in 33% and ovarian cancer in 5% of the control group, whereas no 
gynaecological cancers were found in the group who had prophylactic 
surgery. These findings were later substantiated by Chen et al (2007), who 
confirmed the efficacy in their study.  
 
2.8.4 BREAST CANCER  
The general population‘s risk of developing breast cancer is high with a 1 in 
10 lifetime risk (Lalloo et al 2005). In SA, breast cancer follows similar 
statistics to western countries and is the most common cancer to affect 
women (Sitas et al 1998; Vorobiof et al 2001). The inclusio  of breast cancer 
into the LS spectrum remains controversial. Many authors report a low risk of 
breast cancer (Aarnio et al 1999; Dunlop et al 1997; Parc et al 2003; Vasen et 
al 2001; Watson et al 2008). Geary and co-workers (2008) identified 37 cases 
of breast cancer in their study involving 723 patients with LS. Their results 
showed that the calculated breast cancer risk was only slightly elevated and 
did not suggest a clustering in families or a younger age at diagnosis. Barrow 
et al (2009) reported MLH1 mutation carriers to have double the population 
risk, while the risk in MSH2 carriers was low.  
 
Few studies have confirmed the involvement of the defective MMR gene 
when considering the breast cancer risk in LS. Blokhuis et al (2008) 
incorporated IHC and MSI testing on breast tumours identified in their study 
sample of LS patients in SA. The involvement of the MLH1 gene was 
identified in five of the seven cases that were tested. The seven cases 
occurred at a young age (mean of 46.3 years) and two were bilateral. Two 
smaller studies (Risinger et al 1996; Westenend et al 2005) and a more 
recent study (Walsh et al 2010) have also provided evidence of the 
involvement of MMR genes and motivate for breast cancer to be recognised 
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Watson et al (2008) argue against screening above the population-based
protocols for breast cancer in individuals with LS. This argument has also
been supported by Barrow et al (2009). In contrast, Blokhuis et al (2008) 
encouraged regular breast cancer surveillance in individuals with the common
SA MLH1 C1528T mutation. The incidence of breast cancer in their study, 
while not reaching statistical significance, did illustrate MLH1 involvement in
breast tumour development, accounted for the majority of extracolonic 
cancers (53%) and illustrated features of genetic predisposition (young age of 
onset and bilateral cases). The only other study conducted on this aspect in
SA discouraged routine gynaecological surveillance (Stupart et al 2009a). 
While the authors also identified breast cancer to be the most common of the
extracolonic malignancies in their cohort of 200 MLH1 mutation-positive
individuals with the same MLH1 mutation, only 6% of females in their cohort
developed breast cancer. They therefore support current policies of not
offering routine gynaecological screening or prophylactic surgery to females
with the common SA mutation.
2.8.5 GASTRIC CANCER 
Gastric cancer is the second most frequent extracolonic cancer observed in
individuals with LS (Vasen et al 1990). The majority of gastric cancers within 
the general population occur over the age of 55 years. Geary et al (2008) 
demonstrated that 79% of putatative mutation carriers with gastric cancer
were diagnosed below the age of 55 years. There is a remarkable variability 
of the lifetime gastric cancer risk in individuals within different population
groups. The associated lifetime risk of gastric cancer in the Netherlands is 
2.1% (Vasen et al 2001b), 11-13% in the Finnish population (Aarnio et al
1997; Aarnio et al 1999) and has been predicted to approach 30% within the
Korean population (Park et al 2000). Contrary to previous reports, gastric 
cancer seems to be more frequent than endometrial cancer in the Chinese
population (Cai et al 2003). Environmental factors, such as the prevalence of 
Helicobacter pylori infection are likely to accelerate the development of gastric 
cancer in individuals with MMR mutations, accounting for the higher risk
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suggestion that the gastric cancer risk is higher in carriers of an MSH2 
mutation when compared to MLH1 (Aarnio et al 1999; Geary et al 2008; Lin et 
al 1998).  
 
Surveillance for gastric cancer is questionable and evidence for regular 
screening in all at-risk individuals is insufficient to justify such an approach 
(Koornstra et al 2009). Upper gastrointestinal endoscopy may be 
recommended if more than one family member has developed gastric cancer 
or in countries with a high prevalence of gastric cancer (Park et al 2000; 
Vasen et al 2007). 
 
2.8.6 SMALL BOWEL CANCER 
The lifetime risk of small bowel cancer (SBC) has been reported to range 
from 1% to 4.2%, which is 100 times greater than the general population‘s 
risk for SBC (Aarnio et al 1995; ten Kate et al 2007; Vasen et al 1996; Watson 
et al 2008). Furthermore, Schulmann et al (2005) proclaim that SBC may be 
the first tumour manifestation in 50% of patients with suspected LS.  
 
One of the initial studies on the characteristics of SBC, by Rodriguez-Bigas et 
al (1998), reported SBC in 42 individuals from LS families. The majority were 
classified as LS as a result of fulfilling the Amsterdam criteria and 15 of the 42 
patients had a MMR mutation. Their study was based on mailed 
questionnaires to the ICG-HNPCC, sourcing information from registries in 
Australia, Canada, Denmark, Finland, Israel, Italy, Portugal, Netherlands and 
the USA. Forty-nine cases of SBC were identified in the 42 patients (more 
than one cancer occurred in some of the recruited patients). The median age 
of diagnosis was 49 years, almost 20 years younger than that of the general 
population. The findings from three other large-scale studies, using a similar 
questionnaire methodology, reported consistent findings of clinical features. 
Notably, Park et al (2006) and ten Kate et al (2007) selected their patient 
population to include individuals with MMR mutations only (Park et al 2006; 
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There has been no indication that a significant difference in the lifetime risk of 
SBC between MLH1 and MSH2 mutation carriers exists (ten Kate et al 2007; 
Rodriguez-Bigas et al 1998; Vasen et al 1996). Conversely data does suggest 
that males are at a higher risk than females, with a male to female ratio as 
high as 3:1 (Rodriguez-Bigas et al 1998; Schulmann et al 2005). Most 
adenocarcinomas demonstrate a compatible MMR phenotype, showing high-
MSI at the molecular level (Koornstra et al 2009; Schulmann et al 2005). 
Similar to CRC in LS patients, SBC has been shown to occur at a younger 
age of onset, exhibit metachronous carcinomas and appears to have a better 
prognosis than patients with SBC in the general population (Rodriguez-Bigas 
et al 1998). 
 
As visualisation of the small bowel remains difficult, surveillance guidelines do 
not appear within the scope of management for LS families. New visual 
techniques such as video capsule endoscopy (VCE) and double balloon 
endoscopy (DBE) improve the accessibility of the small bowel, however 
neither of these techniques provide the ideal solution. DBE remains too 
burdensome, time consuming and invasive for periodic screening while VCE, 
although less invasive, is limited by the inability to obtain tissue for 
histopathology.  
 
In a recent paper by the German HNPCC consortium, the group proposed 
screening for SBC by gastroduodenoscopy as they demonstrated that SBC 
developed predominantly in the duodenum of their participants (Schulmann et 
al 2005). Ten Kate et al (2007) identified nearly half of their cases of SBC in 
the duodenum, also reporting a decreasing gradient from duodenum to the 
ileum in their Dutch population. The additional benefit of the 
gastroduodenoscopy is that it facilitates duel screening for gastric cancer and 
SBC. Schulmann et al (2008) argue strongly for this method to be used as a 
screening tool until the cost-effectiveness of different methods such as VCE 
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2.8.7 PANCREATIC AND BILIARY CANCER 
The significance of pancreatic carcinoma in LS remained enigmatic until 
Lynch et al (1985b) reported an association within the LS phenotype. In a 
larger study by Mecklin et al (1992), 18 patients with biliopancreatic cancer 
from suspected LS families were studied. Histological information was 
available on 14 patients. In 11, a biliary tract carcinoma was reported, in three 
a pancreatic carcinoma. A biliary tract carcinoma was suspected in the four 
patients without histological analysis. The study concluded that patients with 
suspected LS were at a greater risk of developing biliary tract carcinomas 
than pancreatic carcinomas. A recent report by Geary et al (2008) 
ascertained the pancreatic cancer risk in 723 individuals with a proven MMR 
mutation. Twenty-two cases of pancreatic cancer were identified, the majority 
in MLH1 and MSH2 gene mutation carriers (12 in MLH1, nine in MSH2 and 
one in MSH6). They identified a seven-fold increased risk for pancreatic 
cancer in individuals with LS as compared to the general population. Seventy 
percent of cases were under the age of 60 years and evidence of family 
clustering was noted. This has also previously been described by Lynch et al 
(1991), but biliary tract carcinoma within their cohort was rare.  
 
The incidence of biliary tract carcinoma and pancreatic carcinoma within the 
LS spectrum remains low at 2% and 0.4% respectively (Aarnio et al 1999; 
Barrow et al 2009). No surveillance approaches have been successful in 
detecting pancreatic cancer at an early stage (Lynch et al 2008). The general 
census on screening is thus currently to discourage it as methods remain 
inefficient for routine examinations (Aarnio et al 1999; Lynch et al 2008). In 
addition, surveillance for biliary tract carcinoma is not recommended 
(Koornstra et al 2009). Notwithstanding, this has been appealed by Barrow et 
al (2009) who suggest that annual transabdominal hepatobiliary ultrasound 
and liver function tests should be performed from the age of 30 years, in 
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2.8.8 URINARY TRACT CANCER 
The risk of urinary tract cancer (UTC) in individuals with LS, has been 
reported to have a lifetime risk of up to 12% (Dutch population), 10% (Finnish 
population), 8% (combination of Danish, Dutch, Finnish and USA) and 3.2% 
(North Western England) (Aarnio et al 1999; Barow et al 2009; Järvinen et al 
2009; Vasen et al 2001b; Watson et al 2008). While the bladder is the most 
common UTC in the general population, the renal pelvis and ureter are 
affected more frequently in LS (Crockett et al 2011; Lynch et al 2008). A large 
study conducted by Watson et al (2008) pooled data from four cancer 
registries to assess incidence estimates of Lynch-related cancers. A total of 
6041 high-risk individuals of families with known MLH1 or MSH2 mutations 
were included in the study. The UTC risk in Watson‘s cohort was comparable 
to the Dutch and Finnish populations (Aarnio et al 1999; Vasen et al 2001b), 
while it was found to be markedly higher than that of the English families 
(Barrow et al 2008). It could be suggested that this difference in incidence 
may relate to the paucity of MSH2 mutation carriers in the English study as 
Watson and colleagues described MSH2 mutation carriers to have a greater 
risk when compared to MLH1. The highest risk for UTC is found between the 
ages of 50 to 70 years with males having a slightly higher risk than females 
for developing a UTC (Watson et al 2008; Van der Post et al 2010).  
 
There is a suggestion that surveillance for early detection and prevention of 
UTC should be considered, especially among carriers of MSH2 mutations. 
Screening can be performed with ultrasound, cystoscopy, urine cytology and 
urinalysis (Barrow et al 2009; Koornstra et al 2009; Watson et al 2008). 
Vasen et al (2001b) recommend urinalysis with cytology and abdominal 
ultrasound, beginning at 30 to 35 years and on an annual to two-yearly basis. 
These authors limit screening to families with a history of UTC. Watson et al 
(2008) propose later surveillance, starting at 50 years, and suggest screening 
should be directed at MSH2 mutation carriers, and should not be limited to 
individuals with a family history of UTC. Koornstra et al (2009) recommend 
annual screening for haematuria by urine dipstick with cytoscopy and 
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years and if a family history of UTC exists, surveillance is recommended five 
years prior to the earliest age of diagnosis within the family. 
2.8.9 BRAIN CANCER 
Brain tumours have been included in the spectrum of LS-related cancers
(Aarnio et al 1999; Bermejo et al 2005; Lin et al 1998; Parc et al 2003; Vasen
et al 2001b). Of all the cancers studied by Watson and colleagues (2008), 
brain tumours ranked the lowest, with a lifetime risk to the age of 70 years of 
2%. As with the majority of extracolonic cancers, MSH2 carriers are at a
higher risk than MLH1 carriers. This is clearly seen in the incidence figures
reported by Barrow et al (2009), 0.6% risk of a brain tumour for MLH1 carriers 
and a 6.3% risk in MSH2 carriers. The median age of diagnosis of brain
cancer is lower in individuals with LS than the general population with 26% of 
diagnoses occurring before the age of 25 years (Koornstra et al 2009; Watson
et al 2008). The most common tumour type in LS is glioblastoma multiforme
and astrocytoma (Koornstra et al 2009). Sarcomas are rarely described as 
part of the LS phenotype. However Geary et al (2008) report an eight-fold
increased risk over the general population. Turcot syndrome, a variant of LS,
describes the concurrence of colorectal adenomas and tumours of the central
nervous system (Lallo et al 2005).
To date, no studies have recommended surveillance for brain tumours in LS. 
Given the absence of surveillance and low risk for developing this specific LS-
related tumour, screening is not recommended (Koornstra et al 2009).
2.8.10 SKIN CANCER 
Skin tumours have been described in LS. However, when characteristic skin 
lesions including sebaceous adenomas, epitheliomas and carcinomas occur 
with a visceral malignant disease, Muir-Torre syndrome (MTS) is suspected 
(Dores et al 2008; Ponti and Ponz de Leon 2005; Lalloo et al 2005). In 1981, 
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this argument by their description of MTS in a descendant of Warthin‘s family 
G (Lynch et al 1985a). Since then it has been postulated that the reverse of 
this may also be true as some cases of MTS may represent LS (Lynch et al 
1981; Lynch et al 1985a; Ponti and Ponz de Leon 2005). Although MTS is 
predominantly associated with mutations in MSH2, mutations in MLH1 and 
MSH6 have been reported as a cause of MTS (Ponti and Ponz de Leon 2005; 
South et al 2008).  
Surveillance for skin cancer in LS has not been recommended. Nevertheless,
dermatological surveillance in MTS families is reasonable and early medical 
attention should be sought for skin abnormalities (Koornstra et al 2009). Ponti 
and Ponz de Leon (2005) support yearly dermatological examinations with
wide local excision for the treatment of any skin carcinoma.
Table 4A and 4B compare data on published lifetime-related risks for CRC 
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 †Calculated on individuals who declined to undergo surveillance. 
CUM-Cumulative lifetime risk (%).  
CRC-Colorectal cancer. 






















































































































   M F  M F         
Denmark/Finland/ 
Netherlands/USA  
(Watson et al 2008) 
MLH1 
       6.1  2.4 6.3 1.7   
England  
(Barrow et al 2009) 
MLH1    38.5 29.7 44.8 29.2 10.9 3 2.8 5.5 0.3 4.5 0 
France  
(Parc et al 2003) 
MLH1       43        
Netherlands 
(Ramsoekh et al 2009) 
MLH1 
71      25        
South Africa  
(Stupart et al 2009a) 
MLH1 
92†              
USA  
(Lin et al 1998) 
MLH1    11 5 19 19        
Denmark/Finland/ 
Netherlands/USA  
(Watson et al 2008) 
MSH2 
       5.2  19.8 11.6 2.5   
England  
(Barrow et al 2009) 
MSH2    35.5 23.8 47.8 24.4 7.8 0.4 4.1 7.5 6.3 1.3 0.7 
France  
(Parc et al 2003) 
MSH2       60.5        
Israel 
(Mukherjee et al 2011) 
MSH2  61.6 61.1    55.6        
Netherlands 
(Ramsoekh et al 2009) 
MSH2 77      49        
USA  
(Lin et al 1998) 
MSH2 
    48 34 69 36        
Australia 
(Jenkins et al 2006) 
Combined 
 45 38  67 72       
  
Finland  
(Aarnio et al 1995) 
Combined 
      43 19 18 10 9  
  
Finland  
(Aarnio et al 1999) 
Combined 
82 100 54    60 13 2 4 12 3.7 
  













































































































































   M F  M F         
Finland  
(Hampel et al 2005b) 
Combined 
68.7 52.2     54    13.5  
  
France 
(Parc et al 2003) 
Combined 
 89 78.5          
  
France 
Bonadona et al 2011) 
Combined 
35      34 0.7 0.6 1.9 8  0.6 
 
Germany  
(Plashchke et al (2004) 
Combined 
   37         
  
Holland  
(Vasen et al 1996) 
Combined 
80 92 83    51.5      
  
Netherlands 
(Van der Post et al 2010) 
Combined 
 70.1 56.6    35.4   7.5   
  
Netherlands  
(Voskuil et al 1997) 
Combined 
40.5 46 36          
  
Netherlands (Quehenberger et 
al 2005) 
Combined 
 26.7 22.4  16 13 31.5      
  
Scotland  
(Dunlop et al 1997) 
Combined 
    74 30 42      
  
Australia 
(Talseth-Palmer et al 2010) 
MSH6 
61      65      
  
England  
(Barrow et al 2009) 
MSH6    43.1 28.4 53.9 48.8 10.4       
Holland  
(Hendriks et al 2004) 
MSH6    33   71        
Netherlands 
(Ramsoekh et al 2009) 
MSH6 75      61        
Sweden  
(Cederquist et al 2005) 
MSH6  68.8 59.1    70.2    32.8    
USA/Canada/Australia/New 
Zealand/Netherlands/Scotland 
(Baglietto et al 2010) 
MSH6 
 22 10  24 40 26        
CUM-Cumulative lifetime risk (%) 
CRC-Colorectal cancer. 
Combined-combination of MLH1/MSH2/MSH6/PMS2. 
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2.9  LYNCH SYNDROME – THE SOUTH AFRICAN CASE 
The first documentation in SA reporting on a hereditary cancer resembling LS 
was described in 1985 (Goldblatt et al 1990). The family, NPC 1, was 
identified by a general practitioner (GP) working in a remote community near 
the Namibian border. The observation of a family history associated with a 
familial susceptibility to early-onset CRC was later recognised by a clinical 
geneticist collaborating with the GP to be typical of LS (Goldblatt et al 1990). 
The diagnosis of LS was made in 16 men on the basis of clinical, surgical and 
pathological data obtained from hospital records and anecdotal information 
from family members. None of the affected family members had extracolonic 
malignancies and the family was classified as type one LS. The age of 
affected family members ranged from 19 years to 68 years, with the reason 
for the male predominance unknown. As many of the males of this family 
worked within a secure diamond-mining village, it is suspected that news of 
the family, particularly of their sisters‘ health, was largely undisclosed, 
accounting in part, for the dearth of reported female cancer. A review of this 
family a decade later described 17 affected males and the identification of two 
affected females with CRC (Ramesar et al 2000).  
 
The NPC 1 family were from the tiny village of Kommagas and of Mixed 
Ancestry descent. Many of the individuals from this family still reside within 
remote communities along the West Coast of SA including: Kleinsee, 
Kommagas, Nababeep, O‘Kiep, Steinkopf, Springbok, Hondeklipbaai, 
Liliefontein, Nourivier and Port Nolloth (Figure A). To date the pedigree 
consists of 545 known members spanning five generations. Males and 
females are affected with CRC and extracolonic cancers have been recorded, 
albeit this being classified as a LS I family.  
 
2.9.1 MANAGEMENT OF LYNCH SYNDROME IN SOUTH AFRICA 
Colonoscopic surveillance services are restricted to established centres in 
tertiary hospitals in SA. As many individuals of the NPC 1 family lived more 
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service was instituted in 1988 offering endoscopic surveillance to all blood 
relatives of affected individuals from the family. Initially screening was only 
offered in one centre, a small mining town hospital in Kleinsee to which the 
family travelled. Later, with the growing burden of disease, the service 
expanded to include four centres along the West Coast of SA. Following the 
yearly screening programme, family members were recruited and offered the 
opportunity of becoming involved in research to determine the genetic cause 
of their familial cancer. Initially the mobile outreach service was limited to 
screening only, but later developed to create a platform for recruitment into 
research which led to the identification of the causative mutation in 1995 
(Ramesar et al 2000). As the genetic basis of LS was known for NPC 1, a 
C1528T alteration resulting in a premature stop codon, producing an 
ineffective peptide within the MLH1 gene (Ramesar et al 2000), molecular 
genetic testing became possible for at–risk relatives. A predictive testing (PT) 
programme, based on the British protocol, was established in 1997/1998 
(Appendix 1). NPC 1 was the first family to enter the PT and colonoscopic 
surveillance outreach programme. To date, 230 individuals have been found 
to carry the C1528T mutation.  
 
The outreach endoscopic service is conducted annually to enable 
surveillance according to recommended screening guidelines. Consistent with 
the current SA policy, PT is only offered once the at-risk individual reaches 
the age of 18 years, with colonoscopic surveillance done earlier if symptoms 
are present.  
 
2.10  PREDICTIVE TESTING FOR LYNCH SYNDROME 
In LS, genetic testing starts with an affected individual. If a mutation is 
identified in a MMR gene, PT is offered to the individual‘s family members, as 
they are at-risk of carrying the mutation. A negative test result for a known 
mutation indicates that the individual is not at an increased cancer risk. 
However, if genetic testing does not identify a mutation in an affected 
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advised to adhere to high-risk surveillance recommendations. For these 
families, genetic testing does not help determine which relatives may or may 
not be at an increased risk for developing LS-related cancers (Prucka et al 
2008; de Wert 1998). 
PT aims to provide future health-related information to the unaffected
individual at a suspected high-risk of developing LS (Brain et al 2005; Evans
et al 2001). Ideally this information can lead to the timely identification and
knowledge of their mutation status enabling targeted screening to detect CRC 
at an early and potentially curable stage (Evans et al 2001; Järvinen et al
2000). The idea of PT and its possible implications, namely, to identify
individuals who are predisposed to a disease that has not yet developed, is a
difficult concept. Furthermore the uncertainty about whether or not the
condition will develop, when it will appear and how severely it will manifest 
itself adds to the complexity of PT (Aktan-Collan et al 2001; Chapman and
Burn 1999). There is thus a strong consensus that PT should be conducted
within a framework of genetic counselling as the process of considering,
arranging and interpreting such a test is not uncomplicated (Ensenauer et al
2005). 
2.10.1 PREDICTIVE TESTING AND COUNSELLING PROTOCOL
PT protocols were originally developed in the context of Huntington disease,
an incurable, usually late-onset, autosomal dominant neurodegenerative
disorder (Evers-Kiebooms et al 2000; Harper 1996). The PT protocol was
developed, not only to protect the test applicant, but also to assist healthcare
professionals in dealing with the difficulties that may arise from the application
of the genetic test, and, even more specifically, the test result. This extended
protocol was implemented to facilitate reflection around the consequences of 
genetic testing in light of a condition for which there is no cure or preventative
management. Numerous authors have highlighted that such extensive 
discussion and reflection may not be required by individuals contemplating PT 
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management is available (Aktan-Collan et al 2001; Bleiker et al 2003; Collins 
et al 2007; Esplen et al 2001; Lerman et al 1996; Meiser et al 2004). These 
studies give cognisance to the opinion that most individuals at a high risk for a 
cancer syndrome have been satisfied with a single pre-test genetic 
counselling session and that no long-term psychological distress has been 
reported by shortening the protocol. Moreover, when the psychological and 
decision-making outcomes were compared between 26 individuals attending 
either a shortened (single pre-test counselling session and test results 
delivered at second session two weeks later) or extended counselling 
protocol (two sessions prior to receiving test results six weeks later) for LS, no 
evidence of harm was identified (Brain et al 2005). The authors however, did 
suggest that in light of a shortened protocol, participants would benefit from 
having information on what to expect, suggesting that a preparatory leaflet or 
telephone call outlining the session could be provided. The shortened 
protocol of only one pre-test session is offered in SA.  
 
2.10.2 PRE-TEST COUNSELLING 
The pre-test counselling session provides the client with extensive information 
on LS and the process of PT. The inheritance and clinical features of the 
condition are discussed together with information on cancer surveillance. A 
well-recognised barrier to the transmission of information is the emotional 
state of the individual (Peters and Biesecker et al 1997) and, therefore, the 
psychological meaning of the disease and the potential impact of the test 
result are extensively explored. The aim of the pre-test session is to aid 
individuals in developing a sense of how they will cope with a favourable or 
unfavourable result (de Wert 1998; Ensenauer et al 2005; Peters and 
Biesecker 1997). It has been suggested that clients have an expectation of 
their test result attributing to preconceived notions, which in turn may 
influence their reactions when the test result is delivered (Evers-Kiebooms et 
al 2000; Prucka et al 2008; Trepanier et al 2004). Counselling is thus used to 
explore all the pros and cons of testing, motivations for testing and elucidates 
the counsellee‘s expectations, identifying and explaining any unrealistic views 
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2.10.3 RISK PERCEPTION 
Many clients enter into PT with a sense of confusion around genetic risk. This 
is understandable if one thinks about the various categories of probabilities: 
the chance of inheriting the pathogenic mutation, the chance of developing 
CRC if a mutation is found, the chance of developing other specific cancers, 
the chance that cancer may develop at a specific age and the chance that 
other family members (such as children) may inherit the predisposing gene 
(Peters and Biesecker 1997). Despite being able to review and explain these 
specific risk figures in counselling, risk perception is often based on more 
abstract factors such as the emotional and psychological aspects shaped by 
the client‘s experiences of cancer (Evers-Kiebooms et al 2000). Appreciating 
the psychosocial side can aid the counsellor in relaying information in a more 
understandable and sensitive manner to the client (Geller et al 1997; Prucka 
et al 2008). 
 
2.10.4 INFORMED CONSENT 
Once a decision is made for an individual to embark on the PT process, there 
is a mandate for informed consent to take place prior to any blood being 
drawn to safeguard an autonomous decision-making process (Prucka et al 
2008). Informed consent is largely defined by the notion that decisions are 
made in a collaborative manner, between the physician and the competent 
patient, whereby the patient provides authorisation for the procedure in a 
voluntary manner based on a substantial understanding of the information 
(Appelbaum et al 1987). The components of informed consent have been 
comprehensively reviewed by the American Society of Clinical Oncology 
(1996) and Geller et al (1997) and it is imperative that certain issues are 
discussed before and after genetic testing is offered. The aspects relating to 
the PT protocol and consent include:  
 
 A discussion of the genetic test. This includes information on the 
type of information that the test may be able to elicit, what it might not 
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management (American Society of Clinical Oncology 1996; Trepanier 
et al 2004). 
 Implications of the test result. A PT provides a positive or negative 
test result, indicating an increased or lowered cancer risk for the 
individual undergoing testing. The health-related risks associated with 
a positive test as well as the risks, even after a negative test result, 
must be elucidated (Trepanier et al 2004). It is imperative that the 
individual understands that the identification of a pathogenic mutation 
does not equate to having cancer nor is it a certainty that cancer will 
imminently develop (Geller et al 1997).  
 Options for risk management without testing. Should an individual 
not want to know his or her genetic status, intensive colonic 
surveillance, as recommended to a mutation-positive individual, should 
be encouraged. 
 Risk of passing on a mutation. Individuals who are identified as 
mutation-positive have a 50% risk of passing on the mutation to each 
of their offspring, while those individuals, without the mutation, do not 
pass on the risk. The offspring (of the individual declining testing) 
should also be made aware of their likelihood of a risk and their parent, 
informed that, should their child be tested and a mutation identified, by 
way of implication, their result (the parent) will be known. Testing of 
minors (individuals under the age of 18 years) is largely dissuaded as 
a result of the potential emotional and psychological harm that may 
result (American Society of Clinical Oncology 1996; Borry et al 2006). 
The appropriate age for PT is assessed on the age of expression of 
the disease. If medical benefits of testing are not apparent in 
childhood, testing is postponed until such an age when the child 
reaches adulthood and is able to make an informed decision for 
her/himself. In the context of LS, PT is usually only offered to 
individuals over the age of 18 years (Aronson 2009; American Society 
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 Technical aspects of the genetic test. This includes information on 
the detection rate, sensitivity and specificity of molecular genetic 
testing. 
 Costs involved. Currently patients seen in the Western and Northern 
Cape are not required to pay for genetic testing due to the research 
nature of the protocol. Apprehension around the implication that 
genetic test results may have on health insurance are thus far less of a 
concern as reimbursement for testing is not requested from medical 
aids/insurance coverage companies.  
 Risks of genetic discrimination. Should genetic testing limit 
coverage in obtaining life or health insurance, it is advised that the 
individual reviews policies prior to testing. Other legal and ethical 
complications may include the possibility of employment discrimination. 
The law governing the prohibition of discrimination of healthy 
individuals based on genetic test results is prohibited (Equal 
Employment Opportunity Commission 1995; National Information 
Resource on Ethics and Human Genetics 1983; Trepanier et al 2004) 
and may be beneficial to divulge during the discussion with the 
individual. 
 Risk of psychological distress. Participants should be informed of 
the potential adverse psychological reactions that may result such as 
anxiety, depression or family dysfunctioning. Dorval et al (2000) 
identified that failure to anticipate the reaction to the result has the 
potential to lead to an increased emotional distress. Even if an 
individual is not found to carry the mutation, aspects of psychological 
and emotional disruption such as regret for making major life 
decisions, prior to knowledge of the test result or even survivor‘s guilt, 
could transpire. Notably, guilt could also be experienced if there is a 
possibility of passing the mutation on to an offspring (American Society 
of Clinical Oncology 1996; Geller et al 1997). Additional elements that 
need to be addressed are the timing and readiness for testing, family 
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 Confidentiality. The individual should be informed of the effort made 
to maintain their confidentiality and to keep the genetic information 
secure. It is also important that the individual is aware of other persons 
with access to the information. For instance, other medical 
professionals involved in their management or the referring physician 
(Geller et al 1997; Trepanier et al 2004). A potential ethical dilemma 
may evolve in maintaining the confidentiality of a client when seen at 
the same clinic that a family member is attending, especially when 
communication about the result has purposefully been restricted within 
the family (Prucka et al 2008). 
 Medical surveillance and screening (options and limitations). 
Medical management following a positive test result can reduce the 
risk of developing CRC (Stupart et al 2009b; Järvinen et al 2000; de 
Jong et al 2004). Information on surveillance, optimal frequency of 
attendance and the limitations of the screening approaches should be 
provided. Recommendations for screening, even if the test result is 
negative, as per the general population requirements, must also be 
discussed. 
 Storage and reuse of genetic material. This is of particular relevance 
in the research setting where a portion of the individual‘s blood sample 
may be kept for possible re-analysis for the benefit of other family 
members or for research purposes (subject to the Research Ethics 
Committees protocol). 
 
The informed consent process attempts to empower the client, through the 
provision of extensive information, to facilitate a more thoroughly considered, 
educated and informed decision about genetic testing (Peters and Biesecker 
1997). The PT protocol (including the informed consent document) is based 
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 Autonomy - the principle of the right to choose whether or not to
proceed with testing. This requires sufficient information to be given to
the patient to allow for an informed independent decision;
 Beneficence and nonmaleficence - the principles of doing good and
not harm requiring the informed consent to disclose all benefits,
limitations as well as possible risks of the testing; and
 Justice and confidentiality - the assurance that the genetic
information will not be disclosed to third parties such as other family
members, insurance companies and employers (Beauchamp and
Childress 2001; de Wert 1998; Ensenauer et al 2005; President‘s
Commission 1983:6).
Implicit in the whole process is the right of the individual to decline testing at
any stage without affecting their or their family member‘s future medical
management (American Society of Clinical Oncology 1996; Ensenauer et al 
2005).
2.10.5 POST-TEST COUNSELLING
Trepanier et al (2004) maintain that the result-disclosure session should take
place during a face-to-face session with the client. Should the individual 
consent to being informed of their results, the disclosure and implications 
thereof are discussed at this stage, with special attention given to the possible
emotional impact (Aronson 2009; Biesecker and Marteau 1999; Biesecker
and Peters 2001; Raymond et al 2009). Peters and Biesecker (1997) state
that the psychological reactions may need to be addressed in an ongoing
manner, and follow-up sessions with the counsellor or a referral to a mental 
health professional may be required. The counselling of the post-test session
is further dedicated to reviewing and co-ordinating the medical management
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Aronson (2009) advises that the matter of disclosing the genetic result should 
be raised during the pre-test session to ensure that the client has already 
considered the issues of disclosure prior to testing. Another means to 
assisting the dissemination of information may be through the provision of 
written documentation (Schneider et al 2006). 
 
Individuals who refrain from having biological children due to their concern 
over passing on a genetic risk can be enlightened to the possibilities of 
adoption, in vitro fertilisation with either sperm donation (if the father is 
mutation-positive) or ovum donation (if the mother is mutation-positive) and 
prenatal diagnosis (PND), including chorionic villi sampling, amniocentesis 
and cordocentesis. Should PND identify a mutation-positive fetus, selective 
termination of pregnancy is optional. Preimplantation genetic diagnosis 
(PGD), whereby the embryo‘s that are selected and implanted are screened 
to ensure that they do not carry the familial mutation is additionally available. 
However, some controversy about offering PND and PGD for late-onset 
cancer syndromes has been raised. Concerns relate mainly to the reduced 
penetrance of the condition, the onset of cancer in adulthood (excluding 
Familial adenomatous polyposis, which manifests in childhood), and the 
effectiveness of surveillance. In an extensive review of the literature by Offit et 
al (2006), no cases of PND could be identified for LS, whilst more than a 
dozen cases utilising PGD, have been reported.  
 
Genetic counselling and PT should, where possible, be undertaken by those 
with experience to ensure that the issues of confidentiality and information 
provision are explained within the consent process (Aronson 2009).  
 
2.11  PSYCHOLOGICAL IMPACT OF GENETIC TESTING ON THE 
INDIVIDUAL  
For families with LS, knowing whether or not an individual carries the 
predisposing mutation can be of benefit as appropriate surveillance, which 
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Despite these benefits, the knowledge of being at a high lifetime risk for the 
development of associated LS cancers may result in psychological distress 
among mutation-positive individuals (Ashida et al 2009). Several articles, on 
the psychological impact of PT for LS, have shown that cancer worry, anxiety 
and depression have remained the same or only incrementally increased for 
mutation-positive individuals after the notification of the test results when 
compared to mutation-negative individuals (Bleiker et al 2003; Esplen et al 
2001; Meiser et al 2004). 
 
Further support for minimal psychological distress was offered by Aktan-
Collan et al (2001) who evaluated the psychological consequences of 
undergoing PT for LS in participants selected from a research registry. During 
their prospective study, 271 healthy at-risk individuals from 36 Finnish LS 
families completed self-rating questionnaires. General anxiety, fear of cancer 
and death, and satisfaction with the future was determined at four intervals for 
both mutation-negative and mutation-positive individuals. Anxiety was 
measured using the 20-item State-Trait Anxiety Inventory (STAI), while fear of 
cancer and death and attitudes towards the future were assessed by five 
statements requiring a Likert-rated response. Measures were completed at 
baseline (before first counselling session), the result session, one month and 
one year after the test disclosure. The results of their study indicated that 
unaffected individuals who received a positive test result exhibited increased 
anxiety immediately after the disclosure of the test result. However, the 
differences between this group and the mutation-negative group disappeared 
during the follow-up period. Furthermore, testing seemed to relieve the fear of 
cancer in both groups and did not result in any harmful consequences at 
follow-up. In addition, all those tested viewed their future as promising and 
were as satisfied with their lives as they had been before embarking on 
testing. The decreased cancer fear, reported by the mutation-positive group, 
may relate to the notion that uncertainty is often more distressing than being 
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Other studies have focused on the psychological impact of individuals within a 
clinical setting. Claes et al (2004), selected self-referred unaffected Dutch 
participants presenting for PT at a clinic-based genetic testing programme. 
Self-report questionnaires were used to gather information at pre-test 
(information and blood taking session) and post-test (one month after 
disclosure of test result) phases. General distress was measured by the STAI 
scale for which norm values for the Dutch population were available. Data 
was captured for 19 mutation-positive and 21 mutation-negative participants 
with mean scores on the STAI found to be within the same range or lower 
than the means in the general Dutch population. Differences between the two 
groups were not statistically significant for mean pre- and post-test scores. 
When considering the subgroup of mutation-negative individuals, however, 
differences between the two time periods were statistically significant (p< 
0.05). Similar results for long-term psychological distress (three year follow-
up) have been reported by an Australian study group (Collins et al 2007).  
 
Key predictors of distress, in healthy individuals undergoing PT, include a 
history of depression (Murakami et al 2004), lower quality of life, social 
support (Arver et al 2004), complicated grief and the number of affected first-
degree relatives (van Oostrom et al 2007). Findings from a longitudinal 
prospective survey highlighted that distress can be anticipated in cases where 
an extended family history of CRC or loss related to CRC are present (Esplen 
et al 2003).  
 
The psychological impact of a positive genetic test result among cancer 
patients has been a relatively neglected topic in the literature (Vernon et al 
1999; Esplen et al 2007). In individuals with CRC a positive test result 
indicates a risk of developing a second cancer and may therefore result in the 
individual being vulnerable to distress. During an American study involving 
126 CRC patients three measures were used to determine psychological 
distress, STAI, CES-D (Centre for Epidemiologic Studies Scale) and RIES 
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identified, whereby race and education were significantly associated with 
increased distress. Non-whites had higher mean scores than whites (STAI, 
p<0.01; CES-D, p<0.01 and RIES, p<0.001) and individuals with lower 
education levels had higher scores than those with higher education levels 
(STAI, p< 0.01; CES-D, p<0.05 and RIES, p<0.01) (Gritz et al 2005). In a 
larger study of 200 patients within the same population group, lower 
education and a poor support structure also determined higher mean scores 
on CES-D and STAI Scales. Additionally, younger age and non-white race 
were associated with increased levels of anxiety, whereas gender (being 
female) was associated with higher mean depression scores (Vernon et al 
1997). Results of these studies suggest that the emotional reaction to a 
positive test result in a CRC patient should not be underestimated. Bonadona 
et al (2002), further propose that one cannot assume that the patient who has 
already had the diagnosis of cancer will consequently expect a positive test 
result. The authors identified more than a third of their patients having stated 
that the disadvantages of knowing their genetic test result outweighed the 
advantages. A favourable outcome, in this group of individuals, was identified 
by Esplen and colleagues (2007) who reported that distress levels were lower 
in individuals found to be mutation-positive, following a previous cancer 
diagnosis than those mutation-positive individuals (unaffected with cancer). 
 
Published data from developing countries, on the psychosocial effect of being 
at-risk for LS, could not be identified for comparison purposes. It is not 
evident whether such countries would display similar or different trends to that 
of studies conducted in the USA, UK, Finland, Netherlands and Australia, as 
has been discussed in this review.  
 
2.11.1 UPTAKE OF PREDICTIVE TESTING 
The uptake rates of PT are variable. Survey‘s conducted prior to the 
availability of genetic testing for LS indicated that the majority (83%) of first-
degree relatives of an individual affected with CRC, would request genetic 
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selected both unaffected and affected family members eligible for genetic 
testing. Among these individuals, only 43% elected to have a genetic test. 
Noteworthy, of the 84 participants who provided a blood sample for genetic 
testing, eight declined to receive their test result when available to them 
(Lerman et al 1999). Interest in genetic testing was further explored in an Irish 
and an American study which identified a slightly increased uptake rate of 
51% (Hadley et al 2003) and 64% (Peterson et al 2003), respectively.   
 
The documented uptake rate reported by Hadley et al (2003) and Lerman et 
al (1999) was significantly lower than predicted by Croyle (1993). However 
figures from a study of the Finnish population (Aktan-Collan et al 2000) 
greatly exceeded those from the American (Peterson et al 2003) and Irish 
(Hadley et al 2003) study, suggesting that interest in genetic testing for a 
predisposition to CRC may be high. Aktan-Collan et al (2000) invited 446 at-
risk unaffected individuals to participate in their study. The research was 
based on questionnaires, which were completed three times during the study 
period (before the initial counselling session, one month after and one year 
after test disclosure). Of the 446 eligible participants, 381 consented to the 
study and 88% (334/381) requested PT. The Finnish authors suggest the 
difference in uptake rates may relate to their health care system, where 
private health insurance does not play a major role and the majority of the 
population is managed by the public health-care system. Genetic testing and 
counselling in countries with a national health system remains expensive and 
has the potential to increase medical insurance policies which may 
collectively lead to decreased uptake rate. 
 
2.11.2 BARRIERS AND FACILITATORS TO PREDICTIVE TESTING 
Several sociodemographic and psychological reasons for not participating in 
PT have been highlighted in the literature. Among individuals undergoing 
genetic testing, higher education (Aktan-Collan et al 2000), being employed 
(Aktan-Collan et al 2000), higher pre-test risk perception (Codori et al 1999; 
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thoughts about cancer (Codori et al 1999) are commonly identified in 
acceptors of PT as compared to decliners. Hadley et al (2003) also identified
that individuals with a personal history of cancer or who are unaffected, but
have a greater number of affected relatives with CRC, accepted testing more
often. Individuals concerned about their ability to handle the emotional effect
and the psychosocial effects on their family, pursued testing less frequently
(Hadley et al 2003; Keller et al 2004; Lerman et al 1996), while the presence
of depression has been identified to significantly reduce uptake rates (Lerman
et al 1999). Studies conducted in the USA have highlighted that insurance
coverage and concern over possible discrimination may also impede the
pursuit of genetic testing (Hadley et al 2003; Kinney et al 2000).
Key motivational factors driving the pursuit of genetic testing for LS include:
early detection of cancer, obtaining knowledge of the offspring‘s risk, the
opportunity to reduce uncertainty as well as obtaining information that may
reduce screening frequencies (Claes et al 2004; Esplen et al 2001; Esplen et
al 2007; Hadley et al 2003).
2.11.3 BARRIERS AND FACILITATORS TO SURVEILLANCE
Screening for CRC facilitates the removal of polyps and the treatment of early 
tumours, preventing CRC mortality in LS. Despite the well recognised benefits
of screening for CRC, adherence to these recommendations has been less 
than optimal (Järvinen 1995; Levin 1996; Lynch et al 1993b; Vernon et al
1997). Compliance with endoscopic screening guidelines has been studied
extensively, with the rate of adherence ranging from 60% to 90% among first-
degree relatives of CRC patients (Harris et al 1997; Houlston et al 1990;
Kinney et al 2000; Mack et al 2009; Richardson et al 1995; Stephenson et al 
1993) and from 58% to 99.5% in studies of LS families (Bleiker et al 2005;
Hadley et al 2004; Halbert et al 2004; Järvinen et al 1995; Järvinen et al 
2000; Liljegren et al 2004; Pylvänäinen; Stanley et al 2000; Stoffel et al 2003;
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Accurate assessment of compliance is complex as attendance for endoscopic 
screening, as used to determine compliance, have varied from study to study. 
Previous research groups have predicted compliance rates on the basis of 
the participant attending at one screening only (Stephenson et al 1993; 
Stupart et al 2009b), while other researchers have delineated specific 
screening intervals (annually, one to three years, and less frequently) (Hadley 
et al 2004; Stoffel et al 2003). Halbert and co-authors reported on yet a 
different categorisation of compliance: individuals indicating that they had 
received a colonoscopy within two years were viewed as compliant, while 
those never attending or seen three or more years ago were non-compliant. 
As colon screening can only be effective if high-risk individuals adhere to 
recommended guidelines, it is important to determine if screening every one 
to two years over a sustained period has occurred in the study participants. 
Secondly, the majority of studies focusing on LS families have obtained data 
from self-reported screening behaviours (Hadley et al 2004; Halbert et al 
2004; Liljegren et al 2004; Stoffel et al 2003; Stoffel et al 2010 Wagner et al 
2005), where attendance rate and time period between screenings may not 
be accurately recalled. The only study to utilise self-reported behaviour and 
combine this with actual uptake of screening (information derived from 
medical records), was conducted in the Netherlands. Bleiker et al (2005) 
determined compliance based on participant attendance rate to screening 
intervals every one to two years and identified these rates to vary between 
84% (according to patient recall) and 72% (according to medical records). 
 
Previous studies examining CRC screening practices have highlighted that 
certain sociodemographic factors can affect adherence to recommended 
CRC screening guidelines. Physician recommendation or advice (Rees et al 
2008; Stephenson et al 1993) and family history of CRC (Gili et al 2006; 
McCarthy et al 1993; Myers et al 1990; Stoffel et al 2010) influence 
adherence rates positively, while a lack of formal education (Glanz et al 1999; 
Myers et al 1990; Sun et al 2004; Vernon et al 1997), lower income and 
socio-economic status (Vernon et al 1997; Weitzman et al 2001) and low 
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Other factors likely to reflect lower levels of adherence include age at 
participation (Denberg et al 2005) and gender (Codori et al 2001; Denberg et 
al 2005; Weitzman et al 2001). The literature, however, remains ambiguous 
on these two aspects, highlighting associations between a young (Denberg et 
al 2005; Gili et al 2006) and older age (Glanz et al 1999) as well as both male 
(Codori et al 2001; Gili et al 2006; Weitzman et al 2001) and female status 
(Denberg et al 2005). Additional barriers to screening include a lower level of 
perceived susceptibility to CRC (Glanz et al 1999; Lynch et al 1999; Denberg 
et al 2005; Vernon et al 1997; Wei et al 2004), fear of discrimination by 
insurance providers (Codori et al 2001; Denberg et al 2005; Guerra et al 
2005; Lynch et al 1999), logistical obstacles (Denberg et al 2005; Price 1993), 
and population characteristics of a minority group including Japanese, Latino, 
Filipino and Korean (within the USA) ethnicity (Glanz et al 1999; Guerra et al 
2005; Maxwell et al 2000). As these population groups are largely reflective of 
a lower socio-economic status, the socio-economic factors rather than the 
ethnicity may account for this.  
 
A substantial body of research has highlighted that psychological factors 
impede on CRC screening. These include, a negative attitude toward 
screening procedures (Beeker et al 2000; Price 1993), fear of cancer (Kruger 
et al 2005; Natale-Pereira et al 2008; Subramanian et al 2004), a fatalistic 
approach (the belief that CRC is incurable) (Powe 1995; Price 1993), concern 
over the prospect that it may lead to colon surgery (Price 1993), denial (Lynch 
et al 1999; Price 1993), anxiety of finding cancer (McCaffery et al 2003), and 
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2.12  IMPACT OF LYNCH SYNDROME ON THE FAMILY  
 
2.12.1 COMMUNICATION OF THE GENETIC INFORMATION TO THE 
FAMILY 
Once a genetic mutation has been identified in an individual, the result not 
only affects the proband, but extends to his or her biological family. Informing 
relatives about the identification of a pathogenic mutation allows unaffected 
family members the opportunity to ascertain their cancer-risk through 
mutation-specific testing and to determine if they require high-risk cancer 
screening (Stoffel et al 2008). Current standards of practice dictate that the 
responsibility of disclosing the genetic information to the at-risk family 
members lies with the individual (American Society of Human Genetics Social 
Issues Subcommittee on Family Disclosure 1998; Forrest et el 2007). 
Consequently, the dissemination of cancer-risk information and subsequent 
access to genetic counselling and testing services among relatives depends, 
partly, on whether or not the proband discusses the test result with family 
members. Family communication and timely disclosure of the health 
information is thus vital to ensure that at-risk family members are informed 
and understand the genetic information. Previous research has found that a 
high proportion of mutation–positive individuals do disclose their test result to 
their family. For example 81-85% of individuals, selected from a cancer 
registry, discussed their BRCA1/2 test result with a family member (Hughes et 
al 1999; Hughes et al 2002) and disclosure usually took place in a timely 
manner (95% of those who discussed their test result did this within a week) 
(Hughes et al 2002). Comparable figures have been published in clinic-based 
studies determining attitudes towards informing relatives about genetic testing 
for breast cancer (Julian-Reynier et al 1996; Julian-Reynier et al 2000). In the 
context of LS, an American study identified that 98% of individuals 
undergoing genetic testing informed their first-degree relatives of their test 
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Overall, rates of communicating genetic test results tend to be lower when 
relatives are outside the immediate (nuclear) family (Bonadona et al 2002; 
Claes et al 2003; Forrest et al 2003; Kausmeyer et al 2006; Mesters et al 
2005). One study identified a 23% decline in the rate of communication when 
second- or third-degree relatives were considered (Stoffel et al 2008). Indeed, 
information about genetic testing is most often disclosed to partners and/or 
siblings and less often to children and parents (Bonadona et al 2002; 
Peterson et al 2003).  
 
Disclosure is less likely to occur when the patient perceives the information as 
potentially disturbing to the relative, if prior conflict or a lack of cohesion exists 
among family members or if there is an unwillingness to cause concern 
(Forrest et al 2003; Julian-Reynier et al 2000; Koehly et al 2003; Kohut et al 
2007; Mesters et al 2005; Stoffel et al 2003). Additional barriers to 
communication, as far as breast cancer is concerned, include: adoption, 
divorce, remarriage, and a large age gap between siblings (Green et al 1997), 
while patients already affected with a cancer are more likely to disclose 
genetic information to their families (Julian-Reynier et al 2000).  
 
Communication of a genetic test result can also be influenced by the mutation 
status of the individual (Patenaude et al 2006). Hughes et al (1999) identified 
that women receiving a mutation-positive BRCA result were more likely to 
convey the information to their family than those with a negative result. In a 
later study by the same author, a similar pattern of disclosure was described 
for sister pairs with a definitive result compared to those with an inconclusive 
result (Hughes et al 2002). Disclosure was additionally less likely to occur 
when an individual had younger children (Kohut et al 2007; Mesters et al 
2005), as telling children about their genetic risk occurred around key life 
decisions, at a specific life stage or when they were old enough to understand 
(Forrest et al 2003). Motives for informing family members are largely to 
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provision of risk information to relatives (Green et al 1997; Hughes et al 2002; 
Mesters et al 2005; Stoffel et al 2008).  
Women have been described to play a greater role in communicating at-risk 
information when compared to their male counterparts, and female relatives, 
rather than male relatives, are more likely to be informed about genetic
testing, particularly in breast cancer (Hughes et al 1999; Koehly et al 2003;
Wilson et al 2004). In the context of LS, where both males and females have
a high risk of developing cancer, the impact of gender has not been as easily
ascertained as that identified from the extensive literature available on breast
cancer. However, in an Australian study investigating this phenomenon in LS
patients, it was tentatively suggested that males may find the process of 
informing the at-risk relatives less natural than females (Gaff et al 2005). The
authors further suggested that men, especially, may therefore benefit from
professional support during the period of communicating genetic test results
to the family. Patients have previously expressed difficulties with being the
person responsible for transmitting the results to their family (Green et al
1997; van Oostrom et al 2007), however these individuals do not advocate for
this role to be taken on by anyone else (Bonodona et al 2002; Forrest et al
2003; Kohut et al 2007). 
Family communication remains a complex issue. Simply telling patients to
inform their at-risk relatives about the implications of their genetic test result is
insufficient. Even though the large majority of individuals are willing to share 
information about the presence of a gene mutation in the family and it has 
been reported that individuals do not deliberately withhold their test result
from family members (Stoffel et al 2008), passive failure to disclose the result
to the at-risk family does occur (Gaff et al 2005; Mesters et al 2005). This is of 
concern as the information can have life-saving implications. 
It has been suggested that a detailed letter containing all relevant information 
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about genetic testing may be of benefit in facilitating family communication 
(Peterson et al 2003; Stoffel et al 2008). Further support and strategies to 
augment communication may include genetic counselling, information 
pamphlets and regular contact by health professionals (Bonadona et al 2002; 
Green et al 1997; Gaff et al 2005; Peterson et al 2003). 
 
2.12.2 ETHICAL ASPECTS: FAMILIAL NATURE OF LYNCH SYNDROME 
When the family is not informed about the implications of the genetic 
information, the healthcare professional‘s duty to maintain confidentiality may 
be at conflict with their responsibility to inform the at-risk relatives about their 
susceptibility to the genetic condition (Lehmann et al 2000). An extensive 
review on the ethical guidelines and policies addressing the communication of 
genetic information in families was conducted by Forrest et al (2007). The 
general recommendations arising from this review are that the health 
professional, at the very least, informs the patient about the implications of 
the genetic information in light of its relevance for family members.  
 
Certain guidelines permit disclosure when attempts to encourage the patient 
to disclose the genetic information have failed. Confidentiality may be 
breached and the genetic information released if the following criteria are met: 
―… (a) reasonable efforts to elicit voluntary consent to disclosure have failed; 
(b) there is a high probability both that harm will occur if the information is 
withheld and that the disclosed information will actually be used to avert 
harm; (c) the harm that identifiable individuals would suffer if the information 
is not disclosed would be serious; and (d) appropriate precautions are taken 
to ensure that only the genetic information needed for diagnosis and/or 
treatment of the disease in question is disclosed‖ (President‘s Commission 
1983:6). In the USA, the healthcare professional is not required by law to 
warn the at-risk family members (American Society of Human Genetics 
1998), while the European (European Commission 2004) guidelines take a 
stronger stance recommending that genetic healthcare professionals actively 
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advocate against disclosure if the patient does not inform the family of the 
genetic concerns, giving priority to the patient‘s privacy (Committee for Public 
Relations and Ethical Issues of the German Society of Human Genetics 2000; 
National Consultative Ethics Committee for Health and Life Sciences 2003). 
There is no SA law applicable to breaching confidentiality or towards warning 
an endangered third party (Taitz et al 1990).  
 
Mostly, patients demonstrate an understanding of the implications of a 
positive genetic test result and consider it their duty to inform at-risk family 
members about the risks of cancer and screening options. However, refusal 
to warn at-risk family members is well recognised (Evans et al 2009; Dugan et 
al 2003; Falk et al 2003; Julian-Raynier et al 2000). In a survey of patients 
from a Canadian Colon Cancer Registry, only 73.5% of individuals were 
willing to give the health care professional permission to inform their at-risk 
relatives if they could or would not inform them (Kohut et al 2007). Suthers et 
al (2006), in an attempt to increase awareness among at-risk family members 
about the availability of genetic testing for a familial condition, sent out letters 
to at-risk relatives with the permission of the proband. The result was an 
uptake of genetic testing, among at-risk relatives, from 23% to 40%. Based on 
similar research conducted in Finland, 92% (n=236) of at-risk relatives 
approved of this form of direct contact (Aktan-Collan et al 2007). The direct 
approach may work well in countries where registries are available (Finland, 
Denmark and to an extent SA), whereby direct recruitment can be facilitated. 
The model may not be as effective in countries without comprehensive 
registries and mailed letters may not be effective where the population is of a 
low functional literacy level. 
 
Importantly, it must be considered that at-risk relatives may not want to be 
informed about a genetic condition for which they are at-risk. On the contrary, 
they may consider the contact an invasion of their privacy, capable of causing 
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2.13  GENETIC COUNSELLING 
Since the first introduction of the term ‗genetic counselling‘, by Sheldon Reed 
in 1974, many and varied definitions have been used to describe the 
profession (American Society of Human Genetics 1975; Fraser 1974; Kelly 
1986; Kessler 1979; Shiloh and Saxe 1989; Street and Soldan 1998). One of 
the most widely published, is that from the American Society of Human 
Genetics (1975), which describes genetic counselling as a communication 
process around the occurrence or risk of occurrence of a genetic disorder in a 
family. In the three decades since the definition was proposed, genetic 
counselling has expanded beyond its traditional borders and importantly 
placed emphasis on the therapeutic relationship and need for emotional 
support (Bisecker and Peters 2001; Evans 2006; National Society of Genetic 
Counselors 2006; Resta 2006; UNESCA International Bioethics Committee 
1995). The definition accepted by the National Society of Genetic Counselors 
(NSGC) enumerates three core aspects which are commonly integrated into 
the process of genetic counselling. These include interpretation and 
education and counselling which are expanded upon below: 
 
 Assessing the chance of disease occurrence or recurrence based on 
the family and medical history; 
 Facilitating patient education in terms of the genetics, testing options, 
management, prevention, ongoing research and available resources; 
and 
 Counselling of clients to enable an informed decision concerning their 
choices and adaptation to the risk or condition (National Society of 
Genetic Counselors 2006). 
 
Essentially, genetic counselling involves the interpretation of complex genetic 
data into information that is easily understood by the client and has the 
potential to help the client make and cope with the decisions relating to 
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Genetic counsellors are healthcare providers with a specialised degree in 
human genetics and counselling. The profession is, however, practiced by a 
variety of professionals from many different disciplines including: clinical 
geneticists, genetic nurses, psychologists, social workers and other medical 
specialists such as neurologists, obstetricians and ophthalmologists. 
Traditionally, genetic counselling centred around prenatal and paediatric 
genetic services and decision-making around reproduction. More recently the 
field has grown to incorporate adult-onset genetic conditions, including the 
rapidly expanding field of cancer genetics. In the 2006 NSGC Professional 
status survey, 39% of genetic counsellors were practicing in the field of 
cancer genetics, the second largest contributor, followed only by the prenatal 
sector. Interestingly, the cancer field was the only sector to illustrate growth 
over the six-year period captured during the survey (34-39%) (Parrott and 
DelVecchio 2007). 
 
A number of elements outline a genetic counselling session. The first, and 
perhaps most integral part, includes taking a medical and family history, 
usually recorded in the format of a three-generation pedigree (Aronson 2009; 
Baker et al 1998; Weil 2000). Verification of medical records such as 
pathology reports can provide clues when assessing hereditary cancer 
susceptibility as certain types of tumours are more likely to be associated with 
a genetic cause (Prucka et al 2008). For example, CRC tumours with MSI or 
other pathological features, as discussed under Section 2.6.3 and 2.6.4, may 
be suggestive of LS. The counselling session also includes educational 
aspects, whereby the client is provided with information on the genetic 
condition including the prognosis, management and treatment options. An 
assessment of reproductive or personal health including the hereditary 
aspects of the genetic condition are also discussed (Bernhardt et al 2000; 
Biesecker 2001; Harper 1998; Resta et al 2006). 
 
If appropriate, informed decisions regarding genetic testing are made by the 
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the counsellees to make certain decisions, but rather to assist them in making
the best decision for themselves, taking into account their beliefs, values and
circumstances (Baker et al 1998; Ensenauer et al 2005; Kessler 1997; Shiloh
1996). Traditionally, genetic counselling aimed to uphold this non-directive
standard described as helping the clients reach a decision based on their
personal perspectives without any particular guidance towards a decision
(Evans 2006; Kessler 1997; Shiloh 1996). Elwyn et al (2000), however, argue
that the counsellor should contribute his or her personal views to the
counsellee if there is a medical benefit to a particular course of action. In the
model, the counsellee‘s values are still respected, but cognisance is also 
taken of the opinion of the medical expert. The concept, ‗shared decision-
making‘, can be applicable in situations such as those in LS where the
individual clearly benefits from medical management.
The most powerful part of the genetic counselling session is the emotional
support and psychological counselling which can help the counsellee prepare
and cope with their genetic concerns (Baker et al 1998). Should genetic 
testing be available and appropriate, informed consent and the discussion of 
other ethical and or legal issues are addressed during the consultations. 
2.14 SATISFACTION WITH GENETIC COUNSELLING SERVICES
Patient satisfaction is an important measure for assessing the quality of a
health care service, as it reflects on the experience of care received from the
patient‘s perspective (Charles et al 2006). Given the importance of patient
satisfaction in genetic counselling and the role it plays in the continual 
advancement of the profession, several scales for assessing satisfaction have
already been developed. These scales, available in quantitative and
qualitative formats, evaluate different components of the patient‘s genetic 
counselling experience (Lea 1996; Shiloh et al 1990; Tercayak et al 2001; 
Veach et al 1999). Typically, three dimensions are usually assessed and
include: (1) competence of the health care profession; (2) the health care
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satisfaction with the administrative procedures including costs and 
convenience of the service (Shiloh et al 1990). Such evaluations facilitate the 
further exploration of counsellee needs from the service, identifying aspects 
where improvements can be implemented (Biesecker and Marteau 1999; Lea 
1996).  
 
Much of the research on patient satisfaction suggests that the majority of 
patients are pleased with the genetic counselling that they receive (Bleiker et 
al 1997; Bjorvatn et al 2007; Charles et al 2006; Collins et al 2000; Davey et 
al 2005; DeMarco et al 2004; Sagi et al 1998). In a study by Stadler and 
Mulvihill (1998) conducted in America, the level of satisfaction among 51 self-
referred patients seen for breast cancer genetic counselling was reported to 
be ―high‖ amongst a significant proportion of women. Overall, the patients 
considered that the consultation was worth their time and money. Similarly, 
Nordin et al (2002) described Swedish patients referred for genetic 
counselling at an oncogenetic clinic (breast, ovarian and colorectal cancer 
referrals) as being ―highly satisfied‖. These and other findings have led to the 
belief that most patients view the genetic counselling session as helpful, 
valuable, informative and capable of addressing concerns adequately. What 
is more, counsellee expectations of genetic counselling are often exceeded, 
as highlighted by Charles et al (2006). 
 
One possible explanation for the high levels of satisfaction may be the lack of 
awareness of what genetic counselling entails among counsellees (Davey et 
al 2005; Hallowell et al 1997). Bernhardt et al (2000) point out that educating 
counsellees about the process of genetic counselling, prior to the session, 
may be one way of promoting realistic expectations. Furthermore, Michie et al 
(1997) and Shiloh et al (1990), found that satisfaction is determined by the 
fulfilment of patient expectations, whereby patient satisfaction increases when 
expectations are in line with what is received from the counselling session. 
Perhaps most importantly, counsellors should be aware that their agendas 
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Dissatisfaction with genetic counselling does, however, occur. For example, 
individuals receiving information on genetic testing that may be negative or 
inconclusive in nature, may assess genetic counselling as less satisfying 
(Shiloh et al 1990), while higher education, younger age, cancer-specific 
distress (prior to the genetic counselling session), pessimism and poor family 
functioning is negatively associated with satisfaction (Collins et al 2000; 
Tercyak et al 2004). Asking too many medical questions and not receiving 
enough medical information during the counselling session is also associated 
with counsellees who are less satisfied (Pieterse et al 2007). Bleiker et al 
(1997) conducted a pilot study on individuals with a family history of cancer 
attending a familial cancer clinic in the Netherlands. The authors identified 
several areas where dissatisfaction was expressed by the 36 counsellees. 
Receiving particular attention was the perceived lack of communication 
between the counsellor and other health care professionals, the limited 
involvement of the family doctor, inadequate information on the possible 
consequences of daily life functioning and a greater need for psychosocial 
support during and after the genetic counselling session. A survey, 
administered to patients who had received genetic counselling in the state of 
Pennsylvania (USA), highlighted additional areas amenable to improvement. 
Suggestions included more frequent outreach visits, more convenient parking, 
amalgamation of the cancer risk assessment appointment with other medical 
appointments and information of updates on ongoing trials. With regard to 
breast cancer patients, Bober et al (2007), identified that women who receive 
more complex information are likely to report lower levels of satisfaction.  
 
Greater satisfaction may be achieved if the information, given to the patient, is 
adapted to their coping style. Nordin et al (2002) identified that ‗monitors‘ 
(individuals who seek more information on a particular health threat) are not 
only less distressed, but are more satisfied with information provision. 
‗Blunters‘ (individuals who avoid information on a particular health threat) on 
the other hand, show the opposite, namely, that less information reduces 
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2.15  OVERVIEW OF SOUTH AFRICA: POPULATION AND HISTORY  
SA lies on the southern most tip of the African continent. It is classified as a 
middle-income country, comprising nine provinces and recognises 11 official 
languages. The republic of SA has an estimated population of over 48 million 
people (Tait et al 1996; World Health Organization 2006), broadly grouped 
into Black (79.6%), White (9.1%), Coloured or Mixed Ancestry (8.9%), and 
Indian/Asian (2.5%) (Statistics South Africa 2005). 
 
As a result of SA‘s troubled and turbulent political past, including the 
implementation of the ‗apartheid‘ system in 1948, a three-tiered racial 
hierarchy was introduced in the country. The Population Registration Act of 
1950 classified and registered all South African‘s according to race, which 
stratified the White minority population at the top of the apex, the numerically 
preponderant Blacks at the bottom and Coloureds (including other minority 
groups that did not fit into either White or Black population groups) in the 
middle (Adhikari 2005; Bank et al 2003; Coovadia et al 2009, Goldin1987; 
Williams et al 2008a). The system could often lead to individuals, from the 
same family, being classified into different population groups as a result of 
their physical appearance. An example of one of the classification criteria was 
the ‗pencil test‘.  This involved sliding a pencil into the hair, if the pencil 
remained in place, the hair was deemed too curly to be that of a White person 
and the individual would not be classified as ‗White‘, even if the rest of their 
family was labelled as that under the Act (Erasmus 2001; Watson 2007). The 
White population regarded themselves as the only civilised race and 
governed over the other population groups from 1948 to 1994.  
 
During this time of White supremacy and racial discrimination, the existing 
property rights of any non-white person were nullified.  The government 
passed the Group Areas Act (1950), segregating trading and residential 
zones by race (Beck 2000). This forced relocation, to racially defined areas, 
led to deliberate inferior living conditions. Reserved employment 
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Amenities Act 1953) were destined upon any person without a light skin 
(Aflolayan 2004; Beck 2000; Johnstone 1976). These two Acts specifically, 
were so severely enforced that separate amenities such as churches, 
hospitals, libraries and public toilets, were established (Erasmus 2001; 
Walker 2001; Worden 2007). Needless to say, those designated for the non-
white races were inadequate. Non-whites were also unable to travel through 
White areas. Passbooks (race identity books), which had to be carried at all 
times, were issued to Black individuals. This document recorded data on race 
classification; residence and place of work to ensure that migration into urban 
areas was controlled when Blacks worked in White areas. If Black individuals 
were identified within a White area without a passbook, they were subject to 
imprisonment (Terreblanche 2002; Watson 2007). 
 
The ‗apartheid‘ government also targeted the education system, enforcing 
separate facilities with different schooling requirements for each race. Only 
White schools required compulsory attendance while those schools educating 
the Coloured and Indian/Asian race, did not. Education for the Black race, 
above that of basic skills, was restricted. The Bantu Education Act of 1953 
stipulated that Blacks were to be educated only in accordance with their 
opportunities in life, which was primarily to serve as a labour force in the 
industrial sector (Worden 2007). As the Black schools provided lower 
standards of education, few non-whites were accepted into universities as a 
result of academic requirements (Johnstone 1976; Terreblanche 2002). Up 
until the late 1980‘s, more than 80% of South African university students were 
White (Beck 2000). 
 
The forced relocation of more than four million non-whites into demarcated 
zones beyond the White suburbs had a devastating effect on families and the 
previously established communities (Beck 2000; Watson 2007). The areas 
reserved for the non-white races, limited to the rural suburbs, were devoid of 
job opportunities and infrastructure. Workers were burdened with high 
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have a job in the lucrative urban region reserved for the White population. 
Consequently, poverty and crime increased. The oppressive living conditions 
in these areas led to a greater prevalence of heavy alcohol abuse, violence 
and gangsterism (Adhikari 2005; Erasmus 2001; Watson 2007). 
Democracy was attained in 1994, transforming the racially segregated South
African society into a single multi-ethnic society governed by the African
National Congress. While the post-apartheid constitution promoted equality 
for all races, because of the enormous costs involved in achieving equitable
services, education and opportunities, the country‘s demographic profile still
reflects trends of the previous racial inequality system of the Nationalist
Government regime (Burgard and Treiman 2006). Socio-economic inequality 
remains. Today, elementary jobs are still largely filled by the Black and
Coloured sectors, while clerical, managerial and professional positions are
mainly occupied by the White and Indian/Asian races (Statistics South Africa
2005). The economical divide is further evident when considering the
unemployment rate of 28.1% in Black, 17.1% in Coloureds and 4.1% in White
population groups (Statistics South Africa 2005) and the large discrepancy in 
the average annual household income for Black families, R37 711 (USA$ 5 
500); Coloured families, R79 423 (USA$ 11 700); and White families, R280
870 (USA$ 41 500) (Statistics South Africa 2005). 
To negate this effect, the new South African dispensation is currently placing 
greater pressure on governmental departments and public institutions to 
redress the racial disadvantages of the past. Steps introduced include the 
implementation of affirmative action, whereby people who are suitably 
qualified, but from a previously disadvantaged group (Blacks, women and 
people with disabilities), are given priority in employment (Rankhumise et al 
2001; Terreblanche 2002). Black economic empowerment, is another 
measure driven by legislation and regulation, offering preferential 
procurement to Black citizens in the financial, construction and tourism sector 
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2.15.1 PROFILES OF THE NORTHERN AND WESTERN CAPE 
COMMUNITIES 
 
Figure 4: The geographic location of the Western and Northern 
Cape in comparison to the other provinces in South Africa. 
 
The population structure of the WC and NC province is very different to the 
national profile as the majority of individuals are Coloured (WC: 53.9%, NC: 
51.6%) and the main language spoken is Afrikaans and not a native Black 
language (Statistics South Africa 2005). 
 
The WC, located on the south-western tip of the African continent borders the 
NC province in the North (Figure 4). The NC constitutes three times the land 
area of the WC, but only accounts for 1.8% (versus 9.7% in the WC) of the 
nation‘s population (Beck 2000; Bradstock 2005; Burger 2009). Due to the 
NC‘s geographical location, with the cold Atlantic Ocean as its western 
boundary, the area experiences extreme weather conditions with an 
extensive temperature range between the summer and winter months (Burger 
2009). The NC is one of the least developed provinces of the country with the 
economy largely dependant on game farming, agriculture and mining. Many 
of the towns have developed around mining industries, and include Alexander 
Bay, Port Nolloth and Kleinsee (alluvial diamonds extracted from the 
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(copper mining) (Figure A). However, many of these operations have been 
suspended due to the uneconomical value of further mining as a result of 
depleted resources. For example, the De Beer‘s Mine at Kleinsee, the largest 
alluvial mine in the world, only employs 6% of its original employees (Ferreira 
2010). 
 
The WC boasts a more favourable geographical location, a Mediterranean 
climate, greater employment opportunities (particularly in the retail and textile 
industry) and a strong network of higher education institutions (Burger 2009). 
It is not surprising that the unemployment rate of the WC (17%) is lower than 
that of the NC (25.7%) (Statistics South Africa 2005). On average, no formal 
education, lower income and rural dwellings are more common to individuals 
from the NC than the WC (Bradshaw et al 2004). Many of the NC households 
still have unsatisfactory access to basic services such as electricity, water 
and sanitation facilities as well as education and healthcare. According to the 
2001 Census, almost a fifth of the NC population have no formal school 
education (as compared to 5.7% of the WC population) and, of great concern, 
54% of the NC‘s population live below the national poverty line (United 
Nations Development Programme 2004). Poverty and unemployment are 
often associated with the rural picture and the discrepancy between the two 
provinces extends into the income sector, with the average monthly 
household income in the WC being R3 234 (USA$ 470) compared to that of 
the NC, R 971 (USA$ 140). 
 
2.16  HEALTHCARE SYSTEM IN SOUTH AFRICA 
The restrictive policies of the ‗apartheid‘ system have had a pronounced 
effect on the healthcare services of the country and the health of its people 
(Coovadia et al 2009; Mooney and McIntyre 2008). Marked differences in 
morbidity and mortality between the different population groups exist as a 
result of the major inequities that were enforced. During this time, the infant 
mortality rate in Blacks was 82 per 1000 live births as compared to 13 in 
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expectancy at birth between the Black and White races (Benatar 1995; 
Walker 2001).  
 
Despite the implementation of major changes to healthcare policy and 
services, including the provision of free healthcare to pregnant women and 
children under the age of 7 years, the distinct mortality profiles still persist 
beyond the ‗apartheid‘ period (Burgard and Treiman 2006). The existing 
differences are explained by the strong relationship between socio-economic 
status (poverty, inequality, inadequate housing and poor education) and 
health (Coovadia et al 2009; Lalloo et al 2004; Mooney and McIntyre 2008; 
Steyn and Bradshaw 2001; Walker 2001). 
 
The coefficient of inequality indicates that SA is still one of the most unequal 
societies in the world (Statistics South Africa 2005). Currently the healthcare 
service has developed into two sectors, fragmented along socio-economic 
lines, whereby the upper and middle classes of all races (14% of the 
population), are managed in the fee-for-service private sector, while the large 
remaining majority are entirely dependent on the public sector (McIntyre et al 
2007). A substantial difference in healthcare expenditure exists between the 
two sectors, with the ratio of private to public spending per person being R9 
500 (USA$ 1 278) and R1 500 (USA$ 201) respectively (South African Health 
Review 2000). The disparity also extends into the human resource sector, 
where one specialist doctor serves 500 patients in private practice, but nearly 
1 100 in the public sector (McIntyre et al 2007). Further inequalities, within the 
public sector, exist in the distribution of infrastructure, level of care, financial 
aid and resources between and within the different provinces (Benatar et al 
1995; Bradshaw et al 2005; Coovadia et al 2009; McIntyre et al 2007). The 
statistics portraying the number of public hospitals per province indicate that 
the WC has 54 state hospitals compared to the 27 hospitals in the NC 











                                                                                                                                                                  CHAPTER TWO: LITERATURE REVIEW                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
81 
 
In addition, the measures implemented to create parity in the public sector‘s 
less well-served areas, through severe budget cuts to the better-served 
areas, has lead to a reduction in the effectiveness of the existing health care 
institutions (Benatar et al 1995). 
 
In summary, one of the most significant challenges facing the South African 
healthcare system remains the inequitable distribution of resources between 
the public, private, urban, rural and interprovincial sectors (Coovadia et al 
2009; McIntyre et al 2007). Proposed healthcare changes to address this 
disparity include the move towards a National Health Insurance system to 
promote access, equality and sustainability for the healthcare system. 
However the precise nature thereof is still the subject of much discussion and 
debate (Department of health n.d; Mooney and McIntyre 2008). In a more 
positive light, SA is one of only a very few developing countries to have been 
able to introduce national disability grants and a pension system. The child 
support grant provides a sum of R250 per month (USA$ 31) per child younger 
than eighteen years and an older person‘s grant (old age pension), R1010 per 
month to males and females older than 60 years of age (USA$150) (South 




































3.1  INTRODUCTION 
In this chapter, the methodological process of the research is described. The
reasons for the selection of the Husserlian approach and a discussion of its
appropriateness are provided. The sampling method and data collection is 
discussed, followed by a detailed explanation of the data analysis. The
chapter concludes with a description of the measures taken to ensure the
validity/trustworthiness and the ethical considerations of the research.
The study involved three major components: 
3.1.1 ANALYSIS OF EXISTING DATA PRIOR TO INTERVIEWING THE 
PARTICIPANTS
Extensive data is captured on each individual seen at the GESC. The registry 
information includes: the age of the individual at PT, gender, physical
address, type of mutation, cancer status at genetic testing (affected or
unaffected with cancer) and the attendance of colonoscopic surveillance. The
latter was used to determine the adherence rate among individuals with LS
(known mutation-positive genetic test result) in the WC and NC. This was 
calculated by obtaining the date of result disclosure (according to the genetic
test report) and subsequent screening attendance (captured on database).
The recommended age-related colonoscopic frequency was taken into
account (guidelines recommend screening every two years prior to the age of 
30 years and annually thereafter) and compliance was determined for each
individual. Five adherence groups, based on the number of missed
colonoscopies, were defined (Table 5). Individuals were selected for 














Semi-structured face-to-face interviews were conducted to gather data from 
participants involved in the GESC. Information pertaining to the PT 
programme and the endoscopic surveillance service was explored and 
analysed. 
 
3.1.3 RECOMMENDATIONS TO IMPROVE AND INCREASE THE UPTAKE 
OF THE SERVICE 
Findings, which could improve the service, were relayed to the genetic and 
clinical team immediately after data analysis. Factors which were identified as 
impacting negatively on the access to and subsequent non-attendance and 
underutilisation of the GESC were identified. Recommendations, many of 
which were suggested by the participants, to address these aspects were 
proposed and implemented where possible. 
 
3.2  RESEARCH DESIGN  
The research used a ‗multi-method‘ approach of both qualitative and 
quantitative methods with a phenomenological design.  
 
Qualitative research enables the researcher to probe and explore 
questions/items referring to personal meaning, identify facilitators and barriers 
to change, and to identify reasons for the success or failure of the existing 
interventions (Starks and Trinidad 2007). Furthermore, qualitative research 
can provide insight into an individual‘s actions, beliefs, thoughts and 
perceptions that quantitative methods alone cannot do (Broadhead 1980; 
Chen and Rossi 1983; McMillan and Schumacher 2001).  
 
Phenomenology is rooted in the late 18th-century European philosophy 
(Holloway and Wheeler 1996), and has increasingly been used as a type of 










 CHAPTER THREE: METHODOLOGY                                                                                                                                                                  
85 
 
human phenomena, from the perspective of the people involved, it is an 
appropriate design for research in humanistic disciplines such as genetic 
counselling. Phenomenological studies provide insight into human experience 
through the use of thick descriptions provided by the individuals involved 
(Brink 1996). This method of conducting research focuses on the 
understanding of the social phenomena from the participant‘s perspective, in 
an attempt to uncover meaning and generate understanding of the particular 
phenomena (Denscombe 2008; Watson et al 2008). In addition, 
phenomenology attempts to capture experience without imposing 
assumptions regarding the reality of the experience, and seeks to reveal 
multifaceted and profound processes beyond the surface appearance 
(Holloway and Wheeler 1996).  
 
The two broad fields of phenomenology, namely interpretive and descriptive, 
arise from the influence of two philosophers, Edmund Husserl and Martin 
Heidegger. Koch (1995) recommends appraising both philosophical 
approaches when choosing a research methodology. Husserl‘s philosophy 
emphasises the description of a person‘s complex lived experience whereas 
Heidegger‘s view requires the researcher to go beyond the description of the 
individual‘s life world by thorough analysis and integrating of self-
interpretation of the recorded text (Carpenter and Suto 2008; Cohen and 
Omery 1994; Morse 1994). As this study sought to describe the GESC from 
the users‘ perspective, a Husserlian phenomenological design was employed 
to guide the research. This is supported by McMillan and Schumacher (2001) 
who state that a descriptive approach is complementary to an initial study of a 
specific phenomenon. 
 
The Husserlian phenomenological approach describes the meaning of the life 
experience from the perspective of the individual involved; and strictly 
cautions against the researcher engaging in a subjective perspective or 
offering a personal interpretation of the meaning. A true description of the 
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disconnecting the description from any preconceived notions of the 
researcher, thereby seeing the phenomenon in its true essence (Carpenter 
and Suto 2008; Cohen and Omery 1994; Knaack 1984). According to Koch 
(1995) reduction is used to ensure the validity of the interpretation by avoiding 
the inclusion of the researcher‘s self-interest. Morse (1994) highlights the 
most common technique of achieving reduction, namely, by identifying and 
articulating assumptions prior to data collection and analysis.  
 
In the research conducted for this study, the researcher examined her 
personal attitudes, beliefs and prejudices prior to the engagement with the 
data collection in order to be as objective as possible. Assumptions made 
were written down and discussed with the supervisors to ensure that 
neutrality was maintained and that an analytic account of reality could be 
captured. 
 
Figure 5 presents an outline of the research methodology detailed in the 
subsequent section of Chapter Three. The figure can be used to follow the 
















Figure 5: An outline of the methodology used during the study. 
 
3.3  PARTICIPANTS AND SETTING 
 
3.3.1 SAMPLING - METHOD AND SELECTION 
More than 500 families have been recruited into the SA LS research 
programme. Disease-causing mutations have been identified in 37 of these 
families, 20 of which are currently involved in the PT programme (a 
pathogenic mutation has been identified in an affected family member and PT 
for any blood relative is available).  
 
As a result of the founder effect in SA and limited geographical movement, 
the majority of these individuals live in the WC and NC Provinces. For many 
(especially those individuals from the rural areas) access to genetic testing 
 Group of individuals who can provide 
information about their experience of the 
Genetic and Endoscopic Surveillance 
Clinic. 
 Interviews, field notes and observations 
made by the researcher and data 
captured on the database. 
 Quantitative analysis (CAT-PCA). 
 Qualitative analysis (thematic analysis). 
 
 Increased sample size to facilitate the 
investigation of emerging concepts from 
the interview analysis. 
 Total number of interviews: 
- Group A (83 participants) 
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and surveillance is only through outreach services offered by GSH. For this 
reason uptake and result-giving of PT is limited to the time of the outreach 
service. Delivery of the result can occur only if the individuals present 
themselves at the outreach clinic. When the study was initiated, PT was 
available for 20 families. Eight hundred and thirty-five individuals had 
requested testing, and 631 of these individuals had received their genetic test 
results. Of the 216 individuals who tested mutation-positive, 191 were known 
to be alive. 
Purposeful sampling was used to recruit individuals who could articulate their
experiences of the phenomenon being investigated – the experience of being
involved in a GESC. This form of sampling is commonly used in qualitative
research as it facilitates the selection of participants who are able to give
richness to the data (Brink 1996; Glaser and Strauss 1967). Clinicians, nurses
or other staff members involved in the service, identified ‗information-rich‘ 
cases (from the list of individual‘s fulfilling the inclusion criteria, Section 3.4.1).
Such cases were, therefore, appropriate for detailed study and of particular 
interest with respect to the research questions. In order to fully describe this 
experience, the researcher selected two study groups. This allowed her to
concentrate on areas of particular salience to each group, which seen
together, could provide a more detailed and accurate account of the topic
being studied. For example, individuals entering into PT were interviewed to
gain information on the PT phase, while those individuals who had already 
received a mutation-positive result and had been recommended to maintain
regular colonoscopic screening could provide information on the surveillance
aspect. Once the interviewing process was initiated, ‗snowball‘ or ‗chain
sampling‘ was further implemented in the recruitment process of the
individuals already involved in the service. This involved a process whereby 
the participants recommended relatives to be interviewed, and these relatives 
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Individuals selected for interviewing and meeting the inclusion criteria were 
contacted by the Colorectal Cancer Genetic Co-ordinator (CRCGC) and the 
background and purpose of the study were explained to them (Appendix 2). 
The names and telephone numbers of those individuals who expressed an 
interest in participating in the study were provided to the researcher by the 
CRCGC. Individuals who declined the invitation to participate were asked, 
telephonically, for their reasons for refusal. It was explained that the 
information would be used to explore the reasons for the drop-out rate. They 
were provided with a list of possible reasons from which to select their 
responses. These responses were grouped into categories including: ‗not 
interested‘, ‗fear of disclosure‘, ‗no time available‘, ‗inconvenient‘ and ‗other‘. 
They were not coerced or persuaded, in any way, to provide reasons. 
 
The researcher contacted the consenting participants and advised them 
about the length of the interview process. It was also mentioned that a 
successive interview could be requested, should the first visit exceed an hour 
and a half, or if the participant became tired during the interview/questioning 
process. The researcher provided the participants with a choice of venues, 
and the most appropriate and private venue was selected by the participant. 
 
All participants contacted by the CRCGC and then subsequently by the 
researcher agreed to participate in the study.  
 
The two groups of participants included: 
 Group A:  individuals who had previously been involved in the PT 
programme, who were mutation-positive and, therefore, recommended to 
adhere to colonoscopic surveillance. These individuals were required to 
be involved in the programme for at least a year so that compliance with 
colonoscopic surveillance could be determined (individuals pending their 
first screening appointment were excluded as they would have been 
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To ensure that a broad range of participants who adhered to the 
recommended surveillance as well as those who did not adhere were 
selected for interviewing, criteria for adherence to recommended screening 
practices were identified. Adherence was determined for the 191 mutation-
positive individuals and the cohort was subsequently categorised into five 
groups demonstrating compliance with recommended colonoscopic 
surveillance. The groupings were based on the number of colonoscopies they 
failed to attend (Table 5).  
 
Table 5: Adherence grouping (1-5) used to define and select the sample frame of the study 
(Group A). 






1 None missed 48  19 39.6% 
2 1 missed 40 27 67.5% 
3 2 missed 32 13 40.6% 
4 3 missed 21 6 28.6% 
5 >3 missed 50 18 36% 
Total  191 83  
†The date of the result disclosure (according to the genetic test report) and recommended age-related colonoscopic 
frequency was taken into account when calculating attendance. The South African screening recommendations 
include biannual colonoscopies for an individual younger than 30 years and annual colonoscopies after the age of 30 
years. 
 
Group B: individuals who were embarking on PT between June 2009 and 
December 2010. These individuals were interviewed three times, initially at 
their information session (prior to testing), immediately after their result 
session, and one month after receiving their test result. The interviewing time 
frame (for Group B) was based on an 18-month period. This was determined 
by the length of time that it took to reach data saturation for Group A. 
 
According to Morse (1994) saturation is reached when no further explanation 
or description can be obtained, with redundancy or duplication of ideas arising 
as a result of the exhaustive exploration. The total number of individuals 
interviewed to attain saturation for Group A and the total number of interviews 
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Table 6: Number of interviews conducted for Group A and Group B. 
Group A Group B 
A1 19 Interview 1 33 
A2 27 Interview 2 23 
A3 13 Interview 3 22 
A4 6 Completed all 3 22 
Total (A): 83 Total (B): 33 
 
3.3.2 RESEARCH SETTING 
Interviews took place in the participants‘ homes or private venues of their 
choice. Marshall and Rossman (1999) suggest that, as the setting of an 
interview can affect the content of the information provided, interviews should 
always be at the interviewee‘s convenience and is usually preferable for this 
to take place in their homes. When an individual is requested to discuss 
sensitive issues, a private venue is more likely to result in a true portrayal of 
the situation (Holloway and Wheeler 1996). By interviewing the participants in 
their home environment, the researcher could observe the home 
circumstances, family interaction and behaviour. This also offered a solution 
to individuals who experienced transport difficulties. However, the researcher 
was also aware that certain individuals did not wish the interviews to take 
place in their homes, for fear of disclosure of their mutation-positive status. In 
these cases alternate private venues were arranged. All venues selected 
provided convenience and privacy. 
 
3.4  ELIGIBILITY CRITERIA 
 
3.4.1. INCLUSION CRITERIA  
Inclusion criteria for Group A required the participants to: 
 Be over the age of 18 years, have received their genetic test result and 
be mutation-positive; 
 Have known their PT result for longer than one year (to enable the 
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 Be accessible for a personal interview; and 
 Have consented to be interviewed and tape-recorded by the 
researcher. 
 
Inclusion criteria for Group B required the participants to: 
 Be individuals from a family where a pathogenic mutation has 
previously been identified and the participant is requesting PT; 
 Be accessible for a personal interview; and 
 Have consented to be interviewed and tape-recorded by the 
researcher.  
 
3.4.2. EXCLUSION CRITERIA 
Criteria for which individuals for Group A were excluded: 
 Participation in a small qualitative research study being conducted during 
the same time period. 
 
Criteria for which individuals for Group B were excluded: 
 Individuals who were seen prior to or after the determined data 
collection period, June 2009 to December 2010 (period defined by the 
length of time taken to reach saturation point for Group A‘s interviews). 
 
3.5  MEASUREMENT INSTRUMENTS 
 
3.5.1 INTERVIEWS 
Interviews, often presented as the ‗gold standard‘ of qualitative research, offer 
the researcher the opportunity to discuss past events by focusing on 
descriptions of what people experienced and the reasons for the manner in 
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1999; Patton 2002). For the purpose of this study, a semi-structured interview 
schedule was selected as the most appropriate measuring tool, because it 
provided the researcher with the ability to engage in a dialogue with the 
participants, enabling in-depth exploration of the events and their experiences 
from the ‗insider perspective‘ (Holloway 2005). This approach is used when a 
researcher is familiar with the components of the phenomenon, but is unable 
to anticipate all the possible responses to a particular question. In semi-
structured interviewing, the interview schedule is used as a rough guide to 
direct the conversation and content to be covered, while being sufficiently 
open in structure to allow in-depth probing of significant responses of the 
participants (Patton 2002). Thus the interviews are interactive and sensitive to 
the interviewee‘s views, ideas and language, while keeping the format flexible 
(Pope and Mays 2000).  
 
The interview schedule included both open- and closed-ended questions. 
Closed-ended questions were used to capture the sociodemographic data 
and data from the different measurement scales (Cancer Worry Scale; Duke 
Anxiety and Depression Scale; Facilitators and Barriers to Adherence Scale; 
Genetic Counselling Satisfaction Scale; Knowledge of Lynch Syndrome; 
Satisfaction with Genetic and Endoscopic Services). The scale responses 
were either nominal or ordinal and were numerically coded to permit the use 
of nonparametric statistics to identify patterns and relationships within the 
data (Morse 1992). While many of the closed-ended questions could have 
been completed by the participant, the researcher completed them personally 
during the interview to ensure consistency as certain individuals were 
functionally illiterate. This also provided the researcher with an opportunity to 
get to know the participants and paved the way for more in-depth responses 
to pertinent and sometimes sensitive questions asked in the open-ended 
items. 
 
For each open-ended question, probes and reflection were included to aid 
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Minichiello et al 1990). Neutral probes were listed to clarify responses if they 
were incomplete or inaccurately understood. The use of open-ended 
questions allowed the researcher to explore the participant‘s thoughts and 
experiences while closed-ended questions were used to collect ‗yes/no‘ or 
pre-categorised scales of various items. The questions were generated from 
the literature, discussions with the supervisors, CRCGC and clinicians at the 
GESC. The interview schedule was designed in such a way that the basic 
questions were answered first followed by the more difficult or personal, 
possibly sensitive, items. This ensured that the researcher could establish a 
rapport with the participant prior to requesting information that they might 
have found difficult to answer. 
A cross-sectional design was used to gather information from each participant 
at one point in time only (Group A), while a longitudinal approach, consisting
of three interviews (pre-, post-PT result and one month after test result) was 
used for Group B. 
In order to obtain content validity of the interview schedule, it was reviewed by
the CRCGC and the research supervisors to ensure that the items were 
comprehensive, easily understandable and the sequencing was appropriate. 
The information sheet and consent form (Appendix 3) were available in both
English and Afrikaans. As the researcher is fluent in both languages, the
interview was conducted in the language of the participant‘s preference. The
same interview schedule was used for all participants, but the order of the
items varied according to the trend of the conversation. The time spent with
each interview depended on the amount of prompting required to answer 
each item comprehensively and the amount of personal information the
participants wished to reveal. Interviews for Group A ranged from one hour to
four hours. Group B‘s first interview ranged from 20 minutes to one hour, two
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3.5.2 INTERVIEW SCHEDULE (APPENDIX 4a and 4b) 
Questions in the interview schedule were grouped into several categories. 
















Figure 6: The interconnectivity of Group A and Group B interview schedules.  
CWS-Cancer Worry Scale.  
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Section A – Sociodemographic Data and Personal History (Group A and 
Group B) 
As it is best to start with questions the interviewee can answer easily, the first 
section utilised closed-ended questions to obtain information on the 
demographic background of the participant. A detailed family pedigree was 
drawn to provide insight into the family history of CRC, and formed an 
important process in establishing rapport with most of the participants. The 
participants provided information about the number of siblings, children, and 
individuals with cancer in the family.  
 
Section B – Knowledge of Lynch syndrome (Group A o ly) 
Knowledge of LS was assessed on a binary basis (knows/does not know) or 
by answering ‗yes‘ or ‗no‘ to questions. The scale used to assess the level of 
knowledge of LS was developed by Domanska et al (2009) and used to 
measure knowledge of LS amongst mutation-positive individuals in a Swedish 
cohort. The questionnaire contained 11 statements covering knowledge of 
CRC in general, LS cancer risk, surveillance, hereditary and genetic testing. 
As highlighted by Kasparian et al (2007), knowledge is not easily transferable 
between research studies as measures capture specific knowledge that may 
not be generalisable to other population groups or countries. This scale was 
thus revised to make it appropriate for the SA population, with the supervisors 
ensuring that the meaning was maintained after changes were implemented. 
This included changing item one, ‗CRC affects 5% of all individuals in 
Sweden‘ to ‗CRC affects 4-5% of all individuals in SA‘ and substituting the 
term ‗LS‘ where HNPCC had been used in the original scale. The Domanska 
scale was selected above the more well known Breast Cancer and Hereditary 
Knowledge Scale and the Breast Cancer Genetic Counselling Knowledge 
Questionnaire as the Domanska scale assesses the level of knowledge in LS 
families specifically, as opposed to assessing the background knowledge of 
individuals with a low to moderate breast cancer risk (Erblich et al 2005; 
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Open-ended questions obtaining insight into the personal interpretation of the 
participants‘ knowledge and their experiences of cancer were also included in 
this section. 
 
Section C – Endoscopic Surveillance Service (Group A only) 
The third section incorporated a combination of open- and closed-ended 
questions to obtain insight into the experience of colonoscopic surveillance. 
Reasons for adherence or non-adherence to the recommended colonoscopic 
surveillance was assessed by a three-point Likert scale ranging from ‗main 
reason‘ to ‗not a reason‘. The responses provided to participants to select 
from, for attending or not attending surveillance, was based on the findings of 
Kruger (2005), whose study highlighted factors contributing to adherence and 
non-adherence to surveillance in the rural populations of the WC and NC. 
While many factors influencing surveillance have been cited in the literature 
(Esplen et al 2001; Hadley et al 2004; Liljegren et al 2004), Kruger‘s study 
was done within the population group selected for the current study and was, 
therefore, selected. 
 
Section D1 - Satisfaction with the Genetic Counselling and Endoscopic 
Surveillance Service (Group A and Group B) 
The participants‘ level of satisfaction with the genetic counselling service was 
assessed mainly, by means of quantitative measures. The ability to provide 
evidence for service development; to identify whether services are effective 
and of value to patients; and to ensure that the service is maintained or 
improved, is determined by the inclusion of these measures during the 
evaluation process (Payne et al 2008). The Satisfaction with Genetic 
Counselling Scale (SGCS) is a widely used assessment tool, designed by 
Shiloh et al (1990), used to measure patient satisfaction with genetic 
counselling (Davy et al 2005; Kasparian et al 2007; Payne et al 2008). The 
32-item (later reduced to 12 items) questionnaire determines patient 
satisfaction with genetic counselling within three delineated domains, namely, 
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which the respondent evaluates the healthcare professional as having the 
required skills. ‗Affective‘ pertains to the client‘s perception of the healthcare 
provider in terms of the amount of time and interest devoted to them during 
their consultation. ‗Procedural‘ concerns the satisfaction with administrative 
procedures. Westwood et al (2006) used this instrument to develop their 
questionnaire, addressing satisfaction in primary care genetic services within 
the UK. In this present study, questions from De Marco et al (2004), 
Groenewegen et al (2005), Poulton (1996), Shiloh et al (1990) and Westwood 
et al (2006) were incorporated with other questions into the sections on 
consultation satisfaction. 
As satisfaction with service is further linked to the process of service delivery
during the PT programme, it was deemed particularly important to evaluate
the genetic counselling session. The satisfaction with genetic counselling was 
assessed by using the recently developed six-item scale designed by
DeMarco et al (2004), the Genetic Counselling Satisfaction Scale (GCSS).
This scale was originally developed by Tercyak et al (2001), for use within the
prenatal setting, and was validated by De Marco et al (2004) for use within
the cancer counselling sector.
Section D2 - Predictive testing and counselling programme (Group B
only)
Open-ended questions were used to determine the experience of being 
involved in a PT programme. Aspects of the clinic such as, referral pathways, 
purpose of genetic testing, and coping mechanisms were explored. Factors 
providing the motivation to undergo PT was determined by eight questions. 
Participants had to indicate the relevance of each statement as it related to 
their reason/s for engaging in the process of PT, by rating each statement on 
a three-point Likert scale ranging from ‗A lot‘ to ‗Not at all‘. The list of items 
was based on a review of the literature and on the researcher‘s clinical 
experience in the field (Balmana et al 2004; Claes et al 2004; Esplen et al 
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Section E - Communication in the Family (Group A only) 
Family communication can be determined by using the Family 
Communication Questionnaire (FCQ), consisting of a seven-item instrument 
developed to assess communication within four dimensions: (1) 
communication of genetic test result; (2) length of time between receipt of 
result and communication with relatives; (3) reasons for the communication of 
the test result and reasons for not informing the family of the result; (4) topics 
discussed with family members (Graham et al 1993; Rubin et al 1988). This 
study used an amalgamation of the FCQ and questions relating to family 
communication, sourced from the literature (Forrest et al 2003; Gaff et al 
2005; Hughes et al 2002; Koehly et al 2003; McCann et al 2009; Peterson et 
al 2003; Stoffel et al 2008), which enabled further exploration of the 
communication process.  
 
Questions relating to: factors used by the participants to aid the decision-
making process of informing the family, the reaction of the family in response 
to the information, and the experience of telling the family, were also included.  
 
Section F - General health of the participant (Group A only) 
This section included questions which could determine the health-related 
status of the individual. The influence of testing positive for the gene 
predisposing to LS on alcohol use, smoking and a healthy lifestyle was 
assessed by the interview schedule, as was self-reported 
compliance/attendance with endoscopic screening. Surgery and/or 
chemotherapy/radiation histories were completed after the interviewing 
process by means of the clinical database.  
 
Duke Anxiety and Depression Scale (Group A and Group B) 
The Duke Anxiety and Depression Scale (DUKE-AD) screens both clinical 
anxiety and depression as diagnosed according to the psychiatric criteria of 
the Diagnostic and Statistical Manual of Mental disorders, Revised Third 










 CHAPTER THREE: METHODOLOGY                                                                                                                                                                  
101 
 
scale investigates nervousness, depression, fatigue and insomnia, difficulty 
with concentration, being comfortable around people and giving up too easily. 
Each question is rated to reflect the intensity of the individual‘s emotions 
during the preceding week. The total score is calculated by adding each 
item‘s rating. A score of five or more (out of a possible 14) indicates major 
anxiety and depression (Parkerson et al 1990; Parkerson and Broadhead 
1997). Validation of the DUKE-AD supports the scale‘s screener accuracy 
with operating characteristic curves of 78.3% for major depression and 72.3% 
for major types of anxiety (Parkerson and Broadhead 1997). Group A 
answered the seven-item scale once, while Group B completed the 
questionnaire on three different occasions (at the information and blood-
taking session, immediately after the result session and o e month after the 
result session), to determine the levels of anxiety and depression during the 
PT programme. 
 
The DUKE-AD scale was selected as it was quick to administer taking just 
over two minutes to complete. As qualitative interviewing is a lengthy process, 
a measuring scale which is brief, but effective in providing information on the 
mental health of the patient, was preferred.  
 
Cancer Worry Scale (Group A and Group B) 
The Cancer Worry Scale (CWS) was originally developed to measure cancer-
related distress, as a four-item measure, in patients with breast cancer 
(Lerman et al 1991a; Lerman et al 1991b). The scale determines how 
frequently patients think and worry about cancer as well as how often such 
thoughts or concerns affect their mood and ability to perform daily activities 
over a period of one month. The response options range from a score of one 
(not at all or rarely) to a score of four (all the time), with a minimum total score 
of four and a maximum total score of 16. 
 
The CWS is commonly used to assess worry about cancer, and as with the 
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complete. The scale was administered once to Group A and three times (at 
the information and blood-taking session, immediately after the result session 
and one month after the result session) to Group B. The CWS has shown 
good validity (Gramling et al 2007; Lerman et al 1991a; Lerman et al 1991b). 
 
Section G - Previous Research Involvement (Group A only) 
As a large majority of individuals from SA LS families are at-risk as a result of 
the effect of a founder mutation, numerous national and international research 
studies have focused on this cohort (Anderson et al 2007; Blokhuis et al 
2008; Burn et al 2008; Felix et al 2006; Goldberg et al 1997; Ramesar et al 
2000). It was, therefore, important to determine the impact that inclusion in 
research studies was having. The willingness of the participants in this study, 
to partake in future research, was explored during the last section of the 
interview.  
 
3.5.2 AUDIOTAPE RECORDINGS 
Audiotape recordings are the primary means of capturing the data of 
qualitative interviews. Although this technique may appear, at first, to be 
intrusive, it allows the researcher the opportunity to foster a dialogue with the 
participant, rather than only asking questions and having to interrupt the 
conversation and engagement by having to write down the responses 
(Carpenter and Suto 2008). An additional advantage of recording the 
interview is the ability to create an accurate written record of the discussion 
which can be converted into text through the transcription process.  
 
3.6  PROCEDURE 
3.6.1 PILOT STUDY 
A pilot study was conducted on two participants from each group, to refine the 
structure of the interview schedule and to identify any changes needed to 
improve the clarity and format. Questions were tested for difficulty of 
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envisaged (Barbour 2008; Brink 1996; Roussow 2003). Piloting also allowed 
the opportunity to investigate the feasibility of the study, to ensure that the 
data obtained was observable and measurable (Barbour 2008; Brink 1996).  
 
Following each pilot interview the researcher asked the interviewees for their 
critical opinion on any confusing categories or any other aspects of the 
schedule which could be considered insightful (Holloway and Wheeler 1996; 
Marshall and Rossman 1999; Roussow 2003). Several questions were 
adapted to eliminate their ambiguous nature and to aid the clarity of the 
interview schedule. Subsequent to these corrections, the schedule was 
rechecked by the researcher‘s supervisors. The participants in the pilot study 
were not included in the study. However, in addition to serving as a pre-test of 
the interview schedule, it provided an estimate of the amount of time required 
to complete each interview. Interviews for Group A took an average of just 
over an hour and a half, interviews exceeding this time span entailed a 
second home visit to complete. The interviews for Group B were, on average, 
45 minutes (first interview), three minutes (second interview) and 20 minutes 
(third interview). Individuals from Group B were interviewed after their clinic 
appointment (in a private room away from the clinic) for the first two 
interviews, followed by a home visit (or any other private venue of their 
choice) for the final interview. Participants were informed about the three 
interviews, including the likely duration thereof, prior to consenting to the 
interview to ensure that they were able to commit this time to the research. 
 
3.6.2 RECRUITMENT 
Study participants for Group A were selected on the basis of having 
undergone experiences about which the researcher wanted to gain 
information. Potential participants meeting the inclusion criteria, accessible 
and likely to be willing to participate, were selected from the LS database by 
the CRCGC familiar with these individuals. As far as possible, individuals 
representative of a generalised broad base in terms of socio-economic status, 
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contacted telephonically by the CRCGC, and invited to participate in the 
study. She then, with the permission of the individuals, provided the contact 
details to the researcher who then made contact with them to arrange the 
convenient interview times and venues. 
 
Group B comprised any individual, entering into PT (during the period of June 
2009 to December 2010) and meeting the inclusion criteria, who consented to 
the three-step interview process. These participants were also initially 
approached by the CRCGC, at their first PT session, to determine if they were 
willing to participate in the research study. They were then seen by the 
researcher following the first counselling session. Every individual invited to 
participate in the study consented to the interviewing. 
 
3.6.3 IMPLEMENTATION OF INTERVIEWS 
Each interview took place in a private venue of the participant‘s choice. The 
researcher conducted every interview personally during the months of June 
2009 and April 2011 (including final (third) interview of Group B). In total 116 
individuals were interviewed.  
 
The aims of the research were explained to each participant, prior to 
interviewing, highlighting the benefit that their honest answers would have on 
improving the programme. Reassurance was given that all information 
discussed would be kept confidential apart from the possibility of being 
published in a scientific journal where names would not be used. It was re-
iterated that other family members would not be discussed to maintain their 
confidentiality. The participants were reassured that their recommendations 
would be relayed to the genetic and clinical team so that they could be 
implemented in the service, but that their names would not be mentioned. 
 
The participants (Group A and B) were advised that some of the questions in 
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would be given the option of further counselling following the interview to 
address any distress caused by talking about their experiences and the 
contact details were provided. 
Each audiotape was dated and labelled with a code.  The participants‘ names 
were kept separately from the tapes and interview schedules and only the 
researcher had access to these. Tape recordings of the interviews were 
transcribed verbatim, in either English or Afrikaans, by the researcher 
immediately afterwards.  
When quotes were incorporated to substantiate the participants‘ responses,
the wording was changed so that it portrayed the meaning of the statement.
This was particularly important to consider as the majority of interviews were 
conducted in Afrikaans, and lost their meaning when directly translated into
English. Denscombe (2008) describes the process of transcription to include
―tidying-up and editing‖ to ensure that the meaning of the data is conveyed to
the reader. While the information may lose some of its authenticity when dealt
with in this manner, Carpenter and Sumo (2008) claim that it is rather the
meaning that matters, not necessarily the words. To ensure validity during
this process, supervisor checks were incorporated to warrant that the
interpretation did not change the participants‘ meanings.
3.7  TRUSTWORTHINESS AND VALIDITY 
The validity of a study is closely linked to the researcher‘s ability to ensure 
that an appropriate meaning has been derived from the specific deductions 
made following data analysis. As Morse (1994) pointed out, the qualitative 
researcher is interested in discovering and learning about the truths as known 
to those participants being studied. Thus if the thoughts and ideas of the 
participant are accurately reflected by the researcher, trustworthiness of the 
data can be established (Holloway 1997). Using triangulation, the use of 
different methods of data collection, the validity of the study can be increased, 
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approach (Daly et al 1997; Golafshani 2003; Marshall and Rossman 1999; 
Patton 2002; Sarantakos 1993). A combination of different data sources 
including, observations, interviewing and analysis of database records was 
used to validate and cross–check findings during the data analysis.  
 
Lincoln and Guba (1985) proposed that the fundamental criterion for 
qualitative research is trustworthiness and that the criteria for judging 
qualitative data include credibility, dependability, confirmability and 
transferability (Ulin et al 2005). Each of these aspects and their application in 
the researcher‘s study is briefly described below:  
 
3.7.1 CREDIBILITY 
Credibility focuses on the confidence in the truth of the findings of the study 
and the provision of an accurate understanding of the context (Carpenter and 
Suto 2008; Ulin et al 2005). This study utilised peer review in an attempt to 
ensure credibility. The researcher regularly met with her neutral co-supervisor 
during the analysis phase, to ensure minimal researcher bias in the 
interpretation and categorisation of the data and subsequent content analysis. 
Furthermore the interviews were electronically recorded and the data were 
captured verbatim during transcription by the researcher to enhance the 
validity by providing an accurate and complete record (McMillan and 
Schumacher 2001).  
 
3.7.2 DEPENDABILITY 
According to Holloway (1997), for a study to be dependable it should 
demonstrate consistent and accurate findings. A detailed description of the 
research method is thus given to ensure the decision trail is clear, process is 
consistent and results are dependable (Holloway 1997; Minichiello et al 
1990). Field notes indicative of the date, time and location, were kept on all 
subject matter discussed between the researcher and her supervisors, the 
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dealt with the qualitative aspects of the study, reviewed the interview 
schedule to ensure that the content was comprehensive and the questions 
were easily understood.  
 
3.7.3 CONFIRMABILITY 
The researcher made a conscious effort to maintain the distinction between 
her personal values and those of the participants to ensure that the findings 
were the result of the research and not due to subjectivity and her personal 
biases. As described by Morse (1994), confirmability pertains to obtaining 
direct and often, repeated affirmations of what the researcher has heard 
during the interview process, with respect to the phenome on being studied. 
The researcher returned to the participants to confirm the findings and re-
check interpretation of the emerging data to establish their confirmability. 
 
3.7.4 TRANSFERABILITY 
Transferability relates to the conclusions of the study and the possibility of 
accurately applying these to ther cohorts or situations. The goal of 
transferability is to produce data which can be applied to other contexts if 
samples are selected to represent viewpoints and experiences that reflect key 
issues in the research problem (Minichiello et al 1990; Ulin et al 2005). 
Similarities to other parallel situations can contribute to extending knowledge 
on the phenomenon (Morse 1994). The use of comprehensive descriptions 
enables peers and/or readers to decide if the findings described may be 
extended and applied to different contexts or settings.  
 
Qualitative research is concerned in deriving a true representation of reality 
as portrayed by the participant sample (Holloway 2005; Watson et al 2008). It 
derives its validity from the thoroughness of its data analysis and not from the 
representativeness of its sample as is customary in quantitative research 
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The use of the pilot study together with the supervisors‘ comments on the 
validity of the interview schedule ensured further trustworthiness (Holloway 
and Wheeler 1996; McMillan and Schumacher 2001).  
 
In quantitative research, validity determines how truthful the research results 
are and whether the research instrument measured what it intended to 
measure (Golafshani 2003). Marshall et al (2000) suggest that the use of 
unpublished or nonvalidated measures can produce biased results and apart 
from selecting the quantitative measures for their brevity, they were 
additionally chosen as they had been tested for validity. The DUKE-AD 
measurement (Parkerson and Broadhead 1997; Wu et al 2002), the CWS 
(Gramling et al 2007; Lerman et al 1991a; Lerman et al 1991b), and the 
GCSS (De Marco et al 2001; Tercyak et al 2001) have all shown good validity 
in several international studies. 
 
3.8  RELIABILITY 
In qualitative research the most common technique of ensuring reliability, 
used by Husserlian researchers, is bracketing. This requires the researcher to 
bracket the emerging data from the rubrics of earlier descriptions, guarding 
against the influence of these on the phenomenon (Cohen and Omery 1994; 
Koch 1995). This was ensured by having the qualitative supervisor check that 
the meanings, derived from the interviews, were reflective of the discussions 
and that the themes derived were congruent.  
 
In quantitative research reliability refers to the consistency of the 
measurement or the degree to which the measure can re-measure with the 
same subjects under similar conditions. A reliable measure will illustrate 
comparable test scores if conducted twice. Cronbach‘s alpha is commonly 
used as a measure of reliability (internal consistency) and involves only one 
administration of the test instrument unlike test/re-test estimates which 
require two administrations. A ‗high‘ Cronbach‘s alpha value indicates that the 
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higher is considered acceptable. In essence computing the alpha coefficient 
provides an indication of the measurement of fit, where a higher value 
represents a better fit. Eigenvalues (discussed further on page 112) are also 
capable of providing an indication of the fit (total variance explained by the 
measurement item) and are better suited when ordinal values rather than 
metric variables are being analysed. 
 
3.9 DATA ANALYSIS 
3.9.1 QUALITATIVE DATA 
Transcripts of interviews provide the descriptive record but cannot provide 
explanations (Pope and Mays 2000), and therefore data analysis is required 
to facilitate the process of bringing order, structure and interpretation to the 
mass of collected information (Marshall and Rossman 1999). Such a 
systematic process is capable of reducing the amount of data to enable the 
researcher to make connections, identify categories and patterns of meaning 
(Carpenter and Suto 2008). This process usually starts early, during the data 
collection phase, and guides the ongoing data collection (Watson et al 2008). 
The advantage thereof, is that the researcher can refine questions and 
pursue emerging avenues of inquiry for further depth (Pope and Mays 2000). 
 
The qualitative data analysis of this study was based on a thematic analysis 
approach (Colaizzi 1978), which incorporated descriptive principles as used in 
Husserlian phenomenonology. The analysis involved a process of data 
reduction, data display, drawing of conclusions and data verification. This is 
described in further detail by steps one to seven: 
 
1. Reading of each participant‘s verbatim transcript with a focus on the 
aims of the study. This allows the researcher to acquire familiarity with 
each case and a sense of the full picture; 
2. Statements, words or phrases seen as significant to the phenomenon 
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3. Meanings are derived for each significant statement;
4. The meanings are organised and data collected from each participant
is constantly compared to that of other participants leading to theme
development. Theme and sub-theme categories are established;
5. A rich and exhaustive description of the phenomenon is formulated;
6. The phenomenon is clarified;
7. Process of validation (Carpenter and Suto 2008; Colaizzi 1978;
Sarantakos 1993).
Interviews were recorded to preserve the data on tape, allowing for the
analysis to be completed subsequent to the interviewing. As the analysis was
done following the communication process, the data could be analysed
without influencing the communicator in any way (Roussow 2003). Once the
recordings were transcribed verbatim, the coding of the data, which fragments
the interviews into separate categories, allowed for the raw data to be
processed (second step in Colazzi‘s approach). The initial categories for 
sorting the data were based on the literature and the researcher‘s background
knowledge of the families at risk for LS. Codes were then assigned to each
category, with the coded material used to explain the nature of the
participant‘s experience. Although several topics had been predetermined
based on the structure of the interview schedule, themes within these topics
and their relatedness to one another emerged from the interview rather than
hypotheses being created, a priori. The coding was then confirmed by the
researcher‘s supervisors before further analysis took place.
The transcripts were read through several times, and the content was 
compared with the earlier collected data. The constant comparing and 
contrasting of categories identified patterns of meaning, recurring ideas and 
significant themes (Holloway 1997), with each category reflecting a concept 
being analysed to describe the participants‘ understanding and experience of 
the GESC. Any new information obtained from subsequent interviews, was 
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ongoing process, whereby the findings of the study drove the sampling 
process as the study progressed. Frequency tables were used to categorise 
the responses into descriptive statistics such as percentages and means. 
This could provide a summary of the categories of some of the aspects of the 
interview (Pope et al 2000). 
 
Quotes were used to illustrate specific views held by participants, reflect the 
content or context of themes and sub-themes or to illustrate typical or unusual 
statements (Cronin et al 2010; Sarantakos 1993). Deviant cases were 
highlighted and the differences described. Once no new insights emerged, 
the point of saturation was declared for the specific category as new data 
would not contribute to further understanding. This was continued until all the 
categories reached saturation point (Daly et al 1997; Minichiello et al 1990). 
The data was then compared with the available literature.  
 
3.9.2 QUANTITATIVE DATA  
The Quantitative data, such as the demographic information, knowledge of 
LS, satisfaction with the surveillance and PT programme, DUKE-AD and 
CWS measures, were gathered during the interviewing process and captured 
on Excel spreadsheets. 
 
The analysis involved a two step process. The first step analysed the mutual 
relationships between the items within the data set using Categorical Principal 
Component Analysis (CAT-PCA). CAT-PCA is part of the procedure option in 
SSPS, a software package for data management and statistical analysis 
(SPSS 2001). CAT-PCA is appropriate for data reduction and identification of 
underlying components of a set of items when variables are categorical (for 
example ordered categories). The primary benefit of using CAT-PCA rather 
than the traditional PCA, is that the restrictions of linear relationships do not 
apply. The scaling technique remains stable when sample sizes are small or 
large avoiding the difficulty in interpreting large numbers of parameter 
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analysis on variables with different measurement levels such as nominal, 
ordinal, interval or ratio. The original set can be replaced by a smaller one 
with as little loss of information as possible. These items are then projected 
as vectors into a two or more dimensional space, whereby the length of the 
vector relates to its relative contribution to a particular dimension. 
Components which are grouped together by means of clusters of responses 
are known as dimensions1. The angle between the vectors represents the 
level of association between the vectors. Thus the technique illustrates a 
strong visual ability to identify potential relationships among variables and 
objectscores (participant‘s responses) in a multidimensional space.  
 
Secondly, if applicable, the items were rescaled by transformations invariant 
to the level of measurement of the items (if the level was not violated) and all 
subsets transformed into one or more scales, dependant on the underlying 
dimensions of the construct. Eigenvalues2 were calculated to indicate how 
successful the maximalisation and minimalisation criteria were. The 
component loadings3 (co-ordinates of the vectors) and mutual relationships of 
these scales were subsequently analysed by appropriate multivariate 
techniques. 
 
3.10  ASSUMPTIONS 
The researcher assumed that each participant answered questions and 
provided unsolicited information honestly and expressed a true reflection of 
their experience. 
 
                                                 
1 Dimensions are labelled by the common characteristic of the variables that determine the 
particular dimension. They are weighted so that they correlate maximally with one dimension, 
but minimally with another. Thus dimensions that are not correlated are created. 
 
2 ―Eigenvalues are a special set of scalars associated with a linear system of equations that 
are sometimes also known as characteristic roots‖ (Marcus and Minc, 1998: p. 144). 
 
3 Component loadings are the factor loadings in a factor analysis and are the weights 
correlated with a dimension. High component loadings are important in the definition of the 
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3.11  ETHICAL CONSIDERATIONS 
The research project maintained the ethical principles of participant 
autonomy, anonymity, confidentiality, justice and respect. Formal ethical 
approval was obtained for the study from the Human Genetics Departmental 
Research Committee and the Human Research Ethics Committee of the 
Faculty of Health Sciences prior to the commencement of the research 
(Rec/Ref: 213/2009) (Appendix 5). 
 
The CRCGC, involved in the initial contact of the selected participants, 
explained the following during the first telephonic contact (Appendix 2): 
 
 Purpose of the research;  
 Participation was voluntary: participants were in no way coerced or 
persuaded to participate in the study;  
 Withdrawal could take place at any time without jeopardising any 
medical services available to them or their families at the clinic or 
hospital; 
 No discussion of the health or genetic status of other family members 
would take place. 
 
When the consenting participants were contacted by the researcher, they 
were encouraged to ask questions or seek clarification of the study. In 
addition they were informed that they could decline to answer any of the 
questions in the interview schedule, request to have the tape-recorder 
switched off, or terminate the interview at any stage. All participants were 18 
years of age or older, and legally competent to sign consent. Written consent 
was obtained prior to any interviewing, audiotaping or if any photographs 
were required. All the participants except one, who was illiterate, could 
provide written consent. For this participant, consent was provided by means 
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Every possible avenue for protecting the anonymity of participants was taken. 
The audiotapes were kept in a locked filing cabinet that only the researcher 
had access to and were destroyed as soon as the transcription process was 
complete. 
 
A coding system was used to further protect the anonymity of the participants. 
The researcher assured the participants that the names and the information 
provided to her during the interview would be kept confidential, apart from the 
future publication in a scientific journal where names would not be used. 
Quotes were used to illustrate certain ideas or themes identified during the 
data analysis; however any details that could possibly result in the 
identification of the participant were not included. 
 
If any anticipation of distress occurred during the recollection of the 
experiences, provision was made for referral to counselling services. The 
researcher ensured that she remained non-judgemental and that her body 
language did not convey disapproval if the information given by the participant 
was at odds with the genetic and medical knowledge or management 
recommendations.  
 
While the purpose of the research interview is to gather data, it is commonly 
reported that interviewees seek advice or confirmation of the information 
given during the interview process (Patton 2002). As a genetic counsellor 
acting as a researcher, it was important that an ethical framework for dealing 
with such issues was established prior to the study to avoid her research role 
being taken over by a counsellor role.  If necessary, and rather than intervene 
in the interview process, information booklets or follow-up sessions were 
arranged. This ensured that the researcher did not interfere with the data-
collection process while maintaining the professional standard and code of 
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One of the critical, yet often neglected, aspects of research is the feedback of 
information obtained from the study to the community involved in the research 
project (Research Ethics and Environmental Health 2002). It was therefore 
ensured that the results and recommendations of the study were provided to 
the clinical and genetic team involved in the management of SA LS families 
as well as to the participants of the study. Participant feedback occurred after 
the completion of the research project and entailed either a written letter, or a 
home visit, depending on the preferences of the participant. 
 
3.12  WEAKNESS OF STUDY 
Any research study has limitations and cannot ever be comprehensively 
completed or include all the implications for practice (Holloway 2005). The 
limitations for this study included: 
 
 The use of a cross-sectional design (Group A) meant that changes to 
the participant‘s experience of the surveillance aspects of the GESC 
could not be assessed over time. It was possible that certain views 
could have changed following further contact with the clinical/genetic 
team;  
 Selection bias: individuals who chose to participate could be 
unrepresentative of the target population. Although all the individuals 
invited to take part in the study agreed to participate, individuals who 
did not attend the GESC to receive their genetic test result or who 
could not be contacted were not included in the cohort. They may not 
have attended because of dissatisfaction with the service; 
 The use of interviews as the research tool was only capable of 
capturing the reconstruction of events as experienced by the 
participants, rather than how the interviewees may have behaved 
(Holloway 2005). It is acknowledged that the participants may have 
provided answers, which they thought, may have been appropriate 
rather than that of their true attitudes (Holloway 1997);  
 As the interview schedule was based on the literature, genetic 
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supervisors, the questions may have missed relevant points from the 
participants‘ perspectives; 
 Minimal international literature and an absence of SA literature on
certain aspects of the research study implied that a limited amount of
data were available for comparison purposes;
 The participants were encouraged to provide the researcher with a true
portrayal of their experience, without being corrected for their
discrepancies. However it is acknowledged that the researcher‘s social
class, gender, level of education and status as a genetic counsellor
could have influenced the interview process.
3.13 STRENGTHS OF STUDY 
 A large amount of rich data were produced through the use of 
interviewing enabling a detailed understanding of why people did what 
they did (Daly et al 1997);
 Each interview was conducted personally by the researcher in a venue
of the participant‘s choice and in a language with which they were
familiar and comfortable;
 Face-to-face interviewing was used which is known to improve
response rates (Daly et al 1997);
 The use of a semi-structured interview as opposed to a structured
questionnaire provided the participants with greater latitude to express 
their personal views and reasons for expressing certain facts and
ideas. This enabled the researcher to focus on issues salient to the
participants, seek clarification and explore or probe areas of interest;
 The analysis was an ongoing process, whereby the findings of the
study could drive the sampling process as the study progressed;
 Certain questions used in the measurement scales were from other
validated studies which increased the trustworthiness of the study;
 The use of a longitudinal design (Group B) meant that changes to the
participant‘s experience of the genetic service, particularly the PT
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recall discrepancies on the part of the participants, as they were asked 
to describe an event that was in the process of happening rather than 
something that occurred in the past and relied on memories interpreted 
over time; 
 By tape-recording the interviews, the exact words of the participants 
were captured as the researcher could provide her full attention to 
what the participant said; 
 Research bias: The researcher was conscious of her own assumptions 
and recorded her experiences and thoughts during each interview, in 
an attempt to overcome any potential bias associated with her 
subjectivity on the information obtained; 
 The recommendations made by the participants were addressed and, 
where changes were requested, have been implemented or are in the 
process of being implemented into the GESC. 
 
The presentation of the analysis, results/findings and discussion are 
combined in Chapter Four. This is customary in qualitative research (McMillan 
and Schumacher 2001) and subtitles are included to connotate the different 
findings. This facilitates the description and prevents unnecessary repetition 





































ANALYSIS, RESULTS/FINDINGS AND DISCUSSION 
 
4.1 INTRODUCTION 
This chapter provides the results/findings of the research study. The data 
obtained from each interview are presented and discussed in sections, with 
graphs and tables used to illustrate mutual relationships between items.  As 
the research set out to evaluate the genetic and surveillance programme, 
data has been compared to the available literature, to highlight any similarities 
or differences. The outreach clinic has developed as a result of 
accommodating the socio-economic constraints of the individuals utilising the 
genetic and surveillance service. Particular focus has been directed at 
describing the participant population (including socio-economic and 
demographic backgrounds) and home environment to fully comprehend the 
effect of these factors on the psychosocial problems experienced. 
 
In light of the volume of data that was collected, and to aid clarity, findings 
from Group A and Group B are presented and discussed separately. 
 
 Group A – data gathered from individuals who were mutation-positive 
and on the surveillance programme for at least one year. The results of 
the evaluation of the surveillance aspects of the GESC are presented 
in Section 4.2 (page 120). 
 Group B – data gathered from individuals who were in the process of 
undergoing PT are presented in Section 4.11 (page 209). The findings 
of the evaluation of the genetic testing and counselling programme of 
the GESC are discussed in this section.  
 
The headings of each section are presented in the same format as the 
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read together, however, the number and description of the items in the 
interview schedule do appear in the text. 
 
Where applicable, direct quotes are included from the participants‘ interviews 
to provide the reader with greater insight into the information and to enhance 
the validity of the identified themes. If a participant‘s response required 
translation from Afrikaans to English, it has been indicated, after the quote. 
/…/ indicates that irrelevant material has been removed to aid clarity. 
 
4.2 GROUP A - GENETIC AND ENDOSCOPIC SURVEILLANCE CLINIC 
(GESC) 
 
Participants in Group A were all mutation-positive and had been involved in 
the surveillance programme for at least one year so that compliance with 
colonoscopic surveillance could be determined. To facilitate a more thorough 
evaluation of the GESC, individuals attending the established endoscopic 
centre (GSH) as well as those accessing the outreach component of the clinic 
were interviewed. While the GESC operates in the same manner whether 
occurring at GSH or on outreach, the participants reside in separate 
provinces in SA and come from very different socio-economic backgrounds. 
At times, and for comparison purposes, especially during the discussion of 
the demographic characteristics, data from Group A has been separated into 
information from the participants attending the hospital clinic (GSH) and those 
seen at the outreach centres. Mostly, however, data from the two clinics have 
been combined to identify trends within the group as a whole. 
 
A total of 83 interviews were conducted to reach saturation, however, for 
three of these, the interviews were terminated (these three participants have 
been excluded from data analysis and do not appear in Table 7). One 
participant was experiencing emotional distress (unrelated to LS), the other 
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recall information requested by the interview schedule. The third interviewee 
was intoxicated during two interview attempts and it was decided by the 
researcher and supervisors, to exclude him from the interviewing process.  
 
Eighty-six percent (69/80) of the interviews were conducted in the 
participants‘ homes, 14% of participants (11/80) preferred to be seen in a 
private room in their local clinic or private office near their place of 
employment or residence. 
 
As participants were selected for their experience of the surveillance service 
offered by the GESC, there was a varying time span from the time that 
genetic testing had occurred to the time when the interviews were conducted 
(Figure 7).  
 
 
Figure 7: The number of years from the time of the genetic test to the 
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4.3 DEMOGRAPHIC DATA AND PERSONAL HISTORY 
Table 7 outlines the demographic data for participants from Group A and lists 
a comparison of the characteristics among participants who attend the 
outreach clinic and the hospital clinic (GSH). Fifty-two participants from the 
outreach clinic and 28 participants from the hospital clinic were included in the 
interviewing process. 
Table 7: Sociodemographic characteristics of the study participants (n=80). 
The participants from both clinics were predominantly female (outreach 73%; 
hospital 61%), married (outreach 63%; hospital 64%) and spoke Afrikaans as 
a home language (outreach 98%; hospital 68%). The mean age of 
participants from the outreach clinic was 40.8 years (range, 21-70, SD=10.6) 
and the hospital clinic 43.1 years (range, 24-55, SD=7.6). Of these 
participants, 100% from the outreach clinic and 85% (24/28) from the hospital 
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clinic classified themselves as Mixed Ancestry. The four White participants 
(14%) were from the WC and attended the hospital clinic. As the general 
population of both the WC and the NC are mostly Mixed Ancestry (53.9% and 
51.6%), the high incidence of this population group among the participants 
was not unexpected (Statistics South Africa 2005). In addition, the common 
founder mutation (C1528T mutation in MLH1), accounting for the majority of 
LS cases in SA, is observed exclusively in individuals of Mixed Ancestry 
(Goldblatt et al 1990; Ramesar et al 2000).  
  
The marked difference noted between the two groups pertained to their 
residential location. Eighty-one percent of participants from the outreach 
clinic, living in the NC, occupied a rural dwelling (42/52), while 96% (26/27) 
from the hospital clinic, in the WC, were from an urban area. As the NC is one 
of the least developed provinces in SA, the high rate of rural residence is 
most likely due to population demographics in this area (Statistics South 
Africa 2005). Photograph 1 depicts a ‗matjieshuis‘ (reed hut dwelling). This 
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Level of Education 
Figure 8 compares the formal levels of education of the outreach to that of the 
hospital-screened group. Ninety-six percent (27/28) of participants from the 
hospital clinic and 88% (46/52) of participants from the outreach clinic 
completed junior school. In contrast, more participants from the outreach 
group completed secondary school than those from the hospital group (52% 
versus 39%). However, tertiary education was three fold higher (27% versus 
9%) in the hospital group when compared to the outreach group. 
Nevertheless, both groups reported higher tertiary levels of education than 
that of the general population in their specific residential regions of the NC 
(6.1%) and WC (11.2%) (Statistics South Africa 2005). The mean years of 
education of the outreach group was 9.3 years compared to that of 12.3 years 
of the hospital group. 
 
 
Figure 8: Level of education as defined by clinic (outreach versus hospital) among 
those participants aged 20 years and older. 
 
Reasons for not completing schooling or tertiary education, reported on by the 
group as a whole, are presented in Table 8. It was not uncommon for both 
groups to have large families. Often the male or ‗brightest‘ child was selected 
to remain in school, while the daughters cared for the family or assisted with 
the household chores. Other families managed these difficulties by providing 
0 20 40 60 80 100
< 7 years (did not complete junior
school)
Junior school certificate
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minimal schooling for all their children rather than full schooling for a few. 
Those participants who indicated ‗other‘, cited ‗expulsion‘, ‗struggling or failing 
at school‘ and ‗having no friends at school‘ as the reasons for not completing 
their schooling. 
 
Table 8: Reasons for not completing or continuing with schooling and/education (n=80). 
 Frequency (n=80) Percentage 
No secondary/tertiary schooling in town/village of 
residence 
10 8% 
Social circumstances* 14 17.5% 
Financial restraints of parent 20 25% 
Preferred to start working/did not feel it was needed  11 13.75% 
Financial/care support required as a result of the loss 
of the parent with cancer 
8 10% 
Other 6 7.5% 
 Data from the outreach and hospital groups have been collated.  
*Social circumstances included pregnancy, concern for the political instability/rioting at the school (apartheid 
era), or joined a gang.  
 
Employment 
As can be seen in Figure 9, the rate of unemployment exceeded that of 
employment for participants in the outreach programme. A concerning 67.3% 
of participants (35/52) from the outreach clinic (NC) and 39.2% (11/28) from 
the hospital clinic (WC) were unemployed. The unemployment rate for 
participants from both clinics was significantly higher than that of the general 




Figure 9: Comparison of unemployment rates for the outreach (n=52) and 
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Reasons cited by participants, for being unemployed, are presented in Table 
9. The down-scaling of the alluvial diamond mining operation at Kleinsee and 
the closing of the copper mine at Nababeep contributed significantly to the 
number of individuals who were unemployed in the NC and attending the 
outreach clinic.  
 
Table 9: Reasons for unemployment (n=80). 
 Frequency Percentage 
Care for family 5 6.3% 
No work available 4 5% 
Health-related 5 6.3% 
Retrenched/business closed down 13 16.3% 
Other family member/partner provides income 7 8.8% 
On a social grant/pension 5 6.3% 
Do not want to work or poor working conditions 2 2.5% 
Other 6 7.5% 
 Data from the outreach and hospital groups have been collated. 
‗Other‘ refers to individuals who were unemployed as they had recently moved to a new area. 
 
Occupation 
The occupation categories among the employed population in SA have been 
defined as per the Census (2001) descriptions (Statistics South Africa 2005). 
The majority of participants from the hospital clinic were employed in the 
managerial, professional and semi-professional sectors (Table 10). This 
percentage was significantly higher than that of the general population in the 
WC (28.5% versus 22.2%). The majority of participants from the outreach 
clinic were employed in the lower income category of elementary 
occupations. It should also be noted that the percentage of participants, for 
each of the occupation categories, was significantly lower than that of general 
population of the NC. 
 










semi-professional 7.7% (4/52) 23.5% 28.5% (8/28) 22.2% 
Clerical, sales, service 7.7% (4/52) 22.3% 3.5% (2/28) 20.6% 
Skilled agriculture, craft, 
operations 0% (0/52) 27.4% 3.5% (2/28) 23.3% 















Figure 10: Comparison of the level of household income between the outreach 
(n=52) and hospital (n=28) group.  
 
Figure 10 illustrates the discrepancy in the total monthly household income 
between the hospital and outreach groups. More participants from the 
hospital clinic were in a higher income bracket than those of the outreach 
clinic. The mean monthly income was R12 625 (USA$ 1 830) for the outreach 
group and R13 750 (USA$1 993) for the hospital group. A comparison to the 
general population was not made as statistics for monthly household income 
were not provided in the Census.  
 
Nearly a third of participants (15/52) from the outreach group were solely 
dependant on social grants. Nine of the 15 participants received a pension 
(old age grant) from their original employer (De Beer‘s mining) following the 
closure of the Kleinsee mine and six participants received a state disability 
grant (DG). The DG, which was R1 080 (USA$ 157) per month, supported a 
mean of 5.5 persons per participant recipient. All participants with a DG (6/6) 
were from the Mixed Ancestry population group. It is interesting to note that 
the six individuals who qualified for this grant, did so as a result of a 
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resection/total colectomy following CRC. Applicants are eligible to apply for a 
DG if they were unable to work as a result of a physical/mental disability. A 
resection or total colectomy, however, does not typically lead to an individual 
being disabled or incapable of working. 
Further information on the types of grants for which the households qualified, 
are given in Figure 11 and explained in Appendix 6. The grants held by the 
participants mentioned above are included in the count below (grants held by 
all households). For ten participants, more than one grant was received by 
the household. 
Figure 11: Type and count of social aid received from government.
The number of individuals dependant on the monthly household income is 
displayed in Figure 12. Three participants were from a household of 13 
occupants (outreach group). The mean number of individuals per household 
was 5.8 for the outreach group and 3.1 for the hospital group. 
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Figure 12: Comparison of the number of individuals per household of the 
outreach (n=52) and hospital group (n=28). 
 
Family history and cancer profile 
 
 Table 11: Parental cancer history profile. 
Affected parent                       Participants Male Female Total 
Paternal 16 (21.6%) 20 (27%) 36 (48.6%) 
Maternal 10 (13.5%) 27 (36.5%) 37 (50%) 
Unknown 0 (0%) 1 (1.3%) 1 (1.4%) 
Total 26 (35.1%) 48 (64.8%) 74 (100%) 
 
Only one participant (1.4%), estranged from his parents, had been unable to 
identify whether or not he had a parent with a family history of cancer (Table 
11). Ninety-one percent (73/80) of the remaining participants had an affected 
parent and 76.7% (56/73) of the affected parents had died following their 
cancer diagnosis. Thirty-four percent (27/80) of the participants had acted as 
a care-giver for a member of their family when they became symptomatic. 
Usually this would be a female participant (21/27). The type of cancer that the 
parent was affected with is illustrated in Figure 13. As would be expected, 
CRC contributed to the majority of cases (76%), while endometrial 
malignancy accounted for only 4% and more than one cancer type occurred 
in 6% of cases (CRC with endometrial, breast or prostrate cancer). Ninety-six 
percent of parents carried a MLH1 mutation. The remaining 4% (3/73) had a 
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Figure 13: Type and frequency of the parental cancer of the 
participants in Group A. 
 
Table 12 presents the age at which participants experienced a parent‘s 
cancer or cancer diagnosis. Most participants recalled a parental cancer 
when they were between the ages of 19-29 years (25%). 
 
 Table 12: Age of participant at parental cancer/cancer diagnosis. 
Age at parental cancer diagnosis Frequency Percentage 
0-6 years 10 12.5% 
6-12 years 11 13.8% 
13-18 years 11 13.8% 
19-29 years 20 25% 
≥30 years 15 18.8% 
Parent not affected 4 5% 
Did not know parent/could not recall 
when parent was diagnosed 
9 11.3% 
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First-degree relatives with colorectal cancer 
 
 
Figure 14: Comparison of participant‘s number of first-degree relatives 
(FDR) with colorectal cancer.  
 
Thirty-seven participants had a single first-degree relative (FDR) with CRC 
(46.3%). The lowest number of FDR‘s with CRC per participant was zero 
(3/80). The highest count was six affected FDR‘s (2/80). The mean number of 
FDR with CRC among the 80 participants was two (Figure 14). 
 
The number of siblings and children per participant is displayed in Table 13. 
The mean number of siblings and children per participant from the outreach 
group was 5 and 1.8 compared to that of the hospital group which was 6.1 
and 2.4, respectively. 
  
Table 13: Number of siblings and children per participant (n=80).  
Frequency of count 
 0 1 2 3 4 5 6 7 8 ≥ 9 
Siblings 9 3 7 12 13 10 12 10 3 1 
Children 10 17 23 22 6 2 0 0 0 0 
 
The incidence of LS in SA is unknown and the uptake of PT among the at-risk 
population has not been determined. Figure 15 and Figure 16 provide the 
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Figure 15 compares the uptake of PT among the siblings of participants 
attending either the hospital or outreach clinic.  
 
 
Figure 15: Comparison of uptake rate of genetic testing among the outreach 
and hospital participants‘ siblings. 
 
The uptake rate among the participants‘ siblings was remarkably high with 
97% (422/431) of the total number of siblings having undergone genetic 
testing. The number of participants, who illustrated a 100% uptake rate 
among their siblings, was comparable between the outreach and hospital 
groups (76% versus 75%).  
 
Figure 16 depicts the comparison of PT uptake among the participants‘ 
children who were eligible to undergo genetic testing (over the age of 18 
years). The uptake rate among the eligible children of the participants was 
high with 73.6% (64/87) of the total number of children undergoing PT. The 
number of participants who illustrated a 100% uptake rate, among all their 
eligible children, was considerably higher in the hospital group (32.1% versus 
20.7%). A possible explanation for this could be that PT opportunities are 
more readily available in the hospital sector. PT, offered through the outreach 
clinic, is only obtainable during the period of the outreach trip, while PT 





































CHAPTER FOUR: ANALYSIS, RESULTS/FINDINGS AND DISCUSSION 
133 
Figure 16: Comparison of uptake rate of genetic testing among the outreach 
and hospital participants‘ children. 
Cancer profile 
Figure 17: Comparison of cancer history of participants attending either the 
outreach or hospital clinic (n=80). 
Marginally more participants from the outreach sector had been diagnosed 
with CRC (21.2%; 11/52) than in the hospital group (17.9%; 5/28). However, 
polyp development was greater in the hospital sector (57.1% versus 32.7%).  
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TC+IRA – total colectomy and ileorectal anastomosis. 
 **Second primary colorectal carcimona. 
 †Breast cancer.  




















50 M MLH1 Descending colon TC+IRA D  x Outreach 1 
P4 47 F MLH1 Caecum TC+IRA D  x Outreach 2 
P6 35 M MLH1 Ascending and 
descending colon 
Hemicolectomy D  x Hospital 2 
P9 43 M MLH1 Ascending Hemicolectomy D  x Outreach 1 
P15  52 F MLH1 Transverse TC+stomach wedge and 
block 
PT  x Outreach 5 
P17 44 M MLH1 Descending Hemicolectomy D  x Outreach 3 
P26 38 M MLH1 Ascending and 
descending 
TC+IRA D  x Outreach 1 
P33 45, 50† F MLH1 Transverse, †duct 
carcinoma 
TC+IRA, †R mastectomy D x  Outreach 2 
P39 39, 49** F MLH1 Ascending, 
**descending 
Hemicolectomy D  x Hospital 2 
P42 44 F MSH2 Sigmoid, 
descending colon 
TC+IRA and small bowel 
resection 
D  x Hospital 2 
P46  46 F MLH1 Ascending TC+IRA D  x Hospital 1 
P50 39 F MLH1 Rectal Defunctioning loop 
colostomy 
PT  x Hospital 5 
P65 29 M MLH1 Caecum TC+IRA D  x Outreach 2 
P71 46 M MLH1 Caecum Right hemicolectomy D  x Outreach 2 
P75  26 M MLH1 Caecum TC+IRA PT  x Outreach 2 
P83 41 M MLH1 Ascending, 
transverse and 
splenic 
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The mean age of the 16 participants who were affected with CRC was 41.5 
years (range 26-52 years) (Figure 18). This is somewhat younger than that 
reported in the literature (Annie Yu et al 2003; Anwar et al 2000; Lynch and 
de la Chapelle 2003; Lynch and Lynch 2000) and the figure determined by 
Stupart et al (2009a) who investigated a SA LS cohort (44 years). Ten 
participants (62.5%) underwent a total colectomy with ileorectal anastomosis, 
five a hemicolectomy and one a defunctioning loop colostomy. Colorectal 
tumours in LS typically occur on the right side of the colon. However, the 16 
participants diagnosed with CRC developed tumours throughout the colon 
and rectum. The majority (75%) of participants developed cancer prior to 
genetic testing. The mean adherence group (indicating compliance with 
screening guidelines) was 2.3, which is relatively compliant with 
recommended colonoscopic screening. 
 
 
Figure 18: Age of onset of first colorectal cancer (n=16). 
 
In this cohort, males presented earlier (mean 39.1 years) than females (mean 
44.5 years). The younger age of onset in males, is however, a typical feature 
of LS (Abdel-Rahman et al 2006; Hampel et al 2005b; Lynch et al 1993b; 
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4.4 KNOWLEDGE OF LYNCH SYNDROME 
 
The level of knowledge of LS was measured with the Domanska et al (2009) 
scale. The hospital and outreach participants were grouped together to allow 
for the determination of overall knowledge and to identify areas least 
understood by the group as a whole. A description of each item has been 
included in Table 15 as it would have been too cumbersome to include in 
Figure 19.  
 
 Table 15: Description of items displayed in Figure 19.  
Item Description 
 
B1a CRC affects approximately 4-5% of all individuals in South Africa 
B1b Individuals who carry the gene for LS will definitely develop cancer 
B1c Individuals who do not carry the gene will never develop CRC 
B1d Females with LS have an additional risk of endometrial cancer 
B1e Females with LS have an additional risk of ovarian cancer 
B1f Colonoscopy is only useful in individuals with LS when there are bowel symptoms 
B1g Individuals with LS need regular colonocopies 
B1h Individuals with LS will pass the faulty gene on to 25% of their children 
B1i Tumour tissue can be used to diagnose LS 
B1j Blood samples can be used for genetic testing 
B1k The disease is most often inherited from the male side of the family 
 CRC-Colorectal cancer. LS-Lynch syndrome. 
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The mean number of correct responses was 6.5 out of 11 (range, 2-11). This 
is considerably lower than the median of 9 reported by Domanska et al 
(2009). However, consideration should be given to the fact that the 
Domanska study was conducted in a developed country (Sweden) where 
81% of the participants had attended university versus 35% in the SA cohort.  
 
The questions regarding the importance of regular surveillance, diagnosis and 
testing for LS had the highest frequency, with 100%; 99% and 99%, 
respectively, of correct answers. This is favourable as knowledge around the 
benefits of screening are associated with adherence to colonoscopic 
screening (Myers et al 1990). In contrast, knowledge about CRC related-risk 
and the genetic aspects of LS was less clearly understood: 69% (55/80) of 
participants felt that having the mutation meant that they would definitely 
develop cancer in their lifetime; 81% (65/80) incorrectly stated that the risk of 
passing on the mutation to their children was 25% (correct answer being 
50%); and half (51%) thought that the mutation could only be inherited from 
the paternal side. While the recognition for regular colonoscopic surveillance 
was high (as previously mentioned, 99% answered this question correctly), 
only 44% (45/80) knew that the colonoscopy was beneficial before the 
presentation of symptoms. The majority of participants (67/80) recognised 
that LS predisposed females to an increased risk of endometrial and ovarian 
cancer.  
 
Areas less clearly understood by the group are similar to those identified by 
Domanska et al (2009), who also found the genetic aspects of LS to be poorly 
understood by patients (Domanska et al 2009). In contrast to this present 
study, the Swedish participants failed to recognise the increased risk of 
gynaecological cancers.  
 
Items B1g (individuals with LS need regular colonoscopies), B1i (tumour 
tissue can be used in LS diagnosis) and B1j (blood samples can be used for 
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further analysis because of a lack of variance. Table 16 shows the number of 
participants with correct answers to the eight selected items (Ba, Bb, Bc, Bd, 
Be, Bf, Bh, Bk).  
 
Table 16: The number of participants with correct answers to 
the eight items on the Domanska et al (2009) scale (n=80). 
Correct answers Frequency Percentage 
2 3 3.8% 
3 15 18.8% 
4 17 21.3% 
5 20 25.0% 
6 20 25.0% 
7 4 5.0% 
8 1 1.3% 
Total 80 100% 
 
The participants‘ main source of knowledge about LS was from the healthcare 
provider at the outreach/hospital clinic (Table 17). The distribution of 
'knowledge' provided by the outreach/hospital clinic is Gaussian (normal 
distribution) peaking at knowing five of the eight items.  
 
Table 17: Effects of the source of information on the level of knowledge (n=80). 
 
 
  † Clinic includes the outreach and hospital service. 
 
The participant with the most accurate knowledge used the internet as a main 
source for locating information on LS. The individual was a 35 year old, 
female, of Caucasian ancestry and reported a high education (completed 
tertiary educating) and socio-economic status (income bracket 11). She was 
also only one of five participants to have the internet available as a resource.  
Source of information 










2 1 2 0 0 3 
3 10 5 0 0 15 
4 15 2 0 0 17 
5 18 2 0 0 20 
6 14 5 0 1 20 
7 3 0 0 1 4 
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The majority of participants did not seek further information on LS (Table 18). 
Of those participants receiving information from the outreach/hospital clinic, 
only 8.9% (7/56) looked to further sources to obtain more information. Forty-
one participants (51.2%) had access to additional information resources. This 
included library books (33/80), magazines (3/80) and the internet (5/80). 
Terms used to search for information on LS included: ‗cancer‘ (1/7); ‗CRC‘ 
(3/7) and ‗HNPCC/LS‘ (3/7). Of interest, only seven of the 80 participants had 
heard of the term ‗HNPCC/LS‘. This would have made obtaining additional 
information on the condition very difficult. 
Table 18: Frequency of individuals seeking more information on Lynch 
syndrome per information source (n=80).
Source of 
information 
Seeks more information 
on LS 




Clinic† 5 56 61 
Family 1 15 16 
Internet 1 0 1 









† Clinic includes the outreach and hospital clinic.
Only 35% (28/80) of participants acknowledged receiving a handout on LS
from the GESC (information in the handout only covered surveillance
preparation). Of these individuals, half (14/28) had retained the handout or 
could access it and 78.6% (22/28) had found it useful. Those six participants,
who did not find it useful, reported that they had struggled to read the
information as it was only available in English, which was not their home
language.
Factors affecting knowledge 
Collins et al (2000) reported a positive association between education and 
knowledge and noted higher knowledge scores among women compared to 
men. The present study does suggest that participants with a tertiary 
education had slightly higher knowledge scores than those with only a 
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Figure 20: Relationship between education and knowledge (as measured by the 
Domanska scale). 
 
However, the gender of participants in this study was unrelated to the level of 
knowledge of LS (Table 19).  
 
Table 19: Knowledge score per gender of participant (n=80). 
 Knowledge score 
2 3 4 5 6 7 8 Total 
Male 1 5 8 3 6 2 0 25 
(4%) (20%) (32%) (12%) (24%) (8%) (0%) (100%) 
Female 2 10 9 17 14 2 10 55 
(3.6%) (18.2%) (16.4%) (30.9%) (25.5%) (3.6%) (1.8%) (100%) 
Total 3 15 17 20 20 4 1 80 
(3.8%) (18.8%) (21.3%) (25%) (25%) (5%) (1.3%) (100%) 
 
The means of the dependent variable (knowledge) and confidence intervals 
are shown in Table 20.  
 
Table 20: The effect of gender on average knowledge score. 
Dependent Variable: Knowledge 
Gender Mean Std. Error 95% Confidence Interval Lower Bound Upper Bound 
Male 4.560 0.269 4.025 5.095 
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Furthermore, no relationship between adherence (Table 5, page 90) and 
knowledge, as measured by average knowledge within an adherence group, 
was found (Figure 21).  
 
 
Figure 21: Level of knowledge per adherence group. 
 
When length of time in the programme (calculated from the date the 
participant received their genetic test result) was considered with relevance to 
knowledge, a trend emerges and those participants with low knowledge 
appear related to the shortest exposure time in the programme. The exact 
length of time that the participants were involved in the programme is 
presented in Table 21. 
 
Table 21: Classification of the number of years of subjects within 
the GESC. 
Number of years in GESC 
programme 
Code 
≤ 3 years 3 
   >3≤8 years 2 
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Table 22 illustrates that knowledge appears to increase with length of time in 
the GESC.  
 
Table 22: Level of knowledge per number of years within GESC. 
  Years in GESC programme Total 




Two 0 0 3 3 
Three 5 6 4 15 
Four 3 6 8 17 
Five 4 12 4 20 
Six 11 4 5 20 
Seven 4 0 0 4 
Eight 0 0 1 1 
Total 27 28 25 80 
1 = >8-17 years in programme. 
2 = >3≤8 years in programme. 
3 = ≤3 years in programme. 
 
The means of the dependent variable (knowledge) falls within the lower and 
upper boundaries of the confidence intervals (Table 23).  
 
Table 23: The relationship between length of time of subjects in the 
GESC and knowledge (n=80). 




Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1 5.222 0.249 4.726 5.718 
2 4.500 0.245 4.013 4.987 
3 4.320 0.259 3.804 4.836 
 
Figure 22 illustrates that participants attending the GESC for a longer period 
were more knowledgeable about LS than those participants who had been 
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Figure 22: Average knowledge of subjects per number of years 
attending GESC. 
1 = >8-17 years in programme. 
2 = ≥3≤8 years in programme. 
3 = ≤3 years in programme. 
 
The trend was tested using Bonferroni Post hoc comparisons to control the 
false positive error rate associated with performing multiple statistical tests. It 
shows that only the difference (0.90) between knowledge of people shortly 
exposed and more extensively exposed to the program differs significantly 
from zero (the probability that there is no difference equals 4.2%).  
 










Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
1 2 0.72 0.349 0.126 -0.13 1.58 
3 0.90* 0.359 0.042 0.02 1.78 
2 1 -0.72 0.349 0.126 -1.58 0.13 
3 0.18 0.356 1.000 -0.69 1.05 
3 1 -0.90* 0.359 0.042 -1.78 -0.02 
2 -0.18 0.356 1.000 -1.05 0.69 
Based on observed means. The error term is Mean Square (Error) = 1.677.  
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Knowledge of Symptoms 
Figure 23: Knowledge of colorectal cancer symptoms among participants (n=80).
CRC-Colorectal cancer.
While 61.2% (49/80) of participants could describe a symptom of CRC, it is of 
concern that 38.8% (31/80) had no knowledge of symptoms (Figure 23). 
Participants citing symptoms relayed that they had mentioned the various 
symptoms as a result of seeing a family member with CRC or having
experienced it themselves. According to all the participants, no mention was 
made of symptoms during any information session.
Knowledge of inheritance
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Knowledge of passing on the genetic mutation was also assessed by asking 
participants about the inherited risk to their siblings and children (Figure 24). 
Forty-nine participants (61.3%) had heard about the 50% risk associated with 
autosomal dominant inheritance, but for 38.8% (31/80) of participants this 
was not clear. This is in contrast to Claes et al (2003) who illustrated a much 
higher correct recall (90%) among participants in their Belgian study. One 
reason for the low frequency of correct recall about inherited risk may be the 
fact that only 5/80 (6.3%) participants felt that they had discussed the 
inheritance of LS with their healthcare provider on a frequent basis. Sixty-nine 
(86.3%) participants reported on receiving information on inheritance at one 
point only, and only 5% (4/80) recalled that they had received this information 
more than once.  
 
Fifty-eight percent (47/80) of participants recalled that the inherited risk to 
their children had been discussed with them, while 2.5% (2/80) felt that this 
discussion had provided them with limited knowledge on the risk. Four 
participants (5%) did not recall this being raised with them and 15 participants 
(18.6%) were told that their children had to be assessed, but they were 
unaware of the exact risk of transmission. 
 
For those participants where this was discussed, feelings that were evoked 
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Table 25: Emotional response to hearing information of children being at risk for colorectal cancer. 
Emotional response to inherited risk for 
children 
Frequency of 
responses (_/80) Quotes used to exemplify particular response category 
Acceptance* 33 
―/…/ well what can one really do about it, if it happens then it just happens and I will still encourage my 
children that at least something can be done, actually it is a privilege that we can go for these tests 
[colonoscopies]‖(translated, male, 39 years). 
 
―It is fine, really it is something beyond your control‖ (translated, female, 49 years). 
 
―Look I thought it was an advantage knowing, cause you can do something about it prior to anything 
happening, if you know there is a chance that they could get it from you‖ (translated, male, 41 years). 
 
―Well it was not really new news, you see this thing happening in your family, affecting grandparents, 





―I prayed so much, you see you don‘t want this type of thing for your children, for their future - the fact that 
I had my blood test after I had my children and then had to find out that as I had it they could also have it, 
it was just…it was unexpected - you try and give them the best in life and then this comes along - you 
don‘t want this for your children! (translated, female, 49 years). 
 
Devastated - at one stage my wife felt that we should not have children /…/ (male, 43 years). 
 
It was difficult, and I was so upset and heart broken when I heard that my daughter stood a chance to 
develop…we all cried that day, it was so difficult to hear the news /…/ (translated, female, 37 years). 
 
Sad 9 
Well I actually felt quite sad, the fact that when I heard that I could inherit it from my father, that my life 
would change so drastically, and that I could not stop thinking about dying…well I wonder if they will go 
through the same thing if they were to inherit it from me‖ (translated, female, 37 years). 
 
Guilty 4 
―/…/ it was just horrible hearing that information, to give this type of thing to your children…‖ (translated, 
female, 27 years). 
 
―A mother will always be heart broken knowing that she can pass it on to her children‖ (translated, female, 
39 years). 
Concerned 2 
―Initially I did not worry about that fact but when I had it happen to me, when I developed cancer I thought 
well if this happened to me it can also happen to my children and that, that is what worries me‖ 
(translated, male, 42 years). 
 
Risk of transmission not discussed with 
participant/participant has no children 21  
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Knowing that their children would accept the news of being at-risk and attend 
regular surveillance if required, acknowledging that surveillance could 
decrease the cancer risk, and realising that it was a family condition, were 
reasons given by 41.3% (33/80) of participants reporting ‗acceptance‘. At 
times, acceptance was influenced by personal theories of inheritance, often 
linked to similar physical characteristics:  
 
―I knew that out of my three children, [X] would be the one to have it…she is the one 
who looks most like me, is built like me and also you see, I was the most like my 
mother - it all makes sense, the three of us are also similar personality wise, and our 
traits /…/‖ (female, 53 years). 
 
―My daughter, [X], was shocked when she found out she did not have it, the two of us 
are so similar, people even tell me she reminds them of me when I was younger, you 
see we had even told her to be prepared to find out that she would have it, it would be 
a bonus if she does not have it, but I told her she would more than likely have it, I 
mean I am incredibly happy that she does not have the risk that we all live with, but we 
were so sure…‖ (female, 49 years). 
 
For four participants (5%), the decision to have children may have been 
negatively influenced if they had known about the transmission risk prior to 
starting a family. Six participants (7.5%) felt that it could potentially have 
impacted on their decision to have children. The large majority (66/80), 
expressed that it would not have made a difference, however, at times the 
decision involved extensive deliberation. The quote from P53 illustrates the 
extensive thought process and concern for the risk of transmission: 
 
―My first thought was well obviously I can‘t have more children because I can‘t, uh, I 
can‘t risk giving this gene to someone else… it feels like a bit mean but then in the end 
I did have another child knowing that I could pass on the gene.  I guess my thought 
was just that I was happy to be born, even though I have the gene - in the end it was a 
five year gap between the children as it was a big decision, can you really take it on 
yourself to pass on the gene, a 50% chance of the risk. I guess the main deciding 
factor was that it is not like I am passing on some kind of debilitating chronic condition, 
I am passing on a risk and a risk that is easily managed. My husband and I spoke 
about it many times and we decided that it was not a reason to not have kids‖ (female, 
32 years). 
 
The participant also highlighted her concern with the intentional decision to 
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―/…/ but I am sure that [X] will be okay with her risk as I did not know about the gene 
when I had her, I did not know that I could potentially pass anything on to her, but with 
[Y] I did know there was a chance and I‘m sure that if she does have the gene she 
may well turn around one day and say: How could you do this to me!‖. 
 
Perceived lifetime risk of developing CRC 
 
 Table 26: Perceived lifetime risk of developing colorectal cancer. 
Category Frequency Percentage 
Inevitable (100%) 6/80 7.5% 
Very high (≥75%≤100%) 33/80 41.3% 
50% risk 7/80 8.7% 
Low  28/80 35% 
Uncertain of lifetime risk 5/80 6.3% 




Bottorff et al (1998) suggest that risk-related information is not capable of 
being presented within a vacuum and a subjective interpretation is most likely 
to occur, framed by social and familial meanings, which may be inconsistent 
with the actual genetic risk (80% lifetime risk of developing CRC). Six 
participants (7.5%) felt that CRC development in their lifetime was inevitable. 
It is of interest to note that these participants had all lost a parent to cancer, 
however, no clear association existed between this view (of cancer being 
inevitable) and adherence to colonoscopic screening. Of the six participants 
who expressed that their lifetime risk of developing CRC was 100%, three 
were adherent (Group 1 and Group 2) and two were non-adherent (Group 5).  
 
Many participants referred to their perceived risk in a qualitative form rather 
than an exact numerical risk, and both are included in Table 26. The majority 
of participants viewed their personal risk as high (ranging from ≥75%), while 
35% (28/80) of participants expressed their risk as ‗low‘. Reasons cited for 
the latter included: having had a hemicolectomy/total colectomy, attending for 
regular surveillance, being beyond the age that cancer affected parent/family 
member with CRC, being a different gender to family members who had 
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―Lower than previous generation as the cancer does not seem to affect everyone 
as badly any more‖ (translated, female, 53 years). 
 ―I think it is high as I am a woman and it comes from the women in the family and 
therefore it will be greater for me‖ (translated, female, 33 years). 
4.5 GENETIC AND ENDOSCOPIC SURVEILLANCE CLINIC 
The approximate travel time and type of transport to the outreach/hospital
GESC is listed in Table 27. Seven of the 80 participants had never attended
any form of surveillance and were therefore excluded from further analysis. 
Table 27: Transport and travel time to Genetic and Endoscopic Surveillance Clinic
(n=73).
Travel time to 
GESC 




Walk 7 8.8% 
Private 1 1.3% 
Public 1 1.3% 
Free hospital ambulance 1 1.3% 10 
< 1 Hour 
Walk 1 1.3% 
Private 11 13.8% 
Public 3 3.8% 
Free hospital ambulance 2 2.5% 
Other 2 2.5% 19 
1 Hour 
Private 7 8.8% 
Public 3 3.8% 
Free hospital ambulance 11 13.8% 21 
< 2 Hours Private 3 3.8% Free hospital ambulance 5 6.3% 8 
> 2 Hours
Private 4 5% 
Public 2 2.5% 
Free hospital ambulance 9 11.3% 15 
Data from the outreach and hospital clinic are presented together. ‗Other‘ indicates hitching a ride took 
place. 
More than 50% (44/73) of the participants attending for surveillance at the 
GESC, travelled ≥ one hour to the clinic. The most utilised form of 
transportation (38.8%) was by ‗free hospital ambulance‘, followed closely by 
‗private‘ transport (35.7%) which included the participant‘s own vehicle or the 
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Participants attending the GESC have access to free transport by means of 
ambulance services arranged by their local primary clinics. Eleven 
participants (21.2%) from the outreach clinic incurred costs for transportation, 
as they made use of their own private transport, preferring this to that of the 
ambulance service. The concern with this service is conveyed by the 
following extracts: 
 
―/…/ the ambulance never stops to allow for toilet breaks‖ (female, translated, 33 years). 
 
―We drove for over four hours to get there, it was terrible, the driver would not stop if you 
needed to go…the road is very dangerous and [X] drove like a maniac to get us there, it 
was a terrifying trip‖ (female, translated, 43 years). 
 
Table 28 shows the relationship between missed appointments and type of 
transport and travel time per participant. Participants with the most missed 
appointments had travelled for approximately an hour. 
 
Table 28: Travel time and mode of transportation for participants attending for 
surveillance but missing one or more colonoscopies (n=54). 
Time to 
GESC 










Walk 2 1  0 3 
Private 1 2  0 3 
Public 0 0  0 0 
Total 3 3  0 6 
< 1 Hour 
Private 4 3  1 8 
Public 1 1  0 2 
Free hospital ambulance 2 0  0 2 
Other 0 0  1 1 
Total 7 4  2 13 
1 Hour 
Private 1 2 1 1 5 
Public 1 1 0 1 3 
Free hospital ambulance 6 2 1 1 10 
Total 8 5 2 3 18 
< 2 Hours 
Private 0   1 1 
Free hospital ambulance 4   0 4 
Total 4   1 5 
>2 Hours 
Private 2  1 0 3 
Public 2  0 0 2 
Free hospital ambulance 1  3 3 7 
Total 5  4 3 12 
Data from the outreach and hospital clinic are presented together and data from Adherence Group 1 
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Patients travelling ≤ one hour who missed most appointments were using 
‗private‘ transport (61.5%; 8/13). Of all the participants, 28.8% (21/73) 
travelled for ≥ one hour, missed most appointments and used the free 
hospital transport (Table 29).  
 
Table 29: Travel time and adherence group for participants utilising free 
hospital transport (n=21). 











1 Hour 6 2 1 1 10 
< 2 Hours 4    4 
> 2 Hours 1  3 3 7 
Total  11  4 4 21 
 
Table 30 shows the level of knowledge on LS for the 21 patients who missed 
appointments using free hospital transport with a travel time of ≥ one hour. 
Non-adherence (missed appointments), however, was not only confined to 
the individuals with a low-knowledge score.  
 
 Table 30: Knowledge of participants using free hospital transport 
(n=21). 






2 1 4.8% 4.8 
3 2 9.5% 14.3 
4 4 19% 33.3 
5 10 47.6% 81.0 
6 3 14.3% 95.2 
7 1 4.8% 100.0 
Total 21 100%  
 
Most of these participants, using free hospital transport, and who missed 
appointments were female (Table 31). This may be a reflection of the high 
number of females within the cohort (68.8%). However, the females within 
this selected group were less compliant (missed more than three 
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Table 31: Gender cross-tabulated with adherence and travel time. 
Gender Travel time Total Hour <2 Hours >2 Hours 
Male Adherence 
group 
Missed 1 1 1  2 
Missed 2 1 0  1 




Missed 1 5 3 1 9 
Missed 2 1 0 0 1 
Missed 3 1 0 3 4 
Missed >3 1 0 3 4 
Total 8 3 7 18 
 
The employment status and age distribution amongst the 18 females using 
free hospital transport is presented in Table 32. Most of these females who 
missed appointments were ≥ 50 years and of Mixed Ancestry. 
 
Table 32: Employment status per age group (n=18). 
 Employment status Total 
Yes No 
Age 
20-29 0 1 1 
30-39 2 3 5 
40-49 1 4 5 
≥ 50 1 6 7 
Total 4 14 18 
 
The age group and number of missed appointments for these participants (18 
females) are compared in Figure 25. The higher age groups were over-
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Surveillance 
Ninety-three percent of participants (74/80) had been for colonoscopic 
surveillance. The number of participants within each adherence group are 
listed in Table 33. Fewer than 25% of all participants obtained 100% 
adherence. 
 
Table 33: Adherence to recommended screening guidelines (n=80). 
Adherence 
group 
Attendance Number of individuals 
interviewed 
Percentage 
1 None missed 19 23.8% 
2 1 Missed 27 33.8% 
3 2 Missed 12 15% 
4 3 Missed 6 7.5% 
5 >3 Missed 16 20% 
Total  80 100% 
 
Participants were questioned extensively regarding the frequency with which 
they attended/missed their surveillance appointments. This self-reported 
adherence was compared to actual adherence as calculated from the 
database records (Figure 26). 
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The greatest discrepancy between actual and self-reported compliance can
be seen in Group 1 (no missed appointments). More participants classified
themselves compliant with screening guidelines than the actual number of 
participants in Group 1 (44 versus 19). It is also interesting to note that non-
adherence was under-represented in Group 4 and Group 5, which are
representative of greater non-compliance. Self-reported adherence was half 
of the actual adherence in Group 4 (6 versus 3) and only six of the 16
participants correctly selected their adherence in Group 5 (missed >3 
surveillance appointments). Thus compliance rates based on self-report are
not consistent with those rates obtained from medical records (reflecting
actual adherence). This confirms the findings of the only other study which 
compared self-reported compliance to objective complia ce (Bleiker et al
2005). This present finding and that of Bleiker et al (2005) suggest that over-
estimation of compliance may occur in studies considering only self-reported
screening behaviour (Ersig et al 2009; Hadley et al 2004; Halbert et al 2004;
Stoffel et al 2003).
When participants were asked how often they thought they should go for
colonoscopic screening, 78.8% (63/80) knew that this had to be on a yearly 
basis, 8% (6/80) responded that this should occur every two years and 6%
(5/80) that screening should take place every two years prior to the age of 30
years, and annually thereafter. Of concern, is that 6% (5/80) did not know
how often colonoscopic surveillance was required and 3% (2/80) of 
participants mentioned that they only had to attend for surveillance when they
were requested to do so by their healthcare provider, or if they were
experiencing symptoms. Only three of the seven participants who had never 
been for a colonoscopy did not know the frequency of required screening. 
The majority of these seven individuals were female (85.7%), of Mixed
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Table 34: Demographic data on the seven participants who had 
never had a colonoscopy. 





P19 F 24 MA No Outreach 
P37 F 42 MA No Outreach 
P49 F 38 MA Yes Outreach 
P60 F 27 MA No Outreach 
P62 F 33 MA No Outreach 
P68 F 40 MA Yes Hospital 
P83 M 40 MA Yes Hospital 
 MA - Mixed Ancestry. 
 
Remarkably, 87% (20/23) of participants who had a total colectomy were 
aware that they required yearly flexible sigmoidoscopies.  
 
Surveillance experience 
The experience of having regular surveillance was determined by asking the 
participants about various stages of the screening process. This included: 
colon preparation (drinking either a low- or high-volume bowel cleansing 
agent), accessibility of toilet facilities and the colonoscopy procedure. The 
broad categories defining this experience are identified in Table 35 and 
described in greater detail in the text. 
 
Table 35: Personal experience of surveillance (n=80). 
Personal experience of surveillance Frequency Percentage 
Colon preparation   
Unpleasant 39/80 48.8% 
Pleasant 27/80 33.8% 
Ambivalent 2/80 2.5% 
Type of prep makes a difference 5/80 6.8% 
Never had a colonoscopy 7/80 8.8% 
Toilet facilities   
Outside toilet 15/80 18.8% 
1 household toilet (indoors) 43/80 53.85 
> 1 household toilet (indoors) 22/80 27.5% 
Procedure   
Fine 27/80 33.85 
Uncomfortable 13/80 16.8% 
Painful 23/80 28.%8 
Anxiety prior to colonoscopy 4/80 5% 
Other 2/80 2.5% 
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For thirty-nine participants (48.8%), the preparation procedure was 
experienced as unpleasant and described as the most difficult part of the 
screening process. More females (52.7%) than males (40%) found drinking 
the bowel cleansing agent distasteful.  
 
―Ohhh-it‘s not nice, the minute I drink it I am nauseous and I immediately throw up 
from it…it‘s horrible‖ (female, translated, 37 years). 
 
―It tastes terrible, but I just have to drink it, it makes me so full and causes my stomach 
to feel incredibly hard - and then sometimes it comes out from the top not only the 
bottom‖ (female, translated, 54 years). 
 
―To drink that...it‘s very difficult, the test [colonoscopy] is actually so easy compared to 
drinking the prep‖ (female, translated, 34 years). 
 
However, over a third (27/80) viewed it as a pleasant experience and 
described it as:  
 
―I drink it as if it is water - it goes down well‖ (translated, female, 58 years). 
 
Seventy-four percent of individuals (20/27) with a positive preparatory 
experience were compliant with screening guidelines (having missed none or 
only one appointment). Only two participants were ambivalent about the 
experience and five participants (6.3%) felt that the type of preparation 
mixture made a difference. Either a low- or high-volume bowel cleansing 
agent was preferred: 
 
―That one packet, [X], it really made me feel sick, but the other one, [Y], that was much 
better, it was a lot easier to do with the other one‖ (female, translated, 37 years). 
 
―The prep has gotten better since I have had the sachet with a glass of water and not 
litres of it - makes it so much easier‖ (female, 53 years). 
 
―/…/ by far the worst bit, that stuff tastes so awful and really hard to get it down, I‘ve 
had, I think seven colonoscopies and it seems to be different every time – the one 
time it made me really sick, I had shivers and I felt really nauseous but the last time it 
was a ginger flavoured concoction and it was not as disgusting as usual - the lemon 
that‘s the worst, with the ginger the whole experience was fine, it was nothing, but that 
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Effective preparation is crucial to the visualisation of the bowel lining (to 
detect polyps or cancer) during a colonoscopy (Järvinen et al 2000). Factors 
affecting compliance with preparation include the volume of the preparation 
liquid consumed (McCann et al 2009) and, in this study, the preference for a 
specific type of preparation.  
 
Amenities 
Gaining information on the accessibility and standard of toilet facilities is 
instrumental in understanding the preparation process, particularly in a 
developing country where these amenities are usually below standard. 
Photograph 2 depicts a typical ‗outside toilet‘ in Buffelsrivier, a rural village in 
the NC (Figure A). Photograph 3 illustrates the abysmal living conditions in 
Nourivier. The yellow bucket in this picture is used as a makeshift toilet at 
night and the individuals from this household have access to their 
neighbour‘s outdoor toilet during the day. 
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Photograph 3: Makeshift bucket toilet in Nourivier, Northern Cape. 
 
As 81% (42/52) of participants from the NC were from a rural dwelling, 
certain individuals only had access to a single toilet that was located outside 
the house. P70 describes how an ‗outside toilet‘ is built and the difficulties in 
acquiring an indoor toilet: 
 
―An outside toilet is basically a hole in the ground - the gravel and bricks are laid in the 
hole and then a slab of cement is poured over it. The draining process happens as a 
result of the spaces between the bricks, and it sort of filters into the ground /…/ to 
have an inside toilet, the municipality has to lay down water pipes - it is quite a difficult 
thing to do and they must also approve your plans first‖ (female, translated, 58 years). 
 
Almost 25% (15/80) of participants had only an ‗outside toilet‘. This exceeds 
the figure of the general population where 10.1% of individuals in the WC and 
11.2% of individuals in the NC report bathroom facilities to only include an 
outside, non-flushable, toilet (Statistics South Africa 2005). More than 50% of 
the participants (43/80) had access to a single indoor toilet which was shared 
with other family members or acquaintances and 27.5% (22/80) of 
participants had access to more than one indoor toilet. The difficulties 
associated with the colon preparation, particularly for participants using an 
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―Look the most difficult part is if you have to venture out at night to go to the toilet /…/ 
the last time I spent the whole evening outside and it was bitterly cold‖ (female, 
translated, 56 years). 
―It was just too cold the last time, so I had to go in a bucket inside the house‖ (female, 
translated, 22 years). 
―My sister has a toilet inside the house, when I drink the prep I stay with her but there 
are three people living with her so at times you have to hold out for the toilet‖ (female, 
translated, 35 years). 
Not having an indoor toilet meant the preparation process was difficult to 
complete and in a few cases the cause for non-adherence to screening 
guidelines:  
―/…/ and before everything was so difficult, I mean we had an outside toilet, we had to
drive for four hours on the ambulance to get there and it was a constant need to go to 
the toilet, which you couldn‘t…it was then that I decided I would rather go when I could
sort out my own amenities – a toilet in the house, then I know I do not have to go
outside at night - its cold and unpleasant. I now have everything in my house, the loo
is inside and I have my own transport - so if I have to go now, I go. There is nothing
else standing in my way‖ (female, translated, 43 years).
Colonoscopy 
It is encouraging to note that 50% (40/80) of the participants viewed the
colonoscopy as ‗fine‘ or only ‗uncomfortable‘. 
―It is not a problem, I actually enjoy it, I can see my colon on screen, it is so interesting
to see your insides like that‖ (female, translated, 37 years).
―It is not that bad, I always go first to show the new people that it is okay‖ (female, 
translated, 58 years). 
―Not a problem, I do it without sedation every time‖ (male, translated, 35 years). 
―It‘s not sore, maybe a bit uncomfortable, especially near the turn of the colon, but I 
prefer to watch it on the screen, so that I can see if I am healthy or not - then you 
know /…/‖ (male, translated, 40 years). 
Participants reporting positive experiences were more likely to be adherent to 
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expressing a favourable experience, were from Group 1 (all recommended 
colonoscopies attended) or Group 2 (missed only a single colonoscopy). This 
finding, of greater adherence among individuals with a positive experience of 
colonoscopies, has been reported elsewhere (Gili et al 2006).  
 
Often, the experience of pain associated with the procedure was operator 
dependant: 
 
―The colonoscopy is nothing, if Dr [X] does it, it is nothing, I must say that I have been 
hurt by others - they just don‘t listen to you. I have probably gone for more 
colonoscopies than some doctors have even done before, so shouldn‘t I get a say? 
/…/ Dr [X] knows I know as much about the procedure as can be known, so Dr [X] 
listens to me, I think it is Dr [X] technique as well as that, that makes a difference to 
the experience‖ (female, 53 years). 
 
―I will never have another colonoscopy if Dr [X] leaves‖ (female, 32 years). 
 
For some participants, the initial procedure may have been painful, however 
the level of discomfort was found to decrease over time: 
 
―It has always gotten easier, the first time was quite sore, but I have been going for 
more than six years now and it‘s actually quite nice the last few times‖ (female, 
translated, 38 years). 
 
―It gets better with every year – I did not even feel anything with the last two, I even 
asked the doctor if they were finished or not (laughs)‖ (female, translated, 29 years). 
 
―/…/ the first time I went, was probably the worst as I did not know what to expect, I 
thought it would be horrible but now, it‘s kind of like going to the dentist (laughs), I 
don‘t hate it that much, it‘s more of an inconvenience‖ (female, 35 years). 
 
Only 28.8% (23/80) described it as a painful experience:  
 
―Sigh…it is really not nice, I experience so much pain during the colonoscopy‖ 
(female, translated, 22 years). 
 
―Every year it is so terribly sore, and then I am also so sick afterwards - at times I am 
terrified to come, but I do it for the benefit of my health, I just have to‖ (female, 
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Pain, experienced during the colonoscopy, was cross-tabulated with actual 
adherence (Table 36). The results show that the observed values are close 
to the expected values based on the margins and therefore negate a 
relationship between missed attendance and pain associated with the 
endoscopic procedure. 
 
Table 36: Cross-tabulation of pain and adherence (n=73). 







Attended all Count 4 14 18 
Expected Count 5.7 12.3 18.0 
Missed 1 Count 7 20 27 
Expected Count 8.5 18.5 27.0 
Missed 2 Count 5 7 12 
Expected Count 3.8 8.2 12.0 
Missed 3 Count 2 4 6 
Expected Count 1.9 4.1 6.0 
Missed >3 Count 5 5 10 
Expected Count 3.2 6.8 10.0 
Total Count 23 50 73 Expected Count 23.0 50.0 73.0 
The seven participants who had never undergone a colonoscopy were excluded from the 
analysis. 
 
Pain occurred during the procedure, particularly at the junction of the 
descending and transverse colon, where the colonoscope has to manoeuvre 
a near 90 degree angle. Pain was also experienced after the procedure, this 
was largely due to air trapped in the bowel as a result of the air blown into the 
colon to aid the visibility during the procedure. For a few participants (4/80), 
feelings of anxiety were evoked prior to the procedure and related specifically 
to fears of finding a polyp or a cancer during the colonoscopy: 
 
―I‘m always worried, see one does not know what the outcome will be, it‘s always a 
relief when you are done and all is okay. But I have made peace with the whole thing, 
so if the result comes back bad one day I will accept it /…/ sometimes I am just a little 
queasy before, the nerves you know‖ (male, translated, 41 years). 
 
Of concern is that a few studies have reported that fear of finding cancer is a 
barrier to screening (Kruger et al 2005; Natale-Pereira et al 2008; 
Subramanian et al 2004). The adherence group for these four participants 
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non-adherence among a group of individuals who experienced anxiety prior 
to colonoscopies.  
 
The seven participants who had never been for a colonoscopy had heard that 
it was painful: 
 
―I have heard it is very sore, I guess it made me scared and as a result I decided not 
to go for it‖ (female, translated, 40 years). 
 
The two participants who indicated ‗other‘ described the procedure in light of 
their fear of needles. As the colonoscopic procedure is usually performed 
under sedation, the sedative is given through an intravenous drip. Although 
greater levels of sedation lead to less pain and discomfort during the 
procedure (McCann et al 2009), the trypanophobia could act as a potential 
barrier to future screening adherence. 
 
Half of the participants (50%) did not view the colonoscopy as a negative 
experience, which is in line with the results of Jones et al (2009), Pylvänäinen 
et al (2006) and McCann et al (2009). As found by Liljegren et al (2004), the 
level of discomfort is also likely to decrease with an increased number of 
colonoscopies. However, those who did experience pain may demonstrate 
anxiety about future colonoscopies which could influence their compliance 
with screening. Furthermore, discussion about the negative experience may 
affect uptake among relatives, as was the case for some of the seven non-
adherent participants, who avoided screening as a result of the relayed 
description of the procedure.  
 
Encouragingly, 91% of participants (who had a previous colonoscopy) were 
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Gynaecological screening 
Wagner et al (2005) reported that 69% of their female mutation-positive 
cohort, over the age of 35 years, underwent gynaecological screening (CA-
125 screening and TVU). Of the 55 women involved in this study, 45 were 
over the age of 35 years. Sixty-two percent (28/45) of these women had been 
for a ‗regular‘ gynaecological check-up and 31.1% (14/45) for endometrial 
cancer screening (endometrial Pap smear and TVU). While these rates are 
lower than those reported by Wagner et al (2005) screening, in the SA 
cohort, includes intrauterine biopsy of the endometrium which has been 
shown to increase detection rates (Renkonen-Sinisalo et al 2007). These low 
rates are however still of concern as the lifetime risk of developing 
endometrial cancer in LS has been suggested to exceed the CRC risk for 
women (Hampel et al 2005b). However, Stupart et al (2009a) has predicted a 
lower lifetime risk in the SA population (3%), specifically in those with the 
common founder mutation in MLH1. 
 
Facilitators and barriers to adherence 
Participants were asked to identify the reasons for attending their 
colonoscopic screening appointments. A list of facilitators was discussed with 
them and they were given the opportunity to highlight any further reasons for 
non-adherence. The facilitators were identified from the literature, with 
particular focus on those influencing screening practises in developing 
communities (Guerra et al 2005; Natale-Pereira et al 2008; Northam et al 
2010; Kruger et al 2005) 
 
Table 37 shows the frequency of responses to these selected facilitators and 
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1 2 3 
C9a
Facilitators 
Maintain health 70 3 7 
C9b Recent death/affected relative in family 50 14 16 
C9c Other family members go 12 8 60 
C9d Polyp/cancer found previously 28 1 51 
C10a
Barriers 
 Colon preparation 8 3 69 
C10b Discomfort of procedure 2 3 75 
C10c Reported painful experience 2 2 76 
C10d Transport problems 8 0 72 
C10e Do not think that I need it 1 0 79 
Figure 27 and 28 display the main factors associated with adherence and
non-adherence.
Figure 27: Major facilitators of adherence (items are not mutually exclusive). The 
seven participants who had never had a colonoscopy were excluded from the 
analysis on adherence (n=73). 
Seventy individuals (97.6%) selected ‗maintaining health‘ as their primary 
reason for attendance. Women, especially mother‘s, highlighted that they 
were adhering to screening recommendations not only for themselves but for 
the future of their children: 
―You can‘t be reckless with this thing, so many of my family are and could have been helped 
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around for them, to see them finish school, get married, have children of their own…my 
mother was not around and I will not do the same to my child, I just have to go…to keep 
myself healthy and alive for them‖ (translated, female, 40 years). 
 
The influence of a cancer diagnosis or related death in the family attributed to 
68.2% (50/73) of responses. Individuals witnessing suffering in the form of a 
relative‘s illness or death often promotes adherence to screening (McCann et 
al 2009). The influence of the family or healthcare professional on attendance 
was surprisingly low (12/73). This is in contrast to numerous studies which 
highlight that the healthcare professional‘s endorsement of surveillance acts 
as a major facilitator of CRC screening (Gili et al 2006; Hadley et al 2004; 
Natale-Pereira et al 2008). The most plausible explanation might be that the 
participants did not disregard the recommendation from the physician, but 
rather underwent self-motivating behaviour. Their attendance was a result of 
seeing the effect of others not going and thereby recognising the benefits for 
their health. Furthermore, 28 of the 45 affected participants with a previous 
polyp/cancer (62.72%) selected that the specific pathology had played a 
major role in their future attendance (Figure 17). 
 
Barriers to adherence 
 
 
Figure 28: Major barriers to adherence (items are not mutually exclusive). 
Participants within Group 1 (attending all recommended colonoscopies) have 
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Figure 28 depicts the main barriers to adherence within the sample group 
(n=61). Participants who had never missed a colonoscopy were not included 
in the analysis on non-adherence. The frequencies of each of the categories 
are low in comparison to those of the facilitators highlighted in Figure 27. 
Colon preparation (17.1%) and transport problems (17.1%), while 
representing a low frequency were mentioned most often. It is encouraging to 
note that while colon preparation rated ‗unpleasant‘ for 48.8% (39/80) of 
participants, it reportedly only affected non-adherence to screening for 17.1% 
of participants.  
 
Additional barriers identified by the participants are presented in Table 38 
(items were not mutually exclusive). All-Pay refers to the monthly 
government-grant pay out. For 11 participants (18.7%) non-adherence was 
attributed to the fact that the government grant ‗income‘ had to be collected in 
person, the date of which co-incided with the surveillance appointment. The 
majority of these barriers (items 1-8) have not been reported previously and 
may be specific to the GESC. The perceived barrier (item 9), including the 
fear that a tumour may be detected during a colonoscopy, or non-compliance 
as a result of the absence of concerning symptoms, are in accordance with 
previous observations (Bleiker et al 2005; Stoffel et al 2003). In contrast to 
the findings of the present study, two smaller SA qualitative studies (n=16 
and n=8) found the actual procedure and preparation process to be the main 
reason for non-adherence (Kruger et al 2005; Northam et al 2010). While 
these barriers were mentioned by the participants, they only accounted for 
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Table 38: Additional barriers to adherence (specific to the GESC) (n=61).  
Item no. Response Frequency Percentage 
1 All-Pay 11 18.7% 
2 Pregnancy 8 17.1% 
3 Work commitments 8 17.1% 
4 Family commitments 6 9.9% 
5 Uncertain of date of appointment 5 8.2% 
6 Uncertain of frequency of screening  5 8.2% 
7 Toilet facilities  4 6.6% 
8 Family unaware of result (non-disclosure) 3 4.9% 
9 Avoidance   
  Cancer is inevitable 2 3.3% 
  Ignorance is bliss/concern of finding cancer 3 4.9% 
  Feels healthy (no symptoms) 2 3.3% 
 
Factors affecting adherence to screening 
Attendance at either the outreach or hospital sector was not expected to 
influence compliance as the service offered, operates in exactly the same 
manner. However, this was investigated to ensure that it was not a 
contributing factor (Table 39). 
 
Table 39: Adherence to recommended screening guidelines defined by clinic 
(outreach versus hospital). 







All compliant Count 14 5 19 
Expected Count 12.4 6.7 19.0 
Missed 1 Count 19 8 27 
Expected Count 17.6 9.5 27.0 
Missed 2 Count 4 8 12 
Expected Count 7.8 4.2 12.0 
Missed 3 Count 5 1 6 
Expected Count 3.9 2.1 6.0 
Missed >3 Count 10 6 16 
Expected Count 10.4 5.6 16.0 
Total Count 52 28 80 
Expected Count 52.0 28.0 80.0 
 
Some cells have too little information to look for statistical differences, in 
particular those in the hospital sector. By comparing the differences between 
expected (based on margins) and observed occurrences, the only adherence 
group which seems to deviate is ‗missed 2‘ and ‗missed 3‘. However, the 
latter is difficult to interpret due to the single cell observation. Even if 










CHAPTER FOUR: ANALYSIS, RESULTS/FINDINGS AND DISCUSSION                                                                                                                                                             
168 
the difference between adherence to the outreach and the hospital sector is 
non-existant (Table 40).  
 
Table 40: Adherence to recommended screening guidelines (compliant 
versus non-compliant) defined by clinic (outreach versus hospital). 
 GESC Total Outreach Hospital 
Adherence All compliant Count 14 5 19 
Expected Count 12.4 6.7 19.0 
Non-compliant Count 38 23 61 
Expected Count 39.7 21.4 61.0 
Total Count 52 28 80 
Expected Count 52.0 28.0 80.0 
 
Educated individuals are suggested to be more knowledgeable on the 
benefits of screening for CRC and likely to be more compliant than those with 
lower education backgrounds (Subramanian et al 2004). The relationship 
between a higher education and greater adherence did not explain 
compliance in this study (Table 41). 
 













 ≤ Senior schooling 16 24 10 6 13 69 (27.2%) (31.8%) (14.2%) (8.7%) (18.7%) (100%) 
≥ College/univ rsity 3 3 2 0 3 11 (27.3%) (27.3%) (18.2%) (0%) (27.3%) (100%) 
Total 19 27 12 6 16 80 23.8% 33.8% 15% 7.5% 20% 100% 
  Some percentages may not add up to a 100% as a result of rounding-off. 
 
Previous studies examining screening practices have found that gender can 
affect adherence (Codori et al 2001; Denberg et al 2005; Gili et al 2006; 
Weitzman et al 2001). With regard to this study, no relationship was found 




                                                 
4 To test the relationship, the three last categories were considered as one category to 
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Table 42: Cross-tabulation of gender and adherence (n=80). 
Nor did the gender of the parent (with LS) of the participant affect adherence.
Table 43 shows the relationship between actual adherence of the participant
per gender of the affected and unaffected parents.
Table 43: Participant adherence cross-tabulated with gender of affected and 
unaffected parent (n=80).
Likewise the relationship between the type of referral and adherence did not












Male 7 9 5 1 3 25 
(28%) (36%) (20%) (4%) (12%) (100%) 
Female 12 18 7 5 13 55 
(21.8%) (32.7%) (12.7%) (9.1%) (23.6%) (100%) 
Total 19 27 12 6 16 80 
(23.8%) (33.8%) (15%) (7.5%) (20%) (100%) 
Adherence 







Affected Male 11 13 6 1 5 36 Female 7 12 6 4 8 37 
Not Affected 
Male 0 2 0 0 0 2 
Female 0 0 0 1 2 3 
Unknown 1 0 0 0 1 2 
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Table 44: Cross-tabulation of adherence and referral type (n=80). 
 
 
A relationship between age and non-adherence seems to exist. The 
youngest age group had the least ‗missings‘ (over-represented within the 
adherent groups) whereas the group in the age 40 to 49 show the most 
‗missings‘ (over-represented in the group with a higher absence rate) (Table 
45). The results suggest that underlying factors related to age could explain 
the absence to screening practices following the delivery of a mutation-
positive result (Crochbach alpha = 0.83). Previous reports have highlighted 
similar findings in individuals with a family history of CRC (Denberg et al 
2005; Gili et al 2006; Glanz et al 1999).  
 




Miss1 Miss2 Miss3 Miss>3 
Age 20-29 5 2 1 0 2 10 
30-39 6 9 5 2 2 24 
40-49 5 10 2 2 9 28 
≥ 50 3 6 4 2 3 18 
Total 19 27 12 6 16 80 
 
The number of missed colonoscopies for each participant within the four 














Clinic 3 4 1 1 1 10 
Self 0 1 1 1 0 3 
Family 9 9 6 3 9 36 
Recruited by GESC 7 12 3 1 5 28 
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 Figure 29: Adherence per age group (n=80). 
 
Possible explanations for this could be that uptake could be easier to 
maintain if recommendations are every two years instead of annually (≤ 30 
years of age according to screening guidelines in SA). Being younger and 
more proactive about health could also enhance greater adherence among 
this group of individuals.  
 
Table 46 suggests that knowing a family member with cancer does not 
necessarily increase actual adherence. For 55 participants (68.8%), the 
effect of a parent/family member‘s cancer diagnosis had led them to become 
more adherent, however these participants were mostly from compliant 
groups: Group 1 (attended all colonoscopies) and Group 2 (missed one 
colonoscopy). For 18 participants no resultant effect on adherence occurred 
and no participants reported that the parent/family member‘s cancer had 
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Table 46: Attitude to surveillance following a family member‘s cancer cross-
















































Total 19 27 12 6 16 80 
(23.8%) (33.8%) (15%) (7.5%) (20%) (100%) 
‗Not applicable‘ applies to individuals who were not exposed to a family member‘s cancer. 
 Some percentages may not add up to a 100% as a result of rounding-off. 
 
Furthermore, acting as a care-giver for an affected family member did not 
influence adherence rates. The results of Table 47 show that the observed 
values are close to the expected values based on the margins. 
 
Table 47: The relationship between adherence and the level of care 
involvement. 







All compliant Count 5 14 19 
Expected Count 6.4 12.6 19.0 
Missed 1 Count 10 17 27 
Expected Count 9.1 17.9 27.0 
Missed 2 Count 3 9 12 
Expected Count 4.1 8.0 12.0 
Missed 3 Count 3 3 6 
Expected Count 2.0 4.0 6.0 
Missed >3 Count 6 10 16 
Expected Count 5.4 10.6 16.0 
Total Count 27 53 80 Expected Count 27.0 53.0 80.0 
 
A common barrier to surveillance is lack of any or adequate health insurance 
(Natale-Pereira et al 2008) or the concern about losing health insurance 
coverage or increased tariffs (Lynch et al 1993a). In SA, and particularly at 
the outreach GESC these factors are unimportant as screening is offered 
free of charge. Furthermore, no participants reported that insurance concerns 
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Many of the recognised barriers and facilitators to screening practices have 
been derived from studies looking at CRC families without a known genetic 
mutation (Codori et al 2001; Beeker et al 2000; Gili et al 2006; Guerra et al 
2005; Harris et al 1997; Natale-Pereira et al 2008; McCarthy et al 1993; 
Weitzman et al 2001). This suggests that these findings may not be 
generalised to families with LS attending the GESC, even though they share 
a common cancer basis. 
 
Understanding of colonoscopic results 
The understanding of the outcome of the colonoscopy is presented in Table 
48. The majority of participants received feedback following their 
colonoscopic screening and illustrated a clear understanding of the outcome 
of their procedure. The purpose of the colonoscopy was described with 
varying degrees of insight: ‗a procedure which can see if you are healthy‘, ‗a 
procedure that can look at the inside of the colon‘, ‗a procedure which can 
identify cancer early‘, ‗a procedure which can identify growths in your colon 
which can develop into cancer if not removed‘, ‗a procedure which is able to 
get a good view of your colon and also able to take biopsies‘. A few 
participants knew that a polyp had the potential to develop into a malignancy: 
  
―/…/ they need to check it out with a biopsy as the polyp is a precursor to cancer‖ 
(male, 43 years). 
 
―It can just be that if you miss one year, that that growth starts developing and you 
have not seen it because you missed the test [colonoscopy], so if you stay away 
for say three years, then it is a problem, you could be looking at a far worse picture 
and it would really just be your own fault if you ended up in that position‖ 
(translated, female, 58 years). 
 
Other participants described it as a ‗growth‘, a ‗wart‘, a ‗sore‘ or a ‗dot/mark‘ 
on the colon. While they knew that it required removal they made no mention 
of the concern for cancer development. Mostly, participants had not heard 
the term before or could not explain what it meant if a polyp was identified 
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polypectomies, which can substantially reduce the risk of CRC, may not be 
fully understood (Liljegren et al 2004). 
 
Knowing when the next colonoscopy would occur and being in possession of 
the GESC contact details rated highly among the participants (Table 48). 
However, when appointments were missed, they were only rescheduled in a 
minority of cases. For the participants attending the outreach GESC, the 
reasons for not rescheduling were attributed to rather waiting another year to 
be seen by the GESC staff than by different doctors (without previous 
management experience within their family).  
 
Table 48: The occurrence of categories of a subset of variables relating to 
colonoscopic screening.  
Item Description Frequency Percentage 
C11 Colonoscopic results given following procedure 69/73* 94.5% 
C12a Results understood by participants 66/73* 90.4% 
C13a Future date for colonoscopy known 72/80** 90% 
C14 In possession of a contact number for the  clinic 66/80** 82.5% 
C15 Missed appointments rescheduled 13/61*** 16.3% 
*Total count (73) reflects the number of participants who have had one or more screening procedures. 
**Total count (80) reflects that this question was applicable to all the participants. 
***Total count (61) is a reflection of the number of participants who have missed a screening 
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4.6 SATISFACTION WITH THE GENETIC AND ENDOSCOPIC 
SURVEILLANCE CLINIC (GESC) 










Everyday language was used to explain LS  







Everything I wanted to know about LS was explained at the 
clinic  











I will follow the clinics advice because I think they are
absolutely right 







I understand why my family has a higher risk than other 
families of developing cancer






The time I spent at the clinic was long enough to deal with 
everything I wanted to discuss







The Dr/nurse/counsellor was easy to reach after the clinic
consultation for any questions/concerns that I had






Were any of your questions unanswered? 







Table 49 shows that most patients were satisfied with their GESC
consultation when measured by the eight dichotomous statements. Although
most items in Table 49 showed little variance, a homogeneity analysis using
CAT-PCA, that treated the variables as single nominal, was conducted. The
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Table 50: Component loadings per item of a two dimensional CAT-PCA on the GESC 














  1 2 
D1a 
Everyday language was used to explain LS  
(Home language was used, easy to understand concepts used to 
explain) 
0.668  -0.131  
D1b  Everything I wanted to know about LS was explained at the clinic  (Cause, age of onset, symptoms, reason for surveillance) 0.635  -0.319  
D1c The counselling received helped me cope better with my condition/risk of developing the condition 0.679  0.050  
D1d  
I will follow the clinics advice because I think they are absolutely right  
(Come for a colonoscopy every year/gynae visits etc/talk to family 
about risk) 
n/a*  n/a*  
D1e 
I understand why my family has a higher risk than other families of 
developing cancer 
(What were you told was the reason for the high-risk) 
0.130  0.839  
D1f 
The time I spent at the clinic was long enough to deal with  
everything I wanted to discuss 
(How much time did you spend with the staff, did you feel this was long 
enough) 
0.636  -0.118  
D1g 
The Dr/nurse/counsellor was easy to reach after the clinic consultation 
for any questions/concerns that I had 
(Were they contacted, was there a need to contact) 
n/a*  n/a * 
D1h Were any of your questions unanswered?  (Did you have any questions at visit, after visit, were they answered) -0.379  -0.587  
  *Items D1d and D1g were not included in the analysis as the responses failed to generate sufficient variance.  
LS-Lynch syndrome. 
 
The component loadings are presented as vectors in two-dimensional space 
(Figure 30). This aids the identification of a possible clustering of items. Item 
D1g and D1d were excluded from further analysis as only a single patient 
claimed that she would not follow the ‗clinics advice‘ and that she had 
difficulty contacting a ‗healthcare professional‘. The participant was a 50 year 
old female who had missed one of her recommended colonoscopies and also 
rated items D1c-D1g as unsatisfactory. This participant‘s score for the 
satisfaction with the GESC is presented in Table 51. 
 
Table 51: Rating per item on the GESC satisfaction scale 
for P59. 
 D1a D1b D1c D1d D1e D1f D1g D1h 
P59 1 1 2 2 2 2 2 2 
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The co-ordinates of the vectors of the variables in the plot are the 
components of each variable per dimension. Figure 30 reveals two sets of 
clusters. This suggests that these questions address different aspects of 
satisfaction. For example, items D1e and D1h, are related and strongly 
dominate dimension 2 (longest vector) although the items are projected 
opposite each other. The clustering can be seen when considering the mirror 
image of D1h. D1e refers to ‗struggling with understanding why the family is 
at a higher risk‘ and D1h ‗questions unanswered following consultations‘.  
 
The next cluster is formed by items D1a, D1b, D1c and D1f. These items 
dominate the first dimension. The length of these vectors are almost equal 
and in the same direction suggesting that these items are more or less equal 
in their weight to define the first dimension. However, the close proximity of 
items D1f to D1b indicates that the individual‘s perception of ‗length of time of 
the appointment‘ is strongly associated with ‗having all information on LS 
explained‘. The close projection to items D1c and D1a suggests that having 
‗information explained in a home language‘ and ‗counselling that leads to 
coping with the risk of developing LS‘ lead to greater satisfaction. 
 
 
Figure 30: A plot of the component loadings of the 
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The second figure shows how the categories are related (Figure 31). The plot 
of the category points suggests a relationship. On the second dimension, 
category two of D1e is projected relatively close to category one of D1h (top 
left quadrant). Thus ‗struggling with understanding why one‘s family is at 
higher risk‘ is related to participants having ‗questions unanswered‘. 
Whereas, category one of D1e is close to category two of D1h (bottom left 
quadrant). Thus ‗understanding why one‘s family is at higher risk‘ is related to 
‗questions were answered‘.  
 
The categories belonging to items D1a, D1b, D1c, and D1f are clearly 
separated with the ‗ones‘ on the left side of the origin (0, 0) and the ‗twos‘ on 
the right side of the origin. Category two of Item D1b is at a distance and the 




Figure 31: Plot of category points of the six items on the GESC 
satisfaction scale. 
 
Further analysis revealed tendencies of gender differences. Those that 
‗struggle with understanding why their family is at risk‘ and ‗have questions 
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‗understand the higher risk‘ and ‗have questions answered‘, appear pre-
dominantly female. This is apparent in Table 52. More males than expected 
struggled with understanding whereas more females than expected claimed 
to understand the higher risk. 
 





More males than expected had questions unanswered whereas more 
females than expected had no questions unanswered (Table 53).  
 
Table 53: Questions addressed at GESC per gender of 
participants (n=80). 
 
D1h - ‗questions addressed‘ 
 
  Questions unanswered 
Questions 
answered Total 
Male Count 5 20 25 Expected Count 3.8 21.3 25.0 
Female Count 7 48 55 Expected Count 8.3 46.8 55.0 
Total Count 12 68 80 Expected Count 12.0 68.0 80.0 
 
In both tables above, however, numbers were too small to reach statistical 
significance.  
 
Furthermore, knowledge about LS did not relate to lack of understanding or 
questions unanswered (Table 54).  
 
 
D1e -‗ understanding of familial risk‘ 
 
  Understands Does not understand Total 
Male Count 15 10 25 Expected Count 16.3 8.8 25.0 
Female Count 37 18 55 Expected Count 35.8 19.3 55.0 
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Table 54: Cross-tabulation of knowledge with understanding of a familial 
risk (n=80). 
Understanding of 
familial risk (D1e) Total 




<50% 1 0 1 
50% 0 1 1 
60% 2 1 3 
75% 2 4 6 
>75% 0 1 1 




<50% 10 7 17 
50% 11 5 16 
60% 11 6 17 
75% 11 3 14 
>75% 4 0 4 
Total 47 21 68 
Knowledge is expressed as a percentage of correct answers to knowledge questionnaire 
(Domanska et al 2009). 
An indicator, however, of the success of the recruitment program is that
those who were recruited by the GESC show better performance in
‗knowledge‘ with only just over ten percent scoring less than 50% (Table 55).
Table 55: Knowledge cross-tabulated with referral type (n=80).
Referral Knowledge Total <50% 50% 60% 75% >75%
Local clinic 3 2 2 3 0 10 
Self 1 1 0 1 0 3 
Family 11 6 7 9 3 36 
Recruited by GESC 3 6 11 6 2 28 
Total 18 15 20 19 5 77 
Although the large majority of participants were satisfied with the service
offered by the GESC, several areas amenable to improvement were 
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4.7 COMMUNICATION WITHIN THE FAMILY 
 
The varying emotional reactions, among the 80 participants, to being 
informed about a positive PT are presented in Table 56. Quotes have been 
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Table 56: Emotional reaction to receiving a mutation-positive test result. 
Emotional response to 
receiving a mutation-positive 
test result 
Frequency of 
responses (_/80) Quotes used to exemplify particular response category 
Shock/disbelief 15 
―I thought…I can't even share this with my husband, I let him believe all was fine. I was so scared I could not handle 
it, I don't know why, but it was such a shock…that day I was feeling fantastic, felt so good, did not think for one 
moment that the result would mess up my life like it did. [Genetic counsellor] asked me how I felt before she gave the 
result and I said I felt quite fine I have had three months to think about it and prepare myself for the result...but it was 
a real shock‖ (translated, female, 37 years). 
 
―Initially, it was a huge shock, I did not even discuss it with my family, I told [genetic counsellor] that she cannot tell 
anyone about the result, I begged her and I walked out of the clinic like nothing had happened - I smiled - everyone 
asked about the result but I said that I was ok, they believed me /…/‖ (translated, female, 43 years). 
 
Expectation as a result of: 
 



















14 ―The counsellor had this long and in-depth discussion, my sister and I went together and she was almost overly 
sensitive and understanding and we were rather blasé because at the time I had already developed a bad polyp so I 
was not really expecting that I would not have it [gene]. It was not really anything that made me emotional - I did not 
hold out any hope that I would not have it - you know my gran had it, my mom had it and I had it‖ (female, 35 years). 
 
―I knew I would be positive, because I had already had cancer, so it was not a shock to find out that I had the gene‖ 
(female, 47 years old). 
 
―I was not surprised that I had the gene, my father died of cancer, his brother and his sister has cancer, my father's 
mother also died of cancer. It actually made it easier because now I know the reason for what happened to them‖ 
(translated, male, 42 years old). 
 
―I was expecting it, you see I know this problem is in my family- it was not really a shock to hear‖ (translated, female, 
33 years old). 
 
―I expected to have it, you see I am very close to my father, very similar to him in so many ways, so if anyone was 
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Table 56:  Emotional reaction to receiving a mutation-positive test result (continued). 
Emotional response to 
receiving a mutation-positive 
test result 
Frequency of 
responses (_/80) Quotes used to exemplify particular response category 
Practical/logical 8 
―I know it means that I may require an operation one day, but it is good to know as I can plan around this thing‖ 
(translated, male, 40 years). 
 
―/…/ look, it was good to find out about it and the result did not necessarily mean that we would get cancer, it's just a 
possibility - it was actually a very good thing to hear‖ (translated, male, 40 years). 
 
―I was terribly nervous, you think the worst, but [genetic counsellor] explained it so nicely that I, I understood and it 
was easy to get over it - you realise you have the gene, you are a carrier but you don't think of it as this terrible thing 
anymore. Once someone tells you what it is all about, then it is actually easier to accept /…/‖ (translated, female, 44 
years). 
Acceptance/reasoning 7 
―I guess I felt alright, I could not do much about being positive. I could not go getting down about the whole thing. You 
see, there is a reason why I am positive, when my sister was in the hospital, when she got it, she was very upset, she 
could not understand why she got cancer and no one else, I was older than her, why did I not also have it, but when 
she found that I also had it, that I was positive, its almost as if we could make it through this thing if we were together 
in it - now both of us at least have the same thing and she can deal with her cancer‖ (translated, female, 49 years). 
Hard/difficult to hear 6 ―When I walked to the hospital to get my results I had a feeling that it may well be positive, but when I heard it…it was difficult, it was very difficult‖ (translated, female, 50 years). 
Anxious 4 
―I was very nervous that day, I did not expect to hear that I had the gene - maybe I could be one of the lucky 
ones…but I felt more relaxed once I heard all the information, I was still worried though /…/‖ (translated, female, 44 
years). 
Cancer diagnosis 4 
―See I thought that high-risk meant you would get sick that you were told you sort of had a cancer, so it was a shock, 
at a later stage [genetic counsellor] explained some things to me again and I could appreciate what high-risk meant, 
see at that stage I thought I had it‖ (translated, male, 42 years). 
 
―Actually at that stage I thought I had cancer, I was under the impression that…that I had cancer, because they spoke 
in English and I thought they were telling me the result showed cancer…I thought I had cancer‖ (translated, female, 
27 years). 
Sense of unfairness 4 
―/…/ why do I have it and not any of my sisters?‖ (translated, female, 38 years). 
 
―/…/ why did I end up with all my father‘s ailments?‖ (translated, female, 30 years). 
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Reactions and emotions to a mutation-positive test result 
Fifteen participants (18.8%) experienced reactions of shock or disbelief, when 
receiving a mutation-positive test result. Secrecy around the participant‘s 
status often occurred when a negative result was expected, but replaced by a 
positive one (Table 56). In contrast to this reaction, was the one of an 
expectation of a positive test result, as occurred in 14 participants (17.5%). 
According to McAllister (2002) individuals who engage with their cancer-
related risk, often believing themselves to be mutation-positive prior to testing, 
cope well even if the outcome of the result is unfavourable. The benefits of a 
previous engagement (with the cancer-related risk), were also recognised by 
Esplen and colleagues, who found that individuals who anticipate having a 
mutation-positive result experience less distress when receiving positive test 
results, as they are already engaging in an active coping strategy (Esplen et 
al 2007). The findings from this study suggests that expectation occurs as a 
result of a previous cancer diagnosis (Esplen et al 2007), the presence of 
existing symptoms, a multitude of family members with CRC or the 
recognition of an inherited familial risk and the resemblance to a mutation-
positive family member (McAllister 2002; McAllsiter 2003).  
 
Participants receiving the news in a positive light were either practical (8/80) 
or illustrated an acc ptance or reason (7/80) for the mutation-positive result. 
Several participants expressed this view as a result of a process of 
intellectualisation listing the benefits of surgery, screening and incomplete 
penetrance. They recognised the benefits of knowing about their CRC-related 
risk. The news was difficult to hear for six participants, anxiety-provoking for 
four and associated with a sense of unfairness for 5% (4/80). Of concern, 
were the 5% of participants (4/80) who misconstrued their result interpreting it 
as a definite cancer diagnosis instead of a cancer-related lifetime risk. 
 
Disclosure of mutation-positive test results 
Participants were asked to name the person from whom they obtained the 
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Table 57 outlines the individuals involved and illustrates that the majority 
(62.5%) of participants obtained support from a family member (usually a 
sibling or parent). This is consistent with the findings of White and Riedmann 
(1992) and Hughes et al (2002), who confirm that siblings are an important 
source of emotional support among mutation-positive individuals in HBOC 
families. 
 
  Table 57: Participants‘ source of emotional support subsequent to 
receiving a mutation-positive test result. 
Support person Frequency (n=80) 
Percentage  
Professional 3 3.75% 
Family member 50 62.5% 
Friend 1 1.25% 
Did not tell anyone about genetic test 
result/did not seek support 24 30% 
Member of church 1 1.25% 
Other 1 1.25% 
 
Sixty-one participants (76.3%) disclosed their genetic test result the same 
day. Generally, disclosure to close relatives occurs within 48 hours to a week 
in LS families (Gaff et al 2005; Hughes et al 2002; Petersen et al 2003). The 
benefit of timely disclosure is highlighted by Petersen et al (2003) who found 
that higher uptake rates, of PT in at-risk family members, are seen if there is 
no delay in disclosure, while lower rates occur when there is a delay. 
Reasons for disclosure included the fact that the information was not viewed 
as secret and that it was a family condition: 
 
―We are not secretive about it - we talk about it, if anyone has ever asked me about it, I 
have responded very openly /…/ it is nothing to hide or be ashamed of‖ (translated, 
female, 46 years). 
 
―It is not this big scary thing in our lives, so no reason to keep it a secret‖ (female, 53 
years). 
 
Disclosure also occurred when the participant was emotionally close to a 
particular person, aware that they could trust/confide in or seek support from 
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―I told her because we are friends and we share everything‖ (translated, female, 22 
years). 
―They must know, they are family…you can‘t keep this type of thing from them - they 
are the ones who will be supporting you through it all‖ (translated, female, 29 years). 
Likewise, the information was divulged when trying to engage a particular 
family member to enter into PT:  
―I told my daughter as soon as I found out about my result, you see she must also be 
tested…it is better to know to be able to keep yourself healthy /…/ for my son it was 
too late, my daughter must go, so that they can look after her‖ (translated, female, 52 
years). 
The individuals to whom the participants disclosed their PT results and the
respective frequencies at which this occurred are presented in Figure 32.
Figure 32: Individuals to whom the participants disclosed their PT results. 
Individuals, most often informed about the participant‘s status, included 
siblings (74/80), spouses (57/80) and parents. Ninety percent of participants 
with a living parent with LS reported that they had disclosed their test result to 
them (29/32). The parent without the family history of LS was informed in 89% 
























CHAPTER FOUR: ANALYSIS, RESULTS/FINDINGS AND DISCUSSION                                                                                                                                                             
187 
congruent with other studies (Bonadona et al 2002; Hughes et al 2002; 
Patenaude et al 2006).  
 
Children were informed about the participants‘ test result in 45 cases (56.3%). 
These findings are much lower than those noted by others, who reported a 
range of 75-90% (Aktan-Collan et al 2011; Ersig et al 2009; Hughes et al 
2002; Patenaude et al 2006; Stoffel et al 2008) in LS families but similar to 
that of disclosure rates in HBOC families (Bonadona et al 2002). Many 
participants were however waiting until their children were older before 
informing them. 
 
Discussion was not necessarily limited to persons at-risk of LS. Disclosure 
occurred to ten work colleagues (12.5%), five participants informed their 
religious leader (6.25%), and six their employ r (7.5%). The employers were 
informed to explain the two-day request for absenteeism, as is often required, 
for the preparation and procedure. Of concern, is that only 21.3% (17/80) of 
participants had informed their general healthcare provider. 
 
Communication about the availability of PT to family members 
While disclosure of personal results may have been high among this group 
(76.3%), 48 participants did not directly discuss the implications of their test 
result with all their at-risk family members. The majority of participants had 
also taken several years to inform these individuals about the relevance and 
importance of finding an inherited predisposition within the family (Table 58). 
This is in contrast to the timely disclosure of PT results, albeit mostly to FDR, 
which occurred within 24 hours for more than 50% of the participants. Simply 
sharing genetic results may not be sufficient to engage relatives with PT, as 
the availability and benefit for the family member is not always discussed 
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Table 58: Informing family about risk implications after receiving a mutation-positive 
test result. 
Information related to discussion Frequency Percentage 
Informed at risk family member of increased risk of CRC 
Yes 32/80 40% 
No 48/80 60% 
Reason for informing family member  
New recruit for PT 8/32 25% 
Non-adherent to surveillance 11/32 34.4% 
Never returned for PT result 1/32 3.1% 
Average time to informing family member about  
mutation-positive status 
 
Immediately after receiving mutation-positive result 8/80 10% 
Months after mutation-positive result 4/80 5% 
Years after mutation-positive result 11/80 13.8% 
Continuously trying to contact family member 6/80 7.5% 
Contacts when clinic team requests it 3/80 3.8% 
Disclosure of personal test result when informing family of risk  
Yes 29/32 90.6% 
No 3/32 9.4% 
  PT - Predictive genetic testing. 
 
The participants cited various reasons for withholding the information from 
certain family members. These are presented in Figure 33.  
 
 
Figure 33: Communication of risk implications (subsequent to receiving mutation-
positive test result) within the family.  
 
Informing at-risk family members has been recognised as a burdensome 
responsibility among more than a third of patients, requesting genetic testing 
for a cancer susceptibility, following the disclosure of their mutation-positive 
Informed family
Assume all the family are
aware of the information
Nuclear family all know
Assume the GESC will inform
them
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test result (Bonadona et al 2002). Sixty percent of participants indicated that 
there were at-risk family members whom they had not directly informed 
(Table 58). As is often noted, a conscious decision to withhold information 
does not necessarily take place (Gaff et al 2005; Peterson et al 2003) and 
36.3% of participants limited the disclosure of information to the boundary of 
their nuclear family, as they felt that it was the responsibility of the parents of 
cousins to inform second-degree relatives. This is similar to other research 
findings, which recognise the tendency to restrict information to FDR (Gaff et 
al 2005; Mesters et al 2005; Petersen et al 2003). Twelve percent of 
individuals failed to communicate because they viewed it as the role of the 
GESC, or had never been informed by the GESC to enlighten additional 
family members (2.5%). Six percent of participants did not pass on 
information to at-risk relatives as a result of a physical or emotional barrier. 
This obstacle to disclosure has been documented in multiple cancer-related 
(LS and HBOC) studies (Claes et al 2003; Gaff et al 2005; Hughes et al 2002; 
Julian-Reynier et al 2000; McCann et al 2009).  
 
The barriers to communication that were not mentioned, but often occur in 
cancer families include: making sense of personal risk before consultation 
with family members about their risk (Keenan et al 2005), having information 
rejected (Blandy et al 2003; Gaff et al 2005), difficulty in understanding 
genetic results (Wagner Costalas et al 2003), harmful nature of information 
(Bonadona et al 2002; d‘Agincourt-Canning et al 2001) inappropriate time to 
disclose (Forrest et al 2003) and being mutation-negative (Foster et al 2004). 
 
It is increasingly recognised that women take on the responsibility for their 
family‘s health (Richards et al 1996; Wilson et al 2004) and in the context of 
communicating genetic risk, women usually take on the responsibility of 
informing family members about genetic risk in LS and HBOC families 
(Forrest et al 2003; Koehly et al 2003). The reluctance to inform relatives 
occurred more frequently among men than women (33.3% versus 19.6%) and 
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 Patients with cancer are also documented key messengers in the discussion 
of genetic risk within the family (Julian-Reynier et al 2000). Half of the 
participants with cancer (8/16) told their at-risk family members about the 
implications of their test result, the other eight participants expressed that all 
the at-risk family members were already aware of the information. These 16 
participants were also more open to disclosing their personal test result with 
their family. With the exception of one participant who did not disclose his 
genetic test result to the living parent with the family history of LS, and two 
participants who did not inform their children (who were under the age of 18 
years), disclosure rates were 100% among parents, siblings and children of 
affected individuals.  
Informing children about their inherited risk 
Sixty-eight participants had biological children at a 50% risk of inheriting LS.
Forty-three of these participants (63%) had informed their children of the
inherited nature of the familial cancer. Figure 34 shows the age when the
risk/PT had been discussed with the participant‘s offspring. Information was 
most often transmitted when the children were between the ages of 17 and 18
years of age (17/43).  
Figure 34: Discussion of PT or cancer-related risk with children. 
According to parents, the right time to inform children about an inherited risk 
is often around key life decisions such as entry into a serious 
0 5 10 15 20 25






Children eligible for PT (≥ 18 years) not yet informed
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relationship/marriage or consideration of parenthood (Bonadona et al 2002). 
Timing of disclosure has also been recognised to occur around the age that 
the child becomes eligible for cancer surveillance or is considered to be 
emotionally ready (Aktan-Collan et al 2011; Forrest et al 2003; Mesters et al 
2005; Stoffel et al 2008). Similarly, 48.8% of participants in this study 
discussed PT when their children were old enough to enter into the testing 
programme or illustrated a mature ability to cope with the information. For 
27.9% (12/43) the discussion occurred following a parent‘s/family member‘s 
cancer diagnosis/death, 11.6% (5/43) when children started asking questions 
about a parent‘s colon preparation/surveillance appointment and 9.3% (4/43) 
described that they had always been open about the particular information of 
being at-risk from when their children were a very young age.  
 
Eighty-eight percent of participants (38/43) mentioned genetic testing (blood 
test) during the discussion with their children and 83.7% (36/43) informed 
their children about surveillance. Seventy-three percent (58/80) of participants 
agreed that PT should be offered at 18 years of age, while 25% (20/80) 
contested this and suggested an earlier age could be considered. 
Surprisingly, two (2.5%) participants preferred this to occur at a later stage 
after 18 years of age. 
 
Discussion of Lynch syndrome-related topics within the family 
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Figure 35 shows that the majority of participants discussed LS-related topics 
on an infrequent basis (75%). Fifty-three percent (42/80) of participants felt 
that they had received all the information that they wanted to know about LS; 
but areas where more information was sought included: ‗origins of family 
cancer‘, ‗cause of cancer‘ and ‗polyp development‘. 
 
The greatest need, as expressed by the participants, was for a 
pamphlet/booklet with information on LS (Figure 36). Currently a pamphlet is 
available on the preparation process for the colonoscopy, but information on 
LS is limited to that verbally discussed by the healthcare professional during 




Figure 36: Information aids required by participants (n=80). 
 
Dissemination of information: communication pathways 
Participants also differed with respect to who notified the family about PT or 
screening appointments. Often family members were enlisted in this process, 
but some participants approached their partner (3.75%) or their local clinic 
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Figure 37: Communication pathways within Lynch syndrome families 
attending the GESC. 
 
The majority (45/80) of participants were clear that the responsibility of 
informing relatives about their potential genetic risk should occur through the 
healthcare professional and not the family. Often families believe the 
responsibility lies with them, but they request a supporting role from their 
healthcare professionals (Aktan-Collan et al 2011; Forrest et al 2003). The 
preference for the healthcare professional is unusual and contradicts the 
findings of Bonadona et al (2002), Kerzin-Storrar et al (2002) and Segal et al 
(2004) who found their cancer (LS and HBOC) families favoured the family 
role when conveying information to their relatives. The different approach to 
communication may be a reflection of the low socio-economic status of the 
participants or the belief that the information may be more trustworthy if heard 
from a healthcare professional: 
 
―/…/ the information will be better understood if it comes from the clinic, you know, how 
do I go about explaining…they do it so well there, rather the family hears it from them 
and can ask questions which will be answered rather than me trying to explain 
something which I have trouble understanding‖ (translated, male, 49 years).  
 
―/…/ for example, if I told my cousin this news and tell her to go to the clinic, well, she 
would not listen to me but if someone from the clinic had to call her, then she would 
have to listen and she would be more likely to go as the information had come from the 
nurse or doctor‖ (translated, female, 38 years). 
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4.8 GENERAL HEALTH OF PARTICIPANT 
 
Health-related behaviour and adapted lifestyle 
Bowel-related concerns/symptoms subsequent to the participants‘ last 
attendance at the GESC were determined. Twenty-seven of the 80 
participants (33.8%) reported that they had experienced problems during the 
interval between their last clinic appointment and the interview. When 
prompted to explain what they had done upon noticing the bowel symptoms, 
nine (33.3%) responded that they had seen a GP; eight (29.6%) had 
contacted a healthcare professional from the GESC; four (1.5%) told a family 
member/friend about their concerns, but did not contact any healthcare 
professional; and six (22.2%) did not contact anyone about their symptoms. 
Of concern is the fact that 37% (10/27) of participants did not discuss this 
issue with a healthcare professional. The lack of recognition of symptoms 
related to CRC (38.3% of participants could not identify any warning 
symptoms) may explain some of the participant‘s behaviour as seven of the 
ten (70%) who did not discuss their concerns with a healthcare professional 
had not been able to identify symptoms of CRC (Figure 23, page 144). 
 
Several lifestyle behaviours, such as smoking and drinking, have been 
suggested to increase the risk of sporadic CRC malignancy (Giovannucci et 
al 1992; Willett et al 1990) and more recently, also of LS-related 
carcinogenesis (Diergaarde et al 2007; Pande et al 2010). The resultant 
influence and/change to the 80 participants‘ lifestyle, once counselled about 
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Table 59: Lifestyle risk behaviours of participants (n=80). 
Category Change to lifestyle related factor Frequency  Percentage  
Diet 
(eating habits) 
Yes 16 20% 
No 64 80% 
Total 80  
Drinking habits 
(alcohol) 
Yes-less 12 15% 
Yes-more 1 1.3% 
No 43 53.8% 
Never drunk alcohol 24 30% 
Total 80  
Smoking habits 
(cigarettes) 
Yes-less 10 12.5% 
Yes-more 1 1.3% 
No 41 51.3% 
Never smoked 27 33.8% 
Total 80  
Some percentages may not add up to a 100% as a result of rounding-off. 
 
In this cohort of participants, 15% and 12.5% of participa ts adopted health 
promoting lifestyles by reducing their alcohol consumption and cigarette 
smoking, respectively, and 20% by dietary changes. Participants who 
adapted their dietary habits (increased fruit and vegetable consumption 
and/or decreased red meat intake) were mostly unaffected (56.3%; 9/16) and 
female (62.5%; 10/16), with a mean age of 43.3 years (range, 31-53). 
Modified dietary habits were lower than those reported by Esplen et al (2001).  
 
Decreased alcohol consumption occurred more frequently among affected 
participants (8/12). The average age of these 12 participants (six male and six 
female) with positive lifestyle behaviours, with respect to alcohol 
consumption, was 37.7 years (range, 24-46). A higher percentage of affected 
participants reduced their smoking habits (7/10 were affected with CRC) 
compared to unaffected (3/10) participants, which corroborates the findings of 
Burton et al (2010) who also found a lower prevalence of smoking among 
affected individuals. Six females and four males reported a reduction in their 
smoking habits. These ten participants were an average age of 44.9 years 
(range, 35-56).  
 
The literature on changes to health behaviours (beyond that of compliance 
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with LS is scant. The prevalence of particular health behaviours or the effect 
thereof on tumour development, rather than the resultant adjustment to the 
behaviour, is typically described (Burton et al 2010; Diergaarde et al 2007; 
Pande et al 2009).  
Psychological distress (DUKE-AD scale) 
Psychological distress in individuals with LS is a reasonably well elucidated
topic in the literature (Aktan-Collan et al 2001; Bonadona et al 2002;
Broadstock et al 2000; Claes et al 2003; Claes et al 2005; Esplen et al 2003;
Gritz et al 2005; Meiser et al 2004), though data for the SA LS population
remains non-existent. Furthermore, no norm values are available for the
general SA population, although a 12 month mental disorder study illustrated
that the prevalence of psychiatric disorders was markedly higher in SA than
other developed countries such as China, Germany, Italy and Japan (Williams
et al 2008b). Table 60 represents the frequency of the ratings of the items in
the DUKE-AD scale, which is capable of identifying clinical levels of 
depression and anxiety.






























































F6a Give up too easily 47 (58.75%) 23 (28.75%) 10 (12.5%) 
F6b Difficulty concentrating 44 (55%) 24 (30%) 12 (15%) 
F6c Comfortable around other people 54 (67.5%) 17 (21.25%) 9 (11.25%) 
F6d Trouble with sleeping 41 (51.25%) 24 (30%) 15 (18.75%) 
F6e Getting tired easily 45 (56.25%) 25 (31.25%) 10 (12.5%) 
F6f Feeling depressed or sad 40 (50%) 23 (28.75%) 17 (21.25%) 
F6g Nervousness 44 (55%) 17 (21.25%) 19 (23.75%) 
The frequency of the ratings of the sum of the items of the DUKE-AD, among 
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Table 61: Frequency of rating the sum of each item of 
DUKE-AD (n=80). 
Total score Frequency Percentage Cumulative 
Percentage 
0 8 10% 10% 
1 9 11.3% 21.3% 
2 17 21.3% 42.5% 
3 8 10% 52.5% 
4 7 8.8% 61.3% 
5 5 6.3% 67.5% 
6 4 5% 72.5% 
7 6 7.5% 80% 
8 6 7.5% 87.5% 
9 2 2.5% 90% 
10 5 6.3% 96.3% 
11 2 2.5% 98.8% 
13 1 1.3% 100% 
Total 80 100%  
 
Eight participants (10%) claimed to have no symptoms of anxiety or 
depression (score of 0 on DUKE-AD). When considering gender, six of the 
eight participants were male (75%). Only two of these participants had a 
previous cancer, however in both cases, the malignancy had been identified 
early without the involvement of metastases. These eight individuals were 
adherent to screening guidelines, with one participant in Group 1 (no missed 
colonoscopies) and the remaining seven in Group 2 (having missed only one 
colonoscopy). 
 
The highest total score was 13 (out of a possible 14), reported by a female 
participant who had a total colectomy with ileorectal anastomosis at the age 
of 31 years (for an adenomatous polyp). She was mostly compliant with 
screening guidelines (Group 2). The mean score of the items on the DUKE-
AD scale was 6 (SD=3.3). 
 
Parkerson and Broadhead (1997) suggested the following interpretation of the 
overall scores (Table 62). 
 
Table 62: Interpretation of overall scores on DUKE-AD (Pakerson 
and Broadhead 1997). 
Total Score 
(sum of items) Description of score 
1 – 5 No excessive symptoms of anxiety and depression  
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Application of the key, identified excessive symptoms of anxiety and 
depression in 32.5% of participants (Table 63). These findings are 
significantly higher than that of other LS studies where minimal adverse 
psychological effects were observed (Bonadona et al 2002; Esplen et al 2001; 
Esplen et al 2007; Liljegren et al 2004). Williams et al (2008b) suggest that 
the SA population may be at a higher risk of mental disorders due to the 
dynamics of the country. Prior to 1994 this included racialised policies and the 
victimisation of the anti-apartheid struggle and following this era, the high 
rates of crime and violence, poor economic circumstances and burden of 
HIV/AIDS in SA. 
  
Table 63: The number of individuals with excessive symptoms of 
anxiety and depression (n=80). 
Total Score 
(sum of items) 




1 – 5 Not Excessive 54 67.5% 67.5% 
>5 Excessive 26 32.5% 100% 
 Total 80 100%  
 
The cohort of individuals reporting excessive symptoms of anxiety and 
depression, comprised 88.4% (23/26) females, which is generally in 
accordance with international findings of females illustrating higher levels of  
depressive symptoms and anxiety than males (Broadstock et al 2000; Esplen 
et al 2003; Meiser et al 2004). The mean age of the 26 participants was 40.8 
years and these individuals were largely unaffected with CRC (13/26). The 
average adherence group among the participants was Group 3 (missed two 
colonoscopies) and the mean number of FDR with cancer 1.7. Fifty-seven 
percent (15/26) of participants with excessive symptoms conveyed a high-
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Table 64: Characteristics of participants with excessive symptoms of anxiety and depression (n=26). 
















Total (Number of 
parents, siblings and 
children with CRC) 
P3 M 50 A 1 Operated-low risk Father 2 0 3 
P8 F 39 P 2 Operated-low risk - 3 0 4 
P10 F 47 A 2 Operated-low risk Father 0 0 1 
P14 F 49 U 5 High - 1 0 2 
P19 F 24 U 5 Inevitable Father 0 0 1 
P29 F 27 U 1 High Mother 0 0 1 
P31 F 56 U 5 Does not know Mother 0 1 2 
P35 F 49 P 5 Regular scopes-low risk Father 0 0 1 
P40 F 55 P 5 Regular scopes-low risk Father 1 0 2 
P41 F 47 A 2 50% Mother 0 0 1 
P42 F 37 U 3 50% Mother 2 0 3 
P43 F 29 U 3 High Mother 0 0 1 
P49 F 38 A 5 Inevitable - 0 0 0 
P55 F 24 U 1 Very high Father 0 0 1 
P56 M 43 U 1 Very high Mother 1 0 2 
P57 F 53 P 3 High Mother 0 0 1 
P59 F 50 P 2 Operated-low risk - 1 0 1 
P60 F 27 P 5 Very high Mother 0 0 1 
P61 F 38 A 2 Inevitable Father 1 0 2 
P62 F 33 U 5 High Mother 0 0 1 
P67 F 52 U 5 Very high Mother 1 1 3 
P74 F 22 U 5 High Father 0 0 1 
P76 F 34 U 1 50% Father 0 0 1 
P77 F 38 P 1 Very high Father 0 0 1 
P81 F 54 U 1 Inevitable - 5 0 5 
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Van Oostrom et al (2007) recognised that individuals, entering into PT, who 
experienced a parental cancer in their childhood (<13 years) or lost a parent 
to cancer during this age period, were more vulnerable to psychological 
distress. The data from this analysis confirms greater distress in individuals 
experiencing parental cancer during their childhood (≤12 years). The number 
of participants with excessive symptoms per age group (childhood, 
adolescence, adulthood) is illustrated in Table 65. 
 
Table 65: Number of participants with excessive symptoms per age group (n=26). 





≤ 12 years 13 9 69.2% 22 
13-18 years 11 5 45.45% 16 
> 18 years 24 11 45.83% 35 
Parent not affected 6 1 16.67% 7 
Total 62 26  80 
 
The nine participants exposed to a parental cancer in childhood with 
excessive symptoms were mostly female (7/9). The parent with cancer had 
died from the malignancy in all cases. Forty-four percent (4/9) of these 
participants defined their perceived lifetime CRC risk as ‗high‘ or ‗inevitable‘. 
 
Cancer Worry Scale (CWS) 
The CWS was used to determine social role dysfuntioning relating to distress 
about developing cancer. Participants‘ responses, based on the four-point 
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How often have you worried about your own 



























The impact of cancer worry on mood (F7c) and performance (F7d) was low. 
Ten percent of participants described mood interference occurring ‗often‘ and
3.8% ‗almost all the time‘. The frequency of responses on performance (F7d) 
indicated that 7.5% of participants felt that cancer worry affected their daily 
activities ‗often‘ and for 1.3% of individuals interviewed the effect occurred
‗almost all the time‘.
The results of a two-dimensional CAT-PCA, explained 90% of the total
variance. Table 67 presents the component loadings of the four items of the
CWS.











F7a How often have you thought about your own chances of developing 
cancer? 0.782 0.542 
F7b How often have you worried about your own chances of developing 
cancer? 0.840 0.426 
F7c How often has thoughts about getting cancer affected your mood? 0.843 - 0.462
F7d How often have thoughts about getting cancer affected your ability to 
perform daily activities? 0.837 - 0.468
The responses to the four items were treated at an ordinal level and the plot 
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categories ‗often‘ and ‗almost all the time‘ are projected close to each other 
and form one extreme pair of vectors. The category ‗rarely‘ represents the 
opposite extreme and ‗sometimes‘ is located more or less in middle of the 
vectors (Figure 38). The first dimension is determined by F7a (thoughts) and 
F7b (worries) and the second dimension by F7c (mood) and F7d (daily 
activities/performance). This illustrates that participants differentiate between 
‗thoughts‘ and ‗worries‘ about cancer and having these ‗thoughts/worries‘ 
affect their ‗moods‘ and ‗behaviour‘. The relatively long vector of item F7d 
(effect on daily activities) is caused by the single (outlier) patient that claimed 
to be ‗highly affected‘ in his performance. The response pattern deviates 
significantly from those of the other participants. P46 is an asymptomatic 31 
year old male who missed two colonoscopic appointments and had a 50% 
score on ‗knowledge‘. 
 
 
Figure 38: Plot of category points of the four items (F7a-F7d) 
on CWS.  
 
A two-dimensional analysis with items about ‗knowledge‘ and ‗adherence‘, 
added to the items of the CWS, resulted in a fit that explained almost 68% of 










CHAPTER FOUR: ANALYSIS, RESULTS/FINDINGS AND DISCUSSION                                                                                                                                                             
203 
related to ‗thoughts‘ or ‗worries‘ about risks nor did it illustrate any effect on 
‗mood‘ and ‗performance‘. 
 
 
Figure 39: A plot of the component loadings of the four items 
(F7a-F7d) combined with ‗knowledge‘ and ‗adherence‘. 
 
The effect of exposure to cancer (the number of FDR with cancer) on the 
CWS score (specifically the effect on ‗thoughts/worries‘ and 
‗mood/performance‘) was determined. The re-coded CWS items are 
displayed in Table 68 for the purpose of transparency: 
 
Table 68: Re-coding of rating items on the CWS to reflect the two new variables 
(thoughts/worries and mood/performance). 
 Re-coded description 
 Rarely Sometimes Often Almost all 
the time 
F7a + F7b Thoughts/ 
Worries 
2=1 3,4=2 5,6 =3 7,8=4 
F7c + F7d Mood/ 
Performance 
2=1 3,4=2 5,6 =3 7,8=4 
 
Table 69 indicates that more respondents than expected have less thought 
disturbances about cancer when two to six of their family members are 
affected by cancer, and more respondents than expected have more thoughts 
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although the pattern is not strong enough to reach statistical significance: 
p=0.18 (ChiSq = 3.42, 2) 
 
Table 69: Cross-tabulation of cancer-related thoughts with number of first-degree 
relatives with cancer. 
 Thoughts (7a and 7b on CWS) 






Few affected  
(0-1 family 
members) 
Count 12 10 18 40 
Expected 
Count 
16.0 9.0 15.0 40.0 
Many affected  
(2-6 family 
members) 
Count 20 8 12 40 
Expected 
Count 
16.0 9.0 15.0 40.0 
Total FDR with cancer 
Count 32 18 30 80 
Expected 
Count 
32.0 18.0 30.0 80.0 
  The re-coded category ‗Almost all the time‘ (7,8=4) received no responses and is not listed as a category. 
 
The relationship between mood and the number of affected family members 
with cancer appears more explicit. Table 70 shows a trend (lowest expected 
value in cell was 4.5) that respondents with many affected family members 
were less affected by mood than expected whereas, respondents with few 
family members affected were more affected by mood than expected: 
p=0.052 (ChiSq=5.92, 2). 
 
Table 70: Cross-tabulation of mood disturbances with number of first-degree relatives 
with cancer. 
 Mood affected (7c and 7d on CWS) 





Few affected  
(0-1 family 
member) 
Count 26 6 8 40 
Expected Count 30.5 4.5 5.0 40.0 
Many  affected 
(2-6 family 
affected) 
Count 35 3 2 40 
Expected Count 30.5 4.5 5.0 40.0 
Total Count 61 9 10 80 
Expected Count 61.0 9.0 10.0 80.0 
The re-coded category ‗Almost all the time‘ (7, 8=4) received no responses and is not listed as a category. 
 
The pattern becomes stronger if mood is dichotomised into ‗rarely‘ and 
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exposure to cancer may create a familiarity with the disorder and as such, 
have less of an impact on cancer worry. 
 
Table 71 shows that ‗thoughts/worries‘ about cancer rather than 
‗mood/performance‘ affects both the 64 unaffected participants and the 16 
participants who developed cancer.  
 
Table 71: Frequency of cancer-related thoughts and mood disturbances among 
affected (n=16) and unaffected (n=64) participants. 
 No cancer Cancer 






Not at all/rarely 59 39.1% 15 46.9% 
Sometimes 28 21.9% 8 25% 






Not at all/rarely 99 77.3% 28 87.5% 
Sometimes 13 10.2% 2 6.3% 
Often 16 12.5% 2 6.3% 
 
 
4.9 RESEARCH  
 
The frequency and experience of involvement in research studies was 
determined and is shown in Table 72. 
 
Table 72: The nature and frequency of the involvement in 
longitudinal and cross-sectional research studies. 
  Frequency Percentage  
Involved in 
longitudinal studies 
Yes 20 25% 
No 60 75% 
Total 80 100% 
Involved in cross-
sectional studies 
Yes 29 36.3% 
No 51 63.7% 
Total 80 100% 
Participate in future 
studies 
Yes 59 73.8% 
No 10 12.5% 
Ambivalent 6 7.5% 
On condition 5 6.3% 
Total 80 100% 
 
Overall, the majority (73.8%; 59/80) of participants welcomed involvement in 
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as a result of being involved in a research study, was acknowledged as an 
added benefit. A desire to help others or to aid the understanding of the 
cancer served the participants with a sense of altruistic purpose: 
―Oh, it was definitely worth it, I feel like I made a difference, like I really helped the doctor‘s 
understand this condition /…/ if it can help me or even those who come after me, that will be 
great‖ (translated, male, 35 years).  
The 12.5% (10/80) of participants who declined future involvement in
forthcoming research studies were mostly female (9/10) and declined to
participate as a result of the side-effects of the medication used during their
trial involvement. The majority of these participants (80%) were involved in 
longitudinal research studies (80%). Eight participants (10%) were ambivalent
about the experience and five (6.3%) expressed that specific criteria had to 
be met prior to re-involvement: research feedback, preference for shorter
study period, direct benefit, exclusion of trials with side-effects. A negative
experience with research has been reported previously, however, as in this 
study it always occurred in the minority (Collins et al 2000; Stadler et al 1998).
4.10 SUMMARY OF RESULTS/FINDINGS FOR GROUP A
Although the majority of participants (90.2%) were satisfied with their 
experience and the services offered by the GESC, more male participants 
were found to have questions unanswered and struggle with the 
understanding of the inherited risk of LS compared to their female 
counterparts. The level of knowledge of LS was poor among individuals within 
Group A (average of 6.5 out of 11 on the Domanska scale) and areas less 
clearly understood related to the genetic aspects of LS. While information on 
LS was almost exclusively gained from the GESC and most participants did 
not seek further information, only half of the individuals interviewed had 
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a shorter period within the programme while greater knowledge appeared to 
increase with length of time in the GESC. 
One of the recognised benefits of the GESC is that individuals presenting for 
screening or PT, not only have access to a free service, but additionally a free
ambulance transport system (from their local clinic to the GESC). As
transportation barriers are often implicated in adherence studies, it was not 
expected to materialise as a barrier to surveillance, among the group of 
participants attending the GESC. Despite this, participants with the most
missed colonoscopic appointments travelled for longer than one hour and
used the free ambulance transport services to the GESC. Most of these
participants were female and over the age of 50 years. The concerns with this 
free service were found to relate to minimal toilet breaks and perceived
reckless/dangerous driving. 
Ninety-three percent of participants had attended some form of surveillance,
however, less than a quarter of participants were adherent with all their
recommended colonoscopies. Rates of compliance differed when comparing
self-report to calculated uptake rates. Typically, over-estimation in the
adherence category (Group 1) and under-estimation in the non-adherence
categories (Group 2-5) occurred.
The experience of the colon preparation was recognised as the most difficult 
part of surveillance. Unfortunately, preparation precedes screening and if not 
carried out successfully, inhibits the completion of the screening process due 
to the inability to visualise the bowel. Simply changing the type of preparation 
mixture, to that of the participant‘s preference, could facilitate a more positive 
preparatory experience. Although certain participants found the procedure 
painful, the pain associated with colonoscopy was recognised to decrease 










CHAPTER FOUR: ANALYSIS, RESULTS/FINDINGS AND DISCUSSION                                                                                                                                                             
208 
One avenue that had to be explored in this study was that of the available 
amenities to the participants, particularly in light of its necessity in the 
preparation process and the knowledge that these facilities are usually below 
standard in developing countries. The number of participants with access to 
an indoor flushable toilet is far below that of the general population in the WC 
and NC. Almost a quarter of participants had to make use of an ‗outside 
toilet‘, which exposed them to the elements of the winter weather and a lack 
of privacy associated with frequent toilet use. 
 
Although facilitators to adherence were similar to those previously described 
in the literature, barriers unique to the GESC were identified and suggestions 
to address these barriers have been implemented and are further discussed 
under Recommendations in Section 6.1. A relationship between the age of 
the participant and non-adherence was identified. The youngest age group 
had the least number of missed colonoscopies, whereas the older age groups 
had a higher surveillance absence rate. 
 
The majority of participants disclosed their genetic test result on the same day 
that they had received the information from the healthcare professional at the 
GESC. Disclosure occurred when a participant was emotionally close to a 
particular person or when trying to engage other family members into PT. 
Unfortunately the implications of the test result were not always discussed 
with the at-risk family members, even if disclosure of their personal result had 
occurred. Simply sharing results did not always include the discussion of the 
familial risk and availability and benefit of PT for family members. There was 
some evidence indicating that females and affected participants were key 
messengers in discussing genetic risk within the family. The calculated 
uptake rate among the nuclear family including siblings and eligible children 
(over the age of 18 years) was 97% and 73.6% respectively. 
 
Of interest, is that more participants approved of the idea that the healthcare 
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potential genetic risk. This view contests the findings from other published 
studies, highlighting the belief that information may be valued as more 
trustworthy if presented by a healthcare professional, especially in an 
environment associated with a low socio-economic context. Moreover, the 
difficulty of conveying information if its implications are less clearly 
understood by the participant themselves is highlighted. 
 
Greater psychological effects, when compared to other LS studies in 
developed countries, were identified within the cohort, and excessive 
symptoms of anxiety and depression occurred in 32.5% of participants. As 
norm scores are not available for the general SA population, a comparison 
could not be made and the psychological distress could be present as a result 
of higher population levels. Another explanation could relate to the high 
number of females within the study cohort (generally associated with higher 
levels of depressive symptoms than in males). The subgroup which exhibited 
the greatest excessive symptoms of distress comprised mainly unaffected 
females.  
 
When considering the CWS, those participants with a greater number of 
affected family members, had cancer-related thoughts (p=0.18) and mood 
(p=0.052) affected less often. Although this pattern was not strong enough to 
reach statistical significance it does suggest that under-exposure rather than 
over-exposure to the familial cancer, is a potentially important predictor of 
distress in individuals with LS.  
 
 
4.11 GROUB B - PREDICTIVE GENETIC TESTING PROGRAMME (PT) 
The protocol for PT for LS (Appendix 1) was developed in 1996/1997 shortly 
after genetic testing became available in SA. Typically, the PT programme 
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and implications of LS and testing (if requested); and (2) delivery of results 
with enrollment into appropriate medical management, if required.  
 
A total of 33 individuals underwent the PT programme offered by the Division 
of Human Genetics, University of Cape Town and Division of Colorectal 
Surgery, Groote Schuur Hospital during the 18 month recruitment period, 
from June 2009 to December 2010. Genetic testing included direct mutation 
analysis and restriction enzyme digest on DNA derived from venous blood 
(Ramesar et al 2000).  
 
All 33 participants consented to being interviewed to evaluate the genetic 
counselling and PT programme (100%), however, data analysis was limited to 
a subset of 23 (69.7%) from the second interview and 22 (66.%) from the third 
interview. The difference in numbers, between the second and third interview 
occurred because one participant selected to discontinue with certain 
sections of the interviewing process after having a sister die from CRC during 
this period. The drop-out rate was strongly determined by the number of 
participants who did not return to receive their genetic test result (10 
participants). Where possible, these individuals were contacted to investigate 
the reasons for dropping out to ensure that they were not relevant to the 
evaluation of the genetic testing and counselling programme. The reasons 
given were: ‗to wait until another family member had to enter into PT and then 
go to the GESC at the same time‘; ‗work/studying made attendance at the 
result-giving appointment difficult‘; ‗relocation to a different province with 
intent to return at a later stage‘; and ‗transport problems associated with the 
distance to GESC‘. 
 
All the primary and secondary interviews were conducted in a private office at 
either the outreach or hospital GESC, immediately after the initial genetic 
counselling and testing session. The majority (51.5%) of the third interviews 
took place at the homes of the participants. The rest of the participants 
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arranged near the participants‘ residence, place of employment or a private 
room at their local clinic. 
 
Three participants (9%) complained of bowel-related symptoms at the time of 
their first visit. Colonoscopies were scheduled for all three participants. The 
procedures occurred subsequent to the PT result session for two and prior to 
the result session for one participant. The outcome of the endoscopic 
procedures were normal in two cases. In one participant a large adenomatous 
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4.12 DEMOGRAPHIC DATA AND PERSONAL HISTORY 
 
The characteristics of the participating sample in Group B are illustrated in 
Table 73. 
 
Table 73: Sociodemographic characteristics of the PT 















The cohort comprised 18 males (54.5%) and 15 females (42.2%) with a mean 
age of 28.7 years (range, 18-61 years, SD=12.7). Most participants were of 
Mixed Ancestry (75.8%) and spoke a home language of Afrikaans (67.7%). 
Twenty-four percent reported themselves to be in a relationship. In contrast to 
Group A, more participants frm Group B were from the WC (81.7%) and 
residing in an urban area (84.7%). The low number of recruited individuals 
from the NC would have been partly as a result of the limited PT 
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average age that participants entered into PT was 28.7 years. This is 
somewhat late considering PT is offered from 18 years of age in this setting. 
Level of education 
Figure 40: Level of education among participants entering into PT.
Eleven percent of the general population of the WC and 6.1% of the NC have
some form of tertiary education (Statistics South Africa 2005). In this cohort,
42.1% (14/33) had enrolled for higher education, which is consistent with
other reports suggesting that individuals undergoing PT for LS have a higher
education level than those from the general population (Aktan-Collan et al
2000; Codori et al 1999). The main reasons provided for not progressing from 
secondary school to tertiary education include: parents financial constraints
(15%), care required at home as a result of a parent with cancer (15.2%) and
for 12.1% social circumstances (including involvement in a gang, expulsion or 
failing at school).
0 5 10 15 20 25 30 35
<7 years (did not complete primary
schooling
Junior school certificate
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Employment and occupation 
 
 
Figure 41: Employment and unemployment rates among participants 
entering into PT (n=33). 
 
Only 27.3% (9/33) of participants from Group B were unemployed, which was 
significantly lower than that of Group A (67.3% outreach versus 39.2% 
hospital). The inclusion of students within the employment stratification (27%) 
may have accounted for this low rate. Of the 15 participants who were 
employed, 46.7% were involved in the managerial or professional sector 
(Table 74). This is much higher than the rates reported for the outreach 
(7.7%) and hospital clinic of Group A (28.5%). 
 
Table 74: Occupation categories for participants entering 



































Occupation Frequency Percentage 
Managerial, professional, semi-
professional 7 21.7% 
Clerical, sales, service 2 6.1% 
Skilled agriculture, craft, 
operations 3 9.1% 
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Income 
The mean monthly household income for the PT participants was R10 700 
(USA$ 1 551) (category: R6 401-R12 800). The total income per household of 
the 33 PT participants appears in Figure 42. 
 
 
Figure 42: The level of household income for the PT participants (n=33). 
 
Four participants (12.1%) were from a household which received an income 
from government grants only. Two of these households held dual grants (All-
Pay and child support grant), the other two lived off pension (old age grant) 
and child support grants. The highest number of occupants within one 
household was 15, the mean number of individuals per household was 4.5 
persons.  
 
Family history and exposure to Lynch syndrome 
Twenty-one (63.3%) participants had an affected parent of which 42.1% were 
paternal and 21.2% maternal. Thirteen (62%) of these parents had died of 
CRC. The mean age of participants, at the age that their parent had been 
diagnosed with cancer, was 20.3 years. 
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Figure 43: Exposure to colorectal cancer (CRC) within family. 
 
Predictive testing uptake in the family 
The number of siblings and children per participant appear in Table 75. The 
mean number per participant was 3.1 and 1.8 respectively. 
 
Table 75: Number of siblings and children per participant (n=33). 
Count 
 0 1 2 3 4 5 8 ≥ 9 
Siblings 2 8 8 4 2 7 1 1 
Children 24 3 5 1 - - - - 
 
For seventeen participants (51.5%), the uptake rate among all eligible siblings 
was 100%. Ten participants (30.3%) had some siblings (but not all eligible 
siblings) enter the PT programme. Four participants (12.1%) had none of the 
eligible siblings, beyond the participant themselves, enter into PT. Siblings 
were either too fearful of testing or had a misconception about the type of 
information obtainable from PT: 
 
―They are scared, more scared than anything, I guess they are aware of the risk but that is 
not enough to make them come‖ (female, 32 years). 
0 2 4 6 8 10 12 14
No exposure
Affected relatives elsewhere
Lived with affected family member (CRC)
Lived with affected family member who died of
CRC
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―My brother say‘s that he will not let them take out his colon, I guess he refuses to come 
because he thinks they will find cancer and then want to operate on him, like they did with 
dad. We have tried to explain the test, like [genetic counsellor] said, the test is just something 
that tells you about your chance of getting it…but he has made up his mind‖ (female, 18 
years). 
 
Some participants believed their siblings would come for PT, but that the right 
time would have to present itself: 
 
―Well, I know they will come, this is very important for our family. Now that we know about the 
fault in our DNA…I know that [genetic counsellor] said that [X], she is in Australia and my 
other sister [Y], who is in London can get the test done through their respective hospitals, but 
I guess they are waiting for the right time…I know [X] has thought about doing it here at home 
when she comes out to visit again, you know so that the family are all here /…/ I guess it is 
just easier when you are comfortable, you know, familiar…‖ (male, 38 years).  
 
Family planning and attitude to termination of pregnancy 
Prior to the first PT interview, nine participants (27.3%) had one or more 
children (Table 76). The participants‘ responses to termination of pregnancy 




Figure 44: Attitude to termination of pregnancy (TOP) in mutation-positive 
fetus. 
 
The majority (72.7%) of participants did not agree with TOP due to moral 
and/religious views (79.2%) and surprisingly only four (16.7%) did not favour 
the concept of TOP due to preventative management, for CRC, being 
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available for LS. One participant (4.2%) did not consider termination as an 
option as he and his wife had been struggling to conceive. Dewanwala et al 
(2011) found that 42% of individuals entering into PT for LS would consider 
prenatal testing in a future pregnancy. However, the consideration of a TOP, 
if prenatal testing identified a disease-causing mutation, was not investigated. 
Prenatal testing for LS remains a contentious issue due to the late-age of 
onset, incomplete penetrance and relatively effective cancer prevention 
programmes including endoscopic screening and prophylactic surgery. Even 
if chorionic villi sampling or amniocentesis is offered, uptake is expected to 
remain low (Aronson et al 2009; Offit et al 2006; Raymond et al 2009). To 
date, no cases of prenatal testing and selective termination have been 
identified for LS within the tertiary hospital centres in the WC and NC province 

























CHAPTER FOUR: ANALYSIS, RESULTS/FINDINGS AND DISCUSSION 
219 
4. 13 GENETIC COUNSELLING PERSPECTIVES AND SATISFACTION
Aspects of the genetic counselling and PT session which held particular 
salience for participants are displayed in Table 76. 
Table 76: Rating frequencies per item of information discussed 



























1 2 3 
1a Cause of the condition (LS) 27 2 3 
1b 
Explanation on why the condition is passed
on from one generation to the next
21 9 3 
1c The medical name for the condition 17 13 3 
1d 
Explanation on who else is at-risk (in the
family) for LS
24 9 - 
1e If treatments are available for LS 28 5 - 
1f 
Potential treatments that may become
available in the future
29 4 - 
1g 
Information on what will happen to someone
with the condition as time goes by
26 7 - 
1h 
Availability of a genetic test to see if I will get 
the condition
29 4 - 
1i 
To be able to contact other families affected
with the condition, for support
18 7 8 
1j 
The information covered during the session
should be written down for future reference
21 10 2 
1k Is ther  a test for this condition in pregnancy 22 7 4 
The information most valued by participants related to four specific domains. 
These included: cause (27/33; 81.7%), recognition (26/33; 78.8%), testing 
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Satisfaction with genetic counselling 
 




























































B3a The staff member at the clinic seemed to understand the stress I was facing 1 8 24 
B3b They helped me to identify what I needed to know to make a decision about the blood test and surveillance 1 3 29 
B3c  Felt better about my health after meeting with them 2 9 22 
B3d The session was about the right length of time 2 4 27 
B3e They were truly concerned about my well-being 1 4 28 
B3f The session was valuable to me 1 3 29 
 Total 8 (4%) 31(15.7%) 159(80.3%) 
 
Overall 80.3% of participants were highly satisfied with the genetic 
counselling they received. Fifteen percent were moderately satisfied (selected 
somewhat satisfactory) and only 4.7% were unsatisfied. Figure 45 shows a 
graphical representation of the frequency of each item that was marked as 
‗highly satisfactory‘ (strongly agreed). 
 
 
Figure 45: Satisfaction with the process and content of genetic counselling 
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The majority of participants felt that the information had been presented 
clearly (87.8%), that the counselling had been valuable to them (87.7%), and 
that the counsellor cared about them (84.7%). The length of the session was 
appropriate for 81.7% of participants. Despite most of the items rating as 
‗highly satisfactory‘, only 66.8% of participants indicated that their health-
related concerns had been decreased and 71% reported that the counsellor 
had understood the stress with which they were faced.  
 
Figure 46 displays the total satisfaction score per participant (n=33). The 
average score among the participants was 16.6 out of a possible 18 
(SD=2.2). The participant with the lowest score (7/18) was male, currently 
attending tertiary education and of White ancestry.  
 
 
Figure 46: Total score per participant on the genetic counselling satisfaction scale. 
 
Generally, participants reported a high level of satisfaction with their genetic 
counselling session, with most of the responses at the top end of the 
satisfaction scale (Table 77). This finding is in line with previous reports of 
satisfaction (76%-89%) in individuals attending cancer genetic counselling in 
familial cancer clinics (Davey et al 2005; Kausmeyer et al 2006; Nordin et al 
2002; Stadler and Mulvihill 1998); in colorectal cancer clinics (Collins et al 
2000) and in breast cancer clinics (Bober et al 2007; Charles et al 2006; 
Tercyak et al 2004).  
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Table 78 presents those variables which were selected to be of relevance to 
the differentiation in response to the level of satisfaction with the genetic 
counselling scale. The analysis was conducted on all 33 participants. Data 
was collected on five demographic variables and the six questions on 
satisfaction were rated on a semantic three-point scale.  
 
Table 78: Demographic variables used in the analysis of the level of 
satisfaction with genetic counselling (n=33). 
Item Category 
Gender 19 (Male) 14 (Female) 
Age 21 (below mean age of 
presenting for PT) 
12 (above mean age of 
presenting for PT) 
Ethnic group 25 (Mixed Ancestry) 8 (White) 
Secondary education 20 (completed 
secondary schooling) 




15 (attended) 18* (Did not attend) 
*One participant was in the process of completing secondary schooling. 
 
The component loadings of the two-dimensional CAT-PCA are presented in 
Table 79. 
 
Table 79: Component loadings per item of a two-dimensional CAT-PCA involving 
participant demographics and the genetic counselling satisfaction scale (n=33). 
Items Demographic information Dimensions 
  1 2 
A3 Ethnicity -0.480 -0.576 
A6b Senior schooling -0.297 -0.856 
A6c College (Tertiary education)  0.336  0.806 
 Genetic Counselling Satisfaction scale  
D3a The staff member at the clinic seemed to understand the stress I 
was facing 0.964 -0.176 
D3b They helped me to identify what I needed to know to make a 
decision about the blood test and surveillance 0.964 -0.181 
D3c  Felt better about my health after meeting with them 0.351 -0.197 
D3d The session was about the right length of time 0.810 0.010 
D3e They were truly concerned about my well-being 0.965 -0.179 
D3f The session was valuable to me 0.967 -0.173 
The variables ‗gender‘ and ‗age‘ had values that did not associate with any other variables. As a result, 
these two variables did not explain more than their own variance and were removed from the analysis. 
 
The results of a two-dimensional categorical analysis CAT-PCA with the 
demographic variables treated as nominal and the satisfaction ratings as 
ordinal are shown in Figure 47. The eigenvalues for the dimensions were 4.96 
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Figure 47: A plot of the component loadings of the demographic 
variables and the six items (3a-3f) on the genetic counselling 
satisfaction scale. 
 
Figure 47 shows the mutual association between the items in relation to each 
dimension after normalisation. Two main clusters appear: education and 
satisfaction. Considering the first cluster, ‗college‘ (tertiary education) and the 
mirror image of the item ‗senior‘ (completed senior schooling) are related and 
contribute relatively strongly to dimension two. Item ‗ethnicity‘ contributes 
almost equally to both dimension one and two. The contribution of gender and 
age is small and explain less than their own variance. Removal of these 
variables results in a better fit and does not affect the projections (76.4% 
explained variance). 
 
The plot of the category scores of education suggests that more White than 
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Figure 48: A plot of the component loadings of the items education 
and ethnicity. n compl = not completed. compl = completed. Na = not applicable as 
still attending senior schooling. 
 
The second cluster is formed by the items of the genetic counselling 
satisfaction scale (3a-3F) (Figure 47). The plot of the category points 
suggests that items 3a, 3b, 3e and 3f are strongly related and contribute 
significantly to dimension one. The close projection of these items indicates 
that the ‗session was viewed as valuable‘ if the participant perceived the 
counsellor to be ‗truly concerned about their well-being‘ and ‗understands the 
stress faced‘ by the participant. Satisfaction, in this dimension, was further 
influenced by the provision of having adequate information to make an 
informed decision about ‗the blood test and surveillance‘. Item 3d is in close 
proximity and suggests that satisfaction with these items was additionally 
influenced by the perception that the session was the ‗right length of time‘. 
Item 3c (feeling better about health after genetic counselling session), acts as 
an outlier and does not contribute significantly to satisfaction. There is 
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demographic variables (characteristics of the study participants), which 
confirms the findings of De Marco et al (2004). 
Referral to predictive testing programme 
The large majority of PT participants had been informed about the availability 
of testing through a family member (93.7%). This occurred via the
participants‘ parent (with LS) in 45.2% (14/31) of cases, by a sibling who had
previously had genetic testing in 29.7% (9/31), via a second-degree relative
for 16.1% (5/31) and by the parent without the family history of LS for 9.7%
(3/31). Only two participants were not informed about PT through a family 
member and reported direct contact by the GESC as their source of
information about the availability of PT.
Period of awareness prior to predictive testing
Figure 49: Period of awareness prior to entering into PT. 
The mean age of participants presenting for genetic testing within weeks or 
months (but less than one year) of learning about the PT programme was 28 
years and for those participants presenting later than one year 31.8 years 
(Figure 49). Seven participants (21.7%) presented for testing in the year that 
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young age and entered into PT upon becoming eligible for testing (18 years of 
age).  
 
Having observed affected relatives with cancer (living elsewhere), or living 
with an affected family member, did not typically influence the time period to 
presenting for PT. However, a trend appeared among those eleven 
individuals living with an affected family member who had died from CRC. 
The majority of these individuals illustrated a shorter period to entering into 
PT (81.8%) suggesting that the exposure of a cancer-related death may act 
as a facilitator towards earlier genetic testing (Table 80). 
 
Table 80: The influence of the level of exposure to colorectal cancer on 
the time to presenting for PT (n=26)*. 
 Frequency 
Exposure to CRC Time to presenting 
for PT N Percentage 
Affected family members living 
elsewhere 
< One year 4/9 (44.5%) 
> One year 5/9 (55.5%) 
Lived with affected family 
member (with CRC) 
< One year 3/6 (50%) 
> One year 3/6 (50%) 
Lived with affected family 
member who died of CRC 
< One year 9/11 (81.8%) 
> One year 2/11 (18.2%) 
*The seven participants who presented as soon as they became eligible were excluded 
from the analysis. 
 
Event triggering request for predictive testing 
The significant life events triggering the participants to request PT are listed in 
Table 81. 
 
Table 81: Life event triggering request for PT (n=33). 
Trigger event  Frequency Percentage 
Family member recently diagnosed/died of CRC 12/33 36.3% 
GESC in town/convenience  
(near physical location of PT centre) 8/33 24.2% 
Major stressful event completed and ready to engage 
with PT 4/33 12.1% 
Request/pressure from family member 3/33 9.1% 
Concerning symptoms 2/33 6.1% 
Youngest sibling eligible  
(facilitates group attendance of siblings) 2/33 6.1% 
Family member‘s clinic appointment 2/33 6.1% 
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Motivation for entering into predictive testing 
Although Hadley et al (2003) illustrated that the majority of individuals 
attending PT believe that the single most important reason for undergoing 
testing is to learn about the children‘s risk, this was not the case in the SA 
cohort. In contrast, it is noteworthy that only 39.8% (13/33) stated that their 
main motivation for testing included clarifying the risk for their (future) 
children.  
 
Most participants reported two or three main reasons for engaging in PT. 
Eighty-four percent (29/33) reported that testing was undertaken to determine 
if cancer screening was required, 81.7% (27/33) to reduce the level of 
uncertainty and 69.7% (23/33) to plan for the future. This planning, however, 
did not seem to take much cognisance of marital planning (15.2%), 
employment decisions (21.2%) or reproductive decisions (39.8%). Having a 
family member recommend PT (51.7%) carried greater weighting than that of 
a doctor‘s recommendation (24.2%) (Table 82). The findings of the primary 
motivations for genetic testing in this study are similar to that reported on by 
Claes et al (2003) and Esplen et al (2001) in individuals undergoing PT for LS 
and Lerman et al (1996), in individuals considering genetic testing if it become 
available to them in the future (individuals were FDR of CRC patients without 
a known mutation). 
 
Table 82: Rating frequencies per item of factors affecting decision to 
























4a Planning for the future 23 5 5 
4b Marital decisions 5 9 19 
4c Reproductive decisions 13 4 16 
4d Clarifying risk for (future) children 13 2 18 
4e Employment decisions 7 7 19 
4f Reducing uncertainty 27 4 2 
4g Doctor recommended it 8 3 22 
4h Self-evident 22 8 3 
4i Family member/partner urged you to go 17 6 10 
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Understanding of predictive testing 
According to Doak et al (1998) simply asking a question which requires a yes 
or no answer does not address understanding or comprehension of the 
medical information given to patients. To verify that the purpose of PT was 
understood by the participants, they were required to explain PT in their own 
words. Education (tertiary education) and ethnicity (White) were associated 
with a greater understanding of the purpose of PT. Participants who could not 
correctly explain PT were most often of a lower education background 
(63.2%) and of Mixed Ancestry (48%) (Table 83). The link between ethnicity 
and education has been identified in Figure 48 (page 224). 
 
Table 83: Cross-tabulation of the understanding of PT and selected 
participant characteristics (n=33). 
 Purpose of predictive genetic testing (PT) 
 Knows Does not know 

























Expected emotional outcome subsequent to predictive testing 
Following the pre-test genetic counselling session, participants were asked 
how they would feel if the PT revealed a mutation-positive status. The 
expected outcomes are shown in Figure 50. 
 
 
Figure 50: Perceived emotional reactions to outcome of PT. 
0 5 10 15 20
Fine/ambivalent-capable of coping with
regular screening
Scared but will cope
No choice in the matter-must come for
surveillance
Terrified/fearful-will not cope
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It is encouraging to know that the majority (54.5%) of participants, embarking 
on PT, expressed that they would be able to cope with a mutation-positive 
test result as they were able to deal with regular colonoscopic screening. 
Eight participants (24.2%) reported that they were scared about surveillance, 
but would cope with the regular colonoscopies and five (15.2%) explained 
that they did not want to think about the implications of being mutation-
positive, but would definitely attend regular screening if required. Of concern 
is the one participant who did not perceive herself coping with a positive test 
result. She was 18 years old, of Mixed Ancestry and had completed 
secondary schooling. Although her father had developed CRC, she had not 
lived with him.  
 
Self-perception of result prior to predictive testing 
 




negative Ambivalent Total 
Perception prior to PT 2/33 (6.1%) 5/33 (15.2%) 26/33 (78.8%)  
PT result 11/22 (50%) 11/22 (50%) -  
Total 56.1% 65.2% 78.8% 100% 
Some percentages may not add up to a 100% as a result of rounding-off. 
 
Seven participants had personal perceptions about their mutation status prior 
to PT, confirming the findings of other studies where expectations are based 
on preconceived notions (Esplen et al 2003; Evers-Kiebooms et al 2000; 
McAllister 2003; Prucka et al 2008; Trepanier et al 2004). For two 
participants, expectation of a mutation-negative result was based on having a 
sibling who had not inherited the mutation and feeling healthy at the time of 
PT. The two participants who perceived themselves to carry a disease-
causing mutation based the expectation on the extent of relatives with CRC 
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4. 14 POST-PREDICTIVE TEST RESULT
Outcome of predictive testing 
The number of mutation-positive and mutation-negative results per gender 
(among those participants who attended their result-giving session) is 
presented in Table 85. The average age of those participants testing positive 
was 28.5 years and those with a negative PT result, 30.9 years. 
Table 85: PT result per gender of the participants 
(n=22). 





Female 4/11 (36.4%) 8/12 (66.7%)
Male 7/11 (63.6%) 4/12 (33.3%)
Total 100% 
The uptake rate of PT was 100% for this study (all 33 individuals participating
in the research study chose to have a genetic test), which greatly exceeds 
published figures (43-75%) and suggests that participants were eager to
accept PT for a treatable disease (Aktan-Collan et al 2000; Codori et al 1999;
Hadley et al 2003). However, only 23 participants (69.7%) returned for the
test result. Eight participants (24.2%) did not attend their scheduled result-
giving session as a result of: waiting for a family member to join; having a
family member die of CRC; conflicts with work/studies and transport
problems. Two participants (6%) were working in a different province at the
time and intended to contact the GESC to schedule an appointment at a more
convenient time. 
The types of mutations identified in the mutation-positive cohort are displayed 
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Table 86: Specific Lynch syndrome mutation among mutation-
positive cohort (n=11). 
Mutation Frequency Percentage 
MLH1 (Exon 13 c. 1528C>T) 8/11 72.7% 
MSH2 (Exon 8 c. 1340-1341insGG; 
exon13 c. 1459C>T) 3/11 27.3% 
 
The characteristics of those participants not returning for their PT result are 
shown in Table 87. 
 
Table 87: Characteristics of participants who did not return for their genetic test result 
(n=10). 





P4 F 19 MA Student Tertiary Outreach 
P5 F 18 W Unemployed Secondary Hospital 
P6 M 22 W Employed Secondary Hospital 
P13 M 20 MA Unemployed Junior Hospital 
P20 M 2 MA Employed Tertiary Outreach 
P21 M 25 MA Employed Tertiary Outreach 
P22 M 20 MA Employed Junior Outreach 
P27 M 40 MA Employed Junior Hospital 
P29 M 23 MA Employed Tertiary Hospital 
P33 F 61 MA Employed Junior Hospital 
 
Disclosure of predictive test results 
There was no specific trend as to who the participants disclosed their genetic 
test results when comparing the mutation-positive to the mutation-negative 
cohort. All except one participant had disclosed the mutation status within one 
month of receiving the PT result. This individual stated that she had not 
disclosed her result to her family as she could not trust them with the 
confidentiality of the information (she had tested positive for the familial 
mutation predisposing to CRC). Eleven participants (47.8%) had disclosed 
their genetic test result to the immediate family only; eight participants 
(34.8%), divulged the information to all their family and friends, and three 
(13%) limited the discussion of their result to their siblings. In all three cases, 
the parent had not been informed as they had already died of CRC. 
Disclosure to children, among those participants testing positive, did not occur 
due to the young age of their offspring (average age 6.3 years) and among 
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Satisfaction with process and outcome of predictive testing 
 
Table 88: A subset of categories relating to satisfaction with the PT process 
(n=22). 
Item Description Agree Disagree 
E2 Satisfied with decision (undertaking PT) 22/22 (100%) 0/22 (0%) 
E3 Trusting of test result 20/22 (91%) 2/22 (9%) 
E6 Eligibility age (18 years) 17/22 (77.3%) 5/22 (22.7%) 
E7 Pre-test counselling and testing on same day 21/22 (95.5%) 1/22 (4.5%) 
E8 Satisfaction with the amount of time taken to 
receive PT result 
15/22 (68.2%) 7/22 (31.8%) 
 
Both the mutation-positive and mutation-negative individuals were satisfied 
with their decision to take the PT (100%) and regret of being tested was not 
expressed by any of the participants. However, two participants did not fully 
trust the test result. One participant received a mutation-positive result where 
some of his personal details were incorrect and the other participant who had 
been given a mutation-negative result expressed that he would always be 
concerned as he had expected to carry the disease-causing mutation. These 
two participants were both male and highly educated. 
 
All participants (100%) would recommend PT and genetic counselling to their 
family members, mostly to ‗obtain information on their health‘, to ‗know their 
status and attend for surveillance only if necessary‘ and to decrease 
uncertainty: ‗better to know than to worry about something you don‘t know 
about‘. This is much higher than the figure of 75% reported by Stadler and 
Mulvihill (1998).  
 
The majority (95.5%) of participants were satisfied with a single pre-test 
genetic counselling session, which is in conformity with previous reports 
highlighting a preference for a shortened PT and counselling protocol among 
individuals with LS (Aktan–Collan et al 2000; Brain et al 2005; Collins et al 
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Over a third (7/22) of individuals undergoing PT were dissatisfied with the 
amount of time taken to receive their test results. These rates are comparable 
to Bleiker et al (1997), who found that 37% of their sample receiving genetic 
counselling for familial cancer were dissatisfied with the length of time that 
they had to wait for their test result. The average time from pre-test 
counselling to the time that the participant was notified that their PT result 
was available, was 5.8 months. The average time from testing to result 
disclosure was 5.2 months and 10 months, for the WC cohort and NC cohort, 
respectively. Factors influencing the length of time taken to receive the test 
result were: availability of an appointment with the genetic counsellor at GSH, 
field trips to the NC (beyond that of the scheduled outreach trip), ability to 
travel to GSH to receive results at the hospital sector of GESC (instead of the 
outreach GESC). 
 
Emotional outcome following predictive test disclosure 
Thoughts about the PT result, during the waiting period, occurred ‗almost all 
the time‘ for three participants (15%), ‗a lot‘ for five participants (25%), ‗every 
now and then‘ for the majority (50%) and ‗not at all‘ for two participants (10%). 
Five of the eight participants who reported thoughts about the PT result to 
occur ‗a lot‘ or ‗almost all the time‘ were male. The mean age of these 
participants were typically older than the average age of the entire group 
(36.6 years versus 28.7 years). The emotional reaction to receiving either a 
mutation-positive of mutation-negative PT result is described in Table 89. As 
would be expected, the majority of participants testing mutation-negative, 
reported feeling incredibly lucky, happy or relieved by the news while those 
testing positive were shocked, saddened or anxious. Overlapping categories 
between both groups included, ‗unexpected result due to a preconceived 
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Excerpts relating to category definition 
Very happy, 
incredibly 
thankful, relived 8/12 
―So relieved, it was like this massive burden had been taken off my 
shoulders, I had this constant worry and now… to have gotten rid 
of it…‖ (female, 18 years). 
 








―Can I tell you that I almost fell off my chair when I heard… 
[laughs], I had prepared myself for bad news and had really 
believed I would carry the gene, it was so unexpected to hear that I 
did not, I still pinch myself to make sure that I am not dreaming/…/‖ 
(male, 45 years). 
 
―Terrified with fear, I had prepared for a positive result and was 
absolutely shocked that it was negative, when [X] died (brother 
who developed CRC at 16 years) I went for the test but I was just 
too scared to go through with it, I knew I would get told that I had 
the same as [X], so I just couldn‘t and then when I had it done,  I 
was ready for the news and then, then it was 
negative…(translated, female, 19 years). 
2/10 
―Well, actually in all honesty I was a little shocked, and surprised, I 
thought the gene was connected to the other side of the family, the [X] 
side, you see my cousin went for this test and he was negative and the 
family history is so much stronger on his side than mine, and he is 
closer, you know more connected to the [X] side of the family, I am 
only half [X], so I did not really expect it. When I heard I cancelled my 
holiday, you kind of want to be around the comfort and safety of the 
known when you hear something like this‖ (male, 38 years).  
 
―I must admit, I was a little shocked by the news - my two brothers 
were free of this thing and I guess I thought that I would also be, I will 
be okay, but it is just that that bit of hope has been taken away, now I 






―I had this feeling that I would be negative, I do not know why, just 
this gut feeling, so the result just confirmed that for me‖ (translated, 
female, 21 years). 1/10 
―I was not really surprised, you see most of my family have it, so I was 







―Nervous but I am very positive, if something is wrong I want to find out 
so that I can fix it and this result allows me that ability‖ (female, 32 
years). 
 
―…did not expect it to be positive so it was hard to deal with that…with 
the news, quite devastating and really gets you down…‖ (translated, 
male, 38 years). 
 
―/…/ I really did not think I would be positive, I was quite shocked by 
the result‖ (translated, male 18 years). 
 
―I was so incredibly upset, but I believe every thing happens for a 
reason, so…there must be some explanation, some good that will 
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Psychological impact of predictive genetic testing 
Hopwood (1997) suggested that a negative psychological outcome, 
subsequent to PT, can be minimised if testing is provided in combination with 
genetic counselling, support and appropriate follow-up. Research has shown 
that individuals undergoing PT for LS do not demonstrate excessive levels of 
anxiety and depression, with the exception of a short-term increase in 
individuals testing positive (Akan-Collan et al 2001; Bleiker et al 2003; Claes 
et al 2005). 
 
Figure 51 depicts the mean scores on the DUKE-AD scale at pre- and post-
testing time periods by the mutation status of the individual. Mutation-positive 
participants illustrated slightly elevated mean scores immediately after 
receiving the PT result, when compared to their mutation-negative 
counterparts (5.0, SD=2.8 versus 4.9, SD=2.9). While mutation-positive 
participants demonstrated higher mean values post-test than the mutation-
negative cohort, both groups could be seen to demonstrate decreased levels 
of anxiety and depression (as measured by DUKE-AD score) one month post 
result delivery. These findings are congruent with other studies, conducted in 
developed countries, which illustrate similar trends for individuals undergoing 
PT (Aktan-Collan et al 2001; Bleiker et al 2003; Claes et al 2004; Esplen et al 
2001; Meiser et al 2004; Shiloh et al 2008; Van Oostrom et al 2007). 
 
 
Figure 51: Comparison of mean DUKE-AD score for mutation-positive and 
mutation-negative participants at assessment time points before and after 
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Mean cancer worry scores displayed an increasing effect from pre-test to the
time period ‗immediately after the disclosure of PT result‘ but decreased
means appeared after one month for both groups (Figure 52). Of interest is 
that the mean score at this time point, for the mutation-negative cohort, was 
higher than the mutation-positive group (8.4, SD=2.5 versus 7.0, SD=2.9),
which is in contrast to expected results. However the measure illustrated a
higher baseline score among those mutation-negative individuals (7.6,
SD=2.2 versus 6.9, SD=2.2) following the pre-test genetic counselling
session. This group of mutation-negative individuals also reported higher 
baseline scores on the DUKE-AD measure (Figure 51). Encouragingly,
however, the mutation-negative individuals reported a score below their
baseline value as well as that of the mutation-positive cohort at the time point
of month preceding the delivery of their test result.
Figure 52: Comparison of mean scores of cancer-related worry for mutation-
positive and mutation-negative participants at assessment time points before and
after disclosure of PT results.
The fluctuating pattern observed in cancer worry scores (from baseline to 
immediately after PT result), is in contrast to other studies, where cancer 
worry has been shown to remain high for mutation-positive individuals and 
decrease for mutation-negative individuals (Gritz et al 2005). Negative results 
are not always associated with stress reduction (Evans 2006). Individuals, 
who receive a mutation-negative result may still continue to worry about their 
cancer-related risk if they have difficulty integrating this new knowledge with 
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―I do not have one word for how I felt that day, if I had to explain the impact of the 
news…I guess I would have to say surprised, relieved, no, more like a sense of the 
news that I received was unexpected. I really believed I was going to be positive /…/ 
the chances were against me - my sister had it and she was the oldest and my brother 
did not have it, he was the middle child, then I should have it as I am the 
youngest…also I look like my dad, we have the same features and that together with 
me being the youngest, the third child, where one had it one did not have it and then 
me, I should have it, if you look at that pattern. So I guess I should be relieved but I still 
worry, as everything was pointing to me having it, the gene…‖ (male, 23 years). 
 
Furthermore, adverse sequelae after obtaining a mutation-negative result 
may relate to ‗survivor guilt‘, disbelief in test result, repercussions of family 
relationships or regret over life decisions made prior to testing based on 
‗believed susceptibility‘ (Hopwood 1997; Baker et al 1998, Harper 1998; Weil 
2000). Notably, the CWS scores were quite comparable between the 
mutation-positive and mutation-negative cohort when the scale was 
completed for the third time (one month preceding PT result delivery) (7.1, 
SD=2.4 versus 7.0, SD=2.9). Mutation-positive individuals may experience 
relief from uncertainty and appreciate the benefits of regular surveillance even 
if found to carry the predisposing mutation. Of interest is that six of the 11 
participants who tested positive had already undergone colonoscopic 
screening prior to the last interview (one month preceding PT result delivery), 
when the CWS was completed for the third time. The trend in these results 
are similar to that of the findings of Hadley et al (2011) who identified that 
mutation-positive individuals, receiveing a colonoscopy within six months of 
their PT result being disclosed, reported less depressive symptoms than 
those carriers who did not undergo a colonoscopy within this time period.  
 
A GLM (general linear model) multivariate repeated measure procedure was 
used to analyse anxiety and depression, as measured by the DUKE-AD 
Scale, and cancer worry, as measured by the CWS, of the 33 participants 
receiving either a mutation-positive or mutation-negative PT result. 
Responses to the scale items at the three time periods were treated as ‗within 
variables‘. The mutation status (either mutation-positive or negative) was 
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A multivariate analysis, considering the average DUKE-AD scores at the 
three assessment time points and the mutation status, showed no significant 
effects. 
Table 90: Multivariate tests at assessment time points on the DUKE-AD scale before and 
after disclosure of PT results including the effect on mutation status. 
Multivariate Testsc
Effect Value F Hyp df Error df Sig. Powerb
DUKE-
AD 
Pillai's Trace 0.255 3.428a 2 20 0.052 0.576 
Wilks' Lambda 0.745 3.428a 2 20 0.052 0.576 
Hotelling's Trace 0.343 3.428a 2 20 0.052 0.576 





Pillai's Trace 0.176 2.137a 2 20 0.144 0.386 
Wilks' Lambda 0.824 2.137a 2 20 0.144 0.386 
Hotelling's Trace 0.214 2.137a 2 20 0.144 0.386 
Roy's Largest Root 0.214 2.137a 2 20 0.144 0.386 
aExact statistic.
bComputed using alpha = 0.05.
cDesign: Intercept + mutation status within subjects design: DUKE-AD.
Table 91 reveals that the changes measured by the DUKE-AD scale over
time (repeated levels of the within factor) were not significant. The interaction
between being mutation-positive or mutation-negative and anxiety and
depression, as measured by the DUKE-AD scale, was not present. This is 
shown in Figure 53 (page 240).
Table 91: Tests of within-subject effects.
Type III 
SS 
df MS F Sig. Powera 
DUKE-AD Sphericity 
Assumed 
0.217 2 0.108 0.998 0.377 0.212 
Greenhouse-
Geisser 
0.217 1.846 0.118 0.998 0.372 0.204 
Huynh-Feldt 0.217 2.000 0.108 0.998 0.377 0.212 





0.565 2 0.282 2.598 0.086 0.490 
Greenhouse-
Geisser 
0.565 1.846 0.306 2.598 0.091 0.468 
Huynh-Feldt 0.565 2.000 0.282 2.598 0.086 0.490 





4.566 42 0.109 
Greenhouse-
Geisser 
4.566 38.774 0.118 
Huynh-Feldt 4.566 42.000 0.109 
Lower-bound 4.566 21.000 0.217 
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Table 92 shows that the difference between those participants testing 
mutation-positive and those with a mutation-negative result and with DUKE-
AD reponses, as a dependent variable, are not significant. 
 
Table 92: Tests of between-subject effects. 
Transformed Variable: Average 





F Sig. Observed 
Powera 
Intercept 135.033 1 135.033 278.437 0.000 278.437 
Mutation 1.120 1 1.120 2.309 0.144 2.309 
Error 10.184 21 0.485    
aComputed using alpha = 0.05. 
 
Table 93 shows that the estimated marginal means over time were not 
significant.  
 
Table 93: The relationship between DUKE-AD score and mutation status 
over assessment time points. 
Mutation 
status 
DUKE-AD Mean Std. 
Error 








Baseline 1.091 0.129 0.823 1.359 
PT result 
session 
1.364 0.154 1.044 1.683 





Baseline 1.583 0.123 1.327 1.840 
PT result 
session 
1.583 0.147 1.277 1.890 
One month 1.417 0.147 1.110 1.723 
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Figure 53: Marginal means of the DUKE-AD measure 
per mutation status.
No multivariate effects of repeated measures as measured by the DUKE-AD
scale and mutation status were found when the DUKE-AD key (Table 63,
page 198) was applied (Table 94).
Table 94: The relationship between CWS score and mutation status when
DUKE-AD key is applied.
Mutation DUKE
-AD
Mean Std. Error 95% Confidence Interval 
Lower Bound Upper Bound 
Mutation-
positive 
1 1.091 0.129 0.823 1.359 
2 1.364 0.154 1.044 1.683 
3 1.364 0.154 1.044 1.683 
Mutation-
negative 
1 1.583 0.123 1.327 1.840 
2 1.583 0.147 1.277 1.890 
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The same procedure was applied to analyse the CWS of the 33 participants 
that received either a mutation-positive or negative test result.  
 
Table 95: Multivariate tests at assessment time points on CWS before and after 
disclosure of PT results including effect on mutation status. 
Multivariate Testsc 
Effect Value F Hyp df Error df Sig. Observed 
Powerb 
CWS Pillai's Trace 0.074 0.802a 2 20 0.462 0.167 
Wilks' Lambda 0.926 0.802a 2 20 0.462 0.167 
Hotelling's 
Trace 
0.080 0.802a 2 20 0.462 0.167 
Roy's Largest 
Root 
0.080 0.802a 2 20 0.462 0.167 
CWS* 
Mutation 
Pillai's Trace 0.071 0.769a 2 20 0.477 0.162 
Wilks' Lambda 0.929 0.769a 2 20 0.477 0.162 
Hotelling's 
Trace 
0.077 0.769a 2 20 0.477 0.162 
Roy's Largest 
Root 
0.077 0.769a 2 20 0.477 0.162 
aExact statistic. 
bComputed using alpha = 0.05. 
cDesign: Intercept + mutation status within subjects design: CWS. 
 
The Mauchly‘s test of sphericity tests the null hypothesis that the error 
covariance matrix of the orthonormalized transformed dependent variables is 
proportional to an identity matrix (Table 96). 
 
Table 96: Mauchly‘s test of sphericity (tests of within-subjects affects). 















CWS 0.717 6. 654 2 0.036 0.779 0.871 0.500 
aMay be used to adjust the degrees of freedom for the averaged tests of significance. Corrected tests are displayed 
in the tests of within-subjects effects (Table 97). 
bDesign: Intercept + mutation within subjects design: CWS. 
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 Table 97: Tests of within-subject effects. 
Source Type III 
SS 
df MS F Sig. Powera 
CWS 
Sphericity Assumed 4.799 2 2.399 0.412 0.665 0.112 
Greenhouse-
Geisser 
4.799 1.559 3.078 0.412 0.616 0.105 
Huynh-Feldt 4.799 1.741 2.756 0.412 0.638 0.108 
Lower-bound 4.799 1.000 4.799 0.412 0.528 0.094 
CWS * 
Mutation 
Sphericity Assumed 5.900 2 2.950 0.506 0.607 0.128 
Greenhouse-
Geisser 
5.900 1.559 3.785 0.506 0.562 0.118 
Huynh-Feldt 5.900 1.741 3.388 0.506 0.582 0.122 
Lower-bound 5.900 1.000 5.900 0.506 0.485 0.104 
Error 
(CWS) 
Sphericity Assumed 244.854 42 5.830 
Greenhouse-
Geisser 
244.854 32.735 7.480 
Huynh-Feldt 244.854 36.567 6.696 
Lower-bound 244.854 21.000 11.660 
aComputed using alpha = 0.05. 
Table 98 shows that the difference between those participants testing
mutation-positive and those with a mutation-negative result and with CWS
responses as a dependant variable is not significant.
Table 98: Tests of between-subject effects.
Transformed Variable: Average 
Source Type III Sum of 
Squares 
df Mean Square F Sig. Observed 
Powera 
Intercept 1254.184 1 1254.184 472.849 0.000 1.000 
Mutation 2.512 1 2.512 0.947 0.342 0.153 
Error 55.700 21 2.652 
aComputed using alpha = 0.05.
Table 99 shows that the estimated marginal means did not illustrate any
significant effects over time.
Table 99: The relationship between CWS score and mutation status over 
assessment time points.  
Mutation CWS Mean Std. Error 95% Confidence Interval 




Baseline 6.909 0.670 5.517 8.302 
PT result 
session 
7.091 0.821 5.383 8.799 
One 
month 





Baseline 7.667 0.641 6.333 9.000 
PT result 
session 
8.417 0.786 6.781 10.052 
One 
month 
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Figure 54 illustrates a graphical representation of the means per the mutation 
status. 
 




4. 15 SUMMARY OF RESULTS/FINDINGS FOR GROUP B 
 
Satisfaction with genetic counselling was high among the participants in 
Group B (80.3%). The information received during the pre-test counselling 
session, found to be the most valued by the participants, related to the cause, 
symptoms, testing and treatment of LS. Satisfaction with genetic counselling 
was not correlated with any demographic variables. However, satisfaction 
may have been uniformly high due to counselling and genetic testing being 
offered free of charge.  
 
The large majority of participants entered into PT to determine if cancer 
surveillance was required (81.7%). Participants were mostly informed about 
the availability of the genetic test through a family member (93.7%). Of 
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even after receiving extensive pre-test counselling. These individuals were 
mostly from a lower education background and of Mixed Ancestry. The 
uptake rate of PT was however not influenced by this and remained high, with 
100% of participants accepting PT (although only 69.7% returned for their test 
result). Seventy percent of individuals presented for PT within a year of 
learning about the availability of the genetic test and having a family member 
die of CRC acted as a facilitator to entering into PT, within a shorter time 
frame.  
The emotional outcome, following the delivery of the PT result, identified that
expectations reflected personal views on family history, coping mechanisms
and having a ‗gut feeling‘. Receiving either a mutation-positive or mutation-
negative test result did not typically influence disclosure rates nor did it
illustrate any trends as to who the participants disclosed their mutation status.
The psychological impact of embarking on a process of PT was investigated
for the first time in SA cohort. Mean DUKE-AD scores, among both the
mutation-positive and mutation-negative participants, were congruent with
reported trends for individuals undergoing PT (mutation-positive participants
demonstrated higher scores than the mutation-negative cohort). However
mean CWS scores were unexpectedly higher among mutation-negative
individuals when compared to the mutation-positive cohort. The results are
somewhat unexpected and warrant further investigation with larger sample
sizes.



































The main aims of this study were firstly, to appraise the GESC from the
perspective of the users to ascertain the experiences and level of satisfaction
with the programme; secondly, to measure the level of adherence to
recommended screening guidelines and to determine the impact of socio-
economic status, education, physical barriers and psychosocial factors on
adherence; and thirdly to determine the uptake rate of PT and to identify and
explore the referral pathways and communication networks leading to the
GESC. 
Two domains anchor the GESC, the PT programme and the endoscopic
surveillance service. This was the first time that research has been conducted
to appraise the GESC. The data, with reference to each of the dimensions
differ somewhat to that of the international literature. In many cases the
discrepancy between the previously published findings and this study can be
attributed to the socio-economic context of the participants, highlighting that 
findings from a specific population group do not illustrate generalisability.
Furthermore, results unique to the GESC may not necessarily apply to other 
established cancer genetic programmes in other parts of the country or 
developed countries.
5.1.1 GENETIC AND ENDOSCOPIC SURVEILLANCE PROGRAMME 
(GROUP A) 
The majority of participants (90.2%) evaluated the service offered by the 
GESC as satisfactory. The participants‘ level of knowledge of LS, however, 
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affecting knowledge was that of ‗length of time in the GESC‘, whereby 
participants who had been in the programme for a longer period of time had a 
greater level of knowledge. This suggests that repetition of information 
facilitates consolidation of concepts and understanding of the message 
received during counselling, particularly in a group of individuals with a low 
education level. 
 
The ‗length of transport time to GESC‘ and use of ‗free ambulance service‘ 
was found to be over-represented in non-adherent participants. In addition 
women over the age of 50 years were more likely to miss their colonoscopic 
appointment. Furthermore, the concept that screening was required prior to 
the presentation of concerning bowel symptoms, even if the participant felt 
‗healthy/fine‘, was not recognised among 56% of participants.  
 
There was a large discrepancy between self-report and actual adherence to 
recommended screening guidelines and basing adherence rates on self-
reported screening attendance led to an over-estimation of compliance. 
Understanding the actual screening process, as experienced by the 
participants, can aid the understanding of fear or undesirable outcomes and 
offer counselling opportunities to prevent or circumvent them. In other words, 
participants with positive experiences are more likely to be compliant with 
screening guidelines underscoring the necessity to try and deal with any 
unpleasant outcomes.  
 
Colon preparation was recognised as the most difficult part of surveillance 
and simply changing the type of preparation mixture, to that of the 
participant‘s preference, could facilitate a more positive preparatory 
experience. Less than a third of participants found the colonoscopy painful 
and the pain/discomfort associated with the procedure was recognised to 













The facilitators to adherence were typically similar to those previously 
identified in the literature, namely to ‗maintain helath‘ and to ‗avoid cancer-
related suffering‘. The barriers pertained mostly to colon preparation and 
transport concerns and additional barriers, unique to the GESC were 
identified (for example All-Pay). The only demographic factor to illustrate an 
effect on adherence was the age of the participant. Older participants were 
less adherent. 
Participants reported high disclosure rates pertaining to their genetic test
results and typically divulged the information within 24 hours of receiving the
result. However, the direct implications to other family members were relayed
less often in conversation, especially in the case of children and second-
degree relatives. The calculated uptake rate of PT among siblings and
children of the participants was high (97% and 73.6%, respectively).
The levels of anxiety and depression of the mutation-positive participants
were significantly higher than those reported in studies conducted in 
developed countries. On analysis of the CWS, participants differentiated into
those who were less severely plagued by cancer thoughts and worries and
those who were more severely affected by having these thoughts affect their
mood and behaviour. Under-exposure rather than over-exposure to the
familial cancer was found to be a potentially important predictor of distress in
individuals with LS.
5.1.2 PREDICTIVE GENETIC TESTING PROGRAMME (GROUP B) 
The vast majority of participants entering into PT judged the genetic 
counselling aspect of the programme as highly satisfactory (80.3%) and 
95.5% of participants were happy with a single pre-test counselling session. 
Aspects of the programme illustrating some dissatisfaction included the time 













The majority of participants had been referred to the GESC by a family 
member and engaged in PT due to one of three main reasons: to determine 
the necessity of screening, reducing uncertainty and planning for the future.  
The uptake rate of PT was high with 100% of participants accepting PT. 
Receiving a mutation-positive test result evoked expected responses such as 
shock, anxiety and sadness while those receiving a mutation-negative result 
were mostly happy or relieved. Regret of being tested for the familial 
susceptibility was not expressed by any of the participants and all participants 
would recommend testing to their family members.  
The DUKE-AD scores were comparable to the trends identified in the
literature, however the CWS scores were higher in participants with a
mutation-negative test result when compared to those receiving a mutation-
positive result, although this value did decline one month post result delivery,
to levels lower than the mutation-positive cohort.
Apects arising from this study of the GESC which need to be addressed in
order to improve the processes from the participants‘ perspective are


























Following the analysis of the data, the recommendations made by the
participants within Group A and Group B as well as those identified by the
researcher were discussed with the genetic and clinical team. It was deemed
particularly important to address the barriers to the GESC and implement
changes, where possible, as soon as they were identified due to the potential
effect on cancer-related morbidity and mortality. The majority of suggestions,
to improve the service offered by the GESC, have been approved and 
implemented as indicated below.
6.1.1 RECOMMENDATIONS FROM THE PARTICIPANTS ATTENDING FOR 
SURVEILLANCE AT THE GESC (GROUP A):
 Provision of written information on LS, available in Afrikaans
with reading levels directed at the literacy level of the
participants. Specific information, as requested by the participants,
has been included in the booklet. This pertained to: the cause of 
cancer (polyp development); concerning bowel symptoms; 
inheritance and contact details. The booklet has been completed
and is in the process of being reviewed with the families attending
the hospital GESC and will be discussed with the families attending
the outreach GESC in August (during the 2011 outreach trip). This
will enable the researcher to determine if the information is written at
the appropriate literacy level.
 Discussion with the ambulance drivers about the need for
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GESC has taken place. Feedback has been sought from 
individuals using the service and if any concerns are reported, 
supervisors are informed about reckless driving. 
 Clinic appointments made on the same day as family members
attending the GESC (unless requested to avoid contact with
known relatives). The participants suggested that having all the
family around them offered additional support, a distraction while
waiting for the colonoscopy and the group attendance acted as a
motivating factor when utilising screening services.
 Report back on trial results following research enrollment. 
Participants have suggested that any new study, within which they
may be involved, should provide them with regular updates and
feedback should occur in an ongoing manner. 
6.1.2 RECOMMENDATIONS FROM THE PARTICIPANTS ATTENDING FOR 
GENETIC COUNSELLING AND PT (GROUP B):
 Telephonic contact if results are to take longer than six weeks. 
Weekly feedback thereafter with updates on expected time of
release of genetic test result to any individual entering into the PT 
programme.
 Amend PT protocol to exclude post-test confirmatory bloods.
Participants feel that this supplementary blood sample raises
concerns about the accuracy of the result and acts as an additional
painful procedure to endure after receiving the PT result, especially
in the case of a positive test result. A complete analysis of all PT
results since October 1996 to August 2011 was conducted.
Concordance between the initial test result and that of the
confirmatory post-test result was determined and the confirmatory
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 More information and details on the colonoscopic procedure 
preceding the first colonoscopy. The PT programme now 
includes a pre-colonoscopic counselling session prior to the first 
endoscopic procedure. This also offers time to discuss the 
preparatory experience and to determine if any changes can be 
made to alleviate problems arising from colon preparation. In 
addition, individuals attending the GESC have access to genetic 
counselling at each follow-up surveillance session to clarify any 
misunderstandings, repetition of the information, consolidation of 
their knowledge of LS and to discuss recruitment of family members 
and address any difficulties encountered. As substantiated during 
this research, knowledge can also be seen to increase with the 
number of years spent at the GESC and promotes greater recall and 
understanding of LS-associated information. 
 
6.1.3 RECOMMENDATIONS IDENTIFIED THROUGH THE STUDY: 
 
 The option of colon preparation at the GESC. If the available 
amenities or lack thereof make the preparation process difficult to 
complete at the individual‘s home, preparation is offered at the 
GESC. Extra enemas are now kept at the GESC to aid with rapid 
colon preparation, if required. As far as possible the preferred 
preparation mixture is to be provided to individuals attending for 
screening. 
 The most skilled operator is to complete the first colonoscopy. 
This ensures that the initial procedure occurs with the least amount 
of pain. A good experience would be more likely to promote regular 
attendance and less anxiety and fear associated with the procedure.  
 Date of annual outreach GESC changed. The date of the outreach 
clinic has been changed so that it does not co-incide with the date of 
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 Telephonic contact reminder. A phone call to the individual, a
week prior to the GESC appointment, as a reminder of the date of
screening.
 Standard letters for family recruitment. The letters are also
available in Afrikaans and are kept on hand at the GESC to be able
to distribute to relatives. The document explains the inherited risk,
option of PT and provides the contact details of GESC (Appendix 7).
 Standard letters for leave of absence. Standard letters on official 
headed paper to be available for individuals to present to their
employers with regards to the need for annual attendance at the
GESC and two day leave of absence for the preparation and
procedure (Appendix 8).
 Greater time devoted to explaining purpose of PT. Most of the
individuals from a lower education background and of Mixed
Ancestry (in this study) struggled to understand the purpose of PT.
Additional time and possibly a more basic explanation of PT should
occur during the counselling session, particularly when individuals 
from this background are seen.
 Emphasis on the benefits and necessities of regular screening 
among the older population. The higher age groups typically 
illustrated greater non-adherence and the concept that screening is 
required even if the individual feels ‗healthy/fine‘ and prior to the
presentation of concerning bowel symptoms, needs to be
emphasised.
 Identification of vulnerable individuals requiring greater
emotional support and further psychological counselling.
Vulnerable individuals include those participants with a parental
cancer diagnosed during their childhood. Cancer worry is also
greater in individuals with less exposure to the effects of the
condition within their family. Individuals should complete a DUKE-
AD form at each post-test session, and if found to be depressed,
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 Approach females and individuals affected with CRC to
increase the awareness of PT (and possible uptake of PT)
among at-risk family members. These individuals should be
targeted as they are more likely to discuss the option and benefits of
PT with the at-risk family members.
 Adherence studies should include adherence rates obtained
from database/medical records. Research aimed at calculating
adherence should capture data from database/medical records to
avoid over-estimation of screening attendance as obtained from
self-reported adherence rates.
 An Afrikaans version of the DUKE-AD scale should be
compiled. The DUKE-AD scale should be translated into Afrikaans
and validated in collaboration with the authors (Pakerson and
Broadhead 1997) who developed it.
 Re-evaluation of the surveillance and PT programme. A re-
evaluation should be conducted after a period of one year following
the recommendations being implemented. Changes in attendance
should be re-calculated to determine the effect of implemented
changes on compliance.
 The DUKE-AD and CWS measures should be conducted with a
larger sample size. A greater number of individuals entering into
PT for LS should be investigated to allow for further definition of 
distress and cancer worry among the SA cohort. It would also be
beneficial to evaluate the effect of PT in a long-term manner, such
as at a yearly follow-up period.
 The reasons for the delay or late uptake of PT should be
investigated. The mean age of entry into PT was 28.7 years among
participants entering into PT in this study. As surveillance is usually
initiated once an individual receives a mutation-positive test result,
the time period from 18 years until 28.7 years is occurring without
colonoscopic screening for many participants. Although LS is
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of cancer diagnosis was 41.5 years in this study, one individual 














Aaltonen, L. A., Peltomaki, P., Mecklin, J. P., Järvinen, H., Jass, J. R., Green, J. S., 
et al. (1994). Replication errors in benign and malignant tumors from 
hereditary nonpolyposis colorectal cancer patients. Cancer Research, 54(7), 
1645-1648.  
Aaltonen, L. A., Salovaara, R., Kristo, P., Canzian, F., Hemminki, A., Peltomaki, P., 
et al. (1998). Incidence of hereditary nonpolyposis colorectal cancer and the 
feasibility of molecular screening for the disease. The New England Journal 
of Medicine, 338(21), 1481-1487.  
Aarnio, M., Mecklin, J. P., Aaltonen, L. A., Nystrom-Lahti, M., & Jarvinen, H. J. 
(1995). Life-time risk of different cancers in hereditary non-polyposis 
colorectal cancer (HNPCC) syndrome. International Journal of Cancer, 
64(6), 430-433.  
Aarnio, M., Salovaara, R., Aaltonen, L. A., Mecklin, J. P., & Jarvinen, H. J. (1997). 
Features of gastric cancer in hereditary non-polyposis colorectal cancer 
syndrome. International Journal of Cancer, 74(5), 551-555.  
Aarnio, M., Sankila, R., Pukkala, E., Salovaara, R., Aaltonen, L. A., de la Chapelle, 
A., et al. (1999). Cancer risk in mutation carriers of DNA-mismatch-repair 
genes. International Journal of Cancer, 81(2), 214-218.  
Abdel-Rahman, W. M., Mecklin, J. P., & Peltomaki, P. (2006). The genetics of 
HNPCC: Application to diagnosis and screening. Critical Reviews in 
oncology/hematology, 58(3), 208-220.  
Abusamra, H., Maximova, S., Bar-Meir, S., Krispin, M., & Rotmensch, H. H. (1987). 
Cancer family syndrome of lynch. The American Journal of Medicine, 83(5), 
981-983.  
Adhikari, M. (2005). Not white enough, not black enough. Racial identity in the South 
African Coloured community. Cape Town: Double Storey books. 
Aktan-Collan, K., Haukkala, A., Mecklin, J. P., Uutela, A., & Kaariainen, H. (2001). 
Psychological consequences of predictive genetic testing for hereditary non-
polyposis colorectal cancer (HNPCC): A prospective follow-up study. 












Aktan-Collan, K., Haukkala, A., Pylvanainen, K., Jarvinen, H. J., Aaltonen, L. A., 
Peltomaki, P., et al. (2007). Direct contact in inviting high-risk members of 
hereditary colon cancer families to genetic counselling and DNA testing. 
Journal of Medical Genetics, 44(11), 732-738.  
Aktan-Collan, K., Mecklin, J. P., Jarvinen, H., Nystrom-Lahti, M., Peltomaki, P., 
Soderling, I., et al. (2000). Predictive genetic testing for hereditary non-
polyposis colorectal cancer: Uptake and long-term satisfaction. International 
Journal of Cancer, 89(1), 44-50.  
Aktan-Collan, K. I., Kaariainen, H. A., Kolttola, E. M., Pylvanainen, K., Jarvinen, H. 
J., Haukkala, A. H., et al. (2011). Sharing genetic risk with next generation:
Mutation-positive parents' communication with their offspring in lynch
syndrome. Familial Cancer, 10(1), 43-50.
American Society of Human Genetics ad Hoc Committee on Genetic Counseling.
(1975). Genetic counseling. American Journal of Human Genetics, 27: 240-
242
American Society of Human Genetics Social Issues Subcommitee on Family
disclosure. (1998). Statement: Professional disclosure of familial genetic 
information. American Journal of Human Genetics, 62(2), 474-483.
American Psychiatric Association. (1994). Diagnostic and Statistical Manual of
Mental Disorders [DSM-IV]. Washington, D.C: American Psychiatric Press.
Anderson, D. W., Goldberg, P. A., Algar, U., Felix, R., & Ramesar, R. S. (2007).
Mobile colonoscopic surveillance provides quality care for hereditary 
nonpolyposis colorectal carcinoma families in south africa. Colorectal
Disease, 9(6), 509-514.
Annie Yu, H. J., Lin, K. M., Ota, D. M., & Lynch, H. T. (2003). Hereditary 
nonpolyposis colorectal cancer: Preventive management. Cancer Treatment 
Reviews, 29(6), 461-470.  
Anwar, S., Hall, C., White, J., Deakin, M., Farrell, W., & Elder, J. B. (2000). 
Hereditary non-polyposis colorectal cancer: An updated review. European 
Journal of Surgical Oncology, 26(7), 635-645.  
Appelbaum, P.S., Ludz, C.W., & Meisel, A. (1987). Informed consent: Legal theory 












Aronson, M. (2009). Genetic counseling for hereditary colorectal cancer: Ethical, 
legal, and psychosocial issues. Surgical Oncology Clinics of North America, 
18(4), 669-685.  
Arver, B., Haegermark, A., Platten, U., Lindblom, A., & Brandberg, Y. (2004). 
Evaluation of psychosocial effects of pre-symptomatic testing for 
breast/ovarian and colon cancer pre-disposing genes: A 12-month follow-
up. Familial Cancer, 3(2), 109-116.  
Ashida, S., Hadley, D. W., Vaughn, B. K., Kuhn, N. R., Jenkins, J. F., & Koehly, L. M. 
(2009). The impact of familial environment on depression scores after 
genetic testing for cancer susceptibility. Clinical Genetics, 75(1), 43-49.  
Baglietto, L., Lindor, N. M., Dowty, J. G., White, D. M., Wagner, A., Gomez Garcia, 
E. B., et al. (2010). Risks of Lynch syndrome cancers for MSH6 mutation
carriers. Journal of the National Cancer Institute, 102(3), 193-201.
Baker, D.L., Schutte, J.L., Uhlmann, W.R. (1998). A guide to genetic counselling. 
New York: Wiley-Liss. 
Balmana, J., Stoffel, E., Emmons, K., Garber, J., & Syngal, S. (2004). Comparison of
motivations and concerns for genetic testing in hereditary colorectal and
breast cancer syndromes [Electronic version]. British Medical Journal, 41(4),
e44. [Retrieved July 2010 from PubMed Online database].
Bank A., Malherbe, C., & van der Spuy, P. (2003). People of the Western Cape: A
history for schools. Cape Town: Juta Gariep.
Barbour, R. (2008). Introducing qualitative research: A student guide to the craft of
doing qualitative research. London: SAGE.
Barnetson, R. A., Tenesa, A., Farrington, S. M., Nicholl, I. D., Cetnarskyj, R., 
Porteous, M. E., et al. (2006). Identification and survival of carriers of 
mutations in DNA mismatch-repair genes in colon cancer. The New England 
Journal of Medicine, 354(26), 2751-2763.  
Barrow, E., Alduaij, W., Robinson, L., Shenton, A., Clancy, T., Lalloo, F., et al. 
(2008). Colorectal cancer in HNPCC: Cumulative lifetime incidence, survival 
and tumour distribution. A report of 121 families with proven mutations. 
Clinical Genetics, 74(3), 233-242.  
Barrow, E., Robinson, L., Alduaij, W., Shenton, A., Clancy, T., Lalloo, F., et al. 












syndrome: A report of 121 families with proven mutations. Clinical Genetics, 
75(2), 141-149.  
Beck, R. B. (2000). The history of South Africa. Cape Town: Greenwood Publishing 
Group. 
Beeker, C., Kraft, J. M., Southwell, B. G., & Jorgensen, C. M. (2000). Colorectal 
cancer screening in older men and women: Qualitative research findings 
and implications for intervention. Journal of Community Health, 25(3), 263-
278.  
Bellacosa, A., Genuardi, M., Anti, M., Viel, A., & Ponz de Leon, M. (1996). Hereditary 
nonpolyposis colorectal cancer: Review of clinical, molecular genetics, and 
counseling aspects. American Journal of Medical Genetics, 62(4), 353-364.  
Benatar, S. R., & van Rensburg, H. C. (1995). Health care services in a new south
africa. The Hastings Center Report, 25(4), 16-21.
Bennett, R. L., Hampel, H. L., Mandell, J. B., & Marks, J. H. (2003). Genetic
counselors: Translating genomic science into clinical practice. The Journal
of Clinical Investigation, 112(9), 1274-1279.
Berends, M. J., Wu, Y., Sijmons, R. H., Mensink, R. G., van der Sluis, T., Hordijk-
Hos, J. M., et al. (2002). Molecular and clinical characteristics of MSH6
variants: An analysis of 25 index carriers of a germline variant. American
Journal of Human Genetics, 70(1), 26-37.
Bermejo, J. L., Eng, C., & Hemminki, K. (2005). Cancer characteristics in swedish 
families fulfilling criteria for hereditary nonpolyposis colorectal cancer.
Gastroenterology, 129(6), 1889-1899.
Bernhardt, B. A., Biesecker, B. B., & Mastromarino, C. L. (2000). Goals, benefits, 
and outcomes of genetic counseling: Client and genetic counselor 
assessment. Medical Genetics, 94(3), 189-197.  
Biesecker, B. B., & Marteau, T. M. (1999). The future of genetic counselling: An 
international perspective. Nature Genetics, 22(2), 133-137. 
Biesecker, B. B., & Peters, K. F. (2001). Process studies in genetic counseling: 













Bjorvatn, C., Eide, G. E., Hanestad, B. R., Oyen, N., Havik, O. E., Carlsson, A., et al. 
(2007). Risk perception, worry and satisfaction related to genetic counseling 
for hereditary cancer. Journal of Genetic Counseling, 16(2), 211-222.  
Blandy, C., Chabal, F., Stoppa-Lyonnet, D., & Julian-Reynier, C. (2003). Testing 
participation in BRCA1/2-positive families: Initiator role of index cases. 
Genetic Testing, 7(3), 225-233.  
Bleiker, E. M., Aaronson, N. K., Menko, F. H., Hahn, D. E., van Asperen, C. J., 
Rutgers, E. J., et al. (1997). Genetic counseling for hereditary cancer: A 
pilot study on experiences of patients and family members. Patient 
Education and Counseling, 32(1-2), 107-116.  
Bleiker, E. M., Hahn, D. E., & Aaronson, N. K. (2003). Psychosocial issues in cancer 
genetics-current status and future directions. Acta Oncologica, 42(4), 276-
286. 
Bleiker, E. M., Menko, F. H., Taal, B. G., Kluijt, I., Wever, L. D., Gerritsma, M. A., et 
al. (2005). Screening behavior of individuals at high risk for colorectal
cancer. Gastroenterology, 128(2), 280-287.
Blokhuis, M. M., Goldberg, P. A., Pietersen, G. E., Algar, U., Vorster, A. A.,
Govender, D., et al. (2008). The extracolonic cancer spectrum in females
with the common 'south african' hMLH1 c.C1528T mutation. Familial
Cancer, 7(3), 191-198.
Bober, S. L., Hoke, L. A., Duda, R. B., & Tung, N. M. (2007). Recommendation recall
and satisfaction after attending breast/ovarian cancer risk counseling.
Journal of Genetic Counseling, 16(6), 755-762.
Boland, C. R. (2005). Evolution of the nomenclature for the hereditary colorectal 
cancer syndromes. Familial Cancer, 4(3), 211-218. 
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., 
Burt, R. W., et al. (1998). A national cancer institute workshop on 
microsatellite instability for cancer detection and familial predisposition: 
Development of international criteria for the determination of microsatellite 
instability in colorectal cancer. Cancer Research, 58(22), 5248-5257.  
Bonadona, V., Bonaiti, B., Olschwang, S., Grandjouan, S., Huiart, L., Longy, M., et 
al. (2011). Cancer risks associated with germline mutations in MLH1, 
MSH2, and MSH6 genes in lynch syndrome. The Journal of the American 












Bonadona, V., Saltel, P., Desseigne, F., Mignotte, H., Saurin, J. C., Wang, Q., et al. 
(2002). Cancer patients who experienced diagnostic genetic testing for 
cancer susceptibility: Reactions and behavior after the disclosure of a 
positive test result. Cancer Epidemiology, Biomarkers & Prevention, 11(1), 
97-104.
Borry, P., Stultiens, L., Nys, H., Cassiman, J. J., & Dierickx, K. (2006). 
Presymptomatic and predictive genetic testing in minors: A systematic 
review of guidelines and position papers. Clinical Genetics, 70(5), 374-381.  
Bottorff, J. L., Ratner, P. A., Johnson, J. L., Lovato, C. Y., & Joab, S. A. (1998). 
Communicating cancer risk information: The challenges of uncertainty. 
Patient Education and Counseling, 33(1), 67-81.  
Bradshaw, D., Nannan, N., Groenewald, P., Joubert, J., Laubscher, R., Nojilana, B.,
et al. (2005). Provincial mortality in south africa, 2000–priority-setting for
now and a benchmark for the future. South African Medical Journal, 95(7),
496-503.
Bradshaw, D., Nannan, N., Laubscher, R., Groenewald, P., Joubert, J., Nojilana, B.,
et al. (2004) South African national burden of disease study 2000: Estimates 
of provincial mortality. Cape Town: South African Medical Research
Council.
Bradstock, A. (2005). Changing livelihoods and land reform: Evidence from the
northern cape province of south africa. World Development, 33(11), 1979-
1992.
Brain, K., Sivell, S., Bennert, K., Howell, L., France, L., Jordan, S., et al. (2005). An
exploratory comparison of genetic counselling protocols for HNPCC
predictive testing. Clinical Genetics, 68(3), 255-261. 
Brink, H. (1996). Fundamentals of research methodology for health care 
professionals. Cape Town: Juta and Company Ltd. 
Broadhead, R. S. (1980). Qualitative analysis in evaluation research: Problems and 
promises of an interactionist approach. Symbolic Interaction, 3(1), 23-40. 
Broadstock, M., Michie, S., & Marteau, T. (2000). Psychological consequences of 
predictive genetic testing: A systematic review. European Journal of Human 












Burgard, S. A., & Treiman, D. J. (2006). Trends and racial differences in infant 
mortality in south africa. Social Science & Medicine (1982), 62(5), 1126-
1137.  
Burger, D. (2009). The land and its people: South African yearbook 2008/09. 
Pretoria: Government Communication and information system. 
Burn, J., Bishop, D. T., Mecklin, J. P., Macrae, F., Moslein, G., Olschwang, S., et al. 
(2008). Effect of aspirin or resistant starch on colorectal neoplasia in the 
lynch syndrome. The New England Journal of Medicine, 359(24), 2567-
2578.  
Burton, A. M., Peterson, S. K., Marani, S. K., Vernon, S. W., Amos, C. I., Frazier, M. 
L., et al. (2010). Health and lifestyle behaviors among persons at risk of 
lynch syndrome. Cancer Causes & Control, 21(4), 513-521.  
Cai, S. J., Xu, Y., Cai, G. X., Lian, P., Guan, Z. Q., Mo, S. J., et al. (2003). Clinical 
characteristics and diagnosis of patients with hereditary nonpolyposis 
colorectal cancer. World Journal of Gastroenterology, 9(2), 284-287.  
Caluseriu, O., Di Gregorio, C., Lucci-Cordisco, E., Santarosa, M., Trojan, J., Brieger, 
A., et al. (2004). A founder MLH1 mutation in families from the districts of 
modena and reggio-emilia in northern italy with hereditary non-polyposis 
colorectal cancer associated with protein elongation and instability 
[Electronic version]. Journal of Medical Genetics, 41(3), e34. [Retrieved May 
2010 from PubMed Online database].  
Campos, F.G., Logullo Waitzberg, A.G., Kiss, D.R., Waitzberg, D.L., Habr-Gama, A., 
Gama-Rodrigues, J. (2005). Diet and colorectal cancer: current evidence for 
etiology and prevention. Nutricion Hospitalaria, 20(1), 18-25. 
CANSA Registry. (1997). Colorectal cancer: numbers and incidence. Retrieved 
February 2009 from 
http://www.cansa.org.za/Research/registry1997_colorectal.asp. 
Carpenter, C., & Suto, M. (2008). Qualitative research for occupational and physical 
therapists: A practical guide. Blackwell Publishing: Oxford.  
Cederquist, K., Emanuelsson, M., Wiklund, F., Golovleva, I., Palmqvist, R., & 
Gronberg, H. (2005). Two swedish founder MSH6 mutations, one nonsense 
and one missense, conferring high cumulative risk of lynch syndrome. 












Chan, T. L., Chan, Y. W., Ho, J. W., Chan, C., Chan, A. S., Chan, E., et al. (2004). 
MSH2 c.1452-1455delAATG is a founder mutation and an important cause 
of hereditary nonpolyposis colorectal cancer in the southern chinese 
population. American Journal of Human Genetics, 74(5), 1035-1042.  
Chapman, P. D., & Burn, J. (1999). Genetic predictive testing for bowel cancer 
predisposition: The impact on the individual. Cytogenetics and Cell 
Genetics, 86(2), 118-124.  
Charles, S., Kessler, L., Stopfer, J. E., Domchek, S., & Halbert, C. H. (2006). 
Satisfaction with genetic counseling for BRCA1 and BRCA2 mutations 
among african american women. Patient Education and Counseling, 63(1-
2), 196-204.  
Chen, H. T., & Rossi, P. H. (1983). Evaluating with sense: The theory-driven
approach. Evaluation Review, 7(3), 283-302. 
Chen, L. M., Yang, K. Y., Little, S. E., Cheung, M. K., & Caughey, A. B. (2007).
Gynecologic cancer prevention in lynch syndrome/hereditary nonpolyposis 
colorectal cancer families. Obstetrics and Gynecology, 110(1), 18-25.
Claes, E., Evers-Kiebooms, G., Boogaerts, A., Decruyenaere, M., Denayer, L., &
Legius, E. (2003). Communication with close and distant relatives in the
context of genetic testing for hereditary breast and ovarian cancer in cancer
patients. American Journal of Medical Genetics, 116(1), 11-19.
Claes, E., Denayer, L., Evers-Kiebooms, G., Boogaerts, A., & Legius, E. (2004).
Predictive testing for hereditary non-polyposis colorectal cancer: Motivation,
illness representations and short-term psychological impact. Patient
Education and Counseling, 55(2), 265-274.
Codori, A. M., Petersen, G. M., Miglioretti, D. L., & Boyd, P. (2001). Health beliefs 
and endoscopic screening for colorectal cancer: Potential for cancer 
prevention. Preventive Medicine, 33(2 Pt 1), 128-136.  
Codori, A. M., Petersen, G. M., Miglioretti, D. L., Larkin, E. K., Bushey, M. T., Young, 
C., et al. (1999). Attitudes toward colon cancer gene testing: Factors 
predicting test uptake. Cancer Epidemiology, Biomarkers & Prevention, 8(4 
Pt 2), 345-351.  
Cohen, M. Z., & Omery, A. (1994). Schools of phenomenology: Implications for 
research. In J.M. Morse (Ed.). Critical Issues in Qualitative Research 












Colaizzi, P. (1978). Psychological research as the phenomenologist views it. In R. 
Valle & M. King (Ed). Existential-phenomenological alternatives for 
psychology. New York: Oxford University Press. 
Collins, V., Halliday, J., Warren, R., & Williamson, R. (2000). Cancer worries, risk 
perceptions and associations with interest in DNA testing and clinic 
satisfaction in a familial colorectal cancer clinic. Clinical Genetics, 58(6), 
460-468.  
Collins, V., Meiser, B., Gaff, C., St John, D., & Halliday, J. (2005). Screening and 
preventive behaviors one year after predictive genetic testing for hereditary 
nonpolyposis colorectal carcinoma. Cancer, 104(2), 273–281.  
Collins, V., Meiser, B., Ukoumunne, O. C., Gaff, C., St John, D. J., & Halliday, J. L. 
(2007). The impact of predictive genetic testing for hereditary nonpolyposis 
colorectal cancer: Three years after testing. Genetics in Medicine, 9(5), 290-
297. 
Committee for public relations and ethical issues of the German Society of Human 
Genetics. (2000). Positional paper of the German Society of Human 
Genetics, 1–13.  
Coovadia, H., Jewkes, R., Barron, P., Sanders, D., & McIntyre, D. (2009). The health 
and health system of south africa: Historical roots of current public health 
challenges. Lancet, 374(9692), 817-834.  
Cornaggia, M., Tibiletti, M. G., Albarello, L., Taborelli, M., Dalla Longa, E., & Capella, 
C. (2000). Low incidence of hereditary nonpolyposis colorectal cancer 
syndrome in a selected area of the lombardy cancer registry. Tumori, 86(6), 
439-444.  
Crockett, D. G., Wagner, D. G., Holmang, S., Johansson, S. L., & Lynch, H. T. 
(2011). Upper urinary tract carcinoma in lynch syndrome cases. The Journal 
of Urology, 185(5), 1627-1630.  
Cronin ,P., Ryan, F., Coughlan, M. (2010). Concept analysis in healthcare research. 
International journal of therapy and rehabilitation, 17(2), 62-68. 
Cronjé, L., Paterson, A., & Becker, P. (2009). Colorectal cancer in south africa: A 
heritable cause suspected in many young black patients. South African 












Croyle, R. T., & Lerman, C. (1993). Interest in genetic testing for colon cancer 
susceptibility: Cognitive and emotional correlates. Preventive Medicine, 
22(2), 284-292.  
Cunningham, J. M., Kim, C. Y., Christensen, E. R., Tester, D. J., Parc, Y., Burgart, L. 
J., et al. (2001). The frequency of hereditary defective mismatch repair in a 
prospective series of unselected colorectal carcinomas. American Journal of 
Human Genetics, 69(4), 780-790.  
d'Agincourt-Canning, L. (2001). Experiences of genetic risk: Disclosure and the 
gendering of responsibility. Bioethics, 15(3), 231-247. 
Daly J., Kellehear, .A, Gliksman, M. (1997). The public health researcher: A 
methodological guide. New York: Oxford University Press. 
Davey, A., Rostant, K., Harrop, K., Goldblatt, J., & O'Leary, P. (2005). Evaluating
genetic counseling: Client expectations, psychological adjustment and
satisfaction with service. Journal of Genetic Counseling, 14(3), 197-206.
de Jong, A. E., Morreau, H., Van Puijenbroek, M., Eilers, P. H., Wijnen, J.,
Nagengast, F. M., et al. (2004). The role of mismatch repair gene defects in
the development of adenomas in patients with HNPCC. Gastroenterology,
126(1), 42-48.
de Jong, A. E., Nagengast, F. M., Kleibeuker, J. H., van de Meeberg, P. C., van Wijk,
H. J., Cats, A., et al. (2006). What is the appropriate screening protocol in 
lynch syndrome? Familial Cancer, 5(4), 373-378.
de Leeuw, W. J., Dierssen, J., Vasen, H. F., Wijnen, J. T., Kenter, G. G., Meijers-
Heijboer, H., et al. (2000). Prediction of a mismatch repair gene defect by
microsatellite instability and immunohistochemical analysis in endometrial
tumours from HNPCC patients. The Journal of Pathology, 192(3), 328-335.
Denscombe, M. (2008). The good research guide for small-scale research projects 
(3rd Edn). Berkshire: Open University Press. 
Department of Health. (NO DATE). Mission and Vision. Retrieved April 2010 from 
http://www.doh.gov.za/. 
Department of Trade and Industry RSA. (2006). South Africa’s economic 













de Vos tot Nederveen Cappel,W.H., Nagengast, F. M., Griffioen, G., Menko, F. H., 
Taal, B. G., Kleibeuker, J. H., et al. (2002). Surveillance for hereditary 
nonpolyposis colorectal cancer: A long-term study on 114 families. Diseases 
of the Colon and Rectum, 45(12), 1588-1594.  
de Wert, G. (1998). Ethics of predictive DNA-testing for hereditary breast and 
ovarian cancer. Patient Education and Counseling, 35(1), 43-52. 
de Wert, G. (1998). Ethics of predictive DNA-testing for hereditary breast and 
ovarian cancer. Patient Education and Counseling, 35(1), 43-52. 
DeMarco, T. A., Peshkin, B. N., Mars, B. D., & Tercyak, K. P. (2004). Patient 
satisfaction with cancer genetic counseling: A psychometric analysis of the 
genetic counseling satisfaction scale. Journal of Genetic Counseling, 13(4), 
293-304.
Denberg, T. D., Melhado, T. V., Coombes, J. M., Beaty, B. L., Berman, K., Byers, T.
E., et al. (2005). Predictors of nonadherence to screening colonoscopy.
Journal of General Internal Medicine, 20(11), 989-995. 
Desai, D. C., Lockman, J. C., Chadwick, R. B., Gao, X., Percesepe, A., Evans, D. G.
R., et al. (2000). Recurrent germline mutation in MSH2 arises frequently de
novo. British Medical Journal, 37(9), 646.
Dewanwala, A., Chittenden, A., Rosenblatt, M., Mercado, R., Garber, J. E., Syngal,
S., et al. (2011). Attitudes toward childbearing and prenatal testing in 
individuals undergoing genetic testing for lynch syndrome [Electronic 
version]. Familial Cancer. [Retrieved July 2011 from PubMed Online
database].
Diergaarde, B., Braam, H., Vasen, H. F., Nagengast, F. M., van Muijen, G. N., Kok, 
F. J., et al. (2007). Environmental factors and colorectal tumor risk in
individuals with hereditary nonpolyposis colorectal cancer. Clinical
Gastroenterology and Hepatology, 5(6), 736-742.
Doak, C. C., Doak, L. G., Friedell, G. H., & Meade, C. D. (1998). Improving 
comprehension for cancer patients with low literacy skills: Strategies for 
clinicians. A Cancer Journal for Clinicians, 48(3), 151-162.  
Domanska, K., Carlsson, C., Bendahl, P. O., & Nilbert, M. (2009). Knowledge about 
hereditary nonpolyposis colorectal cancer; mutation carriers and physicians 
at equal levels. [Electronic version]. BMC Medical Genetics, 10(30). 












Domingo, E., Laiho, P., Ollikainen, M., Pinto, M., Wang, L., French, A. J., et al. 
(2004). BRAF screening as a low-cost effective strategy for simplifying 
HNPCC genetic testing. Journal of Medical Genetics, 41(9), 664-668.  
Dores, G. M., Curtis, R. E., Toro, J. R., Devesa, S. S., & Fraumeni, J. F.,Jr. (2008). 
Incidence of cutaneous sebaceous carcinoma and risk of associated 
neoplasms: Insight into muir-torre syndrome. Cancer, 113(12), 3372-3381.  
Dorval, M., Patenaude, A. F., Schneider, K. A., Kieffer, S. A., DiGianni, L., 
Kalkbrenner, K. J., et al. (2000). Anticipated versus actual emotional 
reactions to disclosure of results of genetic tests for cancer susceptibility: 
Findings from p53 and BRCA1 testing programs. Journal of Clinical 
Oncology, 18(10), 2135-2142.  
Douglas, J. A., Gruber, S. B., Meister, K. A., Bonner, J., Watson, P., Krush, A. J., et
al. (2005). History and molecular genetics of lynch syndrome in family G: A
century later. The Journal of the American Medical Association, 294(17),
2195-2202.
Dove-Edwin, I., Boks, D., Goff, S., Kenter, G. G., Carpenter, R., Vasen, H. F., et al.
(2002). The outcome of endometrial carcinoma surveillance by ultrasound
scan in women at risk of hereditary nonpolyposis colorectal carcinoma and 
familial colorectal carcinoma. Cancer, 94(6), 1708-1712.
Dugan, R. B., Wiesner, G. L., Juengst, E. T., O'Riordan, M., Matthews, A. L., &
Robin, N. H. (2003). Duty to warn at-risk relatives for genetic disease:
Genetic counselors' clinical experience. American Journal of Medical
Genetics. Part C, Seminars in Medical Genetics, 119C(1), 27-34.
Dunlop, M. G., Farrington, S. M., Carothers, A. D., Wyllie, A. H., Sharp, L., Burn, J.,
et al. (1997). Cancer risk associated with germline DNA mismatch repair 
gene mutations. Human Molecular Genetics, 6(1), 105-110.  
Elwyn, G., Gray, J., & Clarke, A. (2000). Shared decision making and non-
directiveness in genetic counselling. Journal of Medical Genetics, 37(2), 
135-138.
Engel, C., Rahner, N., Schulmann, K., Holinski-Feder, E., Goecke, T. O., Schackert, 
H. K., et al. (2010). Efficacy of annual colonoscopic surveillance in
individuals with hereditary nonpolyposis colorectal cancer. Clinical












Ensenauer, R. E., Michels, V. V., & Reinke, S. S. (2005). Genetic testing: Practical, 
ethical, and counseling considerations. Mayo Clinic Proceedings. Mayo 
Clinic, 80(1), 63-73.  
Equal Employment Opportunity Commission. (1995). Compliance Manual. Volume 2, 
Section 902 Order 915.002. 
Erasmus, Z. (2001). Coloured by history shaped by place: New perspectives on 
Coloured identities in Cape Town. Cape Town: Kwela Books. 
Erblich, J., Brown, K., Kim, Y., Valdimarsdottir, H. B., Livingston, B. E., & Bovbjerg, 
D. H. (2005). Development and validation of a breast cancer genetic
counseling knowledge questionnaire. Patient Education and Counseling,
56(2), 182-191.
Ersig, A. L., Hadley, D. W., & Koehly, L. M. (2009). Colon cancer screening practices
and disclosure after receipt of positive or inconclusive genetic test results for 
hereditary nonpolyposis colorectal cancer. Cancer, 115(18), 4071-4079.
Esplen, M. J., Madlensky, L., Butler, K., McKinnon, W., Bapat, B., Wong, J., et al.
(2001). Motivations and psychosocial impact of genetic testing for HNPCC.
American Journal of Medical Genetics, 103(1), 9-15.
Esplen, M. J., Madlensky, L., Aronson, M., Rothenmund, H., Gallinger, S., Butler, K.,
et al. (2007). Colorectal cancer survivors undergoing genetic testing for 
hereditary non-polyposis colorectal cancer: Motivational factors and
psychosocial functioning. Clinical Genetics, 72(5), 394-401.
Esplen, M. J., Urquhart, C., Butler, K., Gallinger, S., Aronson, M., & Wong, J. (2003).
The experience of loss and anticipation of distress in colorectal cancer
patients undergoing genetic testing. Journal of Psychosomatic Research,
55(5), 427-435.
European commission. (2004). Ethical, legal and social aspects of genetic testing: 
Research, development and clinical applications. Luxemburg: European 
Commission.  
Evans, C. (2006). Genetic counseling. A psychological approach. New York: 
Cambridge University Press. 
Evans, D.G., Binchy, .A, Shenton, A., Hopwood, P. Craufurd, D. (2009). Coparison 
of proactive and usual approaches to offering predictive testing for BRCA1/2 












Evans, D. G., Walsh, S., Jeacock, J., Robinson, C., Hadfield, L., Davies, D. R., et al. 
(1997). Incidence of hereditary non-polyposis colorectal cancer in a 
population-based study of 1137 consecutive cases of colorectal cancer. The 
British Journal of Surgery, 84(9), 1281-1285.  
Evans, J. P., Skrzynia, C., & Burke, W. (2001). The complexities of predictive genetic 
testing. British Medical Journal, 322(7293), 1052-1056. 
Evers-Kiebooms, G., Welkenhuysen, M., Claes, E., Decruyenaere, M., & Denayer, L. 
(2000). The psychological complexity of predictive testing for late onset 
neurogenetic diseases and hereditary cancers: Implications for 
multidisciplinary counselling and for genetic education. Social Science & 
Medicine, 51(6), 831-841.  
Falk, M. J., Dugan, R. B., O'Riordan, M. A., Matthews, A. L., & Robin, N. H. (2003).
Medical geneticists' duty to warn at-risk relatives for genetic disease.
American Journal of Medical Genetics. Part A, 120A(3), 374-380.
Felix, R., Bodmer, W., Fearnhead, N. S., van der Merwe, L., Goldberg, P., &
Ramesar, R. S. (2006). GSTM1 and GSTT1 polymorphisms as modifiers of
age at diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) in a 
homogeneous cohort of individuals carrying a single predisposing mutation.
Mutation Research, 602(1-2), 175-181.
Ferreira, A. (2010). Diamond in the dust for local art. Sunday Times Newspaper, 25
April. Retrieved May 2010 from
http://www.timeslive.co.za/sundaytimes/article418944.ece/Diamond-in-the-
dust-for-local-art.
Forrest, K., Simpson, S., Wilson, B., van Teijlingen, E., McKee, L., Haites, N., et al.
(2003). To tell or not to tell: Barriers and facilitators in family communication 
about genetic risk. Clinical Genetics, 64(4), 317-326.  
Forrest, L. E., Delatycki, M. B., Skene, L., & Aitken, M. (2007). Communicating 
genetic information in families-a review of guidelines and position papers. 
European Journal of Human Genetics, 15(6), 612-618.  
Foster, C., Eeles, R., Ardern-Jones, A., Moynihan, C., & Watson, M. (2004). Juggling 
roles and expectations: Dilemmas faced by women talking to relatives about 
cancer and genetic testing. Psychology and Health, 19(4), 439-455.  
Foulkes, W. D., Thiffault, I., Gruber, S. B., Horwitz, M., Hamel, N., Lee, C., et al. 












hereditary nonpolyposis colorectal cancer in the ashkenazi jewish 
population. American Journal of Human Genetics, 71(6), 1395-1412.  
Fraser, F. C. (1974). Genetic counseling. American Journal of Human Genetics, 
26(5), 636-659. 
Froggatt, N. J., Green, J., Brassett, C., Evans, D. G., Bishop, D. T., Kolodner, R., et 
al. (1999). A common MSH2 mutation in english and north american 
HNPCC families: Origin, phenotypic expression, and sex specific 
differences in colorectal cancer. Journal of Medical Genetics, 36(2), 97-102.  
Gaff, C. L., Collins, V., Symes, T., & Halliday, J. (2005). Facilitating family 
communication about predictive genetic testing: Probands‘ perceptions. 
Journal of Genetic Counseling, 14(2), 133-140.  
Geary, J., Sasieni, P., Houlston, R., Izatt, L., Eeles, R., Payne, S. J., et al. (2008).
Gene-related cancer spectrum in families with hereditary non-polyposis 
colorectal cancer (HNPCC). Familial Cancer, 7(2), 163-172.
Geller, G., Botkin, J. R., Green, M. J., Press, N., Biesecker, B. B., Wilfond, B., et al.
(1997). Genetic testing for susceptibility to adult-onset cancer. the process
and content of informed consent. The Journal of the American Medical
Association, 277(18), 1467-1474.
Genereviews. (2006). Hereditary-nonpolyposis colorectal cancer. Retrieved
December 2009 from http://www.ncbi.nlm.nih.gov/books/NBK1211/.
Gili, M., Roca, M., Ferrer, V., Obrador, A., & Cabeza, E. (2006). Psychosocial factors
associated with the adherence to a colorectal cancer screening program.
Cancer Detection and Prevention, 30(4), 354-360.
Giovannucci, E., Stampfer, M. J., Colditz, G., Rimm, E. B., & Willett, W. C. (1992). 
Relationship of diet to risk of colorectal adenoma in men. Journal of the 
National Cancer Institute, 84(2), 91-98.  
Glanz, K., Grove, J., Lerman, C., Gotay, C., & Le Marchand, L. (1999). Correlates of 
intentions to obtain genetic counseling and colorectal cancer gene testing 
among at-risk relatives from three ethnic groups. Cancer Epidemiology, 
Biomarkers & Prevention, 8(4 Pt 2), 329-336.  
Golafshani, N. (2003). Understanding reliability and validity in qualitative research. 












Goldberg, P. A., Madden, M. V., Harocopos, C., Felix, R., Westbrook, C., & 
Ramesar, R. S. (1998). In a resource-poor country, mutation identification 
has the potential to reduce the cost of family management for hereditary 
nonpolyposis colorectal cancer. Diseases of the Colon and Rectum, 41(10), 
1250-1253. 
Goldblatt, J., Madden, M. V., Boshoff, P. J., Wallis, C., & Price, S. K. (1990). 
Hereditary non-polyposis colorectal cancer in a namaqualand kindred. 
South African Medical Journal, 77(1), 42-44.  
Goldin, I. (1987). Making of race: The politics and economics of Coloured identity in 
South Africa. Cape Town: Maskew Miller Longman. 
Goodfellow, P. J., Buttin, B. M., Herzog, T. J., Rader, J. S., Gibb, R. K., Swisher, E., 
et al. (2003). Prevalence of defective DNA mismatch repair and MSH6
mutation in an unselected series of endometrial cancers. Proceedings of the
National Academy of Sciences of the United States of America, 100(10),
5908-5913.
Government Gazette of the Republic of South Africa. (1998). Act No R417 of 1998. 
Pretoria: Government Printers.
Government Gazette of the Republic of South Africa (1992). Act No 52 of 1992. 
Pretoria: Government Printers.
Graham, E.E., Barbato, C.A., & Perse, E.M. (1993). The interpersonal
communication motives model. Communication Quarterly, 41(2), 172-186. 
Gramling, R., Anthony, D., Frierson, G., & Bowen, D. (2007). The cancer worry chart:
A single-item screening measure of worry about developing breast cancer.
Psycho-Oncology, 16(6), 593-597.
Green, J., Richards, M., Murton, F., Statham, H., & Hallowell, N. (1997). Family 
communication and genetic counseling: The case of hereditary breast and 
ovarian cancer. Journal of Genetic Counseling, 6(1), 45-60.  
Gritz, E. R., Peterson, S. K., Vernon, S. W., Marani, S. K., Baile, W. F., Watts, B. G., 
et al. (2005). Psychological impact of genetic testing for hereditary 
nonpolyposis colorectal cancer. Journal of Clinical Oncology, 23(9), 1902-
1910.  
Groenewegen, P. P., Kerssens, J. J., Sixma, H. J., van der Eijk, I., & Boerma, W. G. 
(2005). What is important in evaluating health care quality? an international 












Research, 5(1). [Retrieved April 2009 from BioMed Central Online 
database]. 
Gryfe, R., Kim, H., Hsieh, E. T., Aronson, M. D., Holowaty, E. J., Bull, S. B., et al. 
(2000). Tumor microsatellite instability and clinical outcome in young 
patients with colorectal cancer. The New England Journal of Medicine, 
342(2), 69-77.  
Guerra, C. E., Dominguez, F., & Shea, J. A. (2005). Literacy and knowledge, 
attitudes, and behavior about colorectal cancer screening. Journal of Health 
Communication, 10(7), 651-663.  
Hadley, D. W., Ashida, S., Jenkins, J. F., Calzone, K. A., Kirsch, I. R., & Koehly, L. 
M. (2011). Colonoscopy use following mutation detection in lynch syndrome:
Exploring a role for cancer screening in adaptation. Clinical Genetics, 79(4),
321-328.
Hadley, D. W., Jenkins, J., Dimond, E., Nakahara, K., Grogan, L., Liewehr, D. J., et
al. (2003). Genetic counseling and testing in families with hereditary 
nonpolyposis colorectal cancer. Archives of Internal Medicine, 163(5), 573-
582. 
Hadley, D. W., Jenkins, J. F., Dimond, E., de Carvalho, M., Kirsch, I., & Palmer, C.
G. S. (2004). Colon cancer screening practices after genetic counseling and
testing for hereditary nonpolyposis colorectal cancer. Journal of Clinical
Oncology, 22(1), 39.
Halbert, C. H., Lynch, H., Lynch, J., Main, D., Kucharski, S., Rustgi, A. K., et al.
(2004). Colon cancer screening practices following genetic testing for
hereditary nonpolyposis colon cancer (HNPCC) mutations. Archives of
Internal Medicine, 164(17), 1881-1887.
Hallowell, N., Murton, F., Statham, H., Green, J., & Richards, M. (1997). Women's 
need for information before attending genetic counselling for familial breast 
or ovarian cancer: A questionnaire, interview, and observational study. 
British Medical Journal, 314(7076), 281-283.  
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. 
(2008). Feasibility of screening for lynch syndrome among patients with 
colorectal cancer. Journal of Clinical Oncology, 26(35), 5783-5788.  
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., et al. 












colorectal cancer). The New England Journal of Medicine, 352(18), 1851-
1860.  
Hampel, H., Stephens, J. A., Pukkala, E., Sankila, R., Aaltonen, L. A., Mecklin, J. P., 
et al. (2005b). Cancer risk in hereditary nonpolyposis colorectal cancer 
syndrome: Later age of onset. Gastroenterology, 129(2), 415-421.  
Harper, P.S. (1998). Practical genetic counselling. Oxford: ButterworthHeinemann. 
Harris, M. A., & Byles, J. E. (1997). A survey of screening compliance among first 
degree relatives of people with colon cancer in new south wales. Journal of 
Medical Screening, 4(1), 29-34.  
Hendriks, Y. M., Wagner, A., Morreau, H., Menko, F., Stormorken, A., 
Quehenberger, F., et al. (2004). Cancer risk in hereditary nonpolyposis
colorectal cancer due to MSH6 mutations: Impact on counseling and 
surveillance. Gastroenterology, 127(1), 17-25.
Holloway, I. (1997). Basic concepts for qualitative research. Oxford: Blackwell
Science. 
Holloway, I. (2005). Qualitative research in health care. New York: University Press
McGraw Hill. 
Holloway, I. & Wheeler, S. (1996). Qualitative research for nurses. Oxford: Blackwell
Science. 
Hopwood, P. (1997). Psychological issues in cancer genetics: Current research and
future priorities. Patient Education and Counseling, 32(1-2), 19-31.
Houlston, R. S., Murday, V., Harocopos, C., Williams, C. B., & Slack, J. (1990).
Screening and genetic counselling for relatives of patients with colorectal
cancer in a family cancer clinic. British Medical Journal, 301(6748), 366-
368. 
Hughes, C., Lerman, C., Schwartz, M., Peshkin, B. N., Wenzel, L., Narod, S., et al. 
(2002). All in the family: Evaluation of the process and content of sisters' 
communication about BRCA1 and BRCA2 genetic test results. American 
Journal of Medical Genetics, 107(2), 143-150.  
Hughes, C., Lynch, H., Durham, C., Snyder, C., Lemon, S., Narod, S., et al. (1999). 
Communication of BRCA1/2 test results in hereditary breast cancer families. 












INSIGHT. (2008): International society for gastroenterological tumours. Retrieved 
April 2010 from http://www.insight-group.org/mutations/. 
Irmejs, A., Borosenko, V., Melbarde-Gorkusa, I., Gardovskis, A., Bitina, M., 
Kurzawski, G., et al. (2007). Nationwide study of clinical and molecular 
features of hereditary non-polyposis colorectal cancer (HNPCC) in latvia. 
Anticancer Research, 27(1B), 653-658.  
Itoh, H., Houlston, R. S., Harocopos, C., & Slack, J. (1990). Risk of cancer death in 
first-degree relatives of patients with hereditary non-polyposis cancer 
syndrome (lynch type II): A study of 130 kindreds in the united kingdom. The 
British Journal of Surgery, 77(12), 1367-1370.  
Järvinen, H. J., Aarnio, M., Mustonen, H., Aktan-Collan, K., Aaltonen, L. A., 
Peltomaki, P., et al. (2000). Controlled 15-year trial on screening for
colorectal cancer in families with hereditary nonpolyposis colorectal cancer.
Gastroenterology, 118(5), 829-834.
Järvinen, H. J., Mecklin, J. P., & Sistonen, P. (1995). Screening reduces colorectal
cancer rate in families with hereditary nonpolyposis colorectal cancer.
Gastroenterology, 108(5), 1405-1411.
Järvinen, H. J., Renkonen-Sinisalo, L., Aktan-Collan, K., Peltomaki, P., Aaltonen, L.
A., & Mecklin, J. P. (2009). Ten years after mutation testing for lynch
syndrome: Cancer incidence and outcome in mutation-positive and 
mutation-negative family members. Journal of Clinical Oncology, 27(28),
4793-4797.
Jass, J., Stewart, S., Schroeder, D., & Lane, M. (1992). Screening for hereditary
non-polyposis colorectal cancer in new zealand. European Journal of
Gastroenterology & Hepatology, 4(7), 523-527.
Jass, J. R. (2007). Classification of colorectal cancer based on correlation of clinical, 
morphological and molecular features. Histopathology, 50(1), 113-130. 
Jass, J. R., & Stewart, S. M. (1992). Evolution of hereditary non-polyposis colorectal 
cancer. Gut, 33(6), 783-786. 
Jawień, A., Banaszkiewicz, Z., & Carcinoma, C. (1998). Incidence of hereditary non-
polyposis colorectal cancer (HNPCC)—personal experience. Medical 
Science Monitor, 4(6), 1009-1011.  
Jenkins, M. A., Baglietto, L., Dowty, J. G., Van Vliet, C. M., Smith, L., Mead, L. J., et 












population-based early onset case-family study. Clinical Gastroenterology 
and Hepatology, 4(4), 489-498.  
Johnstone F.A. (1976). Class, race and gold: A study of class relations and racial 
discrimination in South Africa. New York: University Press of America. 
Jones, L. S., Nicholson, R. W., & Evans, D. A. (2001). Experience with a one-stop 
colorectal clinic. Journal of the Royal College of Surgeons of Edinburgh, 
46(2), 96-97.  
Jorde, L. B. (2001). Consanguinity and prereproductive mortality in the utah mormon 
population. Human Heredity, 52(2), 61-65. 
Jorde, L.B., Carey, J.C., Bamshad, M.J., White, R.L. (2006). Medical genetics (3rd 
Edn). Philadelphia: Mosby. 
Julian-Reynier, C., Eisinger, F., Chabal, F., Lasset, C., Nogues, C., Stoppa-Lyonnet, 
D., et al. (2000). Disclosure to the family of breast/ovarian cancer genetic
test results: Patient's willingness and associated factors. American Journal
of Medical Genetics, 94(1), 13-18.
Julian-Reynier, C., Eisinger, F., Vennin, P., Chabal, F., Aurran, Y., Nogues, C., et al.
(1996). Attitudes towards cancer predictive testing and transmission of
information to the family. Journal of Medical Genetics, 33(9), 731-736.
Kasparian, N. A., Wakefield, C. E., & Meiser, B. (2007). Assessment of psychosocial
outcomes in genetic counseling research: An overview of available 
measurement scales. Journal of Genetic Counseling, 16(6), 693-712.
Kastrinos, F., Stoffel, E. M., Balmana, J., Steyerberg, E. W., Mercado, R., & Syngal,
S. (2008). Phenotype comparison of MLH1 and MSH2 mutation carriers in a 
cohort of 1,914 individuals undergoing clinical genetic testing in the united
states. Cancer Epidemiology, Biomarkers & Prevention, 17(8), 2044-2051.
Katballe, N., Christensen, M., Wikman, F. P., Orntoft, T. F., & Laurberg, S. (2002). 
Frequency of hereditary non-polyposis colorectal cancer in danish colorectal 
cancer patients. Gut, 50(1), 43-51.  
Katballe, N., Juul, S., Christensen, M., Orntoft, T. F., Wikman, F. P., & Laurberg, S. 
(2001). Patient accuracy of reporting on hereditary non-polyposis colorectal 
cancer-related malignancy in family members. The British Journal of 












Kausmeyer, D. T., Lengerich, E. J., Kluhsman, B. C., Morrone, D., Harper, G. R., & 
Baker, M. J. (2006). A survey of patients‘ experiences with the cancer 
genetic counseling process: Recommendations for cancer genetics 
programs. Journal of Genetic Counseling, 15(6), 409-431.  
Kee, F., & Collins, B. J. (1991). How prevalent is cancer family syndrome? Gut, 
32(5), 509-512. 
Keenan, K., Simpson, S., Wilson, B., Van Teijlingen, E., Mckee, L., Haites, N., et al. 
(2005). It's their blood not mine': Who's responsible for (not) telling relatives 
about genetic risk? Health, Risk & Society, 7(3), 209-226.  
Keller, M., Jost, R., Kadmon, M., Wullenweber, H. P., Haunstetter, C. M., Willeke, F., 
et al. (2004). Acceptance of and attitude toward genetic testing for
hereditary nonpolyposis colorectal cancer: A compariso of participants and
nonparticipants in genetic counseling. Diseases of the Colon and Rectum,
47(2), 153-162.
Kelly, T.E. (1986). Clinical genetics and genetic counselling, 343-364. Chicago: Year
book medical publishers. 
Kessler, S. (1979). Introduction. In: S. Kessler (Ed). Genetic counseling:
psychological dimensions, 1-15. New York: Academic press.
Kessler, S. (1989). Psychological aspects of genetic counseling: VI. A critical review
of the literature dealing with education and reproduction. American Journal
of Medical Genetics, 34(3), 340-353.
Kessler, S. (1997). Psychological aspects of genetic counseling. XI.
Nondirectiveness revisited. American Journal of Medical Genetics, 72(2),
164-171.
Kinney, A. Y., Choi, Y. A., DeVellis, B., Kobetz, E., Millikan, R. C., & Sandler, R. S. 
(2000). Interest in genetic testing among first-degree relatives of colorectal 
cancer patients. American Journal of Preventive Medicine, 18(3), 249-252.  
Koch, T. (1995). Interpretive approaches in nursing research: The influence of 
husserl and heidegger. Journal of Advanced Nursing, 21(5), 827-836. 
Koehly, L. M., Peterson, S. K., Watts, B. G., Kempf, K. K. G., Vernon, S. W., & Gritz, 
E. R. (2003). A social network analysis of communication about hereditary 
nonpolyposis colorectal cancer genetic testing and family functioning. 












Kohut, K., Manno, M., Gallinger, S., & Esplen, M. J. (2007). Should healthcare 
providers have a duty to warn family members of individuals with an 
HNPCC-causing mutation? A survey of patients from the ontario familial 
colon cancer registry. British Medical Journal, 44(6), 404-407.  
Kolonel, L., Hinds, M., & Hankin, J. (1980). Cancer patterns among migrant and 
native-born japanese in hawaii in relation to smoking, drinking, and dietary 
habits. In: H.V Gelbion, B. MacMohan, T. Matsushima, S. Sugimura, H 
Takebe (Ed). Genetic and Environmental Factors in Experimental and 
Human Cancer, 327-340. Tokyo: Japan Scientific Societies Press.  
Knaack, P. (1984). Phenomenological research. Western Journal of Nursing 
Research, 6(1), 107-123. 
Koornstra, J. J., Mourits, M. J., Sijmons, R. H., Leliveld, A. M., Hollema, H., & 
Kleibeuker, J. H. (2009). Management of extracolonic tumours in patients 
with lynch syndrome. The Lancet Oncology, 10(4), 400-408.  
Kruger, B.J. (2005). Hereditary nonpolyposis colorectal cancer: Factors contributing 
to adherence and non-adherence to surveillance for mutation carriers in 
rural areas of the northern and western cape. Master‘s thesis. University of 
Cape Town, South Africa. 
Laghi, L., Bianchi, P., Roncalli, M., & Malesci, A. (2004). Re: Revised bethesda 
guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) 
and microsatellite instability. Journal of the National Cancer Institute, 96(18), 
1402-1403. 
Lalloo, R., Myburgh, N. G., Smith, M. J., & Solanki, G. C. (2004). Access to health 
care in south africa--the influence of race and class. South African Medical 
Journal, 94(8), 639-642.  
Lambert, R. (1983). Principles of screening adapted to precancerous conditions of 
the gastrointestinal tract. In P. Sherlock, B.C. Morson, L. Barbara, U. 
Veronesi (Ed). Precancerous Lesions of the Gastrointestinal Tract, 292-303. 
New York: Raven Press. 
Lastella, P., Patruno, M., Forte, G., Montanaro, A., Di Gregorio, C., Sabba, C., et al. 
(2011). Identification and surveillance of 19 lynch syndrome families in 
southern italy: Report of six novel germline mutations and a common 












Lea, D. H. (1996). Emerging quality improvement measures in genetic counseling. 
Journal of Genetic Counseling, 5(3), 123-137. 
Lehmann, L. S., Weeks, J. C., Klar, N., Biener, L., & Garber, J. E. (2000). Disclosure 
of familial genetic information: Perceptions of the duty to inform. The 
American Journal of Medicine, 109(9), 705-711.  
Lerman, C., Hughes, C., Trock, B. J., Myers, R. E., Main, D., Bonney, A., et al. 
(1999). Genetic testing in families with hereditary nonpolyposis colon 
cancer. The Journal of the American Medical Association, 281(17), 1618-
1622.  
Lerman, C., Marshall, J., Audrain, J., & Gomez-Caminero, A. (1996). Genetic testing 
for colon cancer susceptibility: Anticipated reactions of patients and
challenges to providers. International Journal of Cancer, 69(1), 58-61.
Lerman, C., Trock, B., Rimer, B. K., Boyce, A., Jepson, C., & Engstrom, P. F.
(1991a). Psychological and behavioral implications of abnormal
mammograms. Annals of Internal Medicine, 114(8), 657-661.
Lerman, C., Trock, B., Rimer, B. K., Jepson, C., Brody, D., & Boyce, A. (1991b).
Psychological side effects of breast cancer screening. Health Psychology,
10(4), 259-267.
Levin, B. (1996). Screening for colorectal cancer. Cancer Control: Journal of the
Moffitt Cancer Center, 3(1), 20-25.
Liljegren, A., Lindgren, G., Brandberg, Y., Rotstein, S., Nilsson, B., Hatschek, T., et
al. (2004). Individuals with an increased risk of colorectal cancer: Perceived
benefits and psychological aspects of surveillance by means of regular 
colonoscopies. Journal of Clinical Oncology, 22(9), 1736-1742.
Lin, K. M., Shashidharan, M., Thorson, A. G., Ternent, C. A., Blatchford, G. J., 
Christensen, M. A., et al. (1998). Cumulative incidence of colorectal and 
extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary 
nonpolyposis colorectal cancer. Journal of Gastrointestinal Surgery, 2(1), 
67-71.
Lincoln, Y.S., & Guba, E.G. (1985). Naturalistic inquiry. California: Sage. 
Lindblom, A., Tannergard, P., Werelius, B., & Nordenskjold, M. (1993). Genetic 
mapping of a second locus predisposing to hereditary non-polyposis colon 












Lindor, N. M., Burgart, L. J., Leontovich, O., Goldberg, R. M., Cunningham, J. M., 
Sargent, D. J., et al. (2002). Immunohistochemistry versus microsatellite 
instability testing in phenotyping colorectal tumors. Journal of Clinical 
Oncology, 20(4), 1043-1048.  
Lindor, N. M., Petersen, G. M., Hadley, D. W., Kinney, A. Y., Miesfeldt, S., Lu, K. H., 
et al. (2006). Recommendations for the care of individuals with an inherited 
predisposition to lynch syndrome: A systematic review. The Journal of the 
American Medical Association, 296(12), 1507-1517.  
Liu, B., Parsons, R. E., Hamilton, S. R., Petersen, G. M., Lynch, H. T., Watson, P., et 
al. (1994). hMSH2 mutations in hereditary nonpolyposis colorectal cancer 
kindreds. Cancer Research, 54(17), 4590-4594.  
Liu, S. R., Zhao, B., Wang, Z. J., Wan, Y. L., & Huang, Y. T. (2004). Clinical features 
and mismatch repair gene mutation screening in chinese patients with 
hereditary nonpolyposis colorectal carcinoma. World Journal of 
Gastroenterology, 10(18), 2647-2651.  
Lodder, L. N., Frets, P. G., Trijsburg, R. W., Meijers-Heijboer, E. J., Klijn, J. G., 
Duivenvoorden, H. J., et al. (1999). Presymptomatic testing for BRCA1 and 
BRCA2: How distressing are the pre-test weeks? Journal of Medical 
Genetics, 36(12), 906-913.  
Lynch, H. T., & de la Chapelle, A. (1999). Genetic susceptibility to non-polyposis 
colorectal cancer. British Medical Journal, 36(11), 801-818.  
Lynch, H. T., & de la Chapelle, A. (2003). Hereditary colorectal cancer. The New 
England Journal of Medicine, 348(10), 919-932.  
Lynch, H. T., Fusaro, R. M., Lynch, J. F., & Brand, R. (2008). Pancreatic cancer and 
the FAMMM syndrome. Familial Cancer, 7(1), 103-112.  
Lynch, H. T., Fusaro, R. M., Roberts, L., Voorhees, G. J., & Lynch, J. F. (1985a). 
Muir-torre syndrome in several members of a family with a variant of the 
cancer family syndrome. The British Journal of Dermatology, 113(3), 295-
301.  
Lynch, H. T., & Krush, A. J. (1971). Cancer family "G" revisited: 1895-1970. Cancer, 
27(6), 1505-1511.  
Lynch, H. T., & Lynch, J. F. (2000). Hereditary nonpolyposis colorectal cancer. 












Lynch, H. T., & Lynch, J. F. (2000). Hereditary nonpolyposis colorectal cancer. 
Seminars in Surgical Oncology, 18(4), 305-313. 
Lynch, H. T., Lynch, P. M., Lanspa, S. J., Snyder, C. L., Lynch, J. F., & Boland, C. R. 
(2009). Review of the lynch syndrome: History, molecular genetics, 
screening, differential diagnosis, and medicolegal ramifications. Clinical 
Genetics, 76(1), 1-18.  
Lynch, H. T., Lynch, P. M., Pester, J., & Fusaro, R. M. (1981). The cancer family 
syndrome: Rare cutaneous phenotypic linkage of torre's syndrome. 
Archives of Internal Medicine, 141(5), 607-611.  
Lynch, H. T., Richardson, J. D., Amin, M., Lynch, J. F., Cavalieri, R. J., Bronson, E., 
et al. (1991). Variable gastrointestinal and urologic cancers in a lynch
syndrome II kindred. Diseases of the Colon and Rectum, 34(10), 891-895.
Lynch, H. T., Shaw, M. W., Magnuson, C. W., Larsen, A. L., & Krush, A. J. (1966).
Hereditary factors in cancer. study of two large midwestern kindreds.
Archives of Internal Medicine, 117(2), 206-212.
Lynch, H. T., & Smyrk, T. (1996). Hereditary nonpolyposis colorectal cancer (lynch
syndrome). An updated review. Cancer, 78(6), 1149-1167.
Lynch, H. T., Smyrk, T., & Lynch, J. F. (1998). Molecular genetics and clinical-
pathology features of hereditary nonpolyposis colorectal carcinoma (lynch
syndrome): Historical journey from pedigree anecdote to molecular genetic
confirmation. Oncology, 55(2), 103-108.
Lynch, H. T., Smyrk, T. C., Lanspa, S. J., Jenkins, J. X., Cavalieri, J., & Lynch, J. F.
(1993a). Cancer control problems in the lynch syndromes. Diseases of the 
Colon and Rectum, 36(3), 254-260.
Lynch, H. T., Smyrk, T. C., Watson, P., Lanspa, S. J., Lynch, J. F., Lynch, P. M., et 
al. (1993b). Genetics, natural history, tumor spectrum, and pathology of 
hereditary nonpolyposis colorectal cancer: An updated review. 
Gastroenterology, 104(5), 1535-1549.  
Lynch, H. T., Voorhees, G. J., Lanspa, S. J., McGreevy, P. S., & Lynch, J. F. 
(1985b). Pancreatic carcinoma and hereditary nonpolyposis colorectal 
cancer: A family study. British Journal of Cancer, 52(2), 271-273.  
Mack, L. A., Cook, L. S., Temple, W. J., Carlson, L. E., Hilsden, R. J., & Paolucci, E. 












colorectal cancer patients: Benefits and barriers. Annals of Surgical 
Oncology, 16(8), 2092-2100.  
Marcus, M. & Minc, H. (1988). Introduction to linear algebra. New York: Dover. 
Marshall, M., Lockwood, A., Bradley, C., Adams, C., Joy, C., & Fenton, M. (2000). 
Unpublished rating scales: A major source of bias in randomised controlled 
trials of treatments for schizophrenia. The British Journal of Psychiatry, 176, 
249-252.  
Marshall, C. & Rossman, G.B. (1999). Designing qualitative research (3rd Edn). 
California: Sage. 
Maxwell, A. E., Bastani, R., & Warda, U. S. (2000). Demographic predictors of 
cancer screening among filipino and korean immigrants in the united states. 
American Journal of Preventive Medicine, 18(1), 62-68.  
Mcallister, M. (2002). Predictive genetic testing and beyond: A theory of 
engagement. Journal of Health Psychology, 7(5), 491-508.  
McAllister, M. (2003). Personal theories of inheritance, coping strategies, risk 
perception and engagement in hereditary non-polyposis colon cancer 
families offered genetic testing. Clinical Genetics, 64(3), 179-189.  
McCaffery, K., Wardle, J., & Waller, J. (2003). Knowledge, attitudes, and behavioral 
intentions in relation to the early detection of colorectal cancer in the united 
kingdom. Preventive Medicine, 36(5), 525-535.  
McCann, S., Macauley, D., Barnett, Y., Bunting, B., Bradley, A., Jeffers, L., et al. 
(2009). Family communication, genetic testing and colonoscopy screening 
in hereditary non-polyposis colon cancer: A qualitative study. Psycho-
Oncology, 18(11), 1208-1215. 
McCarthy, B. D., & Moskowitz, M. A. (1993). Screening flexible sigmoidoscopy: 
Patient attitudes and compliance. Journal of General Internal Medicine, 8(3), 
120-125.  
McIntyre, M. T., Nkosi, M., Mutyambizi, V., Castillo-Riquelme, M., Gilson, L., 
Erasmus, E., et al. (2007). Shield work package 1 report. Retrieved June 
2010 from www.web.uct.ac.za/depts/heu/SHIELD/reports/SouthAfrica1.pdf. 
Mcintyre, D., Thiede, M., Nkosi, M. et al. (2007). A critical analysis of the current 












of Cape Town and the Centre for Health Policy, University of the 
Witwatersrand. 
McMichael, A., McCall, M., Hartshore, J., & Woodings, T. (1980). Patterns of gastro-
intestinal cancer in european migrants to australia: The role of dietary 
change. International Journal of Cancer, 25(4), 431-437.  
McMillan, J.H. & Schumacher, S. (2001). Research in education: A conceptual 
introduction (5th Edn). New York: Longman. 
Mecklin, J. P. (1987). Frequency of hereditary colorectal carcinoma. 
Gastroenterology, 93(5), 1021-1025. 
Mecklin, J. P., Jarvinen, H. J., Hakkiluoto, A., Hallikas, H., Hiltunen, K. M., Harkonen, 
N., et al. (1995). Frequency of hereditary nonpolyposis colorectal cancer. A
prospective multicenter study in finland. Diseases of the Colon and Rectum,
38(6), 588-593.
Mecklin, J. P., Jarvinen, H. J., & Peltokallio, P. (1986). Cancer family syndrome.
Genetic analysis of 22 finnish kindreds. Gastroenterology, 90(2), 328-333.
Mecklin, J. P., Jarvinen, H. J., & Virolainen, M. (1992). The association between
cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma.
Cancer, 69(5), 1112-1114. 
Mecklin, J. P., & Ponz de Leon, M. (1994). Epidemiology of HNPCC. Anticancer
Research, 14(4B), 1625-1629.
Meiser, B., Collins, V., Warren, R., Gaff, C., St John, D. J., Young, M. A., et al.
(2004). Psychological impact of genetic testing for hereditary non-polyposis 
colorectal cancer. Clinical Genetics, 66(6), 502-511. 
Mesters, I., Ausems, M., Eichhorn, S., & Vasen, H. (2005). Informing one's family 
about genetic testing for hereditary non-polyposis colorectal cancer 
(HNPCC): A retrospective exploratory study. Familial Cancer, 4(2), 163-167. 
Michels, K. B., Fuchs, C. S., Giovannucci, E., Colditz, G. A., Hunter, D. J., Stampfer, 
M. J., et al. (2005). Fiber intake and incidence of colorectal cancer among
76,947 women and 47,279 men. Cancer Epidemiology Biomarkers &
Prevention, 14(4), 842-849.
Michie, S., McDonald, V., & Marteau, T. M. (1997). Genetic counselling: Information 













Minichiello, V., Aroni, R., Timewell, E., Alexander, L. (1990). In depth-interviewing: 
Researching people. Melbourne: Longman Cheshire. 
Miyaki, M., Konishi, M., Tanaka, K., Kikuchi-Yanoshita, R., Muraoka, M., Yasuno, M., 
et al. (1997). Germline mutation of MSH6 as the cause of hereditary 
nonpolyposis colorectal cancer. Nature Genetics, 17(3), 271-272.  
Modica, S., Roncucci, L., Benatti, P., Gafa, L., Tamassia, M. G., Dardanoni, L., et al. 
(1995). Familial aggregation of tumors and detection of hereditary non-
polyposis colorectal cancer in 3-year experience of 2 population-based 
colorectal-cancer registries. International Journal of Cancer, 62(6), 685-690.  
Moisio, A. L., Sistonen, P., Weissenbach, J., de la Chapelle, A., & Peltomaki, P. 
(1996). Age and origin of two common MLH1 mutations predisposing to 
hereditary colon cancer. American Journal of Human Genetics, 59(6), 1243-
1251.  
Mooney, G. H., & McIntyre, D. E. (2008). South africa: A 21st century apartheid in 
health and health care? The Medical Journal of Australia, 189(11-12), 637-
640.  
Morse, J. M. (1992). Qualitative health research. Newbury Park, California: Sage.  
Morse, J. M. (1994). Critical issues in qualitative research methods. Thousand Oaks, 
California: Sage.  
Mqoqi, N. (2004). Incidence of histologically diagnosed cancer in south africa, 1998-
1999 National Cancer Registry of South Africa. South Africa: National 
Health Laboratory Service. 
Mukherjee, B., Rennert, G., Ahn, J., Dishon, S., Lejbkowicz, F., Rennert, H. S., et al. 
(2011). High risk of colorectal and endometrial cancer in ashkenazi families 
with the MSH2 A636P founder mutation. Gastroenterology, 140(7), 1919-
1926.  
Murakami, Y., Okamura, H., Sugano, K., Yoshida, T., Kazuma, K., Akechi, T., et al. 
(2004). Psychologic distress after disclosure of genetic test results 
regarding hereditary nonpolyposis colorectal carcinoma. Cancer, 101(2), 
395-403.  
Myers, R. E., Trock, B. J., Lerman, C., Wolf, T., Ross, E., & Engstrom, P. F. (1990). 
Adherence to colorectal cancer screening in an HMO population. Preventive 












Natale-Pereira, A., Marks, J., Vega, M., Mouzon, D., Hudson, S. V., & Salas-Lopez, 
D. (2008). Barriers and facilitators for colorectal cancer screening practices
in the latino community: Perspectives from community leaders. Cancer
Control, 15(2), 157-165.
Natarajan, N., Watson, P., Silva-Lopez, E., & Lynch, H. T. (2010). Comparison of 
extended colectomy and limited resection in patients with lynch syndrome. 
Diseases of the Colon and Rectum, 53(1), 77-82.  
National Cancer Registry. (1999). Lifetime Risk for five leading cancers in adults by 




National Consultative Ethics Committee for Health and Life Sciences. (2003).
Regarding the Obligation to Disclose Genetic Information of Concern to the
Family in the Event of Medical Necessity. France: National Consultative 
Ethics Committee for Health and Life Sciences.
National Research Council. (1982). Commitee on diet, nutrition and cancer. 
Washington, DC: National Academy Press.
National Society of Genetic Counselors' Definition Task Force, Resta, R., Biesecker,
B. B., Bennett, R. L., Blum, S., Hahn, S. E., et al. (2006). A new definition of
genetic counseling: National society of genetic counselors' task force report.
Journal of Genetic Counseling, 15(2), 77-83.
Naussbaum, R.L., McInnes, R.R., & Willard, H.F. (2004). Thompson and Thompson:
Genetics in medicine (6th Edn). New York: W.B. Saunders Company.
Neuhausen, S. L. (2000). Founder populations and their uses for breast cancer 
genetics. Breast Cancer Research, 2(2), 77-81. 
Neville, C. (2007). The complete guide to referencing and avoiding plagiarism. New 
York: Open University Press McGrawHill. 
Newcomb, P. A., Baron, J., Cotterchio, M., Gallinger, S., Grove, J., Haile, R., et al. 
(2007). Colon cancer family registry: An international resource for studies of 
the genetic epidemiology of colon cancer. Cancer Epidemiology, 
Biomarkers & Prevention, 16(11), 2331-2343.  
Nordin, K., Liden, A., Hansson, M., Rosenquist, R., & Berglund, G. (2002). Coping 












attending genetic counselling for hereditary cancer. Journal of Medical 
Genetics, 39(9), 689-694.  
Northam, A. (2010). Colorectal cancer: A neuropsychological approach to non-
adherence screening guidelines of individuals with Lynch syndrome in the 
Western Cape. Master‘s thesis. University of Cape Town, South Africa. 
Nystrom-Lahti, M., Sistonen, P., Mecklin, J. P., Pylkkanen, L., Aaltonen, L. A., 
Jarvinen, H., et al. (1994). Close linkage to chromosome 3p and 
conservation of ancestral founding haplotype in hereditary nonpolyposis 
colorectal cancer families. Proceedings of the National Academy of 
Sciences of the United States of America, 91(13), 6054-6058.  
Offit, K., Kohut, K., Clagett, B., Wadsworth, E. A., Lafaro, K. J., Cummings, S., et al. 
(2006). Cancer genetic testing and assisted reproductio . Journal of Clinical 
Oncology, 24(29), 4775-4782.  
Ondrusek, N., Warner, E., & Goel, V. (1999). Development of a knowledge scale 
about breast cancer and heredity (BCHK). Breast Cancer Research and 
Treatment, 53(1), 69-75.  
Pande, M., Lynch, P. M., Hopper, J. L., Jenkins, M. A., Gallinger, S., Haile, R. W., et 
al. (2010). Smoking and colorectal cancer in lynch syndrome: Results from 
the colon cancer family registry and the university of texas MD anderson 
cancer center. Clinical Cancer Research, 16(4), 1331-1339.  
Parc, Y., Boisson, C., Thomas, G., & Olschwang, S. (2003). Cancer risk in 348 
french MSH2 or MLH1 gene carriers. Journal of Medical Genetics, 40(3), 
208-213.  
Park, J. G., Kim, D. W., Hong, C. W., Nam, B. H., Shin, Y. K., Hong, S. H., et al. 
(2006). Germ line mutations of mismatch repair genes in hereditary 
nonpolyposis colorectal cancer patients with small bowel cancer: 
International society for gastrointestinal hereditary tumours collaborative 
study. Clinical Cancer Research, 12(11 Pt 1), 3389-3393.  
Park, Y. J., Shin, K. H., & Park, J. G. (2000). Risk of gastric cancer in hereditary 
nonpolyposis colorectal cancer in korea. Clinical Cancer Research, 6(8), 
2994-2998.  
Parkerson, G. R.,Jr, & Broadhead, W. E. (1997). Screening for anxiety and 
depression in primary care with the duke anxiety-depression scale. Family 












Parkerson, G. R.,Jr, Broadhead, W. E., & Tse, C. K. (1990). The duke health profile. 
A 17-item measure of health and dysfunction. Medical Care, 28(11), 1056-
1072.  
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. 
A Cancer Journal for Clinicians, 55(2), 74-108. 
Parrott, S., & DelVecchio, M. (2007). Professional Status Survey 2006. National 
Society of Genetic Counselors, Inc. Retrieved May 2010 from 
www.nsgc.org/client_files/careers/2006_PSS_Results.doc. 
Patenaude, A. F., Dorval, M., DiGianni, L. S., Schneider, K. A., Chittenden, A., & 
Garber, J. E. (2006). Sharing BRCA1/2 test results with first-degree
relatives: Factors predicting who women tell. Journal of Clinical Oncology,
24(4), 700-706.
Patton, M.Q. (2002). Qualitative research and evaluation methods (3rd Edn). London:
Sage. 
Payne, K., Nicholls, S., McAllister, M., Macleod, R., Donnai, D., & Davies, L. M.
(2008). Outcome measurement in clinical genetics services: A systematic 
review of validated measures. Value in Health: The Journal of the
International Society for Pharmacoeconomics and Outcomes Research,
11(3), 497-508.
Peel, D. J., Ziogas, A., Fox, E. A., Gildea, M., Laham, B., Clements, E., et al. (2000).
Characterization of hereditary nonpolyposis colorectal cancer families from
a population-based series of cases. Journal of the National Cancer Institute,
92(18), 1517-1522.
Peltomaki, P. (2003). Role of DNA mismatch repair defects in the pathogenesis of 
human cancer. Journal of Clinical Oncology, 21(6), 1174-1179. 
Peltomaki, P., Aaltonen, L. A., Sistonen, P., Pylkkanen, L., Mecklin, J. P., Jarvinen, 
H., et al. (1993). Genetic mapping of a locus predisposing to human 
colorectal cancer. Science, 260(5109), 810-812.  
Peters, J. A., & Biesecker, B. B. (1997). Genetic counselling and hereditary cancer. 
Cancer, 80(S3), 576-586. 
Peterson, S. K., Watts, B. G., Koehly, L. M., Vernon, S. W., Baile, W. F., Kohlmann, 
W. K., et al. (2003). How families communicate about HNPCC genetic
testing: Findings from a qualitative study. American Journal of Medical












Pieterse, A. H., van Dulmen, A. M., Beemer, F. A., Bensing, J. M., & Ausems, M. G. 
(2007). Cancer genetic counseling: Communication and counselees' post-
visit satisfaction, cognitions, anxiety, and needs fulfillment. Journal of 
Genetic Counseling, 16(1), 85-96.  
Pilnick, A., & Dingwall, R. (2001). Research directions in genetic counselling: A 
review of the literature. Patient Education and Counseling, 44(2), 95-105. 
Plaschke, J., Engel, C., Kruger, S., Holinski-Feder, E., Pagenstecher, C., Mangold, 
E., et al. (2004). Lower incidence of colorectal cancer and later age of
disease onset in 27 families with pathogenic MSH6 germline mutations 
compared with families with MLH1 or MSH2 mutations: The german
hereditary nonpolyposis colorectal cancer consortium. Journal of Clinical
Oncology, 22(22), 4486-4494.
Ponti, G., & Ponz de Leon, M. (2005). Muir-torre syndrome. The Lancet Oncology,
6(12), 980-987. 
Ponz de Leon, M., Benatti, P., Percesepe, A., Di Gregorio, C., Fante, R., Losi, L., et
al. (1999). Epidemiology of cancer of the large bowel-the 12-year
experience of a specialized registry in northern italy. Italian Journal of 
Gastroenterology and Hepatology, 31(1), 10-18.
Ponz de Leon, M., Sassatelli, R., Benatti, P., & Roncucci, L. (1993). Identification of
hereditary nonpolyposis colorectal cancer in the general population. The 6-
year experience of a population-based registry. Cancer, 71(11), 3493-3501. 
Ponz de Leon, M., Sassatelli, R., Sacchetti, C., Zanghieri, G., Scalmati, A., &
Roncucci, L. (1989). Familial aggregation of tumors in the three-year
experience of a population-based colorectal cancer registry. Cancer
Research, 49(15), 4344-4348.
Pope, C., Ziebland, S., & Mays, N. (2000). Qualitative research in health care. 
Analysing qualitative data. British Medical Journal, 320(7227), 114-116. 
Pope, C. & Mays, N. (2000). Qualitative methods in health research. In: C. Pope, N. 
Mays (Ed). Qualitative research in Health Care (2nd Edn). London: BMJ 
Books. 
Poulton, B. C. (1996). Use of the consultation satisfaction questionnaire to examine 
patients' satisfaction with general practitioners and community nurses: 
Reliability, replicability and discriminant validity. The British Journal of 












Powe, B. D. (1995). Fatalism among elderly african americans. effects on colorectal 
cancer screening. Cancer Nursing, 18(5), 385-392.  
President‘s Commission. (1983). Screening and Counselling for Genetic Conditions. 
The ethical, social, and legal implications of genetic screening, counselling, 
and education programs. Washington, DC: US.GPO. 
Price, J. H. (1993). Perceptions of colorectal cancer in a socioeconomically 
disadvantaged population. Journal of Community Health, 18(6), 347-362.  
Prucka, S. K., McIlvried, D. E., & Korf, B. R. (2008). Cancer risk assessment and the 
genetic counseling process: Using hereditary breast and ovarian cancer as 
an example. Medical Principles and Practice, 17(3), 173-189.  
Pylvanainen, K., Kairaluoma, M., & Mecklin, J. P. (2006). Compliance and 
satisfaction with long-term surveillance in finnish HNPCC families. Familial 
Cancer, 5(2), 175-178.  
Quehenberger, F., Vasen, H. F., & van Houwelingen, H. C. (2005). Risk of colorectal 
and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 
gene: Correction for ascertainment. Journal of Medical Genetics, 42(6), 491-
496.  
Ramesar, R. S., Madden, M. V., Felix, R., Harocopos, C. J., Westbrook, C. A., 
Jones, G., et al. (2000). Molecular genetics improves the management of 
hereditary non-polyposis colorectal cancer. South African Medical Journal, 
90(7), 709-714.  
Ramsoekh, D., Wagner, A., van Leerdam, M. E., Dooijes, D., Tops, C. M., 
Steyerberg, E. W., et al. (2009). Cancer risk in MLH1, MSH2 and MSH6 
mutation carriers; different risk profiles may influence clinical management. 
[Electronic version]. Hereditary Cancer in Clinical Practice, 7(1), 17. 
[Retrieved April 2010 from PubMed Online database]. 
Rankhumise, E., Netswera, G., & Meyer, M. (2001). Employees' perceptions of the 
implementation of affirmative action in the health sector in the standerton 
district in south africa. Curationis, 24(4), 52-58.  
Ravnik-Glavac, M., Potocnik, U., & Glavac, D. (2000). Incidence of germline hMLH1 
and hMSH2 mutations (HNPCC patients) among newly diagnosed 













Raymond, V. M., & Everett, J. N. (2009). Genetic counselling and genetic testing in 
hereditary gastrointestinal cancer syndromes. Best Practice & 
Research.Clinical Gastroenterology, 23(2), 275-283.  
Research ethics and environmental health. (2002): Conference 2003 ‘dialogues for 
improving research ethics in environmental and public health’. Retrieved 
September 2009 from http://www.researchethics.org/conference2.pdf. 
Read, A. & Donnai, D. ( 2007). New clinical genetics. Oxford: Scion Publishing. 
Rees, G., Martin, P. R., & Macrae, F. A. (2008). Screening participation in individuals 
with a family history of colorectal cancer: A review. European Journal of 
Cancer Care, 17(3), 221-232.  
Renkonen-Sinisalo, L., Butzow, R., Leminen, A., Lehtovirta, P., Mecklin, J. P., & 
Jarvinen, H. J. (2007). Surveillance for endometrial cancer in hereditary 
nonpolyposis colorectal cancer syndrome. International Journal of Cancer, 
120(4), 821-824.  
Resnick, K. E., Hampel, H., Fishel, R., & Cohn, D. E. (2009). Current and emerging 
trends in lynch syndrome identification in women with endometrial cancer. 
Gynecologic Oncology, 114(1), 128-134.  
Resta, R. G. (2006). Defining and redefining the scope and goals of genetic 
counseling. American Journal of Medical Genetics. Part C, Seminars in 
Medical Genetics, 142C(4), 269-275.  
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, 
R. M., et al. (2003). Tumor microsatellite-instability status as a predictor of 
benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. 
The New England Journal of Medicine, 349(3), 247-257.  
Richards, M. (1996). Families, kinship and genetics. In: T. Marteau and M. Richards 
(Ed). The Troubled Helix: Social and Psychological Implications of the New 
Human Genetics, 249-273. Cambridge: Cambridge University Press. 
Richardson, J. L., Danley, K., Mondrus, G. T., Deapen, D., & Mack, T. (1995). 
Adherence to screening examinations for colorectal cancer after diagnosis 
in a first-degree relative. Preventive Medicine, 24(2), 166-170.  
Riegler, G., Savastano, A., Selvaggi, F., Ciociano, R., Martino, R., Riccio, G., et al. 
(1999). Prevalence of HNPCC in a series of consecutive patients on the first 
endoscopic diagnosis of colorectal cancer: A multicenter study. The italian 












Risinger, J. I., Barrett, J. C., Watson, P., Lynch, H. T., & Boyd, J. (1996). Molecular 
genetic evidence of the occurrence of breast cancer as an integral tumor in 
patients with the hereditary nonpolyposis colorectal carcinoma syndrome. 
Cancer, 77(9), 1836-1843.  
Rodriguez-Bigas, M. A., Boland, C. R., Hamilton, S. R., Henson, D. E., Jass, J. R., 
Khan, P. M., et al. (1997). A national cancer institute workshop on 
hereditary nonpolyposis colorectal cancer syndrome: Meeting highlights and 
bethesda guidelines. Journal of the National Cancer Institute, 89(23), 1758-
1762.  
Rodriguez-Bigas, M. A., Vasen, H. F., Lynch, H. T., Watson, P., Myrhoj, T., Jarvinen, 
H. J., et al. (1998). Characteristics of small bowel carcinoma in hereditary 
nonpolyposis colorectal carcinoma. international collaborative group on 
HNPCC. Cancer, 83(2), 240-244.  
Rossouw, D. (2003). Intellectual tools: Skills for the human sciences (2nd Edn). Cape 
Town: Van Schaik. 
Rubin, R. B., Perse, E. M., & Barbato, C. A. (1988). Conceptualization and 
measurement of interpersonal communication motives. Human 
Communication Research, 14(4), 602-628.  
Ruppelt, T. (2011). Personal communication with Theresa Ruppelt [National Health 
Laboratory Services, South Africa]. 
Sagi, M., Kaduri, L., Zlotogora, J., & Peretz, T. (1998). The effect of genetic 
counseling on knowledge and perceptions regarding risks for breast cancer. 
Journal of Genetic Counseling, 7(5), 417-434.  
Salovaara, R., Loukola, A., Kristo, P., Kaariainen, H., Ahtola, H., Eskelinen, M., et al. 
(2000). Population-based molecular detection of hereditary nonpolyposis 
colorectal cancer. Journal of Clinical Oncology, 18(11), 2193-2200.  
Samowitz, W. S., Curtin, K., Lin, H. H., Robertson, M. A., Schaffer, D., Nichols, M., et 
al. (2001). The colon cancer burden of genetically defined hereditary 
nonpolyposis colon cancer. Gastroenterology, 121(4), 830-838.  
Sankila, R., Aaltonen, L. A., Jarvinen, H. J., & Mecklin, J. P. (1996). Better survival 
rates in patients with MLH1-associated hereditary colorectal cancer. 
Gastroenterology, 110(3), 682-687.  












Savanhu, T.K. (2005). Haplotyping and estimating the age of the founder mutation 
identifying familial colorectal cancer. Bachelor of Science thesis. University 
of Cape Town, South Africa. 
Schmeler, K. M., Lynch, H. T., Chen, L. M., Munsell, M. F., Soliman, P. T., Clark, M. 
B., et al. (2006). Prophylactic surgery to reduce the risk of gynecologic 
cancers in the lynch syndrome. The New England Journal of Medicine, 
354(3), 261-269.  
Schneider, K. A., Chittenden, A. B., Branda, K. J., Keenan, M. A., Joffe, S., 
Patenaude, A. F., et al. (2006). Ethical issues in cancer genetics: Whose 
information is it? Journal of Genetic Counseling, 15(6), 491-503.  
Schulmann, K., Reiser, M., & Schmiegel, W. (2002). Colonic cancer and polyps. Best 
Practice & Research Clinical Gastroenterology, 16(1), 91-114.  
Schulmann, K., Brasch, F. E., Kunstmann, E., Engel, C., Pagenstecher, C., 
Vogelsang, H., et al. (2005). HNPCC-associated small bowel cancer: 
Clinical and molecular characteristics. Gastroenterology, 128(3), 590-599.  
Schulmann, K., Engel, C., Propping, P., & Schmiegel, W. (2008). Small bowel cancer 
risk in lynch syndrome. Gut, 57(11), 1629-1630.  
Scott, R. J., McPhillips, M., Meldrum, C. J., Fitzgerald, P. E., Adams, K., Spigelman, 
A. D., et al. (2001). Hereditary nonpolyposis colorectal cancer in 95 families: 
Differences and similarities between mutation-positive and mutation-
negative kindreds. American Journal of Human Genetics, 68(1), 118-127.  
Segal, J., Esplen, M. J., Toner, B., Baedorf, S., Narod, S., & Butler, K. (2004). An 
investigation of the disclosure process and support needs of BRCA1 and 
BRCA2 carriers. American Journal of Medical Genetics. Part A, 125A(3), 
267-272.  
Shiloh, S. (1996). Decision-making in the context of genetic risk. In: T. Marteau, M. 
Richards (Ed). The troubled helix. The social and psychological implications 
of the new human genetics. Cambridge: Cambridge University Press. 
Shiloh, S., Avdor, O., & Goodman, R. M. (1990). Satisfaction with genetic 
counseling: Dimensions and measurement. American Journal of Medical 
Genetics, 37(4), 522-529.  
Shiloh, S., & Saxe, L. (1989). Perception of recurrence risks by genetic counselees. 












Shiloh, S., Koehly, L., Jenkins, J., Martin, J., & Hadley, D. (2008). Monitoring coping 
style moderates emotional reactions to genetic testing for hereditary 
nonpolyposis colorectal cancer: A longitudinal study. Psycho-Oncology, 
17(8), 746-755.  
Sitas, F., Madhoo, J., & Wessie, J. (1998). Incidence of histologically diagnosed 
cancer in south africa, 1993-1995. Johannesburg: National Cancer Registry 
of South African Institute Medical Research. 
Smyrk, T. C., Lynch, H. T., Watson, P. A., & Appelman, H. D. (1990). Histologic 
features of hereditary nonpolyposis colorectal carcinoma. In: J. Utsunomiya 
and H.T. Lynch (Ed). Hereditary Colorectal Cancer, 357-362. Tokyo: 
Springer-Verlag. 
South, C. D., Hampel, H., Comeras, I., Westman, J. A., Frankel, W. L., & de la
Chapelle, A. (2008). The frequency of muir-torre syndrome among lynch 
syndrome families. Journal of the National Cancer Institute, 100(4), 277-
281. 
South African Health Review (2006). Health systems trust. Retrieved March 2010
from http://www.hst.org.za/publications/item.php?item_id=697. 
South Africa Government. (2008). Minister of social development Zola Skweyiya 
announces increases on social grants. Retrieved April 2010 from
http://www.dsd.gov.za/index.php?option=com_content&task=view&id=79&It
emid=106.
South African Government Services: (2010). Child grants and older person grants 
2010. Retrieved May 2010 from
http://www.services.gov.za/servicesforpeople/Socialbenefits/oldagegrant.as
px?Language=en-ZA.
SPSS Inc. (2001). Statistical package for the social sciences. Chicago: SPSS Inc. 
Stanley, A. J., Gaff, C. L., Aittomaki, A. K., Fabre, L. C., Macrae, F. A., & St John, J. 
(2000). Value of predictive genetic testing in management of hereditary non-
polyposis colorectal cancer (HNPCC). The Medical Journal of Australia, 
172(7), 313-316.  
Starks, H., & Trinidad, B. (2007). Choose your method: A comparison of 
phenomenology, discourse analysis, and grounded theory. Qualitative 












American society of clinical oncology:.(1996). Genetic testing for cancer 
susceptibility, adopted on february 20, 1996. Journal of Clinical Oncology, 
14(5), 1730-1736. 
Statistics South Africa. (2005). National 2001 census. Retrieved March 2010 from 
http://www.statssa.gov.za/. 
Stella, A., Surdo, N. C., Lastella, P., Barana, D., Oliani, C., Tibiletti, M. G., et al. 
(2007). Germline novel MSH2 deletions and a founder MSH2 deletion 
associated with anticipation effects in HNPCC. Clinical Genetics, 71(2), 130-
139.  
Stephenson, B. M., Murday, V. A., Finan, P. J., Quirke, P., Dixon, M. F., & Bishop, D. 
T. (1993). Feasibility of family based screening for colorectal neoplasia: 
Experience in one general surgical practice. Gut, 34(1), 96-100.  
Steyn, K., & Bradshaw, D. (2001). Non-communicable disease surveillance in 
developing countries. Scandinavian Journal of Public Health, 29(3), 161-
165.  
Stoffel, E. M., Ford, B., Mercado, R. C., Punglia, D., Kohlmann, W., Conrad, P., et al. 
(2008). Sharing genetic test results in lynch syndrome: Communication with 
close and distant relatives. Clinical Gastroenterology and Hepatology, 6(3), 
333-338.  
Stoffel, E. M., Garber, J. E., Grover, S., Russo, L., Johnson, J., & Syngal, S. (2003). 
Cancer surveillance is often inadequate in people at high risk for colorectal 
cancer [Electronic version]. Journal of Medical Genetics, 40(5), e54. 
[Retrieved August 2010 from PubMed Online database].  
Stoffel, E. M., Mercado, R. C., Kohlmann, W., Ford, B., Grover, S., Conrad, P., et al. 
(2010). Prevalence and predictors of appropriate colorectal cancer 
surveillance in lynch syndrome. The American Journal of Gastroenterology, 
105(8), 1851-1860.  
Stormorken, A. T., Clark, N., Grindedal, E., Maehle, L., & Moller, P. (2007). 
Prevention of colorectal cancer by colonoscopic surveillance in families with 
hereditary colorectal cancer. Scandinavian Journal of Gastroenterology, 
42(5), 611-617.  
Strate, L. L., & Syngal, S. (2005). Hereditary colorectal cancer syndromes. Cancer 












Street, E.C., & Soldan, J. (1998). A conceptual framework for the psychosocial 
issues faced by families with genetic conditions. Families Systems and 
Health, 16, 217-231. 
Stupart, D. A., Goldberg, P. A., Algar, U., & Ramesar, R. (2009a). Cancer risk in a 
cohort of subjects carrying a single mismatch repair gene mutation. Familial 
Cancer, 8(4), 519-523. 
Stupart, D. A., Goldberg, P. A., Algar, U., & Ramesar, R. (2009b). Surveillance 
colonoscopy improves survival in a cohort of subjects with a single 
mismatch repair gene mutation. Colorectal Disease, 11(2), 126-130.  
Subramanian, S., Klosterman, M., Amonkar, M. M., & Hunt, T. L. (2004). Adherence 
with colorectal cancer screening guidelines: A review. Preventive Medicine,
38(5), 536-550.
Sun, W. Y., Basch, C. E., Wolf, R. L., & Li, X. J. (2004). Factors associated with 
colorectal cancer screening among chinese-americans. Preventive 
Medicine, 39(2), 323-329.
Suthers, G. K., Armstrong, J., McCormack, J., & Trott, D. (2006). Letting the family 
know: Balancing ethics and effectiveness when notifying relatives about
genetic testing for a familial disorder. Journal of Medical Genetics, 43(8),
665-670.
Syngal, S., Fox, E. A., Eng, C., Kolodner, R. D., & Garber, J. E. (2000). Sensitivity 
and specificity of clinical criteria for hereditary non-polyposis colorectal
cancer associated mutations in MSH2 and MLH1. Journal of Medical
Genetics, 37(9), 641-645.
Tait, N., Joubert, J., Whiteford, A., van Zyl, J., Krige, D., & Pillay, B. (1996). A socio-
economic atlas of south africa: A demographic, socio-economic and cultural 
profile of South Africa. Pretoria: HSRC Press.  
Taitz, J. (1990). The rule of medical confidentiality v. the moral duty to warn an 
endangered third party. South African Medical Journal, 78(1), 29-33.  
Talseth-Palmer, B. A., McPhillips, M., Groombridge, C., Spigelman, A., & Scott, R. J. 
(2010). MSH6 and PMS2 mutation positive australian lynch syndrome 
families: Novel mutations, cancer risk and age of diagnosis of colorectal 
cancer. [Electronic version]. Hereditary Cancer in Clinical Practice, 8(1), 5. 












Tanyi, M. (2009). Our experience with the incidence of hereditary non-polyposis 
colorectal cancer. Magyar Sebeszet, 62(2), 87-94.  
ten Kate, G. L., Kleibeuker, J. H., Nagengast, F. M., Craanen, M., Cats, A., Menko, 
F. H., et al. (2007). Is surveillance of the small bowel indicated for lynch 
syndrome families? Gut, 56(9), 1198-1201.  
Tercyak, K. P., DeMarco, T. A., Mars, B. D., & Peshkin, B. N. (2004). Women's 
satisfaction with genetic counseling for hereditary breast-ovarian cancer: 
Psychological aspects. American Journal of Medical Genetics, 131(1), 36-
41.  
Tercyak, K. P., Johnson, S. B., Roberts, S. F., & Cruz, A. C. (2001). Psychological 
response to prenatal genetic counseling and amniocentesis. Patient 
Education and Counseling, 43(1), 73-84.  
Terreblanche, S. (2002). A history of inequality in South Africa 1652-2002. 
Pietermaritzburg: University of Natal Press. 
Thibodeau, S. N., Bren, G., & Schaid, D. (1993). Microsatellite instability in cancer of 
the proximal colon. Science, 260(5109), 816-819.  
Thiffault, I., Foulkes, W. D., Marcus, V. A., Farber, D., Kasprzak, L., MacNamara, E., 
et al. (2004). Putative common origin of two MLH1 mutations in italian-
quebec hereditary non-polyposis colorectal cancer families. Clinical 
Genetics, 66(2), 137-143.  
Trepanier, A., Ahrens, M., McKinnon, W., Peters, J., Stopfer, J., Grumet, S. C., et al. 
(2004). Genetic cancer risk assessment and counseling: Recommendations 
of the national society of genetic counselors. Journal of Genetic Counseling, 
13(2), 83-114.  
Tsubono, Y., Otani, T., Kobayashi, M., Yamamoto, S., Sobue, T., Tsugane, S., et al. 
(2005). No association between fruit or vegetable consumption and the risk 
of colorectal cancer in japan. British Journal of Cancer, 92(9), 1782-1784.  
Turnpenny, P. D., Ellard, S., Emery, A. E. H., & Mueller, R. F. (2005). Emery's 
elements of medical genetics. New York: Churchill Livingstone.  
Ulin, P.R., Robinson, E.T., Tolley, E.E. (2005). Qualitative methods in public health: 
A field guide for applied research. San Fransico: Jossey-Bass. 
Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., 












colorectal cancer (lynch syndrome) and microsatellite instability. Journal of 
the National Cancer Institute, 96(4), 261-268.  
UNESCO International Bioethics Committee. (1995). Proceedings of the third 
session. Retrieved July 2010 from 
unesdoc.unesco.org/images/0010/001051/105160e.pdf. 
United Nations Development Programme (2004) South African human development 
report 2003. Cape Town: Oxford University Press. 
van der Post, R. S., Kiemeney, L. A., Ligtenberg, M. J., Witjes, J. A., Hulsbergen-van 
de Kaa, C. A., Bodmer, D., et al. (2010). Risk of urothelial bladder cancer in 
lynch syndrome is increased, in particular among MSH2 mutation carriers. 
Journal of Medical Genetics, 47(7), 464-470.  
van der Velde, N. M., Mourits, M. J., Arts, H. J., de Vries, J., Leegte, B. K., Dijkhuis, 
G., et al. (2009). Time to stop ovarian cancer screening in BRCA1/2 
mutation carriers? International Journal of Cancer, 124(4), 919-923.  
van Oostrom, I., Meijers-Heijboer, H., Duivenvoorden, H. J., Brocker-Vriends, A. H., 
van Asperen, C. J., Sijmons, R. H., et al. (2007). Comparison of individuals 
opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to 
coping, illness perceptions, illness experiences, family system 
characteristics and hereditary cancer distress. Patient Education and 
Counseling, 65(1), 58-68.  
Vasen, H., & Morreau, H. (2002). Familial and hereditary colorectal cancer with 
emphasis on the hereditary non-polyposis colorectal cancer syndrome. 
Current Diagnostic Pathology, 8(4), 241-248.  
Vasen, H. F., Abdirahman, M., Brohet, R., Langers, A. M., Kleibeuker, J. H., 
Kouwen, M. V., et al. (2010). One to 2-year surveillance intervals reduce 
risk of colorectal cancer in families with lynch syndrome. Gastroenterology, 
138(7) 2300-2306. 
Vasen, H. F., & Boland, C. R. (2005). Progress in genetic testing, classification, and 
identification of lynch syndrome. The Journal of the American Medical 
Association, 293(16), 2028-2030.  
Vasen, H. F., & de Vos tot Nederveen Cappel,W.H. (2011). Cancer: Lynch 
syndrome--how should colorectal cancer be managed? Nature 












Vasen, H. F., den Hartog Jager, F. C., Menko, F. H., & Nagengast, F. M. (1989). 
Screening for hereditary non-polyposis colorectal cancer: A study of 22 
kindreds in the netherlands. The American Journal of Medicine, 86(3), 278-
281.  
Vasen, H. F., Mecklin, J. P., Khan, P. M., & Lynch, H. T. (1991). The international 
collaborative group on hereditary non-polyposis colorectal cancer (ICG-
HNPCC). Diseases of the Colon and Rectum, 34(5), 424-425.  
Vasen, H. F., Morreau, H., & Nortier, J. W. (2001a). Is breast cancer part of the 
tumor spectrum of hereditary nonpolyposis colorectal cancer? American 
Journal of Human Genetics, 68(6), 1533-1535.  
Vasen, H. F., Moslein, G., Alonso, A., Bernstein, I., Bertario, L., Blanco, I., et al. 
(2007). Guidelines for the clinical management of lynch syndrome 
(hereditary non-polyposis cancer). Journal of Medical Genetics, 44(6), 353-
362.  
Vasen, H. F., Offerhaus, G. J., den Hartog Jager, F. C., Menko, F. H., Nagengast, F. 
M., Griffioen, G., et al. (1990). The tumour spectrum in hereditary non-
polyposis colorectal cancer: A study of 24 kindreds in the netherlands. 
International Journal of Cancer, 46(1), 31-34.  
Vasen, H. F., Stormorken, A., Menko, F. H., Nagengast, F. M., Kleibeuker, J. H., 
Griffioen, G., et al. (2001b). MSH2 mutation carriers are at higher risk of 
cancer than MLH1 mutation carriers: A study of hereditary nonpolyposis 
colorectal cancer families. Journal of Clinical Oncology, 19(20), 4074-4080.  
Vasen, H. F., Watson, P., Mecklin, J. P., & Lynch, H. T. (1999). New clinical criteria 
for hereditary nonpolyposis colorectal cancer (HNPCC, lynch syndrome) 
proposed by the international collaborative group on HNPCC. 
Gastroenterology, 116(6), 1453-1456.  
Vasen, H. F., Wijnen, J. T., Menko, F. H., Kleibeuker, J. H., Taal, B. G., Griffioen, G., 
et al. (1996). Cancer risk in families with hereditary nonpolyposis colorectal 
cancer diagnosed by mutation analysis. Gastroenterology, 110(4), 1020-
1027.  
Vernon, S. W., Gritz, E. R., Peterson, S. K., Amos, C. I., Perz, C. A., Baile, W. F., et 
al. (1997). Correlates of psychologic distress in colorectal cancer patients 
undergoing genetic testing for hereditary colon cancer. Health Psychology, 












Vernon, S. W., Gritz, E. R., Peterson, S. K., Perz, C. A., Marani, S., Amos, C. I., et 
al. (1999). Intention to learn results of genetic testing for hereditary colon 
cancer. Cancer Epidemiology, Biomarkers & Prevention, 8(4 Pt 2), 353-360.  
Viiala, C. H., & Olynyk, J. K. (2008). Outcomes for women in a flexible 
sigmoidoscopy-based colorectal cancer screening programme. Internal 
Medicine Journal, 38(2), 90-94.  
Vogelstein, B., & Kinzler, K. W. (1993). The multistep nature of cancer. Trends in 
Genetics, 9(4), 138-141.  
Vorobiof, D. A., Sitas, F., & Vorobiof, G. (2001). Breast cancer incidence in south 
africa. Journal of Clinical Oncology, 19(18 Suppl), 125S-127S.  
Vorster, A. (2011). Personal communication with Alvera Vorster [Division of Human 
Genetics, University of Cape Town]. 
Voskuil, D. W., Vasen, H. F., Kampman, E., & van't Veer, P. (1997). Colorectal 
cancer risk in HNPCC families: Development during lifetime and in 
successive generations. National collaborative group on HNPCC. 
International Journal of Cancer, 72(2), 205-209.  
Wagner Costalas, J., Itzen, M., Malick, J., Babb, J. S., Bove, B., Godwin, A. K., et al. 
(2003). Communication of BRCA1 and BRCA2 results to at-risk relatives: A 
cancer risk assessment program's experience. American Journal of Medical 
Genetics. Part C, Seminars in Medical Genetics, 119C(1), 11-18.  
Wagner, A., Barrows, A., Wijnen, J.T., van der Klift, H., Franken, P.F., Verkuijlen, P., 
et al. (2003). Molecular analysis of hereditary nonpolyposis colorectal 
cancer in the United States: High mutation detection rate among clinically 
selected families and characterization of an American founder genomic 
deletion of the MSH2 gene. American Journal of Human Genetics, 72(5), 
1088-1100. 
Wagner, A., van Kessel, I., Kriege, M. G., Tops, C. M., Wijnen, J. T., Vasen, H. F., et 
al. (2005). Long term follow-up of HNPCC gene mutation carriers: 
Compliance with screening and satisfaction with counseling and screening 
procedures. Familial Cancer, 4(4), 295-300.  
Walker, A., & Segal, I. (2002). Colorectal cancer in an african city population in 
transition. European Journal of Cancer Prevention, 11(2), 187-191.  
Walker, A. R. (2001). Changes in public health in south africa from 1876. The 












Walsh, M. D., Buchanan, D. D., Cummings, M. C., Pearson, S. A., Arnold, S. T., 
Clendenning, M., et al. (2010). Lynch syndrome-associated breast cancers: 
Clinicopathologic characteristics of a case series from the colon cancer 
family registry. Clinical Cancer Research, 16(7), 2214-2224.  
Wang, J., Luo, M. H., Zhang, Z. X., Zhang, P. D., Jiang, X. L., Ma, D. W., et al. 
(2007). Clinical and molecular analysis of hereditary non-polyposis 
colorectal cancer in chinese colorectal cancer patients. World Journal of 
Gastroenterology, 13(10), 1612-1617.  
Ward, R. L., Turner, J., Williams, R., Pekarsky, B., Packham, D., Velickovic, M., et al. 
(2005). Routine testing for mismatch repair deficiency in sporadic colorectal 
cancer is justified. The Journal of Pathology, 207(4), 377-384.  
Warthin, A. (1913). Hereditary with reference to carcinoma. Archives of Internal
Medicine, 12, 546-555. 
Watson, R. (2008). Nursing research: Designs and methods. New York: Churchill
Livingstone. 
Watson, W. (2007). Brick by brick: An informal guide to the history of South Africa.
South Africa: New Africa Books.
Watson, P., Lin, K. M., Rodriguez-Bigas, M. A., Smyrk, T., Lemon, S., Shashidharan,
M., et al. (1998). Colorectal carcinoma survival among hereditary
nonpolyposis colorectal carcinoma family members. Cancer, 83(2), 259-
266. 
Watson, P., & Lynch, H. T. (2001). Cancer risk in mismatch repair gene mutation
carriers. Familial Cancer, 1(1), 57-60.
Watson, P., Vasen, H. F., Mecklin, J. P., Bernstein, I., Aarnio, M., Jarvinen, H. J., et 
al. (2008). The risk of extra-colonic, extra-endometrial cancer in the lynch 
syndrome. International Journal of Cancer, 123(2), 444-449.  
Watson, P., Vasen, H. F., Mecklin, J. P., Jarvinen, H., & Lynch, H. T. (1994). The risk 
of endometrial cancer in hereditary nonpolyposis colorectal cancer. The 
American Journal of Medicine, 96(6), 516-520.  
Weil, J. (2000) Psychosocial genetic counselling. New York: Oxford University Press. 
Weitzman, E. R., Zapka, J., Estabrook, B., & Goins, K. V. (2001). Risk and 
reluctance: Understanding impediments to colorectal cancer screening. 












Westenend, P. J., Schutte, R., Hoogmans, M. M., Wagner, A., & Dinjens, W. N. 
(2005). Breast cancer in an MSH2 gene mutation carrier. Human Pathology, 
36(12), 1322-1326.  
Westwood, G., Pickering, R. M., Latter, S., Lucassen, A., Little, P., & Karen Temple, 
I. (2006). Feasibility and acceptability of providing nurse counsellor genetics 
clinics in primary care. Journal of Advanced Nursing, 53(5), 591-604.  
White, L. K., & Riedmann, A. (1992). Ties among adult siblings. Social Forces, 71, 
85.  
Willett, W. C., Stampfer, M. J., Colditz, G. A., Rosner, B. A., & Speizer, F. E. (1990). 
Relation of meat, fat, and fiber intake to the risk of colon cancer in a 
prospective study among women. The New England Journal of Medicine, 
323(24), 1664-1672.  
Williams, D. R., Gonzalez, H. M., Williams, S., Mohammed, S. A., Moomal, H., & 
Stein, D. J. (2008a). Perceived discrimination, race and health in south 
africa. Social Science & Medicine, 67(3), 441-452.  
Williams, D. R., Herman, A., Stein, D. J., Heeringa, S. G., Jackson, P. B., Moomal, 
H., et al. (2008b). Twelve-month mental disorders in south africa: 
Prevalence, service use and demographic correlates in the population-
based south african stress and health study. Psychological Medicine, 38(2), 
211-220.  
Wilson, B. J., Forrest, K., van Teijlingen, E. R., McKee, L., Haites, N., Matthews, E., 
et al. (2004). Family communication about genetic risk: The little that is 
known. Community Genetics, 7(1), 15-24.  
Wilson, B. J., Forrest, K., van Teijlingen, E. R., McKee, L., Haites, N., Matthews, E., 
et al. (2004). Family communication about genetic risk: The little that is 
known. Community Genetics, 7(1), 15-24.  
Worden,N. (2007). The making of Modern South Africa: Conquest, apartheid, 
democracy, 4th edn. Oxford: Blackwell publishing. 
World Health Organisation (WHO). (2006): South African Statistics. Retrieved April 
2010 from http://www.who.int/countries/zaf/en/. 
Wu, L. R., Parkerson, G. R.,Jr, & Doraiswamy, P. M. (2002). Health perception, pain, 
and disability as correlates of anxiety and depression symptoms in primary 













Young, I.D. (2001). Medical Genetics. New York: Oxford University Press. 
Zeegers, M. P., van Poppel, F., Vlietinck, R., Spruijt, L., & Ostrer, H. (2004). Founder 














DIVISION OF HUMAN GENETICS 
Faculty of Health Sciences · University of Cape Town 
GENETIC TESTING 
Genetic testing is an examination of the DNA (basic material of hereditary) of an 
individual. Results of these tests may disprove or confirm a suspected fault or 
change (mutation) in the DNA. Genetic testing of DNA is performed on a blood 
sample collected from an individual. 
Predictive genetic testing is a means of knowing one‘s genetic status with regard to a
particular condition. To undergo a predictive genetic test implies that one is
forewarned about one‘s risk of developing a particular disorder before the signs and
symptoms of that condition manifest itself in an individual.
Lynch syndrome (LS) is a dominant inherited disorder with the result that all family 
members of an affected individual (first degree relative) are at 50% risk of developing
cancer at an early age. Predictive genetic test for LS is a relatively recent option
available to individuals at risk for having inherited the gene for LS. This test allows
an individual a chance of knowing whether he / she has the mutation. Knowledge of
one‘s genetic status, with regard to LS, allows the individual to make informed
decisions about commencing preventative screening for cancer.
To take the test is a very serious decision. Therefore, it is important that subjects are 
well informed and understand the programme and procedures of predictive genetic 
testing that are necessary before finally getting the result. If after careful 
consideration, you decide to take the test, you will be requested to come to the 
Division of Human Genetics on at least 2 occasions to see the geneticist involved in 
running the programme. Arrangements can be made to link you with the clinical team 













PROGRAMME FOR PREDICTIVE TESTING – LYNCH SYNDROME 
1. Telephonic contact with family members re interest in predictive genetic 
testing. Setting up date(s) for meeting with geneticist or genetic counsellor.  
2. 1st Meeting with geneticists or counsellor: (Group session) Information 
and implication of predictive genetic testing. 
 
The outcome of this meeting can be:  
o You need time to assimilate what you have heard. The registered 
nurses will make contact with you within a week to discuss your 
decision.  
o You have opted to know your genetic status on LS - 1st Blood 
samples collected, with informed consent. 
3. 2nd Meeting with geneticist or counsellor:  
o Those who have opted to know their genetic status during the 1st 
meeting: meet individually with the geneticist and receive their genetic 
information. They have the opportunity of asking further questions 
pertinent to their specific situation. A second blood sample will be 
collected for confirmatory analysis. Contact numbers of the support 
team will be given. Plan of action with regard to preventative 
screening will be discussed. Appointments (support team + screening) 
can be arranged.  
o Those who have decided to know their genetic status subsequent to 
the 1st meeting: meet individually with geneticist to clear up any 
uncertainties. Meet with registered nurse to take 1st blood specimen. 
4. 3rd Meeting with geneticist or counsellor:  
o Those who have opted to know their genetic status during the 2nd 
meeting: meet individually with the geneticist and receive their genetic 
information. They have the opportunity of asking further questions 
pertinent to their specific situation. A second blood sample will be 
collected for confirmatory analysis. Contact numbers of the support 












screening will be discussed. Appointments (support team + screening) 
can be arranged.  
 
GENERAL INFORMATION ON THE LS PREDICTIVE GENETIC TESTING 
PROGRAMME 
1. We strongly recommend that you inform your family doctor of your decision to 
undertake the test. If you do not have a family doctor we recommend you find 
one. As part of the policy of this programme, we believe that the on-going 
medical care and support your doctor is able to give is very important to you 
and your family. A letter will be sent to your doctor (with your permission) to 
inform him/her about the programme after the 2 / 3rd meeting.  
2. Support is essential and we therefore strongly advise that you choose a 
family member or a trusted friend to accompany you to all the meetings. 
(optional)  
3. The final results will be given to you approximately 1 month after your blood 
samples have been taken and will be strictly confidential. No results will be 
given to you by telephone. With your permission your family doctor will be 
contacted and written to regarding the results.  
4. If at any stage in the programme you decide you do not wish to continue, the 
decision is entirely yours. Your decision will in no way prejudice our 
relationship with you or your family. We will be happy to continue to offer you 
the support and help you need, within our capabilities.  
5. Reactions to predictive genetic testing might vary widely. Some people who 
might have the predisposing genetic defect may suffer a sense of shock and 
grief however well they may have been prepared beforehand. People whose 
test is negative may feel relief but at the same time suffer guilt and anxiety. A 
health care professional will be available to discuss any questions / problems 
you might encounter after entering into the LS predictive genetic testing 
programme.  
6. No children under the age of 18 years will be included in the LS predictive 
genetic test programme.  
7. Those individuals who carry the mutation for LS will be counselled with 
regard to best practice regarding regular colonoscopic and other relevant 












8. Cost for the research leading to the finding of the genetic defect predisposing 
to colorectal cancer has been borne by the Division of Human Genetics. The 
(confirmation of diagnosis/predictive) laboratory test is available to members 












INFORMATION SHEET FOR TELEPHONIC CONTACT 
PhD Genetic Counselling Research Project 
 
AN INVESTIGATION INTO PSYCHOSOCIAL FACTORS WHICH HAVE AN IMPACT ON 
ACCESS TO AND UTILISATION OF THE ENDOSCOPIC SURVEILLANCE SERVICE OFFERED 
TO HIGH-RISK MEMBERS OF KNOWN LYNCH FAMILIES 
 
Basic outline of information to be discussed by the Colorectal Cancer Genetic Co-
ordinator when contacting individuals with LS, eligible for participation in the 
research study. 
 
Background information on the study: 
You have been invited to participate in a genetic counselling study conducted by a 
researcher of the University of Cape Town in the Division of Human Genetics. 
 
Purpose of the study: 
To gain insight into your experience of the GESC in order to evaluate the PT and 
surveillance programme. This will help the researcher determine the value and 
effectiveness of the service in an attempt to ensure the service quality is maintained 
or improved. 
 
What is required to participate in the study: 
Participation in a one-on-one interview with the researcher and you will be 
encouraged to answer all the questions in as much detail as possible. Your answers 
will be marked down as well as tape-recorded. All the information will remain 
confidential. 
 
If you say yes: 
You will be contacted by the researcher who will discuss further details of the study 
with you. A private venue and time will be arranged for the interview and this will 












but should you experience any form of psychological distress, please inform the 
researcher immediately and referral to genetic counselling services will be arranged. 
 
If you say no: 
You have every right to say no to participation in this study. Withdrawal can also take 
place at any time without jeopardising any medical services available to you or your 














PHD GENETIC COUNSELLING RESEARCH PROJECT 
 
AN INVESTIGATION INTO PSYCHOSOCIAL FACTORS WHICH HAVE AN IMPACT ON 
ACCESS TO AND UTILIZATION OF THE ENDOSCOPIC SURVEILLANCE SERVICE OFFERED 
TO HIGH-RISK MEMBERS OF KNOWN LYNCH FAMILIES 
 
INFORMATION AND CONSENT FORM 
 
STATEMENT BY PARTICIPANT 
 
I, ………………………………………………………………. Living at (address) 
…………………………………………………………………. 
confirm that: 
1. I have been invited to participate in the above research project, which has 
been initiated through the Division of Human Genetics, University of Cape 
Town because I am currently involved in the surveillance and/or predictive 
testing programme. 
 
2.1 I understand that the aim of this study is to: 
 
 To appraise the GESC from the users‘ perspective using face-to-face 
interviews to ascertain their experiences and satisfaction with the clinic;  
 To measure the level of the adherence to recommended surveillance 
screening guidelines; 
 To determine the impact of socio-economic status, education, physical 
barriers and psychosocial factors on adherence to the recommended 
surveillance programme;  
 To determine the uptake of PT among participants and their family members; 
 To identify and explore the referral pathways and communication networks 
leading to the GESC 
 
 
2.2 I understand that the interview will take place in my home or at another venue 
of my choice and that it may take one or two visits of up to two hours each. 
 
2.3 I am aware that this is a once off procedure that will be implemented in 
2009/2010 at a time convenient to me. 
 
2.4 I understand that some of the questions may make me angry or sad, but the 
risks to me from the study are minimal. The researcher will refer me to a genetic 
counsellor if necessary. She will show me respect, acceptance and empathy 
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3.1 I have been assured that all the information will be handled confidentially. 
Information may be used for a thesis, publications in scientific journals and at 
presentations at professional congresses, but names will not be included. 
 
3.2 I understand that the interview will be tape recorded so that the researcher 
does not have to write too much during the interview. The tape will be stored in a 
safe place until the research has been written up and will then be destroyed 
immediately. The data stored on the computer will have a numerical code only 
and my name does not appear anywhere. 
 
4.1 I have been assured that the recorded and transcribed information discussed 
at the meeting will only be made available to the researcher‘s supervisors with 
my study code number and that they do not know that it refers to my name. 
 
5. I have not been persuaded to consent to taking part in the study and I have 
been informed that I my refuse to participate in this project, that I may stop 
participating at any stage, and that such refusal or stoppage will not in any way 
negatively affect my future access to medical and genetic services to which I am 
entitled. 
 
6. ………………………………….  has explained the information of the study to 
me in English/Afrikaans. I am proficient in that language and my questions have 
been answered satisfactorily. 
 
7. I understand that there will be no medical benefits to me from this study. 
 
8. I have been assured that participation in this project will not lead to additional 
costs for me and I will not benefit from it financially. 
 
 
I hereby declare that I voluntarily agree to participate in the above research 
study 
Signed at: 




……………………………………                            …………………………….. 
Participant‘s signature     Witness 
 
I hereby declare that I agree to have my interview audiotape recorded 
Signed at: 




……………………………………                            …………………………….. 
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I give permission/consent for any requested photographs to be taken 
Signed at: 




……………………………………                            …………………………….. 







Thank-you very much for your participation in this study. If you have any questions 
about the research concerning: 
 
1. problems due to the research, or 
2. questions relating to the information about the project 
 
you can contact me or Prof. Raj Ramesar on: 
 
Zandre Bruwer (021) 406 6373 
E-mail: zbruwer@uct.ac.za 
 
Prof Raj Ramesar (021) 406 6337 
 
If you have any questions relating to your right as a participant, contact Prof. Marc 













GENETIC ENDOSCOPIC SURVEILLANCE CLINIC (GESC) RESEARCH 
PROJECT  
GROUP A: INTERVIEW SCHEDULE - English version 
SECTION A - DEMOGRAPHIC DATA AND PERSONAL HISTORY 
1. Gender Male1 Female2 A1
2. Age A2
3. Ethnic group Mixed Ancestry1 White2 A3
4(a). Occupation Employed1 Unemployed2 Part-time/casual3 A4a
4(b). Type of work/occupation? A4b
Managerial, professional, semi-professional1 
Clerical, sales, service2 
Skilled agricultural, craft, operators3 
Elementary occupations4 
Other5 
4(c). If currently unemployed, were you previously employed? A4c
 Yes1 No2
4(d). Reason for unemployment: A4d
5(a). Monthly household income: A5a
 No income1 Grant 2 R1 - R4003 
 R401 - R8004 R801 - R16005 R1601 - R32006 
 R3201- R64007 R6401 - R12 8008 R12 801 - R25 6009 
 R25 601 - R51 20010 R51 201 - R102 40011 R102 401 - R204 80012 
R 204 801 and more13
5(b). How many people are dependant on this income? A5b
5(c). Type: A5c
All pay/disability grant1
Child support grant/care dependancy grant2 
Pension3 
5(d). Number of grants per household: A5d
5(e). Total income of grants: A5e
R1 - R4001 R401 - R8002 R801 - R16003 R1601 - R32004 
R3201- R64005 R6401 - R12 8006 
6. Education Years completed at: 
(a) Junior school (out of 7) A6a
(b) Senior school (out of 5) A6b
(c) College/University Yes1  No2 A6c
7. Was there any reason for not completing school or college? A7
8. Marital status  Single1 Widow2 Married/Partner3 Divorced4 A8
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The following information will be obtained by drawing your family pedigree. This drawing will also be used 
to answer the questions in Section G. 
10. Number of children (all biological children): A10 
          
Name of child 
    
M/F Age of child 
                               
Additional notes   
    
 
          
                
                
                
                
                
                
                
          
11(a). How many children eligible for predictive testing? A11a 
11(b). How many children eligible for predictive testing have been tested? A11b 
12(a). Number of siblings eligible for testing when it became available to your family? A12a 
12(b). Number who have been tested? A12b 
          
Name of sibling       M/F           Age of brother/sister              Additional notes   
  








      
          
13(a). Affected parent: Male1 Female2 Unaffected male3 Unaffected female4 A13a 
  Does not know5   
13(b). Tested before1 or after proband2: Never tested3 A13b 
14(a). If the parent was affected, are they still currently alive? Yes1 No2 A14a 
14(b). If your parent was affected, what type of cancer did they have? A14b 
CRC(colorectal cancer)1 Endometrial2 Breast3 Other4 No cancer5   
15. Your age (the earliest memory), when you found out/knew your parent had cancer? A15 
16(a). Family size (nuclear) A16a 
16(b). Family size (total) A16b 
17. Have you had to care for anyone with cancer in your family? Yes1 No2 A17 
18. In terms of your family history of cancer how do you feel about your risk of developing cancer? A18 
19. Referral to clinic: A19 
20. What were you told, or what did you expect? A20 
21 (a). Year first seen at the mobile endoscopic clinic (MEC)/ hospital clinic Year: A21a 
21 (b). Seen at the: MEC1 Hospital clinic2 A21b 
22. Seen for: Colonoscopy1 Genetic testing2 Both3 A22 
23. Affected with colorectal cancer (CRC) at this 
stage Yes1 No2 Symptomatic3 A23 
24. Previously affected with CRC Yes1 No2 Polyps3 A24 










                                                                                                                                                              APPENDIX 4A 
314 
26. Affected with any other cancer? Yes1  No2 A26 
27. Age affected with this cancer? A27 
28. Test result (mutation identified) MLH11  MSH22 A28 
29. Residential area: Western Cape1 Northern Cape2 A29 
30. Location: Rural1 
  
Urban2 A30 
31. Total number of family members affected with cancer in the nucleur family (parent,sibling,child) A31 
 
SECTION B - KNOWLEDGE OF LYNCH SYNDROME  
1. The following section is not to be viewed as a test. The questions relate to what you understand about  
Lynch Syndrome (LS) and how the condition has been explained to you at the clinic.   
Please answer yes or no to the following questions (adapted from Domanska et al 2009). 
 
(a) CRC affects ~ 4-5% of all individuals in South Africa Yes1 No2 B1a 
(b) Individuals who carry the gene for LS will definitely develop cancer Yes1 No2 B1b 
(c) Indivduals who do not carry the gene will never develop CRC Yes1 No2 B1c 
(d) Females with LS have an additional risk of endometrial cancer Yes1 No2 B1d 
(e) Females with LS have an additional risk of ovarian cancer Yes1 No2 B1e 
(f) Colonoscopy is only useful in indivduals with LS when there are bowel 
symptoms Yes1 No2 B1f 
(g) Indivduals with LS need regular colonocopies Yes1 No2 B1g 
(h) Indivduals with LS will pass the faulty gene on to 25% of their children Yes1 No2 B1h 
(i) Tumour tissue can be used to diagnose LS Yes1 No2 B1i 
(j) Blood samples can be used for genetic testing Yes1 No2 B1j 
(k) The disease is most often inherited from the male side of the family Yes1 No2 B1k 
 
2. What is the most important thing about LS that you are aware of? B2 
 (Cause, signs and symptoms, age of onset, inherited cancer predisposition)   
3(a). Do you know anything else about the condition, which you choose not to tell people? B3a 
3(b). If yes, what? B3b 
4. Were your parents very secretive about the cancer in the family (kept their diagnosis a secret)? B4 
5.  What symptoms would make you worry that you might have LS? B5 
6. What do you know about the symptoms in your family? B6 
7. What risk do you have of developing LS? B7 
8. Does it affect males and females equally? B8 
9. What chance do the following individuals have of developing LS?   
 
(a) Brothers and sisters B9a 
 
(b) Children B9b 
 
(C) Heard of the 50% risk? Yes1 No2 B9c 
10. Where did you learn about LS/how did you come to learn about your risk for CRC? B10 
11(a). Did you seek further information Yes1 No2 B11a 
11(b). Did you have any resources available to use: B11b 
12(a). If Yes, what terminology did you use/what name do you refer to it as? B12a 
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12(b). Have you heard of the term HNPCC/LS? Yes1 No2 B12b 
13(a). Have you received any handouts or information on LS? Yes1 No2 B13a 
If yes:          
(b) Do you still have it? Yes1 No2 B13b 
(c) Did you find it useful? Yes1 No2 B13c 
14. When was the first time that the genetics of LS was discussed with you? B14 
First session1 At a later stage2 Can't remember3 Never4   
15. How often is the genetics/inheritance of LS discussed with you? B15 
16. Was the inherited risk to the children discussed with you? B16 
17. How did you feel when you heard this information? B17 
18.Would this information have impacted on your decision to have a family (children)? B18 
19. How has your parent's or (family member's) cancer affected the way you deal with your risk,  
in terms of: 
(a) Surveillance (similar, different because of how they dealt with it) B19a 
More adherent1  
The same/no effect2  
Less adherent3  
Did not know parent/family member with cancer4  
Other5  
(b) Watching for symptoms (go to Dr immediately, denial, worry at first sign of something wrong) B19b 
Yes1 No2  
          
SECTION C – ENDOSCOPIC SURVEILLANCE SERVICE             
          
1. What transport was used to get to the clinic?  
  
(a). Type C1a 
Walked1 
  
Own transport2 Borrowed a car3 Public transport (bus/taxi)4   
Free hospital ambulance5 
  




Free1 Cost2 C1b 
  
(c). Arranged by:  You1 Someone else2 C1c 
2. How long does it take you to get to the MEC/ hospital clinic? C2 
3. Have you received a colonoscopy? Yes1 No2 C3 
4. How many/how often do you go (every year, missed some etc) 
(Self-report) C4 
4(c). How often do you think you should go for a colonoscopy/sigmoidoscopy? 
 C4c 
4(d). If you have had an operation for cancer, do you know that you must come for yearly 
sigmoidoscopy's? C4d 
  Yes1 No2   
5. As a woman, do you go for gynaecological 
surveillance? (what was done) Yes1 No2 
  
C5 
6. How often? C6 
7. How has your experience been of a colonoscopy? 
(a). Colo-prep (taste, amount of fluid, nauseous) C7a 
(b). Toilet facilities (at home, clinic, did you manage without facilities) C7b 
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(d). If you have never been what have you heard about it? C7d 
8. Would you go for a colonoscopy again? Yes1 Maybe2 No3 C8 
 




































What are your reasons for going for a colonoscopy?  
(a) Maintain health C9a 
(b) Recent death/affected relative in family C9b 
(c) Family member/doctor's recommendation C9c 
(d) Polyp/cancer found previously C9d 
(e) Is there any other reason why you go for colonoscopies? C9e 
          
Those times that you did not go 
10. What are your reasons for not going for a colonoscopy? 
(a) Colon preparation C10a 
(b) Discomfort of procedure C10b 
(c) Reported painful experience C10c 
(d) Transport problems C10d 
(e) Do not think that I need it C10e 
(f) Is there any other reason why you do not go for colonoscopies? C10f 
 
11. Were the results of you colonoscopy discussed with you? Yes1 No2 C11 
12(a). Can you explain your results to me (what it means in terms 
of your health and management. What did they say to you after 
your last colonoscopy) Knows1 Does not know2 C12a 
12(b). What is the purpose of the colonscopy? Knows1 Does not know2 C12b 
12(c). What does it mean if they identify a polyp during the 
colonoscopy? Knows1 Does not know2 C12c 
Does not know what a polyp is3   
12(d). Why do you think the procedure must be done every year? Knows1 Does not know2 C12d 
13(a). Did you know when to come again? C13a 
13(b). If no, why not: C13b 
14. Do you have the number of a contact person at the clinic? Yes1 No2 C14 
15. If you missed an appointment, did you reschedule? Yes1 No2 C15 
16. Would it be possible to get a colonoscopy elsewhere? Yes1 No2 C16 
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SECTION D - SATISFACTION WITH GESC             
          1. This section relates to the satisfaction with your previous clinic appointments. Please answer this as 
truthfully as possible, everything will remain confidential from the staff at the clinic. It is only through your 
honesty that the service could be improved. 
 
This section requires you to answer yes or no to the following statements: 
(a) Everyday language was used to explain LS 
(home language was used, easy to understand concepts used to explain) Yes1 No2 D1a 
(b) Everything I wanted to know about LS was explained at the clinic1,2 
(cause, age of onset, symptoms, reason for surveillance) Yes1 No2 D1b 
(c) The counselling received helped me cope better with my condition/ risk of 
developing the condition4 Yes1 No2 D1c 
(d) I will follow the clinics advice because I think they are absolutely right2 
 (Come for a colonoscopy every year/gynae visits etc/talk to family about risk) Yes1 No2  D1d 
(e) I understand why my family has a higher risk than other families of 
developing cancer Yes1 No2  D1e 
(f) The time I spent at the GESC was long enough to deal with everything I 
wanted to discuss2 (how much time did you spend with the staff, did you feel 
this was long enough) Yes1 No2 D1f  
(g) The Dr/nurse/counsellor was easy to reach after the clinic consultation for 
any questions/concerns that I had3 (Were they contacted, was there a need to 
contact) Yes1 No2  D1g 
(h) Were any of your questions unanswered?1 (did you have any unanswered 
questions at visit, after visit, were they answered) Yes1 No2 D1h 
1Westwood 2006. 
2Poulton 1996. 
3Groenewegen et al 2005. 
4Shiloh et al 1990. 
 
SECTION E - COMMUNICATION IN THE FAMILY  
 1. Can you tell me about the time (how you felt) when you received your positive test result?  
(the time leading up to the result, your expectations of the result, your reaction, how you are    
coping) E1 
2. Did you seek any emotional support? E2 
3. Did anyone know that you were going to receive your result that day? 
Yes1 No2 E3 
4(a). Did you tell anyone about your result that day? 
  
E4a 
(b) Who: E4b 
(c) Why them: E4c 
 5. Using the pedigree, indicate who on the list has been told and use the table below to select the 
most appropriate answer as to why they were told. E5 
 
List of relatives 
  
                 
Told1 Not told2 Too young3 
                   
Passed 









  E5a 




    E5b 




    E5c 






    E5d 
























  E5g 
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7(a). LS is an inherited form of cancer and the rest of your family would also be at-risk for the condition. 
Have you informed any family member (sibs, parents, aunts, uncles, cousins) about testing and/or 
screening? 
 
Yes1 No2 E7a 
(b). If no: why not?  E7b 
(c). Was this person(s) unaware of the programme or non-adherent? E7c 
New1 Non-adherent2 Has not come for genetic testing3   
(d). How long after you received your result, did you tell them? E7d 
(e). Did you mention your test result when discussing this risk with them? Yes1 No2 E7e 
8(a). Have your children been informed that they may be at risk of developing LS? E8a 
 Yes1 No2   
8(b). Age information discussed with them? E8b 
8(c). If you have informed them already, why did you choose this specific time? E8c 
8(d). Did you tell them about the genetic test (blood test)? Yes1 No2 E8d 
8(e). Did you tell them about surveillance? Yes1 No2 E8e 
9. Predictive testing is usually offered from 18 years. At what age do you think people should be tested? 
18 years is the right time1 Should be earlier2 Should be later3 E9 
10. How often do you discuss LS with your family members? E10 
11(a). Is there anything that would have helped you tell your family that they are at-risk? E11a 
11(b). Is there anything you want more information on? E11b 
12. Who usually communicates important information to the rest of the family? E12 
13. Who should tell the family about the familial risk? Family1 Clinic2 E13 
 
SECTION F - GENERAL HEALTH OF PARTICIPANT  
 
1(a). Since your last visit to the clinic have you had any bowel-related concerns? Yes1 No2 F1a 
1(b). If yes, what have you done about this?  F1b 
2. Has testing positive for the gene predisposing to the cancer in your family influenced your eating 
habits? F2 
 Yes1 No2   
3. Has testing positive for the gene predisposing to the cancer in your family influenced your drinking 
habits? F3 
 Yes(less)1 No2 Not applicable3  
 Yes(more)4   
4. Has testing positive for the gene predisposing to the cancer in our family, influenced your smoking 
habits? F4 
    Yes(less)1 No2 Not applicable3   
 Yes(more)4    
5. Screening behaviour (information from database):   
(a). Attendance rate for colonoscopy (adherence group) F5a 
(b). Attendance and type of gynaecological examinations  
(Women only) Yes1 No2 Once only3 F5b 
(c). Type of genetic test PT1 Diagnostic test2  F5c 
(d). Development of polyp or cancer? Polyp1 Cancer2 Not applicable3 F5d 











                                                                                                                                                              APPENDIX 4A 
319 
(f). History of surgery Yes1 No2 Type F5f 
(g). Chemotherapy and or radiation Yes1 No2 F5g 
 
DUKE-AD SCALE – Pakerson and Broadhead (1997) 
6. The following questions are about your health and feelings experienced.  
Please read each question carefully and select the best answer. Do not spend too much time on any statement. 















































(a) I give up too easily  ______2 ____1 ____0 
(b) I have difficulty concentrating ______2 ____1 ____0 
(c) I am comfortable being around people ______0 ____1 ____2 
  
  
DURING THE PAST WEEK: None Some A lot 
How much trouble have you had with: 
  
(d) Sleeping ______0 ____1 ____2 
(e) Getting tired easily ______0 ____1 ____2 
(f) Feeling depressed or sad ______0 ____1 ____2 
(g) Nervousness ______0 ____1 ____2 
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CANCER WORRY SCALE- (Lerman et al 1991). 
7. Please answer the following questions with the statement which best describes how you felt: 










































(a) How often have you thought about your own chances of developing cancer? 
      ___1 ____2 ___3 ____4 
(b) How often have you worried about your own chances of developing cancer? 
     ___1 ____2 ___3 ____4 
(c) How often has thoughts about getting cancer affected your mood? 
    ____1 ___2 ___3 ____4 
(d) How often have thoughts about getting cancer affected your ability to perform daily activities? 
 ____1 ____2 ___3 _____4 
  
Total score F7 
 
SECTION G - RESEARCH  
1. Have you been involved in the CAPP study? Yes1 No2 G1 
2. What was your experience of the study like? G2 
3(a). Have you been involved in any other research studies? Yes1 No2 G3a 
3(b). What has this been like? G3b 
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GENETIC AND ENDOSCOPIC SURVEILLANCE CLINIC (GESC) RESEARCH 
PROJECT  
GROUP B:  INTERVIEW SCHEDULE - English version 
      
          SECTION A - DEMOGRAPHIC DATA AND PERSONAL HISTORY           
          
1. Gender   Male1 Female2           A1 
2. Age                 A2 
3. Ethnic group     Mixed Ancestry1  White
2    A3 
4(a). Occupation Presently:  Employed1         Unemployed2 Part-time/casual3 A4a 
4(b). Type of work if employed:   A4b 
Managerial, professional, semi-professional1              
Clerical, sales, service2                 
Skilled agricultural, craft, operators3               
Elementary occupations4                 
4(c). If currently unemployed were you previously: Employed1   Unemployed2 A4c 
4(d). Reason for unemployment:           A4d 
5(a). Monthly household income:             A5a 
No income1 Disability grant 2 R1 - R4003   
R401 - R8004 R801 - R16005 R1601 - R32006   
R3201- R64007 R6401 - R12 8008 R12 801 - R25 6009   
R25 601 - R51 20010 R51 201 - R102 40011 R102 401 - R204 80012   
R 204 801   and more13                
5(b). How many people (including you) are dependant on this income? A5b 
5(c). Type:                A5c 
Disability grant(All pay)1                 
Child support grant/care dependancy grant2             
Pension3                   
5(d). Number of grants per household:             A5d 
5(e). Total income of grants:             A5e 
R1 - R4001   R401 - R8002     R801 - R16003 R1601 - R32004   
R3201- R64005 R6401 - R12 8006             
6. Education   Years completed at:             
        (a) Junior school (out of 7)   A6a 
        (b) Senior school (out of 5)   A6b 
        (c) College/University Yes1 No2 N/a3 A6c 
7. Was there any reason for not completing school or college? A7 
8. Marital status:  Single1 Widow2 Married/Partner3 Divorced4   A8 
9. Home language:  English1  Afrikaans2 Both3   Other4   A9 
10(a). Number of children (all biological 
children):          A10a 
10(b). Number of children eligible for testing:           A10b 
10(c). Number of eligible children who have been 
tested?         A10c 
11(a). Affected parent:  Male
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11(b). Tested:         Before1 or after proband2                         Never tested3   A11b 
12. Are they still alive?       Yes1 No2   A12 
13(a). Your age when your parent was affected?           A13a 
13(b). Exposure to CRC                 
None1 Affected relatives elsewhere2 Lived with affected family member with CRC3 A13b 
Lived with affected family member who died of CRC4     Other5       
14(a). Number of siblings (lineage of affected or mutation positive parent). A14a 
14(b). Number of eligible siblings:             A14b 
14(c). Number of eligible siblings who have been tested?         A14c 
15(a). How would you feel if you tested positive? (very anxious, not too worried, etc)   A15b 
          
SECTION D1 - GENETIC COUNSELLING PERSPECTIVES AND SATISFACTION 
          
1. The following list describes the information that may have been covered during your session with the 
Dr/Sr/counsellor when blood was taken for genetic testing. 
How important was each of the following to you?       































(a) Cause of the condition       
(b) Explanation on why the condition is passed on from one generation to the 
next       
(c) The medical name for the condition               
(d) Explanation on who else is at-risk (in the family) for LS         
(e) If treatments are available for LS             
(f) Potential treatments that may become available in the future           
(g) Information on what will happen to someone with the condition as time goes 
by       
(h) Availability of a genetic test to see if I will get this condition           
(i) To be able to contact other families affected with  the condition for support       
(j)The information covered in the session should be written down for future 
reference       
(k) Is there a test for this condition in pregnancy       
          
2(a). If one could test for LS during pregnancy, what would your thoughts be on TOP if the foetus tested 
positive for the condition? 
 Agree
1 Disagree2 Disagree but okay for others to do it3  Other
4 D2a 
2(b). If disagree (2) 
why:   D2b 
 Morals/Religion1 Not a poor enough prognosis-something can be done
2 
 Other
3        
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3. Satisfaction with Genetic Counselling 
(De Marco et al 2004).        
Please rate each statement: 
Please answer this section as truthfully as possible, everything will remain confidential from the staff at the 
clinic. It is only through your honesty that the service can be improved. 
        





























(a). The staff member of the clinic seemed to understand the stress I was 
facing       D3a 
(b). They helped me to identify what I needed to know to make decisions 
about the blood test and surveillance       D3b 
(c). I felt better about my health after meeting with them          D3c 
(d). The session was about the right length of time           D3d 
(e). They were truly concerned about my well-being           D3e 
(f). The session was valuable to me             D3f 
          
SECTION D2 - PREDICTIVE TESTING AND COUNSELLING PROGRAMME 
        
1. How did you hear about the clinic Clinic1 Self2 GP3 Family4 Other5  d1 
2. How long after you heard about the clinic did you come for predictive testing?  d2 
3. What made you decide to go to the clinic?      d3 
4. Did any of the following statements affect your decision to be tested (predictive blood test) 



















(a) Planning for the 
future               d4a 
(b) Marital decisions               d4b 
(c) Reproductive decisions       d4c 
(d) Clarifying risk for (future) children             d4d 
(e) Employment decisions       d4e 
(f) Reducing uncertainty               d4f 
(g) Dr recommended it               d4g 
(h) Self-evident               d4h 
(i) Family member/partner urged me to do it           d4i 
(j) To find out if surveillance needed to be continued           d4j 
(k) Other reasons, please state             d4k 
        
5. What do you think is the purpose of predictive genetic 
testing? Knows
1 Does not know2 d5 
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7. Duke anxiety and depression scale- (Parkerson and Broadhead 1997). 
The following questions are about your health and feelings experienced.  
Please read each question carefully and select the best answer. Do not spend too much time on any statement. 
There are no right or wrong answers. 
      








































(a) I give up too easily  _____2 _____1 _____0 
(b) I have difficulty concentrating _____2 _____1 _____0 
(c) I am comfortable being around people _____0 _____1 _____2 
DURING THE PAST WEEK: 
  None Some A lot 
How much trouble have you had with:    
(d) Sleeping _____0 _____1 _____2 
(e) Getting tired easily _____0 _____1 _____2 
(f) Feeling depressed or sad _____0 _____1 _____2 
(g) Nervousness _____0 _____1 _____2 
Total Score d7 
Cancer worry scale- Lerman et al 1991 
8. Please answer the following questions with the statement which best describes how you felt: 
  
In the past month...          



































(a) How often have you thought about your own chances of developing cancer? 
        _____
1 ______2 ____3 _____4  
(b) How often have you worried about your own chances of developing cancer? 
    _____
1 ______2 ____3 _____4  
(c) How often has thoughts about getting cancer affected your mood? 
         _____
1 ______2 ____3 _____4  
(d) How often have thoughts about getting cancer affected your ability to perform daily activities? 
   _____
1 ______2 ____3 _____4  
          
Total Score         d8 
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Second interview – immediately after result delivery session 
 
1. Duke anxiety and depression scale- (Parkerson and Broadhead 1997). 
The following questions are about your health and feelings experienced.  
Please read each question carefully and select the best answer. Do not spend too much time on any statement. 
There are no right or wrong answers. 
 








































(a) I give up too easily  _____2 _____1 ______0 
(b) I have difficulty concentrating _____2 _____1 ______0 
(c) I am comfortable being around people _____0 _____1 ______2 
DURING THE PAST WEEK:     None Some A lot 
How much trouble have you had with:        
(d) Sleeping _____0 _____1 ______2 
(e) Getting tired easily      _____
0 _____1 ______2 
(f) Feeling depressed or sad     _____
0 _____1 ______2 
(g) Nervousness           _____0 _____1 ______2 
Total Score d1 
Cancer worry scale – (Lerman et al 1991). 
2. Please answer the following questions with the statement which best describes how you felt: 
  
In the past month...          



































(a) How often have you thought about your own chances of developing cancer? 
        _____
1 ____2 ____3 ______4  
(b) How often have you worried about your own chances    of developing cancer? 
    _____
1 ____2 ____3 ______4  
(c) How often has thoughts about getting cancer affected your mood? 
         _____
1 ____2 ____3 ______4  
(d) How often have thoughts about getting cancer affected your ability to perform daily activities? 
        _____
1 ____2 ____3 ______4  
          
Total Score         d2 
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Section H (Third interview) – one month after result delivery  
  
1. How did you feel immediately after you received your genetic test result? H1 
2. Are you satisfied with your decision to go for predictive genetic testing? H2 
  Yes1 No2        
3. Do you trust the test result?       H3 
  Yes1 No2 Other3       
4. Now that you know your result, would you have taken the test in the first place? H4 
  Yes1 No2        
5(a). Would you advise other family members to be tested:   Yes1 No2 H5a 
5(b). Yes, and why1?        H5b 
5(c). No, and why2?        H5c 
6. Predictive testing is usually offered from 18 years, at what age do you think people should be offered testing? 
         H6 
7. Do you think blood should be taken on the same day as the pre-test counselling (first session with 
counsellor)? 
           Yes1 No2 H7 
8. Were you happy with the amount of time that it took for you to receive your test results (how long did 
you wait, were you told how long it would take)?  
         Yes1 No2 H8 
9. How often did you think of your test result during this waiting period?     
Not at all1  Every now and then2  A lot3 Almost all the time4 H9 
10. What would have helped you cope better during this waiting time?    H10 
11(a). Have you seen someone outside of the clinic for emotional support (social worker, psychologist, 
Sr at local clinic, family member)?  
          Yes1 No2 H11a 
11 (b). If yes, who?        H11b 
12 (a). Have you told anyone about your PT result?      H12a 
12 (b). If yes, who?        H12b 
          
          
Duke anxiety and depression scale (Parkerson and Broadhead 1997). 
The following questions are about your health and feelings experienced.      
Please read each question carefully and select the best answer. Do not spend too much time on any statement. 
There are no right or wrong answers. 
 








































                  
(a) I give up too easily      ______2 ________1 _______0 
(b) I have difficulty concentrating    ______2 ________1 _______0 
(c) I am comfortable being around people   ______0 ________1 _______2 
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DURING THE PAST WEEK:    None Some A lot 
How much trouble have you had with:       
(d) Sleeping      ______0 ________1 _______2 
(e) Getting tired easily     ______0 ________1 _______2 
(f) Feeling depressed or sad    ______0 ________1 _______2 
(g) Nervousness         ______0 ________1 _______2 
Total Score H1 
       
CANCER WORRY SCALE – (Lerman et al 19991).       
    
2. Please answer the following questions with the statement which best describes how 
you felt:    
In the past month...         





































                    
(a) How often have you thought about your own chances of developing cancer? 
  
        _____1 _____2 _____3 ____4   
(b) How often have you worried about your own chances of developing cancer? 
  
        _____1 _____2 _____3 ____4   
(c) How often has thoughts about getting affected your mood? 
  
         _____1 _____2 _____3 ____4   
(d) How often have thoughts about getting cancer affected your ability to perform daily activities? 
  
        _____1 _____2 _____3 ____4   
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SOCIAL SECURITY GRANTS IN SOUTH AFRICA 
 
Social security grants are financed through nationally collected tax revenues and are 
available in the form of: 
 
Old Age Grant 
This grant is available to males and females over the age of 60 years, where the 
spouse complies by the means test and the recipient is not in the possession of 
another social grant. R1010 is allocated per month. 
 
Disability Grant 
Males between the ages of 18 to 59 years and females between the ages of 18 to 64 
years, with a disability (which declares the individual mentally or physically unfit to 
work) and, who are not receiving any other social grants are eligible for the R1080 
per month. 
 
Grant in Aid 
This grant is available to persons with a disability grant but requiring full-time 
attendance for care owing to their physical or mental disabilities. R250 per month is 
made available for the care-giver. 
 
Child Support Grant 
R250 per month per child is made available with this social grant. Applicants are 
required to be the child‘s primary care giver and over the age of 16 years. 
 
Care Dependency Grant 
This grant is available to parents of children who are one to 18 years of age with a 
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Foster Child Grant  
This grant of R710 per month is available to a foster parent, holding a court order 
indicating foster parent status and complying with the means test. The grant is 
available until the foster child turns 18 years of age (Government Gazette Act Nos 
R417 of 1998; and 52 of 1992; South African Government Services: Child grants and 
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DIVISION OF HUMAN GENETICS    
 








RE: Genetic testing for your family 
 
The Division of Human Genetics at the University of Cape Town has been doing 
genetic research on colorectal cancer since 1987, in order to improve clinical 
management of the disorder. 
 
The Colorectal Cancer Registry at the University of Cape Town received blood 
samples from members of your family, which were donated for research. Our 
research has recently led to the discovery of a specific genetic change which results 
in members of your family, who are carrying the change, having an inherited 
tendency to develop cancer. Even if people who carry the genetic change have not 
developed cancer themselves, they can pass this inherited tendency to their 
children. If a person has an increased chance of developing cancer, there are 
effective ways of reducing this risk. 
 
Please contact us for further information or if you would like to find out more about 
the services available to you. You can be assured that the information we give you 
and any information we receive from you is treated confidentially. 
 















Genetic counselling service – University of Cape Town, Faculty of Health Sciences: 



















  DIVISION OF HUMAN GENETICS  
 AND GROOTE SCHUUR HOSPITAL 
Dear …………………………. 
RE: Leave of absence 
The Division of Human Genetics at the University of Cape Town together with 
Groote Schuur Hospital has seen ……..………………… on the ……/……/…...
This patient was seen at the ……………….. (clinic or hospital) for a procedure on 
the ……/……/…… which required preparation on the ……/……/…… prior to their
scheduled appointment. 
Yours sincerely 
Date: ……/……/……
